NZ614776B2 - Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith - Google Patents
Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith Download PDFInfo
- Publication number
- NZ614776B2 NZ614776B2 NZ614776A NZ61477612A NZ614776B2 NZ 614776 B2 NZ614776 B2 NZ 614776B2 NZ 614776 A NZ614776 A NZ 614776A NZ 61477612 A NZ61477612 A NZ 61477612A NZ 614776 B2 NZ614776 B2 NZ 614776B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- alkyl
- substituted
- compound
- cycloalkyl
- mmol
- Prior art date
Links
- 150000003230 pyrimidines Chemical class 0.000 title abstract description 7
- 239000000203 mixture Substances 0.000 title description 142
- CTAWBMDQTAZKIE-UHFFFAOYSA-N N,N-diaminoformamide Chemical class NN(N)C=O CTAWBMDQTAZKIE-UHFFFAOYSA-N 0.000 title description 4
- -1 diaminocarboxamide pyrimidine compounds Chemical class 0.000 claims abstract description 336
- 150000001875 compounds Chemical class 0.000 claims abstract description 241
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 171
- 201000010099 disease Diseases 0.000 claims abstract description 48
- 210000004185 Liver Anatomy 0.000 claims abstract description 38
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 17
- 231100000240 steatosis hepatitis Toxicity 0.000 claims abstract description 17
- 230000003176 fibrotic Effects 0.000 claims abstract description 12
- 208000006454 Hepatitis Diseases 0.000 claims abstract description 11
- 231100000283 hepatitis Toxicity 0.000 claims abstract description 11
- 102100005528 MAPK9 Human genes 0.000 claims abstract description 10
- 206010053219 Non-alcoholic steatohepatitis Diseases 0.000 claims abstract description 10
- 206010016654 Fibrosis Diseases 0.000 claims abstract description 9
- 102100005531 MAPK8 Human genes 0.000 claims abstract description 9
- 101710029922 MAPK9 Proteins 0.000 claims abstract description 9
- 230000004761 fibrosis Effects 0.000 claims abstract description 9
- 101710029924 MAPK8 Proteins 0.000 claims abstract description 8
- 230000001684 chronic Effects 0.000 claims abstract description 8
- 201000004044 liver cirrhosis Diseases 0.000 claims abstract description 8
- 206010004661 Biliary cirrhosis primary Diseases 0.000 claims abstract description 7
- 201000002728 primary biliary cirrhosis Diseases 0.000 claims abstract description 7
- 230000037406 food intake Effects 0.000 claims abstract description 6
- 206010072268 Drug-induced liver injury Diseases 0.000 claims abstract description 5
- 201000009910 diseases by infectious agent Diseases 0.000 claims abstract description 5
- 231100000595 drug-induced hepatitis Toxicity 0.000 claims abstract description 5
- 125000000217 alkyl group Chemical group 0.000 claims description 247
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 113
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 79
- FUXJMHXHGDAHPD-UHFFFAOYSA-N pyrimidine-2-carboxamide Chemical compound NC(=O)C1=NC=CC=N1 FUXJMHXHGDAHPD-UHFFFAOYSA-N 0.000 claims description 71
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 70
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 54
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 49
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 44
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 44
- OAKJQQAXSVQMHS-UHFFFAOYSA-N hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims description 42
- XSQUKJJJFZCRTK-UHFFFAOYSA-N urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 41
- 125000000623 heterocyclic group Chemical group 0.000 claims description 38
- 229910052736 halogen Inorganic materials 0.000 claims description 36
- 150000002367 halogens Chemical class 0.000 claims description 36
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 31
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 27
- 239000011780 sodium chloride Substances 0.000 claims description 27
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 27
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 25
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 24
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims description 24
- 150000002148 esters Chemical class 0.000 claims description 23
- 125000003118 aryl group Chemical group 0.000 claims description 22
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 22
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 22
- 150000003839 salts Chemical class 0.000 claims description 22
- 125000003545 alkoxy group Chemical group 0.000 claims description 21
- 125000005119 alkyl cycloalkyl group Chemical group 0.000 claims description 21
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 21
- IVRMZWNICZWHMI-UHFFFAOYSA-N azide Chemical compound [N-]=[N+]=[N-] IVRMZWNICZWHMI-UHFFFAOYSA-N 0.000 claims description 20
- 239000004202 carbamide Substances 0.000 claims description 20
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 20
- 150000003949 imides Chemical class 0.000 claims description 20
- 150000002466 imines Chemical class 0.000 claims description 20
- 150000002576 ketones Chemical class 0.000 claims description 20
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 20
- 150000002923 oximes Chemical class 0.000 claims description 20
- 150000003573 thiols Chemical class 0.000 claims description 20
- QRXWMOHMRWLFEY-UHFFFAOYSA-N Isoniazid Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 claims description 19
- IQPQWNKOIGAROB-UHFFFAOYSA-N [N-]=C=O Chemical compound [N-]=C=O IQPQWNKOIGAROB-UHFFFAOYSA-N 0.000 claims description 19
- 125000004442 acylamino group Chemical group 0.000 claims description 19
- 125000003282 alkyl amino group Chemical group 0.000 claims description 19
- 150000001409 amidines Chemical class 0.000 claims description 19
- ZHXTWWCDMUWMDI-UHFFFAOYSA-N dihydroxyboron Chemical compound O[B]O ZHXTWWCDMUWMDI-UHFFFAOYSA-N 0.000 claims description 19
- 150000007857 hydrazones Chemical class 0.000 claims description 19
- AVXURJPOCDRRFD-UHFFFAOYSA-N hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 claims description 19
- 150000003457 sulfones Chemical class 0.000 claims description 19
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 18
- 150000001204 N-oxides Chemical class 0.000 claims description 18
- FDDDEECHVMSUSB-UHFFFAOYSA-N Sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 claims description 18
- ZBKFYXZXZJPWNQ-UHFFFAOYSA-N [N-]=C=S Chemical compound [N-]=C=S ZBKFYXZXZJPWNQ-UHFFFAOYSA-N 0.000 claims description 18
- 150000001299 aldehydes Chemical class 0.000 claims description 18
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims description 18
- 125000005262 alkoxyamine group Chemical group 0.000 claims description 18
- ZRALSGWEFCBTJO-UHFFFAOYSA-N guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 claims description 18
- 229960001663 sulfanilamide Drugs 0.000 claims description 18
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 18
- 150000002081 enamines Chemical class 0.000 claims description 17
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 claims description 17
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M isothiocyanate Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 claims description 17
- 125000005936 piperidyl group Chemical group 0.000 claims description 17
- 150000003568 thioethers Chemical class 0.000 claims description 17
- JOYRKODLDBILNP-UHFFFAOYSA-N ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 claims description 16
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 15
- 125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 claims description 15
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims description 14
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 13
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 13
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 12
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims description 12
- 125000005916 2-methylpentyl group Chemical group 0.000 claims description 11
- 125000004076 pyridyl group Chemical group 0.000 claims description 11
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims description 11
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 9
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 9
- 239000003981 vehicle Substances 0.000 claims description 9
- 206010012601 Diabetes mellitus Diseases 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 8
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 claims description 8
- 125000005917 3-methylpentyl group Chemical group 0.000 claims description 7
- 125000004122 cyclic group Chemical group 0.000 claims description 7
- 125000003566 oxetanyl group Chemical group 0.000 claims description 7
- 150000001408 amides Chemical class 0.000 claims description 6
- 125000001072 heteroaryl group Chemical group 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 208000001145 Metabolic Syndrome Diseases 0.000 claims description 5
- 125000002541 furyl group Chemical group 0.000 claims description 5
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 5
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 5
- XYFCBTPGUUZFHI-UHFFFAOYSA-N phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 claims description 5
- 229910000073 phosphorus hydride Inorganic materials 0.000 claims description 5
- 125000001544 thienyl group Chemical group 0.000 claims description 5
- 125000003764 2,4-dimethylpentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 4
- 241000229754 Iva xanthiifolia Species 0.000 claims description 4
- 108010087301 Mitogen-Activated Protein Kinase 8 Proteins 0.000 claims description 4
- 108010087313 Mitogen-Activated Protein Kinase 9 Proteins 0.000 claims description 4
- 150000001412 amines Chemical class 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 claims description 4
- 239000000546 pharmaceutic aid Substances 0.000 claims description 4
- 125000005879 dioxolanyl group Chemical group 0.000 claims description 3
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims description 3
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 3
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 3
- 238000000338 in vitro Methods 0.000 claims description 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 18
- XHTJLMYQJHCUPE-UHFFFAOYSA-L dioxido-oxo-phosphanyl-$l^{5}-phosphane Chemical compound [O-]P([O-])(P)=O XHTJLMYQJHCUPE-UHFFFAOYSA-L 0.000 claims 15
- XLJMAIOERFSOGZ-UHFFFAOYSA-M cyanate Chemical compound [O-]C#N XLJMAIOERFSOGZ-UHFFFAOYSA-M 0.000 claims 14
- 125000004043 oxo group Chemical group O=* 0.000 claims 14
- 241001024304 Mino Species 0.000 claims 2
- SECMDRYLMRTEHH-GJZGRUSLSA-N ethyl (2S)-2-[[5-cyano-2-[[(2S)-1-ethoxy-3-methyl-1-oxobutan-2-yl]amino]pyrimidin-4-yl]amino]-3-methylbutanoate Chemical compound CCOC(=O)[C@H](C(C)C)NC1=NC=C(C#N)C(N[C@@H](C(C)C)C(=O)OCC)=N1 SECMDRYLMRTEHH-GJZGRUSLSA-N 0.000 claims 1
- VPPLAEMYMBLESZ-GJZGRUSLSA-N methyl (2S)-2-[[5-cyano-2-[[(2S)-1-methoxy-4-methyl-1-oxopentan-2-yl]amino]pyrimidin-4-yl]amino]-4-methylpentanoate Chemical compound COC(=O)[C@H](CC(C)C)NC1=NC=C(C#N)C(N[C@@H](CC(C)C)C(=O)OC)=N1 VPPLAEMYMBLESZ-GJZGRUSLSA-N 0.000 claims 1
- QDXGKRWDQCEABB-UHFFFAOYSA-N pyrimidine-5-carboxamide Chemical compound NC(=O)C1=CN=CN=C1 QDXGKRWDQCEABB-UHFFFAOYSA-N 0.000 abstract description 20
- XVIAPHVAGFEFFN-UHFFFAOYSA-N pyrimidine-5-carbonitrile Chemical compound N#CC1=CN=CN=C1 XVIAPHVAGFEFFN-UHFFFAOYSA-N 0.000 abstract description 11
- 206010008609 Cholangitis sclerosing Diseases 0.000 abstract description 6
- 239000003112 inhibitor Substances 0.000 abstract description 6
- 201000000742 primary sclerosing cholangitis Diseases 0.000 abstract description 5
- 206010073071 Hepatocellular carcinoma Diseases 0.000 abstract description 4
- 231100000844 hepatocellular carcinoma Toxicity 0.000 abstract description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N acetic acid ethyl ester Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 271
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 143
- 239000000243 solution Substances 0.000 description 130
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N DMSO-d6 Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 116
- 239000007787 solid Substances 0.000 description 111
- 238000005160 1H NMR spectroscopy Methods 0.000 description 106
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 104
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 98
- YMWUJEATGCHHMB-UHFFFAOYSA-N methylene dichloride Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 93
- 238000006243 chemical reaction Methods 0.000 description 91
- 239000011541 reaction mixture Substances 0.000 description 80
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 79
- KFZMGEQAYNKOFK-UHFFFAOYSA-N iso-propanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 78
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 75
- UIIMBOGNXHQVGW-UHFFFAOYSA-M NaHCO3 Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 71
- SECXISVLQFMRJM-UHFFFAOYSA-N NMP Substances CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 61
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 60
- SJRJJKPEHAURKC-UHFFFAOYSA-N n-methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 58
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 57
- RTZKZFJDLAIYFH-UHFFFAOYSA-N diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 56
- 238000003756 stirring Methods 0.000 description 53
- 239000002904 solvent Substances 0.000 description 50
- 239000000047 product Substances 0.000 description 49
- 239000008079 hexane Substances 0.000 description 42
- ZMANZCXQSJIPKH-UHFFFAOYSA-N N,N-Diethylethanamine Substances CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 41
- 239000010410 layer Substances 0.000 description 40
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 40
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 40
- LWIHDJKSTIGBAC-UHFFFAOYSA-K Tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 38
- 230000002829 reduced Effects 0.000 description 38
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 33
- CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 33
- 239000003960 organic solvent Substances 0.000 description 33
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 33
- 235000017557 sodium bicarbonate Nutrition 0.000 description 33
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 33
- AFABGHUZZDYHJO-UHFFFAOYSA-N 2-Methylpentane Chemical class CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 description 32
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 32
- 238000010898 silica gel chromatography Methods 0.000 description 32
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 32
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 30
- 239000003921 oil Substances 0.000 description 30
- 239000012044 organic layer Substances 0.000 description 30
- WEVYAHXRMPXWCK-UHFFFAOYSA-N acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 28
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 28
- 239000012267 brine Substances 0.000 description 27
- 239000000706 filtrate Substances 0.000 description 27
- 238000007792 addition Methods 0.000 description 26
- HEDRZPFGACZZDS-UHFFFAOYSA-N chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 26
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 26
- FJDQFPXHSGXQBY-UHFFFAOYSA-L Caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 24
- JNWBBCNCSMBKNE-UHFFFAOYSA-N HATU Chemical compound F[P-](F)(F)(F)(F)F.C1=CN=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 JNWBBCNCSMBKNE-UHFFFAOYSA-N 0.000 description 24
- 239000000463 material Substances 0.000 description 24
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 24
- LRHPLDYGYMQRHN-UHFFFAOYSA-N n-butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 24
- PMZURENOXWZQFD-UHFFFAOYSA-L na2so4 Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 24
- 229910052938 sodium sulfate Inorganic materials 0.000 description 24
- 235000011152 sodium sulphate Nutrition 0.000 description 24
- IIHQNAXFIODVDU-UHFFFAOYSA-N pyrimidine-2-carbonitrile Chemical compound N#CC1=NC=CC=N1 IIHQNAXFIODVDU-UHFFFAOYSA-N 0.000 description 22
- 239000000725 suspension Substances 0.000 description 22
- KWYUFKZDYYNOTN-UHFFFAOYSA-M potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 21
- 239000000741 silica gel Substances 0.000 description 21
- 229910002027 silica gel Inorganic materials 0.000 description 21
- VLKZOEOYAKHREP-UHFFFAOYSA-N hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 20
- 239000001184 potassium carbonate Substances 0.000 description 20
- 229910000027 potassium carbonate Inorganic materials 0.000 description 20
- 239000001187 sodium carbonate Substances 0.000 description 20
- 229910000029 sodium carbonate Inorganic materials 0.000 description 20
- 235000017550 sodium carbonate Nutrition 0.000 description 20
- 102000001253 Protein Kinases Human genes 0.000 description 19
- 229910000160 potassium phosphate Inorganic materials 0.000 description 19
- 238000000746 purification Methods 0.000 description 19
- 235000019798 tripotassium phosphate Nutrition 0.000 description 19
- NHQDETIJWKXCTC-UHFFFAOYSA-N Meta-Chloroperoxybenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 16
- MHAJPDPJQMAIIY-UHFFFAOYSA-N hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 16
- CSNNHWWHGAXBCP-UHFFFAOYSA-L mgso4 Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 16
- SSUJUUNLZQVZMO-UHFFFAOYSA-N 1,2,3,4,8,9,10,10a-octahydropyrimido[1,2-a]azepine Chemical compound C1CCC=CN2CCCNC21 SSUJUUNLZQVZMO-UHFFFAOYSA-N 0.000 description 15
- 108091000081 Phosphotransferases Proteins 0.000 description 15
- 230000015572 biosynthetic process Effects 0.000 description 15
- 239000012043 crude product Substances 0.000 description 15
- 229910052757 nitrogen Inorganic materials 0.000 description 15
- 239000003208 petroleum Substances 0.000 description 15
- MISVBCMQSJUHMH-UHFFFAOYSA-N pyrimidine-4,6-diamine Chemical class NC1=CC(N)=NC=N1 MISVBCMQSJUHMH-UHFFFAOYSA-N 0.000 description 15
- 238000003786 synthesis reaction Methods 0.000 description 15
- NLXLAEXVIDQMFP-UHFFFAOYSA-N ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 14
- 230000002194 synthesizing Effects 0.000 description 14
- YAAWASYJIRZXSZ-UHFFFAOYSA-N 2,4-Diaminopyrimidine Chemical compound NC1=CC=NC(N)=N1 YAAWASYJIRZXSZ-UHFFFAOYSA-N 0.000 description 13
- 235000019270 ammonium chloride Nutrition 0.000 description 13
- 230000037396 body weight Effects 0.000 description 13
- 238000001914 filtration Methods 0.000 description 13
- 239000011734 sodium Substances 0.000 description 13
- 229910052708 sodium Inorganic materials 0.000 description 13
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 12
- 230000001590 oxidative Effects 0.000 description 12
- 239000003826 tablet Substances 0.000 description 12
- 102000019145 JUN kinase activity proteins Human genes 0.000 description 11
- 108040008094 JUN kinase activity proteins Proteins 0.000 description 11
- 125000004429 atoms Chemical group 0.000 description 11
- 239000012299 nitrogen atmosphere Substances 0.000 description 11
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 11
- 229910052799 carbon Inorganic materials 0.000 description 10
- 238000001035 drying Methods 0.000 description 10
- 229910052739 hydrogen Inorganic materials 0.000 description 10
- 239000001257 hydrogen Substances 0.000 description 10
- 230000014759 maintenance of location Effects 0.000 description 10
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 10
- 239000000651 prodrug Substances 0.000 description 10
- 229940002612 prodrugs Drugs 0.000 description 10
- 150000003254 radicals Chemical class 0.000 description 10
- PVBLJPCMWKGTOH-UHFFFAOYSA-N 1-aminocyclohexan-1-ol Chemical compound NC1(O)CCCCC1 PVBLJPCMWKGTOH-UHFFFAOYSA-N 0.000 description 9
- HPXRVTGHNJAIIH-UHFFFAOYSA-N Cyclohexanol Chemical compound OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 description 9
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- KXDHJXZQYSOELW-UHFFFAOYSA-M carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 9
- 125000004432 carbon atoms Chemical group C* 0.000 description 9
- 239000006184 cosolvent Substances 0.000 description 9
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 9
- WMFOQBRAJBCJND-UHFFFAOYSA-M lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- BZKBCQXYZZXSCO-UHFFFAOYSA-N sodium hydride Chemical compound [H-].[Na+] BZKBCQXYZZXSCO-UHFFFAOYSA-N 0.000 description 9
- PAFZNILMFXTMIY-UHFFFAOYSA-N Cyclohexylamine Chemical compound NC1CCCCC1 PAFZNILMFXTMIY-UHFFFAOYSA-N 0.000 description 8
- DYHSDKLCOJIUFX-UHFFFAOYSA-N Di-tert-butyl dicarbonate Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 8
- 229940035295 Ting Drugs 0.000 description 8
- 239000002775 capsule Substances 0.000 description 8
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 8
- CURLTUGMZLYLDI-UHFFFAOYSA-N carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 8
- 235000011089 carbon dioxide Nutrition 0.000 description 8
- 239000003054 catalyst Substances 0.000 description 8
- 210000004027 cells Anatomy 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 238000004128 high performance liquid chromatography Methods 0.000 description 8
- 150000007530 organic bases Chemical class 0.000 description 8
- ZFCHNZDUMIOWFV-UHFFFAOYSA-N pyrimidine-2-carboxylic acid Chemical compound OC(=O)C1=NC=CC=N1 ZFCHNZDUMIOWFV-UHFFFAOYSA-N 0.000 description 8
- 125000001424 substituent group Chemical group 0.000 description 8
- XUSXTHMTOSFZII-UHFFFAOYSA-N 1-(aminomethyl)cyclohexan-1-ol Chemical compound NCC1(O)CCCCC1 XUSXTHMTOSFZII-UHFFFAOYSA-N 0.000 description 7
- FXHOOIRPVKKKFG-UHFFFAOYSA-N DMA Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 7
- OKBMCNHOEMXPTM-UHFFFAOYSA-M Potassium peroxymonosulfate Chemical compound [K+].OOS([O-])(=O)=O OKBMCNHOEMXPTM-UHFFFAOYSA-M 0.000 description 7
- 229920002472 Starch Polymers 0.000 description 7
- 239000002253 acid Substances 0.000 description 7
- 239000007822 coupling agent Substances 0.000 description 7
- 125000002883 imidazolyl group Chemical group 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- QDHHCQZDFGDHMP-UHFFFAOYSA-N monochloramine Chemical compound ClN QDHHCQZDFGDHMP-UHFFFAOYSA-N 0.000 description 7
- 230000037361 pathway Effects 0.000 description 7
- 150000002978 peroxides Chemical class 0.000 description 7
- 239000012071 phase Substances 0.000 description 7
- 235000015320 potassium carbonate Nutrition 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 235000019698 starch Nutrition 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 125000004793 2,2,2-trifluoroethoxy group Chemical group FC(CO*)(F)F 0.000 description 6
- MQWCXKGKQLNYQG-UHFFFAOYSA-N 4-methylcyclohexan-1-ol Chemical compound CC1CCC(O)CC1 MQWCXKGKQLNYQG-UHFFFAOYSA-N 0.000 description 6
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 6
- 206010025135 Lupus erythematosus Diseases 0.000 description 6
- WFDIJRYMOXRFFG-UHFFFAOYSA-N acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
- VHUUQVKOLVNVRT-UHFFFAOYSA-N ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 6
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 6
- 239000000460 chlorine Substances 0.000 description 6
- 230000002354 daily Effects 0.000 description 6
- IPZJQDSFZGZEOY-UHFFFAOYSA-N dimethylmethylene Chemical compound C[C]C IPZJQDSFZGZEOY-UHFFFAOYSA-N 0.000 description 6
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 6
- 230000000155 isotopic Effects 0.000 description 6
- 239000007800 oxidant agent Substances 0.000 description 6
- NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 description 6
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 description 6
- 239000002244 precipitate Substances 0.000 description 6
- WQDUMFSSJAZKTM-UHFFFAOYSA-N sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 6
- 239000008107 starch Substances 0.000 description 6
- 101700067048 CDC13 Proteins 0.000 description 5
- 102000038027 MAP kinase family Human genes 0.000 description 5
- 108091007472 MAP kinase family Proteins 0.000 description 5
- XKJCHHZQLQNZHY-UHFFFAOYSA-N Phthalimide Chemical compound C1=CC=C2C(=O)NC(=O)C2=C1 XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 5
- 235000011114 ammonium hydroxide Nutrition 0.000 description 5
- 239000012298 atmosphere Substances 0.000 description 5
- 239000001913 cellulose Substances 0.000 description 5
- 238000001816 cooling Methods 0.000 description 5
- 230000000875 corresponding Effects 0.000 description 5
- 125000006312 cyclopentyl amino group Chemical group [H]N(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 5
- 239000003085 diluting agent Substances 0.000 description 5
- 238000001704 evaporation Methods 0.000 description 5
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 5
- 125000005842 heteroatoms Chemical group 0.000 description 5
- IOQPZZOEVPZRBK-UHFFFAOYSA-N octan-1-amine Chemical compound CCCCCCCCN IOQPZZOEVPZRBK-UHFFFAOYSA-N 0.000 description 5
- 239000012074 organic phase Substances 0.000 description 5
- 230000003647 oxidation Effects 0.000 description 5
- 238000007254 oxidation reaction Methods 0.000 description 5
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- YOQDYZUWIQVZSF-UHFFFAOYSA-N sodium borohydride Substances [BH4-].[Na+] YOQDYZUWIQVZSF-UHFFFAOYSA-N 0.000 description 5
- 229910000033 sodium borohydride Inorganic materials 0.000 description 5
- ODGROJYWQXFQOZ-UHFFFAOYSA-N sodium;boron(1-) Chemical compound [B-].[Na+] ODGROJYWQXFQOZ-UHFFFAOYSA-N 0.000 description 5
- 239000007858 starting material Substances 0.000 description 5
- 150000003462 sulfoxides Chemical class 0.000 description 5
- 125000001425 triazolyl group Chemical group 0.000 description 5
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2R,3R,4S,5R,6S)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2S,3R,4S,5R,6R)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2R,3R,4S,5R,6R)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 4
- KZONVVMANSSIRZ-UHFFFAOYSA-N CSC1=NC(=NC=C1)C(=O)N Chemical compound CSC1=NC(=NC=C1)C(=O)N KZONVVMANSSIRZ-UHFFFAOYSA-N 0.000 description 4
- FBPFZTCFMRRESA-KAZBKCHUSA-N D-Mannitol Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KAZBKCHUSA-N 0.000 description 4
- BJHIKXHVCXFQLS-UYFOZJQFSA-N Fructose Natural products OC[C@@H](O)[C@@H](O)[C@H](O)C(=O)CO BJHIKXHVCXFQLS-UYFOZJQFSA-N 0.000 description 4
- 241000282414 Homo sapiens Species 0.000 description 4
- 206010022114 Injury Diseases 0.000 description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 4
- BZLVMXJERCGZMT-UHFFFAOYSA-N MeOtBu Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 4
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-Bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 4
- CTSLXHKWHWQRSH-UHFFFAOYSA-N Oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 4
- 108060006633 Protein Kinases Proteins 0.000 description 4
- QIQXTHQIDYTFRH-UHFFFAOYSA-N Stearic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-K [O-]P([O-])([O-])=O Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 4
- UQYZFNUUOSSNKT-UHFFFAOYSA-N [benzotriazol-1-yloxy(dimethylamino)methylidene]-dimethylazanium;hexafluorophosphate Chemical compound F[P-](F)(F)(F)(F)F.C1=CC=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 UQYZFNUUOSSNKT-UHFFFAOYSA-N 0.000 description 4
- 125000003710 aryl alkyl group Chemical group 0.000 description 4
- 235000020127 ayran Nutrition 0.000 description 4
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 4
- 239000011230 binding agent Substances 0.000 description 4
- 239000012455 biphasic mixture Substances 0.000 description 4
- 230000005587 bubbling Effects 0.000 description 4
- 235000010980 cellulose Nutrition 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- 239000012230 colorless oil Substances 0.000 description 4
- 125000006311 cyclobutyl amino group Chemical group [H]N(*)C1([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 4
- 125000000532 dioxanyl group Chemical group 0.000 description 4
- UFHFLCQGNIYNRP-JMRXTUGHSA-N ditritium Chemical compound [3H][3H] UFHFLCQGNIYNRP-JMRXTUGHSA-N 0.000 description 4
- FFLYUXVZEPLMCL-UHFFFAOYSA-N ethylchloranuidyl formate Chemical compound CC[Cl-]OC=O FFLYUXVZEPLMCL-UHFFFAOYSA-N 0.000 description 4
- 239000000314 lubricant Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 4
- 235000019341 magnesium sulphate Nutrition 0.000 description 4
- 239000000594 mannitol Substances 0.000 description 4
- 235000010355 mannitol Nutrition 0.000 description 4
- 229920000609 methyl cellulose Polymers 0.000 description 4
- 239000001923 methylcellulose Substances 0.000 description 4
- 235000010981 methylcellulose Nutrition 0.000 description 4
- 125000002950 monocyclic group Chemical group 0.000 description 4
- 125000002757 morpholinyl group Chemical group 0.000 description 4
- 239000010452 phosphate Substances 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 4
- 239000011591 potassium Substances 0.000 description 4
- 229910052700 potassium Inorganic materials 0.000 description 4
- 238000010791 quenching Methods 0.000 description 4
- 229920005989 resin Polymers 0.000 description 4
- 239000011347 resin Substances 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- YXFVVABEGXRONW-UHFFFAOYSA-N toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 4
- AQRLNPVMDITEJU-UHFFFAOYSA-N triethylsilane Chemical compound CC[SiH](CC)CC AQRLNPVMDITEJU-UHFFFAOYSA-N 0.000 description 4
- RRPYHFHHVVWXIX-UHFFFAOYSA-N 1-aminopentan-2-one Chemical compound CCCC(=O)CN RRPYHFHHVVWXIX-UHFFFAOYSA-N 0.000 description 3
- JFNCRLYQBHZFEE-UHFFFAOYSA-N 4-methylcyclohexen-1-amine Chemical compound CC1CCC(N)=CC1 JFNCRLYQBHZFEE-UHFFFAOYSA-N 0.000 description 3
- TVFDJXOCXUVLDH-UHFFFAOYSA-N Cesium Chemical compound [Cs] TVFDJXOCXUVLDH-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 3
- 102100005527 MAPK10 Human genes 0.000 description 3
- 239000004698 Polyethylene (PE) Substances 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 239000007868 Raney catalyst Substances 0.000 description 3
- 229910000564 Raney nickel Inorganic materials 0.000 description 3
- 210000003491 Skin Anatomy 0.000 description 3
- AKHNMLFCWUSKQB-UHFFFAOYSA-L Sodium thiosulphate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 3
- CZMRCDWAGMRECN-GDQSFJPYSA-N Sucrose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)[C@@]1(CO)[C@H](O)[C@@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-GDQSFJPYSA-N 0.000 description 3
- 235000010443 alginic acid Nutrition 0.000 description 3
- 229920000615 alginic acid Polymers 0.000 description 3
- 125000005907 alkyl ester group Chemical group 0.000 description 3
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 3
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 3
- 229910052792 caesium Inorganic materials 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 229910052801 chlorine Inorganic materials 0.000 description 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 230000001808 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- WZCRDVTWUYLPTR-UHFFFAOYSA-N cyclohept-2-en-1-one Chemical compound O=C1CCCCC=C1 WZCRDVTWUYLPTR-UHFFFAOYSA-N 0.000 description 3
- YZCKVEUIGOORGS-OUBTZVSYSA-N deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 239000002158 endotoxin Substances 0.000 description 3
- KVXNKFYSHAUJIA-UHFFFAOYSA-M ethoxyethane;acetate Chemical compound CC([O-])=O.CCOCC KVXNKFYSHAUJIA-UHFFFAOYSA-M 0.000 description 3
- BDAGIHXWWSANSR-UHFFFAOYSA-N formic acid Chemical compound OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 125000002632 imidazolidinyl group Chemical group 0.000 description 3
- 239000012535 impurity Substances 0.000 description 3
- 125000001041 indolyl group Chemical group 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 3
- 239000011777 magnesium Substances 0.000 description 3
- 229910052749 magnesium Inorganic materials 0.000 description 3
- 125000006216 methylsulfinyl group Chemical group [H]C([H])([H])S(*)=O 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 230000000051 modifying Effects 0.000 description 3
- PXHVJJICTQNCMI-UHFFFAOYSA-N nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 3
- 230000003000 nontoxic Effects 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 125000002971 oxazolyl group Chemical group 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
- 238000006366 phosphorylation reaction Methods 0.000 description 3
- 230000000865 phosphorylative Effects 0.000 description 3
- 125000004193 piperazinyl group Chemical group 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000002953 preparative HPLC Methods 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 125000003373 pyrazinyl group Chemical group 0.000 description 3
- 125000003226 pyrazolyl group Chemical group 0.000 description 3
- 125000002098 pyridazinyl group Chemical group 0.000 description 3
- IIVUJUOJERNGQX-UHFFFAOYSA-N pyrimidine-5-carboxylic acid Chemical compound OC(=O)C1=CN=CN=C1 IIVUJUOJERNGQX-UHFFFAOYSA-N 0.000 description 3
- 125000000714 pyrimidinyl group Chemical group 0.000 description 3
- 125000000168 pyrrolyl group Chemical group 0.000 description 3
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 3
- 235000019345 sodium thiosulphate Nutrition 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- 125000003831 tetrazolyl group Chemical group 0.000 description 3
- 125000000335 thiazolyl group Chemical group 0.000 description 3
- 239000001993 wax Substances 0.000 description 3
- HCHKCACWOHOZIP-UHFFFAOYSA-N zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 3
- 239000011701 zinc Substances 0.000 description 3
- 229910052725 zinc Inorganic materials 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- QWIRGHYGINHLFE-UXHICEINSA-N (1S,3R)-3-(dibenzylamino)cyclohexan-1-ol Chemical compound C1[C@@H](O)CCC[C@H]1N(CC=1C=CC=CC=1)CC1=CC=CC=C1 QWIRGHYGINHLFE-UXHICEINSA-N 0.000 description 2
- NIQIPYGXPZUDDP-RITPCOANSA-N (1S,3R)-3-aminocyclohexan-1-ol Chemical compound N[C@@H]1CCC[C@H](O)C1 NIQIPYGXPZUDDP-RITPCOANSA-N 0.000 description 2
- NINIDFKCEFEMDL-AKLPVKDBSA-N (35)S Chemical compound [35S] NINIDFKCEFEMDL-AKLPVKDBSA-N 0.000 description 2
- ZKYNWDXZHPFGMM-UHFFFAOYSA-N 1-(dibenzylamino)cyclohexan-1-ol Chemical compound C=1C=CC=CC=1CN(CC=1C=CC=CC=1)C1(O)CCCCC1 ZKYNWDXZHPFGMM-UHFFFAOYSA-N 0.000 description 2
- VYDQUABHDFWIIX-UHFFFAOYSA-N 2,2-difluoro-2-fluorosulfonylacetic acid Chemical compound OC(=O)C(F)(F)S(F)(=O)=O VYDQUABHDFWIIX-UHFFFAOYSA-N 0.000 description 2
- OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-Lutidine Chemical compound CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 2
- FBLDVWHNOYBREN-UHFFFAOYSA-N 2-(3-hydroxycyclohexyl)isoindole-1,3-dione Chemical compound C1C(O)CCCC1N1C(=O)C2=CC=CC=C2C1=O FBLDVWHNOYBREN-UHFFFAOYSA-N 0.000 description 2
- KEVABZQAQGBKCA-UHFFFAOYSA-N 2-[tert-butyl(dimethyl)silyl]oxy-2H-pyran-5-one Chemical compound CC(C)(C)[Si](C)(C)OC1OCC(=O)C=C1 KEVABZQAQGBKCA-UHFFFAOYSA-N 0.000 description 2
- YYRYKNXDWXDXSN-UHFFFAOYSA-N 2H-pyran-5-one Chemical compound O=C1COCC=C1 YYRYKNXDWXDXSN-UHFFFAOYSA-N 0.000 description 2
- GXQWZLUWOXOEHQ-UHFFFAOYSA-N 3-aminocycloheptan-1-ol Chemical class NC1CCCCC(O)C1 GXQWZLUWOXOEHQ-UHFFFAOYSA-N 0.000 description 2
- FQAWBGAIOYWONH-UHFFFAOYSA-N 3-chloroperoxybenzoic acid Chemical compound OC(=O)C1=CC=CC(OOCl)=C1 FQAWBGAIOYWONH-UHFFFAOYSA-N 0.000 description 2
- PRVXZIQLVKRULX-UHFFFAOYSA-N 4-(3-methylbutylamino)-2-[3-(2-methylpiperidin-1-yl)propylamino]pyrimidine-5-carbonitrile Chemical compound C1=C(C#N)C(NCCC(C)C)=NC(NCCCN2C(CCCC2)C)=N1 PRVXZIQLVKRULX-UHFFFAOYSA-N 0.000 description 2
- GBKXVXDNYFHIKP-UHFFFAOYSA-N 4-(cycloheptylamino)-2-[3-(2-methylpiperidin-1-yl)propylamino]pyrimidine-5-carbonitrile Chemical compound CC1CCCCN1CCCNC1=NC=C(C#N)C(NC2CCCCCC2)=N1 GBKXVXDNYFHIKP-UHFFFAOYSA-N 0.000 description 2
- OBRZLFUDLHNMRP-UHFFFAOYSA-N 4-[(4-methylcyclohexyl)amino]-2-[3-(2-methylpiperidin-1-yl)propylamino]pyrimidine-5-carbonitrile Chemical compound C1CC(C)CCC1NC1=NC(NCCCN2C(CCCC2)C)=NC=C1C#N OBRZLFUDLHNMRP-UHFFFAOYSA-N 0.000 description 2
- 208000002353 Alcoholic Hepatitis Diseases 0.000 description 2
- HUMNYLRZRPPJDN-UHFFFAOYSA-N Benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 2
- 210000004556 Brain Anatomy 0.000 description 2
- PFPCYIHYOPAJPI-UHFFFAOYSA-N C(=O)(O)C1=NC=CC(=N1)SC Chemical compound C(=O)(O)C1=NC=CC(=N1)SC PFPCYIHYOPAJPI-UHFFFAOYSA-N 0.000 description 2
- 229960004424 Carbon Dioxide Drugs 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate dianion Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- JHIVVAPYMSGYDF-UHFFFAOYSA-N Cyclohexanone Chemical compound O=C1CCCCC1 JHIVVAPYMSGYDF-UHFFFAOYSA-N 0.000 description 2
- NKLCNNUWBJBICK-UHFFFAOYSA-N Dess–Martin periodinane Chemical compound C1=CC=C2I(OC(=O)C)(OC(C)=O)(OC(C)=O)OC(=O)C2=C1 NKLCNNUWBJBICK-UHFFFAOYSA-N 0.000 description 2
- FAMRKDQNMBBFBR-BQYQJAHWSA-N Diethyl azodicarboxylate Chemical compound CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 description 2
- HPNMFZURTQLUMO-UHFFFAOYSA-N Diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 2
- HVTICUPFWKNHNG-UHFFFAOYSA-N Ethyl iodide Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 2
- 210000003414 Extremities Anatomy 0.000 description 2
- 208000004930 Fatty Liver Diseases 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- 206010019708 Hepatic steatosis Diseases 0.000 description 2
- 206010019728 Hepatitis alcoholic Diseases 0.000 description 2
- 206010022489 Insulin resistance Diseases 0.000 description 2
- 102000000589 Interleukin-1 Human genes 0.000 description 2
- 108010002352 Interleukin-1 Proteins 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 101710009221 LD Proteins 0.000 description 2
- 210000004072 Lung Anatomy 0.000 description 2
- 101700067074 MAPK Proteins 0.000 description 2
- 101710029927 MAPK10 Proteins 0.000 description 2
- 101710041325 MAPKAPK2 Proteins 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N Methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 108090000139 Mitogen-Activated Protein Kinase 14 Proteins 0.000 description 2
- 102000003841 Mitogen-Activated Protein Kinase 14 Human genes 0.000 description 2
- 210000004940 Nucleus Anatomy 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N P-Toluenesulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 210000000496 Pancreas Anatomy 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- 206010039073 Rheumatoid arthritis Diseases 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L Sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- MFRIHAYPQRLWNB-UHFFFAOYSA-N Sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 101710040537 TNF Proteins 0.000 description 2
- JRMUNVKIHCOMHV-UHFFFAOYSA-M Tetra-n-butylammonium bromide Chemical compound [Br-].CCCC[N+](CCCC)(CCCC)CCCC JRMUNVKIHCOMHV-UHFFFAOYSA-M 0.000 description 2
- 206010052779 Transplant rejections Diseases 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H Tricalcium phosphate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N Triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- 206010047461 Viral infection Diseases 0.000 description 2
- 208000001756 Virus Disease Diseases 0.000 description 2
- GTLDTDOJJJZVBW-UHFFFAOYSA-N Zinc cyanide Chemical compound [Zn+2].N#[C-].N#[C-] GTLDTDOJJJZVBW-UHFFFAOYSA-N 0.000 description 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 125000005426 adeninyl group Chemical group N1=C(N=C2N=CNC2=C1N)* 0.000 description 2
- 125000004414 alkyl thio group Chemical group 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- 239000000908 ammonium hydroxide Substances 0.000 description 2
- 229940045988 antineoplastic drugs Protein kinase inhibitors Drugs 0.000 description 2
- 125000005334 azaindolyl group Chemical group N1N=C(C2=CC=CC=C12)* 0.000 description 2
- 125000003725 azepanyl group Chemical group 0.000 description 2
- 125000002393 azetidinyl group Chemical group 0.000 description 2
- 125000004069 aziridinyl group Chemical group 0.000 description 2
- UHOVQNZJYSORNB-UHFFFAOYSA-N benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 2
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 description 2
- 125000005605 benzo group Chemical group 0.000 description 2
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 2
- 125000005874 benzothiadiazolyl group Chemical group 0.000 description 2
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 2
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 2
- HTZCNXWZYVXIMZ-UHFFFAOYSA-M benzyl(triethyl)azanium;chloride Chemical compound [Cl-].CC[N+](CC)(CC)CC1=CC=CC=C1 HTZCNXWZYVXIMZ-UHFFFAOYSA-M 0.000 description 2
- 230000002051 biphasic Effects 0.000 description 2
- FBXVOTBTGXARNA-UHFFFAOYSA-N bismuth;trinitrate;pentahydrate Chemical compound O.O.O.O.O.[Bi+3].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O FBXVOTBTGXARNA-UHFFFAOYSA-N 0.000 description 2
- 125000001246 bromo group Chemical group Br* 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Inorganic materials [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 230000003197 catalytic Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 239000007910 chewable tablet Substances 0.000 description 2
- 235000019868 cocoa butter Nutrition 0.000 description 2
- 229940110456 cocoa butter Drugs 0.000 description 2
- 235000008504 concentrate Nutrition 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 238000005100 correlation spectroscopy Methods 0.000 description 2
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 description 2
- VEJFFUKFKNSOBD-UHFFFAOYSA-N cyclohepten-1-ol Chemical compound OC1=CCCCCC1 VEJFFUKFKNSOBD-UHFFFAOYSA-N 0.000 description 2
- BCNGSDJWEGQJLT-UHFFFAOYSA-N cyclohepten-1-yl methyl carbonate Chemical compound COC(=O)OC1=CCCCCC1 BCNGSDJWEGQJLT-UHFFFAOYSA-N 0.000 description 2
- 201000004624 dermatitis Diseases 0.000 description 2
- 229910052805 deuterium Inorganic materials 0.000 description 2
- NPOMSUOUAZCMBL-UHFFFAOYSA-N dichloromethane;ethoxyethane Chemical compound ClCCl.CCOCC NPOMSUOUAZCMBL-UHFFFAOYSA-N 0.000 description 2
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 description 2
- 125000005883 dithianyl group Chemical group 0.000 description 2
- 229940079593 drugs Drugs 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- CHDFNIZLAAFFPX-UHFFFAOYSA-N ethoxyethane;oxolane Chemical compound CCOCC.C1CCOC1 CHDFNIZLAAFFPX-UHFFFAOYSA-N 0.000 description 2
- LJWKFGGDMBPPAZ-UHFFFAOYSA-N ethoxyethane;toluene Chemical compound CCOCC.CC1=CC=CC=C1 LJWKFGGDMBPPAZ-UHFFFAOYSA-N 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 239000012065 filter cake Substances 0.000 description 2
- 238000003818 flash chromatography Methods 0.000 description 2
- 125000001153 fluoro group Chemical group F* 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 125000004415 heterocyclylalkyl group Chemical group 0.000 description 2
- 238000002868 homogeneous time resolved fluorescence Methods 0.000 description 2
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine hydrate Chemical compound O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 2
- 150000003840 hydrochlorides Chemical class 0.000 description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
- 238000005984 hydrogenation reaction Methods 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000003834 intracellular Effects 0.000 description 2
- 230000000302 ischemic Effects 0.000 description 2
- 125000000842 isoxazolyl group Chemical group 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- HPQVWDOOUQVBTO-UHFFFAOYSA-N lithium aluminium hydride Substances [Li+].[Al-] HPQVWDOOUQVBTO-UHFFFAOYSA-N 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 230000002503 metabolic Effects 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N methanesulfonic acid Chemical class CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 239000003226 mitogen Substances 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 210000000056 organs Anatomy 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 2
- 125000000394 phosphonato group Chemical group [O-]P([O-])(*)=O 0.000 description 2
- 125000003367 polycyclic group Chemical group 0.000 description 2
- 235000019814 powdered cellulose Nutrition 0.000 description 2
- 229920003124 powdered cellulose Polymers 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 239000003909 protein kinase inhibitor Substances 0.000 description 2
- 201000004681 psoriasis Diseases 0.000 description 2
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 2
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- LJXQPZWIHJMPQQ-UHFFFAOYSA-N pyrimidin-2-amine Chemical compound NC1=NC=CC=N1 LJXQPZWIHJMPQQ-UHFFFAOYSA-N 0.000 description 2
- 125000006085 pyrrolopyridyl group Chemical group 0.000 description 2
- 230000000171 quenching Effects 0.000 description 2
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 2
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 2
- 230000002285 radioactive Effects 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 230000001105 regulatory Effects 0.000 description 2
- 101710024887 rl Proteins 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 150000003385 sodium Chemical group 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 101700045897 spk-1 Proteins 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- HBWLTSDYLCAHDX-UHFFFAOYSA-N tert-butyl N-(3-hydroxycycloheptyl)carbamate Chemical compound CC(C)(C)OC(=O)NC1CCCCC(O)C1 HBWLTSDYLCAHDX-UHFFFAOYSA-N 0.000 description 2
- NHGXDBSUJJNIRV-UHFFFAOYSA-M tetrabutylammonium chloride Chemical compound [Cl-].CCCC[N+](CCCC)(CCCC)CCCC NHGXDBSUJJNIRV-UHFFFAOYSA-M 0.000 description 2
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 2
- 125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 description 2
- 125000001984 thiazolidinyl group Chemical group 0.000 description 2
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 2
- 230000000699 topical Effects 0.000 description 2
- KPZSTOVTJYRDIO-UHFFFAOYSA-K trichlorocerium;heptahydrate Chemical compound O.O.O.O.O.O.O.Cl[Ce](Cl)Cl KPZSTOVTJYRDIO-UHFFFAOYSA-K 0.000 description 2
- YZCKVEUIGOORGS-NJFSPNSNSA-N tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 2
- 230000017613 viral reproduction Effects 0.000 description 2
- 239000003039 volatile agent Substances 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- NIQIPYGXPZUDDP-NTSWFWBYSA-N (1R,3S)-3-aminocyclohexan-1-ol Chemical compound N[C@H]1CCC[C@@H](O)C1 NIQIPYGXPZUDDP-NTSWFWBYSA-N 0.000 description 1
- QIEXLPYWSYJIPR-HHQFNNIRSA-N (1R,3S)-3-methoxycyclohexan-1-amine;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.CO[C@H]1CCC[C@@H](N)C1 QIEXLPYWSYJIPR-HHQFNNIRSA-N 0.000 description 1
- ZFSXKSSWYSZPGQ-FHAQVOQBSA-N (1S,2S)-2-aminocyclopentan-1-ol;hydrochloride Chemical compound Cl.N[C@H]1CCC[C@@H]1O ZFSXKSSWYSZPGQ-FHAQVOQBSA-N 0.000 description 1
- JIMSXLUBRRQALI-RYUDHWBXSA-N (1S,2S)-2-phenylmethoxycyclopentan-1-amine Chemical compound N[C@H]1CCC[C@@H]1OCC1=CC=CC=C1 JIMSXLUBRRQALI-RYUDHWBXSA-N 0.000 description 1
- BKZDTBUSMBWOHZ-RTWAWAEBSA-N (1S,3R)-3-(dibenzylamino)-1-methylcyclohexan-1-ol Chemical compound C1[C@@](C)(O)CCC[C@H]1N(CC=1C=CC=CC=1)CC1=CC=CC=C1 BKZDTBUSMBWOHZ-RTWAWAEBSA-N 0.000 description 1
- YWUIUNGMQOICND-UHFFFAOYSA-N (2Z)-2-diazo-1,1,1-trifluoroethane Chemical compound FC(F)(F)C=[N+]=[N-] YWUIUNGMQOICND-UHFFFAOYSA-N 0.000 description 1
- RKVXAQBTCYQPKE-LJQANCHMSA-N (3R)-3-(dibenzylamino)cyclohexan-1-one Chemical compound C1C(=O)CCC[C@H]1N(CC=1C=CC=CC=1)CC1=CC=CC=C1 RKVXAQBTCYQPKE-LJQANCHMSA-N 0.000 description 1
- QYJPFTAKVBDDPD-UHFFFAOYSA-N (4,4-difluorocyclohexyl)azanium;chloride Chemical compound Cl.NC1CCC(F)(F)CC1 QYJPFTAKVBDDPD-UHFFFAOYSA-N 0.000 description 1
- ASZLNPRMVCGYCI-UHFFFAOYSA-N 1$l^{2}-azolidine Chemical group C1CC[N]C1 ASZLNPRMVCGYCI-UHFFFAOYSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N 1,2-ethanediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- NQPJDJVGBDHCAD-UHFFFAOYSA-N 1,3-diazinan-2-one Chemical compound OC1=NCCCN1 NQPJDJVGBDHCAD-UHFFFAOYSA-N 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N 1,4-Butanediol, dimethanesulfonate Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- PZDLYKZGEPFNGJ-UHFFFAOYSA-N 1-(2,2,2-trifluoroethoxy)cyclohexan-1-amine Chemical compound FC(F)(F)COC1(N)CCCCC1 PZDLYKZGEPFNGJ-UHFFFAOYSA-N 0.000 description 1
- ZNNAOKGPJUTEPQ-UHFFFAOYSA-N 1-aminocycloheptan-1-ol Chemical compound NC1(O)CCCCCC1 ZNNAOKGPJUTEPQ-UHFFFAOYSA-N 0.000 description 1
- NWAGFVPLMRQOBA-UHFFFAOYSA-N 1-ethoxycyclohexan-1-amine;hydrochloride Chemical compound Cl.CCOC1(N)CCCCC1 NWAGFVPLMRQOBA-UHFFFAOYSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- DCTOHCCUXLBQMS-UHFFFAOYSA-N 1-undecene Chemical compound CCCCCCCCCC=C DCTOHCCUXLBQMS-UHFFFAOYSA-N 0.000 description 1
- 238000004293 19F NMR spectroscopy Methods 0.000 description 1
- XZNLIPDDBVEGQR-UHFFFAOYSA-N 2-(2-bromo-3-hydroxycyclohexyl)isoindole-1,3-dione Chemical compound BrC1C(O)CCCC1N1C(=O)C2=CC=CC=C2C1=O XZNLIPDDBVEGQR-UHFFFAOYSA-N 0.000 description 1
- OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 1
- MKHGVMIXRPGHOO-UHFFFAOYSA-N 2-(benzenesulfonyl)-3-phenyloxaziridine Chemical compound C=1C=CC=CC=1S(=O)(=O)N1OC1C1=CC=CC=C1 MKHGVMIXRPGHOO-UHFFFAOYSA-N 0.000 description 1
- LCGFVWKNXLRFIF-UHFFFAOYSA-N 2-Aminotetralin Chemical compound C1=CC=C2CC(N)CCC2=C1 LCGFVWKNXLRFIF-UHFFFAOYSA-N 0.000 description 1
- VUKAUDKDFVSVFT-UHFFFAOYSA-N 2-[6-[4,5-bis(2-hydroxypropoxy)-2-(2-hydroxypropoxymethyl)-6-methoxyoxan-3-yl]oxy-4,5-dimethoxy-2-(methoxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)-5-methoxyoxane-3,4-diol Chemical compound COC1C(OC)C(OC2C(C(O)C(OC)C(CO)O2)O)C(COC)OC1OC1C(COCC(C)O)OC(OC)C(OCC(C)O)C1OCC(C)O VUKAUDKDFVSVFT-UHFFFAOYSA-N 0.000 description 1
- KVRFDIMJUHHIFW-BDAKNGLRSA-N 2-chloro-4-[[(1R,3S)-3-hydroxycyclohexyl]amino]pyrimidine-5-carbonitrile Chemical compound C1[C@@H](O)CCC[C@H]1NC1=NC(Cl)=NC=C1C#N KVRFDIMJUHHIFW-BDAKNGLRSA-N 0.000 description 1
- HMTXWVRLPMCEGE-UHFFFAOYSA-N 2-cyclohex-2-en-1-ylisoindole-1,3-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCCC=C1 HMTXWVRLPMCEGE-UHFFFAOYSA-N 0.000 description 1
- BOABLGZTHBBHPW-UHFFFAOYSA-N 2-hydroxy-2H-pyran-5-one Chemical compound OC1OCC(=O)C=C1 BOABLGZTHBBHPW-UHFFFAOYSA-N 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- BUDQDWGNQVEFAC-UHFFFAOYSA-N 3,4-dihydro-2H-pyran Chemical compound C1COC=CC1 BUDQDWGNQVEFAC-UHFFFAOYSA-N 0.000 description 1
- ATRNJTJDHWBIRT-UHFFFAOYSA-N 3,6-dihydro-2H-pyran-2-ol Chemical compound OC1CC=CCO1 ATRNJTJDHWBIRT-UHFFFAOYSA-N 0.000 description 1
- AJKDUJRRWLQXHM-UHFFFAOYSA-N 3-bromocyclohexene Chemical compound BrC1CCCC=C1 AJKDUJRRWLQXHM-UHFFFAOYSA-N 0.000 description 1
- LULAYUGMBFYYEX-UHFFFAOYSA-N 3-chlorobenzoic acid Chemical compound OC(=O)C1=CC=CC(Cl)=C1 LULAYUGMBFYYEX-UHFFFAOYSA-N 0.000 description 1
- RWMDJQJCEISWRT-UHFFFAOYSA-N 4-(dibenzylamino)cyclohexan-1-ol Chemical compound C1CC(O)CCC1N(CC=1C=CC=CC=1)CC1=CC=CC=C1 RWMDJQJCEISWRT-UHFFFAOYSA-N 0.000 description 1
- DMPPZXYYBUMIHQ-SFYZADRCSA-N 4-[[(1R,3S)-3-hydroxycyclohexyl]amino]-2-methylsulfanylpyrimidine-5-carboxylic acid Chemical compound CSC1=NC=C(C(O)=O)C(N[C@H]2C[C@@H](O)CCC2)=N1 DMPPZXYYBUMIHQ-SFYZADRCSA-N 0.000 description 1
- FBMRJYCKHVQJSW-SFYZADRCSA-N 4-[[(1R,3S)-3-hydroxycyclohexyl]amino]-2-methylsulfonylpyrimidine-5-carboxamide Chemical compound CS(=O)(=O)C1=NC=C(C(N)=O)C(N[C@H]2C[C@@H](O)CCC2)=N1 FBMRJYCKHVQJSW-SFYZADRCSA-N 0.000 description 1
- ZOVITZYQFFMXJG-UHFFFAOYSA-N 6-hydroxypyran-2-one Chemical compound OC1=CC=CC(=O)O1 ZOVITZYQFFMXJG-UHFFFAOYSA-N 0.000 description 1
- 101700037792 AURKB Proteins 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 229940022659 Acetaminophen Drugs 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N Acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- XJKJWTWGDGIQRH-BFIDDRIFSA-N Alginic acid Chemical compound O1[C@@H](C(O)=O)[C@@H](OC)[C@H](O)[C@H](O)[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](C)[C@@H](O)[C@H]1O XJKJWTWGDGIQRH-BFIDDRIFSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- PZZYQPZGQPZBDN-UHFFFAOYSA-N Aluminium silicate Chemical compound O=[Al]O[Si](=O)O[Al]=O PZZYQPZGQPZBDN-UHFFFAOYSA-N 0.000 description 1
- 229940063655 Aluminum stearate Drugs 0.000 description 1
- 206010001897 Alzheimer's disease Diseases 0.000 description 1
- YPZUZOLGGMJZJO-LQKXBSAESA-N Ambroxan Chemical compound CC([C@@H]1CC2)(C)CCC[C@]1(C)[C@@H]1[C@]2(C)OCC1 YPZUZOLGGMJZJO-LQKXBSAESA-N 0.000 description 1
- 206010002556 Ankylosing spondylitis Diseases 0.000 description 1
- 206010059512 Apoptosis Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 208000006673 Asthma Diseases 0.000 description 1
- 206010060945 Bacterial infection Diseases 0.000 description 1
- 102000024678 Bcl-2 family Human genes 0.000 description 1
- 108091011726 Bcl-2 family Proteins 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N Benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N Benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- KCXMKQUNVWSEMD-UHFFFAOYSA-N Benzyl chloride Chemical compound ClCC1=CC=CC=C1 KCXMKQUNVWSEMD-UHFFFAOYSA-N 0.000 description 1
- 210000004369 Blood Anatomy 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- JMSRBKPMLUGHCR-UHFFFAOYSA-N Bromohydrin Chemical compound BrC[C]1CO1 JMSRBKPMLUGHCR-UHFFFAOYSA-N 0.000 description 1
- 210000000621 Bronchi Anatomy 0.000 description 1
- 206010006451 Bronchitis Diseases 0.000 description 1
- HBWLTSDYLCAHDX-VHSXEESVSA-N CC(C)(C)OC(=O)N[C@H]1CCCC[C@@H](O)C1 Chemical compound CC(C)(C)OC(=O)N[C@H]1CCCC[C@@H](O)C1 HBWLTSDYLCAHDX-VHSXEESVSA-N 0.000 description 1
- 101700046984 CDK20 Proteins 0.000 description 1
- WWTIBSDXMJPIAV-UHFFFAOYSA-N COC(=O)C1(Cl)NC=CC(Cl)=N1 Chemical compound COC(=O)C1(Cl)NC=CC(Cl)=N1 WWTIBSDXMJPIAV-UHFFFAOYSA-N 0.000 description 1
- 229960005069 Calcium Drugs 0.000 description 1
- 229960003563 Calcium Carbonate Drugs 0.000 description 1
- 229960004256 Calcium Citrate Drugs 0.000 description 1
- FNAQSUUGMSOBHW-UHFFFAOYSA-H Calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L Calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 229910052684 Cerium Inorganic materials 0.000 description 1
- 210000003679 Cervix Uteri Anatomy 0.000 description 1
- FOCAUTSVDIKZOP-UHFFFAOYSA-N Chloroacetic acid Chemical compound OC(=O)CCl FOCAUTSVDIKZOP-UHFFFAOYSA-N 0.000 description 1
- VDANGULDQQJODZ-UHFFFAOYSA-N Chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
- 229960002023 Chloroprocaine Drugs 0.000 description 1
- 229960001231 Choline Drugs 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 206010063209 Chronic allograft nephropathy Diseases 0.000 description 1
- 241000207199 Citrus Species 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 210000001072 Colon Anatomy 0.000 description 1
- LSXDOTMGLUJQCM-UHFFFAOYSA-M Copper(I) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 206010011401 Crohn's disease Diseases 0.000 description 1
- 208000004703 Crush Injury Diseases 0.000 description 1
- 208000004921 Cutaneous Lupus Erythematosus Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- DEZRYPDIMOWBDS-UHFFFAOYSA-N DCM Dichloromethane Chemical compound ClCCl.ClCCl DEZRYPDIMOWBDS-UHFFFAOYSA-N 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N Diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 208000005679 Eczema Diseases 0.000 description 1
- 206010015037 Epilepsy Diseases 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 210000003238 Esophagus Anatomy 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 229940012017 Ethylenediamine Drugs 0.000 description 1
- 210000001508 Eye Anatomy 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- XPFVYQJUAUNWIW-UHFFFAOYSA-N Furfuryl alcohol Chemical compound OCC1=CC=CO1 XPFVYQJUAUNWIW-UHFFFAOYSA-N 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 210000001035 Gastrointestinal Tract Anatomy 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-N Gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 206010018651 Graft versus host disease Diseases 0.000 description 1
- 208000009329 Graft vs Host Disease Diseases 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 208000004551 Gunshot Wounds Diseases 0.000 description 1
- 210000003128 Head Anatomy 0.000 description 1
- 210000002216 Heart Anatomy 0.000 description 1
- 206010019668 Hepatic fibrosis Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 201000001971 Huntington's disease Diseases 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 102100002729 IRS1 Human genes 0.000 description 1
- 101700048020 IRS1 Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010021972 Inflammatory bowel disease Diseases 0.000 description 1
- 208000006897 Interstitial Lung Disease Diseases 0.000 description 1
- 229940044173 Iodine-125 Drugs 0.000 description 1
- 208000002551 Irritable Bowel Syndrome Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 210000003734 Kidney Anatomy 0.000 description 1
- 210000001865 Kupffer Cells Anatomy 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 229960004873 LEVOMENTHOL Drugs 0.000 description 1
- 210000000867 Larynx Anatomy 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 101710039093 MAP3K1 Proteins 0.000 description 1
- 102100016522 MAP3K1 Human genes 0.000 description 1
- 101700083887 MAPK1 Proteins 0.000 description 1
- 102100016823 MAPK1 Human genes 0.000 description 1
- 101700064507 MARK2 Proteins 0.000 description 1
- 102100000541 MARK2 Human genes 0.000 description 1
- 210000002540 Macrophages Anatomy 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N Meglumine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 229940041616 Menthol Drugs 0.000 description 1
- 230000036740 Metabolism Effects 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- TZIHFWKZFHZASV-UHFFFAOYSA-N Methyl formate Chemical compound COC=O TZIHFWKZFHZASV-UHFFFAOYSA-N 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N Methyl iodide Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 108010081246 Mitogen-Activated Protein Kinase 10 Proteins 0.000 description 1
- 238000006751 Mitsunobu reaction Methods 0.000 description 1
- 210000000214 Mouth Anatomy 0.000 description 1
- 206010028154 Multi-organ failure Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 208000010125 Myocardial Infarction Diseases 0.000 description 1
- QJITUZDKRABEGK-UHFFFAOYSA-N N'-propylmethanediimine;hydrochloride Chemical compound Cl.CCCN=C=N QJITUZDKRABEGK-UHFFFAOYSA-N 0.000 description 1
- 150000007945 N-acyl ureas Chemical class 0.000 description 1
- JHWLAKBUVOCSAP-UHFFFAOYSA-N NC1CCC(OC1)O Chemical compound NC1CCC(OC1)O JHWLAKBUVOCSAP-UHFFFAOYSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 210000003739 Neck Anatomy 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 210000001331 Nose Anatomy 0.000 description 1
- 108010089610 Nuclear Proteins Proteins 0.000 description 1
- 102000007999 Nuclear Proteins Human genes 0.000 description 1
- GUTVYQWBRYACQY-UHFFFAOYSA-M ON(C([O-])=O)C1CCCCCC1 Chemical compound ON(C([O-])=O)C1CCCCCC1 GUTVYQWBRYACQY-UHFFFAOYSA-M 0.000 description 1
- 239000012425 OXONE® Substances 0.000 description 1
- 206010053159 Organ failure Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 210000001672 Ovary Anatomy 0.000 description 1
- 241000283898 Ovis Species 0.000 description 1
- XAPRFLSJBSXESP-UHFFFAOYSA-N Oxycinchophen Chemical compound N=1C2=CC=CC=C2C(C(=O)O)=C(O)C=1C1=CC=CC=C1 XAPRFLSJBSXESP-UHFFFAOYSA-N 0.000 description 1
- YJVFFLUZDVXJQI-UHFFFAOYSA-L Palladium(II) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 206010061536 Parkinson's disease Diseases 0.000 description 1
- 210000003800 Pharynx Anatomy 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- CHKVPAROMQMJNQ-UHFFFAOYSA-M Potassium bisulfate Chemical compound [K+].OS([O-])(=O)=O CHKVPAROMQMJNQ-UHFFFAOYSA-M 0.000 description 1
- FYRHIOVKTDQVFC-UHFFFAOYSA-M Potassium phthalimide Chemical compound [K+].C1=CC=C2C(=O)[N-]C(=O)C2=C1 FYRHIOVKTDQVFC-UHFFFAOYSA-M 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N Procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 108010076669 Proline-Directed Protein Kinases Proteins 0.000 description 1
- 102000011732 Proline-Directed Protein Kinases Human genes 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N Propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 210000002307 Prostate Anatomy 0.000 description 1
- 102000009516 Protein-Serine-Threonine Kinases Human genes 0.000 description 1
- 108010009341 Protein-Serine-Threonine Kinases Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 210000000664 Rectum Anatomy 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-N Salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 1
- 208000010157 Sclerosing Cholangitis Diseases 0.000 description 1
- 210000002966 Serum Anatomy 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N Silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M Sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 210000000952 Spleen Anatomy 0.000 description 1
- 210000002784 Stomach Anatomy 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 206010042953 Systemic sclerosis Diseases 0.000 description 1
- DBGVGMSCBYYSLD-UHFFFAOYSA-N Tributyltin hydride Chemical compound CCCC[SnH](CCCC)CCCC DBGVGMSCBYYSLD-UHFFFAOYSA-N 0.000 description 1
- JBWKIWSBJXDJDT-UHFFFAOYSA-N Triphenylmethyl chloride Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(Cl)C1=CC=CC=C1 JBWKIWSBJXDJDT-UHFFFAOYSA-N 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K Trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- HWKQNAWCHQMZHK-UHFFFAOYSA-N Trolnitrate Chemical compound [O-][N+](=O)OCCN(CCO[N+]([O-])=O)CCO[N+]([O-])=O HWKQNAWCHQMZHK-UHFFFAOYSA-N 0.000 description 1
- 208000001072 Type 2 Diabetes Mellitus Diseases 0.000 description 1
- 210000003932 Urinary Bladder Anatomy 0.000 description 1
- JFLVVCGMJYMWML-WDSKDSINSA-N [(1R,2S)-2-aminocyclopentyl]methanol Chemical compound N[C@H]1CCC[C@H]1CO JFLVVCGMJYMWML-WDSKDSINSA-N 0.000 description 1
- AVFUHBJCUUTGCD-UHFFFAOYSA-M [Br-].[Mg+]C Chemical compound [Br-].[Mg+]C AVFUHBJCUUTGCD-UHFFFAOYSA-M 0.000 description 1
- 230000001594 aberrant Effects 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- ZCHPKWUIAASXPV-UHFFFAOYSA-N acetic acid;methanol Chemical compound OC.CC(O)=O ZCHPKWUIAASXPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute Effects 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminum Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 238000010640 amide synthesis reaction Methods 0.000 description 1
- 150000001414 amino alcohols Chemical class 0.000 description 1
- QGZKDVFQNNGYKY-OUBTZVSYSA-N ammonia-15N Chemical compound [15NH3] QGZKDVFQNNGYKY-OUBTZVSYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000002491 angiogenic Effects 0.000 description 1
- 238000002399 angioplasty Methods 0.000 description 1
- 125000005428 anthryl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C3C(*)=C([H])C([H])=C([H])C3=C([H])C2=C1[H] 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 235000015197 apple juice Nutrition 0.000 description 1
- 125000002102 aryl alkyloxo group Chemical group 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- 201000001320 atherosclerosis Diseases 0.000 description 1
- 125000005602 azabenzimidazolyl group Chemical group 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- 229940095076 benzaldehyde Drugs 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000004622 benzoxazinyl group Chemical group O1NC(=CC2=C1C=CC=C2)* 0.000 description 1
- PUJDIJCNWFYVJX-UHFFFAOYSA-N benzyl carbamate Chemical compound NC(=O)OCC1=CC=CC=C1 PUJDIJCNWFYVJX-UHFFFAOYSA-N 0.000 description 1
- 125000000440 benzylamino group Chemical group [H]N(*)C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- UWTDFICHZKXYAC-UHFFFAOYSA-N boron;oxolane Chemical compound [B].C1CCOC1 UWTDFICHZKXYAC-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- QJBRNNNJBVJKPK-UHFFFAOYSA-N but-1-en-3-yne Chemical group C=[C]C#C QJBRNNNJBVJKPK-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000001354 calcium citrate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- GWXLDORMOJMVQZ-UHFFFAOYSA-N cerium Chemical compound [Ce] GWXLDORMOJMVQZ-UHFFFAOYSA-N 0.000 description 1
- 108091006028 chimera Proteins 0.000 description 1
- SSBVJILJXCVPQD-UHFFFAOYSA-M chloride;heptahydrate Chemical compound O.O.O.O.O.O.O.[Cl-] SSBVJILJXCVPQD-UHFFFAOYSA-M 0.000 description 1
- 229940106681 chloroacetic acid Drugs 0.000 description 1
- CRBHXDCYXIISFC-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CC[O-] CRBHXDCYXIISFC-UHFFFAOYSA-N 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000010779 crude oil Substances 0.000 description 1
- 238000010192 crystallographic characterization Methods 0.000 description 1
- YSWRZALBDSJANW-UHFFFAOYSA-L cyanate;thiocyanate Chemical compound [O-]C#N.[S-]C#N YSWRZALBDSJANW-UHFFFAOYSA-L 0.000 description 1
- 125000006165 cyclic alkyl group Chemical group 0.000 description 1
- 125000004367 cycloalkylaryl group Chemical group 0.000 description 1
- 125000001162 cycloheptenyl group Chemical group C1(=CCCCCC1)* 0.000 description 1
- 125000003678 cyclohexadienyl group Chemical group C1(=CC=CCC1)* 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- AUELWJRRASQDKI-UHFFFAOYSA-N cyclohexyl carbamate Chemical compound NC(=O)OC1CCCCC1 AUELWJRRASQDKI-UHFFFAOYSA-N 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 201000003883 cystic fibrosis Diseases 0.000 description 1
- 238000005695 dehalogenation reaction Methods 0.000 description 1
- 230000003111 delayed Effects 0.000 description 1
- 231100000406 dermatitis Toxicity 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 229940043237 diethanolamine Drugs 0.000 description 1
- 125000005433 dihydrobenzodioxinyl group Chemical group O1C(COC2=C1C=CC=C2)* 0.000 description 1
- 125000000723 dihydrobenzofuranyl group Chemical group O1C(CC2=C1C=CC=C2)* 0.000 description 1
- 125000001070 dihydroindolyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000004925 dihydropyridyl group Chemical group N1(CC=CC=C1)* 0.000 description 1
- 125000000597 dioxinyl group Chemical group 0.000 description 1
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 1
- 238000007907 direct compression Methods 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 238000007908 dry granulation Methods 0.000 description 1
- 231100001003 eczema Toxicity 0.000 description 1
- 230000003028 elevating Effects 0.000 description 1
- 101710024775 erkB Proteins 0.000 description 1
- 101700038100 estB Proteins 0.000 description 1
- VRHAQNTWKSVEEC-UHFFFAOYSA-N ethyl 1,3-dioxoisoindole-2-carboxylate Chemical compound C1=CC=C2C(=O)N(C(=O)OCC)C(=O)C2=C1 VRHAQNTWKSVEEC-UHFFFAOYSA-N 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 125000006437 ethyl cyclopropyl group Chemical group 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 1
- 238000005755 formation reaction Methods 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 229920000591 gum Polymers 0.000 description 1
- 235000015220 hamburgers Nutrition 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 230000028974 hepatocyte apoptotic process Effects 0.000 description 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 1
- 125000005844 heterocyclyloxy group Chemical group 0.000 description 1
- LMYQAZODCDGPSE-UHFFFAOYSA-N hexa-1,2,3,4-tetraene Chemical group [CH2+][C]=C=C=C=C LMYQAZODCDGPSE-UHFFFAOYSA-N 0.000 description 1
- 125000001245 hexylamino group Chemical group [H]N([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- ZTUJDPKOHPKRMO-UHFFFAOYSA-N hydron;2,2,2-trifluoroethanamine;chloride Chemical compound Cl.NCC(F)(F)F ZTUJDPKOHPKRMO-UHFFFAOYSA-N 0.000 description 1
- 125000001867 hydroperoxy group Chemical group [*]OO[H] 0.000 description 1
- 239000001341 hydroxy propyl starch Substances 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxyl anion Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000013828 hydroxypropyl starch Nutrition 0.000 description 1
- 229940071676 hydroxypropylcellulose Drugs 0.000 description 1
- 239000012216 imaging agent Substances 0.000 description 1
- YAMHXTCMCPHKLN-UHFFFAOYSA-N imidazolidin-2-one Chemical compound O=C1NCCN1 YAMHXTCMCPHKLN-UHFFFAOYSA-N 0.000 description 1
- 125000002636 imidazolinyl group Chemical group 0.000 description 1
- 125000005945 imidazopyridyl group Chemical group 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 200000000018 inflammatory disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- FGKJLKRYENPLQH-UHFFFAOYSA-M isocaproate Chemical compound CC(C)CCC([O-])=O FGKJLKRYENPLQH-UHFFFAOYSA-M 0.000 description 1
- BYXYCUABYHCYLY-UHFFFAOYSA-N isoindole-1,3-dione;potassium Chemical compound [K].C1=CC=C2C(=O)NC(=O)C2=C1 BYXYCUABYHCYLY-UHFFFAOYSA-N 0.000 description 1
- 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- GWYFCOCPABKNJV-UHFFFAOYSA-M isovalerate Chemical compound CC(C)CC([O-])=O GWYFCOCPABKNJV-UHFFFAOYSA-M 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- OCZDCIYGECBNKL-UHFFFAOYSA-N lithium;alumanuide Chemical compound [Li+].[AlH4-] OCZDCIYGECBNKL-UHFFFAOYSA-N 0.000 description 1
- 238000011068 load Methods 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000035786 metabolism Effects 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M methanoate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- MAJTXTYGACTQGY-UHFFFAOYSA-N methylcyclobutane Chemical group [CH2+][C]1CCC1 MAJTXTYGACTQGY-UHFFFAOYSA-N 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N nicotinic acid Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 238000002414 normal-phase solid-phase extraction Methods 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000003287 optical Effects 0.000 description 1
- 235000015205 orange juice Nutrition 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000003204 osmotic Effects 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N p-acetaminophenol Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- PYWFAPLYHPJXPW-UHFFFAOYSA-M palladium(2+);prop-1-ene;chloride Chemical class [Pd+]Cl.[CH2-]C=C PYWFAPLYHPJXPW-UHFFFAOYSA-M 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000003182 parenteral nutrition solution Substances 0.000 description 1
- VZCFNJNTQPIJHV-UHFFFAOYSA-N penta-1,2-dien-4-yne Chemical group C=C=[C]C#[C-] VZCFNJNTQPIJHV-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- NPDODHDPVPPRDJ-UHFFFAOYSA-N permanganate Chemical compound [O-][Mn](=O)(=O)=O NPDODHDPVPPRDJ-UHFFFAOYSA-N 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229910000343 potassium bisulfate Inorganic materials 0.000 description 1
- HVAHYVDBVDILBL-UHFFFAOYSA-M potassium;oxidooxy hydrogen sulfate Chemical compound [K+].OS(=O)(=O)OO[O-] HVAHYVDBVDILBL-UHFFFAOYSA-M 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000002335 preservative Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 230000002062 proliferating Effects 0.000 description 1
- 230000002035 prolonged Effects 0.000 description 1
- 125000006308 propyl amino group Chemical group 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 230000026731 protein phosphorylation Effects 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 150000003217 pyrazoles Chemical class 0.000 description 1
- 125000002755 pyrazolinyl group Chemical group 0.000 description 1
- YKSDLYFRZAUBMW-UHFFFAOYSA-N pyrimidine-2-carboxamide;hydrochloride Chemical compound Cl.NC(=O)C1=NC=CC=N1 YKSDLYFRZAUBMW-UHFFFAOYSA-N 0.000 description 1
- IIVUJUOJERNGQX-UHFFFAOYSA-M pyrimidine-5-carboxylate Chemical compound [O-]C(=O)C1=CN=CN=C1 IIVUJUOJERNGQX-UHFFFAOYSA-M 0.000 description 1
- 125000001422 pyrrolinyl group Chemical group 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 200000000008 restenosis Diseases 0.000 description 1
- 239000000565 sealant Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 229960001407 sodium bicarbonate Drugs 0.000 description 1
- 229910001467 sodium calcium phosphate Inorganic materials 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 description 1
- 125000006296 sulfonyl amino group Chemical group [H]N(*)S(*)(=O)=O 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 238000004808 supercritical fluid chromatography Methods 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 201000010874 syndrome Diseases 0.000 description 1
- 201000009594 systemic scleroderma Diseases 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 238000003419 tautomerization reaction Methods 0.000 description 1
- CBZNOKAFOMSSLW-UHFFFAOYSA-N tert-butyl N-(3-hydroxy-4-methylcyclohexyl)carbamate Chemical compound CC1CCC(NC(=O)OC(C)(C)C)CC1O CBZNOKAFOMSSLW-UHFFFAOYSA-N 0.000 description 1
- GQWFMCBUKYHHSW-UHFFFAOYSA-N tert-butyl N-(3-oxocycloheptyl)carbamate Chemical compound CC(C)(C)OC(=O)NC1CCCCC(=O)C1 GQWFMCBUKYHHSW-UHFFFAOYSA-N 0.000 description 1
- HBWLTSDYLCAHDX-ZJUUUORDSA-N tert-butyl N-[(1R,3S)-3-hydroxycycloheptyl]carbamate Chemical compound CC(C)(C)OC(=O)N[C@@H]1CCCC[C@H](O)C1 HBWLTSDYLCAHDX-ZJUUUORDSA-N 0.000 description 1
- KZDYTPGCOWPXET-ZJUUUORDSA-N tert-butyl N-[(1R,3S)-3-methoxycyclohexyl]carbamate Chemical compound CO[C@H]1CCC[C@@H](NC(=O)OC(C)(C)C)C1 KZDYTPGCOWPXET-ZJUUUORDSA-N 0.000 description 1
- LBJSEPNOVVUVJA-UHFFFAOYSA-N tert-butyl N-[3-(hydroxymethyl)cyclohexyl]carbamate Chemical compound CC(C)(C)OC(=O)NC1CCCC(CO)C1 LBJSEPNOVVUVJA-UHFFFAOYSA-N 0.000 description 1
- DZLFLBLQUQXARW-UHFFFAOYSA-N tetrabutylammonium Chemical compound CCCC[N+](CCCC)(CCCC)CCCC DZLFLBLQUQXARW-UHFFFAOYSA-N 0.000 description 1
- ODGCEQLVLXJUCC-UHFFFAOYSA-O tetrafluoroboric acid Chemical compound [H+].F[B-](F)(F)F ODGCEQLVLXJUCC-UHFFFAOYSA-O 0.000 description 1
- 125000005944 tetrahydroimidazopyridyl group Chemical group 0.000 description 1
- 125000005888 tetrahydroindolyl group Chemical group 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000003507 tetrahydrothiofenyl group Chemical group 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000004927 thianaphthalenyl group Chemical group S1C(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000004305 thiazinyl group Chemical group S1NC(=CC=C1)* 0.000 description 1
- 125000002769 thiazolinyl group Chemical group 0.000 description 1
- 125000004001 thioalkyl group Chemical group 0.000 description 1
- 210000001519 tissues Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 102000003995 transcription factors Human genes 0.000 description 1
- 108090000464 transcription factors Proteins 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- PIILXFBHQILWPS-UHFFFAOYSA-N tributyltin Chemical compound CCCC[Sn](CCCC)CCCC PIILXFBHQILWPS-UHFFFAOYSA-N 0.000 description 1
- 235000013337 tricalcium citrate Nutrition 0.000 description 1
- VFJYIHQDILEQNR-UHFFFAOYSA-M trimethylsulfanium;iodide Chemical compound [I-].C[S+](C)C VFJYIHQDILEQNR-UHFFFAOYSA-M 0.000 description 1
- 239000011778 trisodium citrate Substances 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 201000006704 ulcerative colitis Diseases 0.000 description 1
- 125000004417 unsaturated alkyl group Chemical group 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- XTXRWKRVRITETP-UHFFFAOYSA-N vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000003612 virological Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/38—One sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Abstract
Provided are substituted diaminocarboxamide pyrimidine compounds, of general formula (I), and substituted diaminocarbonitrile pyrimidine compounds, of general formula (IB), where the variables are as defined in the specification. Examples of the compounds include 4-(isopropylamino)-2-((1R,4R)-4-(2,2,2-trifluoroethoxycyclohexylamino)pyrimidine-5-carboxamide and 2-((1R,4S)-4-ethoxycyclohexylamino)-4-((1S,3R)-3-hydroxycyclohexyl-amino)pyrimidine-5-carbonitrile. The compounds are JNK1/JNK2 inhibitors. The compounds may be useful in the treatment of liver fibrotic disorders such as non-alcoholic steatohepatitis, steatosis, cirrhosis, primary sclerosing cholangitis, primary biliary cirrhosis, hepatitis, hepatocellular carcinoma, or liver fibrosis coincident with chronic or repeated alcohol ingestion, with infection, with liver transplant, or with drug induced liver injury. ,2-trifluoroethoxycyclohexylamino)pyrimidine-5-carboxamide and 2-((1R,4S)-4-ethoxycyclohexylamino)-4-((1S,3R)-3-hydroxycyclohexyl-amino)pyrimidine-5-carbonitrile. The compounds are JNK1/JNK2 inhibitors. The compounds may be useful in the treatment of liver fibrotic disorders such as non-alcoholic steatohepatitis, steatosis, cirrhosis, primary sclerosing cholangitis, primary biliary cirrhosis, hepatitis, hepatocellular carcinoma, or liver fibrosis coincident with chronic or repeated alcohol ingestion, with infection, with liver transplant, or with drug induced liver injury.
Description
SUBSTITUTED DIAMINOCARBOXAMIDE AND DIAMINOCARBONITRILE
PYRIMIDINES, COMPOSITIONS F, AND METHODS OF
ENT THEREWITH
Provided herein are certain diaminocarboxamide and diaminocarbonitrile
pyrimidine compounds, compositions comprising an effective amount of such compounds,
and methods for treating or preventing liver f1brotic disorders or a condition treatable or
preventable by inhibition of a JNK pathway, comprising stering an ive
amount of such diaminocarboxamide and diaminocarbonitrile pyrimidine compounds to a
subject in need thereof.
OUND
The connection between abnormal protein phosphorylation and the cause or
consequence of diseases has been known for over 20 years. Accordingly, protein kinases
have become a very important group of drug targets. [See Cohen, Nature, 1:309-315
(2002), Gaestel et al. Carr.Med.Chem.14: 23 (2007); Grimminger et al. Nat. Rev.
Drag Disc. 9(12):956-970 (2010)]. Various protein kinase inhibitors have been used
clinically in the treatment of a wide variety of diseases, such as cancer and chronic
inflammatory diseases, including rheumatoid arthritis and psoriasis. [See Cohen, EW. J.
Biochem. 268:5001-5010 (2001); Protein Kinase Inhibitors for the ent of Disease:
The Promise and the Problems, Handbook ofExperimental Pharmacology, Springer Berlin
Heidelberg, 167 (2005)].
JNK is a tously expressed serine/threonine kinase belonging, er
with ERK (extracellular-regulated kinase) and p38, to the family of mitogen-activated
protein s (MAPKs). [Kyriakis JM, Sci. STKE e1 (2000); Whitmarsh AJ, et al.
Sci. STKE (1):pe1 (1999); Schramek H, News Physio]. Sci.17:62-7 (2002); Ichijo H,
Oncogene 18(45):6087-93 (1999)]. MAPKs are important mediators of signal
transduction from the cell surface to the nucleus, using phosphorylation cascades to
te a coordinated response by a cell to an external stimulus by phosphorylation of
ed intracellular proteins, including transcription factors. Additionally, JNK also
phosphorylates non-nuclear proteins, for example, IRS-1, and Bcl-2 family members.
ATI—25 14175v1
[Davis R], Trends Biochem. Sci. 9(11):470-473 (1994); Seger R et al., FASEB J.;
9(9):726-35 (1995); Fanger GR et al., Curr. Opin. Genet. Dev.; 7(1):67-74 (1997)].
The mitogen activated protein (MAP) s ipate in the uction
of signals to the nucleus of the cell in response to extracellular stimuli. Examples ofMAP
kinases from the ERK p38 and JNK isoforms include but are not limited to, mitogen-
activated n kinase 1 (ERK2), mitogen-activated protein kinase 8 (JNKl), mitogen-
activated protein kinase 9 (MAPK9 or JNK2), mitogen-activated protein kinase 10
(MAPK10 or JNK3) and mitogen-activated protein kinase 14 (MAPK14 or p3 8alpha).
MAP kinases are a family of proline-directed /threonine kinases that mediate signal
transduction from ellular receptors or heat shock, osmotic stress, reactive oxidant
species (ROS) or UV radiation. [See Sridhar et al., Pharmaceutical Research, 17: 11 1345-
1353 (2000)]. MAP kinases are activated via the phosphorylation of theonine and tyrosine
by upstream dual-specificity protein kinases, including MK and MEKK kinases. Cell
proliferation and differentiation have been shown to be under the regulatory control of
multiple MAP kinase cascades. [See Sridhar et al., Pharmaceutical Research, 17:11 1345-
1353 (2000)]. As such, the MAP kinase pathway plays critical roles in a number of
disease states. For e, s in activities ofMAP kinases have been shown to lead
to aberrant cell proliferation and carcinogenesis. [See Hu et al., Cell Growth Difi’er.
-200 (2000); and Das et al., Breast Cancer Res. Treat. 40: 141 (1996)]. Moreover,
MAP kinase activity has also been ated in insulin resistance ated with type-2
diabetes [See Virkamaki et al., J. Clin. Invest. 103:931-943 (1999)] and obesity. s
in insulin resistance may have a direct impact on the metabolism of glucose and lipid in
the liver contributing to the development of steatosis that may progress to liver fibrosis
rie et al. Science Translational Medicine 2(60):1-7 (2010)].
Steatosis may p in the presence of either saturated or unsaturated free
fatty acids (FFA). FFA promote robust JNK activation in liver and excessive
concentrations of FFA may lead to hepatocyte apoptosis. It has been reported that JNK2-/—
mice are partially protected from steatosis and apoptosis by saturated FFA (e.g. stearic
acid) but not by unsaturated FFA [Malhi et al. J.Bi0l. Chem. 281 :12093-12101 (2006)].
JNK1-/— mice were not protected from FFA induced injury. The role of JNK1 and JNK2
has been studied in CDAA-fed mice that progressed from steatosis to hepatitis to
ATI—25 14175v1
WO 45569
hepatic fibrosis [Kodama et al., Gastroenterology 137:1467-1477 (2009)]. While both
JNKl-/— and JNK2-/— mice developed steatosis, the JNKl-/— mice, but not JNK2-/— mice,
were remarkably resistant to progression to tis and fibrosis. Chimeric mice with
— deletion restricted to bone marrow cells were similarly resistant to hepatitis and
fibrosis implicating the activated Kupffer cell as a key trigger for e progression
beyond steatosis. Indeed, JNKl-/— macrophages do not express IL-1, IL-6, TNF and NO
in response to LPS [Sanchez-Tillo et al., JBiol Chem. 282(17): 73 (2007)], and
Kupffer cells derived fiom JNKl -/- mice or fiom wild-type mice and treated with JNK
inhibitor SP600125 display reduced TNF, IL-6, and IL-1 expression in response to LPS
[Kodama et al., Gastroenterology 137: 1467-1477 (2009)].
The ation of the intricacy of protein kinase ys and the
complexity of the relationship and interaction among and between the various protein
kinases and kinase pathways ghts the importance of developing pharmaceutical
agents capable of acting as n kinase modulators, regulators or inhibitors that have
ial activity on multiple kinases or multiple kinase pathways. Accordingly, there
remains a need for new kinase modulators, and in particular JNK modulators.
Citation or identification of any reference in Section 2 of this application is
not to be construed as an admission that the reference is prior art to the t application.
SUMMARY
Provided herein are compounds having the following formula (I):
N \ NH2
JL ,
HN N NH
R1 R2
and pharmaceutically acceptable salts, tautomers, isotopologues,
stereoisomers and prodrugs thereof, wherein R1, and R2 are as defined herein.
Provided herein are compounds having the following formula (1B):
ATI—2514l75vl
H[\l N NH
R3 R4
(13)
and pharmaceutically acceptable salts, tautomers, isotopologues,
isomers and prodrugs thereof, wherein R3 and R4 are as defined herein.
A compound of formula (I) or formula (IE) or a ceutically
acceptable salt, tautomer, isotopologue, stereoisomer or prodrug thereof (each being
ed to herein as an “Diaminopyrimidine Compound”) is useful for treating or
ting liver f1brotic disorders, or diabetes and/or metabolic syndrome leading to liver
f1brotic ers, as described herein. In another , a Diaminopyrimidine Compound
is useful for treating or preventing a condition treatable or preventable by inhibition of a
JNK pathway, as described herein.
In one aspect, provided herein are Diaminopyrimidine Compounds as
bed in the instant disclosure, such as, for example, in Tables 1, 2 and 3.
In one aspect, provided herein are pharmaceutical itions comprising
an effective amount of a Diaminopyrimidine Compound as described herein, and a
pharmaceutically acceptable carrier, excipient or vehicle. In some embodiments the
pharmaceutical composition is suitable for oral, parenteral, mucosal, transdermal or topical
administration.
In one aspect, provided herein are methods for treating or preventing liver
f1brotic disorders, such as non-alcoholic steatohepatitis, steatosis, cirrhosis, primary
sclerosing cholangitis, primary biliary cirrhosis, hepatitis, hepatocellular oma, and
liver fibrosis coincident with chronic or repeated l ingestion, with infection, with
liver lant, or with drug d liver injury, comprising administering to a subject in
need thereof an effective amount of a Diaminopyrimidine Compound as described herein;
and a pharmaceutically acceptable carrier, excipient or vehicle. In another aspect,
provided herein are methods for treating or preventing diabetes or lic syndrome
leading to liver f1brotic disorders, such as non-alcoholic steatohepatitis, steatosis, tis,
or cirrhosis, comprising administering to a subject in need thereof an effective amount of a
Diaminopyrimidine Compound. Also provided herein are methods for treating or
ATI—2514l75vl
preventing a condition treatable or table by inhibition of a JNK y,
comprising administering to a t in need thereof an effective amount of a
Diaminopyrimidine Compound as described herein; and a pharmaceutically acceptable
carrier, excipient or vehicle.
[0013a] In another aspect, provided herein is the use of a compound as described
herein in the manufacture of a medicament for the treatment of a liver fibrotic disorder, or
diabetes or metabolic syndrome leading to a liver fibrotic er.
In one aspect, provided herein are methods for ting a kinase, for
example JNK1, JNK2 or both, in a cell sing said kinase, comprising contacting said
cell with an effective amount of a Diaminopyrimidine Compound as described herein.
[0014a] In another aspect provided herein is the use of a compound as described
herein in the manufacture of a ment for inhibiting a JNK1 or JNK2 kinase.
In another aspect provided herein are methods for preparing
Diaminopyrimidine Compounds as bed herein.
The present embodiments can be understood more fully by reference to the
detailed description and examples, which are intended to exemplify non-limiting
embodiments.
ED DESCRIPTION
TIONS
An ” group is a saturated, partially saturated, or unsaturated straight
chain or branched non-cyclic hydrocarbon having from 1 to 10 carbon atoms, typically
from 1 to 8 carbons or, in some embodiments, from 1 to 6, 1 to 4, or 2 to 6 or carbon
atoms. Representative alkyl groups include -methyl, -ethyl, -n-propyl, -n-butyl, -n-pentyl
and -n-hexyl; while saturated branched alkyls include -isopropyl, utyl, tyl,
-tert-butyl, -isopentyl, -neopentyl, tert-pentyl, methylpentyl, methylpentyl,
methylpentyl, -2,3-dimethylbutyl and the like. Examples of unsaturated alkyl groups
include, but are not limited to, vinyl, allyl, -CH=CH(CH3), -CH=C(CH3)2, -C(CH3)=CH2,
-C(CH3)=CH(CH3), -C(CH2CH3)=CH2, -C≡CH, -C≡C(CH3), -C≡C(CH2CH3), CH,
-CH2C≡C(CH3) and -CH2C≡C(CH7CH3), among others. An alkyl group can be
tuted or unsubstituted. When the alkyl groups described herein are said to be
“substituted,” they may be substituted with any substituent or substituents as those found
in the exemplary compounds and embodiments disclosed herein, as well as halogen
(chloro, iodo, bromo, or fluoro); alkyl; hydroxyl; alkoxy; alkoxyalkyl; amino; alkylamino;
carboxy; nitro; cyano; thiol; thioether; imine; imide; e; guanidine; enamine;
aminocarbonyl; acylamino; phosphonato; phosphine; thiocarbonyl; sulfonyl; sulfone;
WO 45569
sulfonamide; ketone; de; ester; urea; ne; oxime; hydroxyl amine;
alkoxyamine; aralkoxyamine; e; hydrazine; ide; hydrazone; azide;
isocyanate; isothiocyanate; e; thiocyanate; B(OH)2, or O(alkyl)aminocarbonyl.
A “cycloalkyl” group is a saturated, partially saturated, or unsaturated
cyclic alkyl group of from 3 to 10 carbon atoms haVing a single cyclic ring or multiple
condensed or bridged rings which can be optionally substituted with from 1 to 3 alkyl
groups. In some embodiments, the cycloalkyl group has 3 to 8 ring members, whereas in
other ments the number of ring carbon atoms ranges from 3 to 5, 3 to 6, or 3 to 7.
Such cycloalkyl groups include, by way of example, single ring structures such as
cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl,
l-methylcyclopropyl, 2-methylcyclopentyl, 2-methylcyclooctyl, and the like, or multiple
or bridged ring structures such as l-bicyclo[l . ntyl, bicyclo[2.l.l]hexyl,
bicyclo[2.2. l]heptyl, bicyclo[2.2.2]octyl, adamantyl and the like. Examples of
unsaturared cycloalkyl groups include cyclohexenyl, cyclopentenyl, cyclohexadienyl,
butadienyl, pentadienyl, hexadienyl, among others. A cycloalkyl group can be substituted
or unsubstituted. Such substituted cycloalkyl groups include, by way of example,
cyclohexanol and the like.
An “aryl” group is an aromatic carbocyclic group of from 6 to 14 carbon
atoms haVing a single ring (e.g., phenyl) or multiple sed rings (e.g., naphthyl or
anthryl). In some embodiments, aryl groups contain 6-l4 carbons, and in others from 6 to
12 or even 6 to 10 carbon atoms in the ring portions of the groups. Particular aryls include
phenyl, biphenyl, naphthyl and the like. An aryl group can be substituted or unsubstituted.
The phrase “aryl groups” also includes groups containing fused rings, such as fused
aromatic-aliphatic ring systems (e.g., indanyl, tetrahydronaphthyl, and the like).
A “heteroaryl” group is an aryl ring system haVing one to four heteroatoms
as ring atoms in a aromatic ring system, wherein the remainder of the atoms are
carbon atoms. In some embodiments, heteroaryl groups n 3 to 6 ring atoms, and in
others from 6 to 9 or even 6 to 10 atoms in the ring portions of the groups. Suitable
heteroatoms include oxygen, sulfur and en. In certain embodiments, the heteroaryl
ring system is monocyclic or bicyclic. Non-limiting examples include but are not limited
to, groups such as pyrrolyl, pyrazolyl, imidazolyl, triazolyl, tetrazolyl, oxazolyl,
ATI—ZS 14175Vl
isoxazolyl, benzisoxazolyl (e.g., benzo[d]isoxazolyl), thiazolyl, pyrolyl, pyridazinyl,
pyrimidyl, pyrazinyl, thiophenyl, benzothiophenyl, furanyl, benzofuranyl, indolyl
(e.g., indolylonyl or isoindolin-l-onyl), azaindolyl (pyrrolopyridyl or lH-pyrrolo[2,3-
b]pyridyl), lyl, benzimidazolyl (e.g., lH-benzo[d]imidazolyl), imidazopyridyl
(e.g., azabenzimidazolyl or lH-imidazo[4,5-b]pyridyl), pyrazolopyridyl, triazolopyridyl,
benzotriazolyl (e. g., lH-benzo[d][l,2,3]triazolyl), benzoxazolyl (e. g., benzo[d]oxazolyl),
hiazolyl, benzothiadiazolyl, isoxazolopyridyl, phthalenyl, purinyl, xanthinyl,
adeninyl, yl, quinolinyl, isoquinolinyl (e. g., 3,4-dihydroisoquinolin-l(2H)-onyl),
tetrahydroquinolinyl, quinoxalinyl, and quinazolinyl groups.
A “heterocyclyl” is an aromatic (also referred to as heteroaryl) or non-
aromatic cycloalkyl in which one to four of the ring carbon atoms are independently
replaced with a heteroatom from the group consisting of O, S and N. In some
embodiments, heterocyclyl groups include 3 tolO ring members, Whereas other such
groups have 3 to 5, 3 to 6, or 3 to 8 ring members. Heterocyclyls can also be bonded to
other groups at any ring atom (i.e., at any carbon atom or heteroatom of the heterocyclic
ring). A heterocycloalkyl group can be substituted or unsubstituted. Heterocyclyl groups
encompass unsaturated, partially saturated and ted ring systems, such as, for
example, imidazolyl, olinyl and imidazolidinyl (e. g., imidazolidinone or
imidazolidin-2,4-dionyl) groups. The phrase heterocyclyl includes fused ring species,
ing those comprising fiased aromatic and non-aromatic groups, such as, for example,
l-and 2-aminotetraline, benzotriazolyl (e. g., lH-benzo[d][l,2,3]triazolyl), benzimidazolyl
(e.g., lH-benzo[d]imidazolyl), 2,3-dihydrobenzo[l,4]dioxinyl, and benzo[l,3]dioxolyl. The
phrase also includes bridged polycyclic ring systems ning a heteroatom such as, but
not limited to, quinuclidyl. Representative examples of a heterocyclyl group include, but
are not d to, aziridinyl, azetidinyl, azepanyl, yl, idyl, imidazolidinyl
(e. g., olidinonyl or imidazolidin-2,4-dionyl), pyrazolidinyl, thiazolidinyl,
ydrothiophenyl, tetrahydrofuranyl, yl, furanyl, thiophenyl, pyrrolyl, pyrrolinyl,
imidazolyl, imidazolinyl, pyrazolyl, pyrazolinyl, triazolyl, tetrazolyl, oxazolyl, olyl,
benzisoxazolyl (e. g., benzo[d]isoxazolyl), thiazolyl, thiazolinyl, isothiazolyl, thiadiazolyl,
oxadiazolyl, piperidyl, piperazinyl (e. g., piperazinonyl), morpholinyl, thiomorpholinyl,
tetrahydropyranyl (e.g., tetrahydro-2H-pyranyl), tetrahydrothiopyranyl, oxathianyl, dioxyl,
ATI—ZS 14175Vl
dithianyl, pyranyl, pyridyl, pyrimidyl, pyridazinyl, pyrazinyl, nyl, dihydropyridyl,
dihydrodithiinyl, dihydrodithionyl, l,4-dioxaspiro[4.5]decanyl, homopiperazinyl,
quinuclidyl, indolyl (e.g. , indolylonyl or isoindolin- l -onyl), indolinyl, isoindolyl,
isoindolinyl, azaindolyl (pyrrolopyridyl or lH-pyrrolo[2,3-b]pyridyl), indazolyl,
indolizinyl, benzotriazolyl (e. g. lH-benzo[d][l,2,3]triazolyl), benzimidazolyl
(e.g., zo[d]imidazolyl or lH-benzo[d]imidazol-2(3H)—onyl), benzofilranyl,
benzothiophenyl, benzothiazolyl, benzoxadiazolyl, benzoxazinyl, benzodithiinyl,
benzoxathiinyl, benzothiazinyl, benzoxazolyl (i.e., benzo[d]oxazolyl), benzothiazolyl,
benzothiadiazolyl, benzo[l,3]dioxolyl, pyrazolopyridyl (for example, lH-pyrazolo[3,4-
b]pyridyl, lH-pyrazolo[4,3-b]pyridyl), opyridyl (e. g., zimidazolyl or
dazo[4,5-b]pyridyl), triazolopyridyl, isoxazolopyridyl, purinyl, nyl, adeninyl,
guaninyl, quinolinyl, isoquinolinyl (e. g., 3,4-dihydroisoquinolin-l(2H)-onyl), quinolizinyl,
quinoxalinyl, quinazolinyl, cinnolinyl, azinyl, naphthyridinyl, pteridinyl,
thianaphthalenyl, dihydrobenzothiazinyl, dihydrobenzofuranyl, dihydroindolyl,
dihydrobenzodioxinyl, tetrahydroindolyl, tetrahydroindazolyl, tetrahydrobenzimidazolyl,
tetrahydrobenzotriazolyl, tetrahydropyrrolopyridyl, tetrahydropyrazolopyridyl,
tetrahydroimidazopyridyl, tetrahydrotriazolopyridyl, ydropyrimidin-2(lH)-one and
tetrahydroquinolinyl groups. Representative non-aromatic heterocyclyl groups do not
include fused ring species that comprise a fused aromatic group. Examples of non-
ic heterocyclyl groups include aziridinyl, azetidinyl, azepanyl, pyrrolidyl,
imidazolidinyl (e.g., imidazolidinonyl or imidazolidin-2,4-dionyl), pyrazolidinyl,
thiazolidinyl, tetrahydrothiophenyl, tetrahydrofilranyl, piperidyl, piperazinyl
(e. g., zinonyl), morpholinyl, thiomorpholinyl, tetrahydropyranyl (e.g., tetrahydro-
2H-pyranyl), tetrahydrothiopyranyl, oxathianyl, dithianyl, l,4-dioxaspiro[4.5]decanyl,
homopiperazinyl, quinuclidyl, or tetrahydropyrimidin-2(lH)—one. Representative
substituted heterocyclyl groups may be mono-substituted or substituted more than once,
such as, but not limited to, pyridyl or morpholinyl groups, which are 2-, 3-, 4-, 5-, or
6-substituted, or disubstituted with various substituents such as those listed below.
A “cycloalkylalkyl” group is a radical of the formula: -cycloalkyl,
wherein alkyl and cycloalkyl are as defined above. Substituted lkylalkyl groups
may be substituted at the alkyl, the cycloalkyl, or both the alkyl and the cycloalkyl
ATI—2514l75v1
portions of the group. Representative cycloalkylalkyl groups include but are not limited to
cyclopropyl, methylcyclobutyl, cyclopentyl, methylcyclohexyl,
ethylcyclopropyl, ethylcyclobutyl, yclopentyl, ethylcyclohexyl, propylcyclopentyl,
propylcyclohexyl and the like.
An “aralkyl” group is a radical of the formula: -alkyl-aryl, wherein alkyl
and aryl are defined above. Substituted aralkyl groups may be substituted at the alkyl, the
aryl, or both the alkyl and the aryl portions of the group. Representative aralkyl groups
e but are not d to benzyl and phenethyl groups and fused (cycloalkylaryl)alkyl
groups such as 4-ethyl-indanyl.
An “heterocyclylalkyl” group is a radical of the formula: -
heterocyclyl, wherein alkyl and cyclyl are defined above. Substituted
heterocyclylalkyl groups may be substituted at the alkyl, the heterocyclyl, or both the alkyl
and the heterocyclyl portions of the group. Representative heterocylylalkyl groups include
but are not limited to 4-ethyl-morpholinyl, 4-propylmorpholinyl, 2-yl methyl,
furan-3 -yl methyl, pyridin-3 -yl methyl, ydrofidranyl ethyl, and indolyl propyl.
A “halogen” is fluorine, chlorine, bromine or iodine.
A “hydroxyalkyl” group is an alkyl group as bed above substituted
with one or more hydroxy groups.
An “alkoxy” group is -O-(alkyl), wherein alkyl is defined above.
An “alkoxyalkyl” group is -(alkyl)-O-(alkyl), wherein alkyl is defined
above.
An “amino” group is a radical of the formula: -NH2.
An “alkylamino” group is a radical of the formula: -NH-alkyl or —N(alkyl)2,
wherein each alkyl is independently as defined above.
[003 l] A “carboxy” group is a radical of the formula: -C(O)OH.
An “aminocarbonyl” group is a radical of the formula: -C(O)N(R#)2,
-C(O)NH(R#) or -C(O)NH2, wherein each R# is independently a substituted or
unsubstituted alkyl, cycloalkyl, aryl, aralkyl, heterocyclyl or heterocyclyl group as defined
herein.
An “acylamino” group is a radical of the formula: -NHC(O)( R#) or
-N(alkyl)C(O)(R#), wherein each alkyl and R# are independently as defined above.
ATI—2514l75v1
A “sulfonylamino” group is a radical of the formula: -NHSOZ(R#) or
-N(alkyl)SOz(R#), wherein each alkyl and R# are defined above.
A “urea” group is a radical of the formula: -N(alkyl)C(O)N(R#)2,
-N(a1kyl)C(O)NH(R#), —N(alkyl)C(O)NH2, -NHC(O)N(R#)2, -NHC(O)NH(R#), or
-NH(CO)NHR#, wherein each alkyl and R# are independently as defined above.
When the groups described , with the exception of alkyl group, are
said to be “substituted,” they may be substituted with any appropriate substituent or
substituents. Illustrative examples of substituents are those found in the exemplary
compounds and embodiments disclosed , as well as halogen (chloro, iodo, bromo, or
fluoro); alkyl; hydroxyl; alkoxy; alkyl; amino; alkylamino; carboxy; nitro; cyano;
thiol; her; imine; imide; amidine; guanidine; enamine; aminocarbonyl; acylamino;
phosphonato; phosphine; rbonyl; sulfonyl; sulfone; sulfonamide; ketone; aldehyde;
ester; urea; urethane; oxime; hydroxyl amine; alkoxyamine; aralkoxyamine; N—oxide;
hydrazine; hydrazide; hydrazone; azide; isocyanate; isothiocyanate; cyanate; thiocyanate;
oxygen (=0); B(OH)2, O(alkyl)aminocarbonyl; lkyl, which may be monocyclic or
fused or non-fused polycyclic (e.g., cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl),
or a heterocyclyl, which may be monocyclic or fused or non-fused polycyclic
(e. g., idyl, piperidyl, piperazinyl, morpholinyl, or thiazinyl); monocyclic or fused or
non-fused polycyclic aryl or aryl (e.g., phenyl, yl, pyrrolyl, indolyl, furanyl,
thiophenyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, lyl, tetrazolyl, pyrazolyl,
pyridyl, quinolinyl, isoquinolinyl, acridinyl, pyrazinyl, pyridazinyl, pyrimidyl,
benzimidazolyl, benzothiophenyl, or benzofuranyl) aryloxy; aralkyloxy; heterocyclyloxy;
and heterocyclyl alkoxy.
[003 7] As used herein, the term “Diaminopyrimidine Compound” refers to
compounds of a (I) and formula (1B) as well as to further embodiments provided
. In one ment, a “Diaminopyrimidine Compound” is a compound set forth in
Tables 1, 2 and 3. The term “Diaminopyrimidine Compound” includes pharmaceutically
acceptable salts, tautomers, isotopologues, stereoisomers, and prodrugs of the compounds
provided herein.
As used herein, the term “pharmaceutically acceptable salt(s)” refers to a
salt prepared from a ceutically acceptable non-toxic acid or base including an
ATI—2514l75v1
nic acid and base and an organic acid and base. Suitable ceutically
acceptable base addition salts of the compounds of formula (I) include, but are not limited
to metallic salts made from aluminum, calcium, m, magnesium, potassium, sodium
and zinc or organic salts made from lysine, N,N’-dibenzylethylenediamine,
chloroprocaine, choline, diethanolamine, ethylenediamine, ine (N-methylglucamine
) and procaine. Suitable non-toxic acids include, but are not limited to, inorganic
and organic acids such as acetic, alginic, anthranilic, benzenesulfonic, benzoic,
camphorsulfonic, citric, ethenesulfonic, , filmaric, furoic, galacturonic, gluconic,
glucuronic, glutamic, glycolic, romic, hydrochloric, isethionic, lactic, maleic, malic,
mandelic, methanesulfonic, mucic, nitric, pamoic, pantothenic, phenylacetic, phosphoric,
propionic, salicylic, stearic, succinic, ilic, sulfilric, ic acid, and p-
toluenesulfonic acid. Specific non-toxic acids include hloric, romic, maleic,
phosphoric, sulfiaric, and methanesulfonic acids. Examples of c salts thus include
hydrochloride and mesylate salts. Others are well-known in the art, see for example,
Remington ’s Pharmaceutical Sciences, 18th eds., Mack Publishing, Easton PA (1990) or
Remington: The Science and Practice ofPharmacy, l9th eds., Mack Publishing, Easton PA
(1 995).
As used herein and unless otherwise indicated, the term “prodrug” means a
Diaminopyrimidine nd that can hydrolyze, oxidize, or otherwise react under
biological conditions (in vitro or in vivo) to provide an active compound, particularly a
Diaminopyrimidine Compound or a compound of formula (1). Examples of prodrugs
include, but are not limited to, derivatives and lites of a Diaminopyrimidine
Compound that e biohydrolyzable moieties such as biohydrolyzable amides,
rolyzable esters, biohydrolyzable carbamates, biohydrolyzable carbonates,
biohydrolyzable ureides, and biohydrolyzable phosphate analogues. In certain
embodiments, prodrugs of compounds with carboxyl functional groups are the lower alkyl
esters of the carboxylic acid. The carboxylate esters are iently formed by
esterifying any of the carboxylic acid moieties present on the molecule. Prodrugs can
typically be prepared using well-known methods, such as those described by Burger ’s
Medicinal Chemistry and Drug Discovery 6th ed. (Donald J. Abraham ed., 2001, Wiley)
ATI—2514l75v1
and Design and Application ofProdrugs (H. Bundgaard ed., 1985, Harwood Academic
Publishers Gmih).
As used herein and unless otherwise indicated, the term “stereoisomer” or
“stereomerically pure” means one stereoisomer of a Diaminopyrimidine Compound that is
substantially free of other stereoisomers of that compound. For example, a stereomerically
pure nd having one chiral center will be substantially free of the opposite
enantiomer of the nd. A stereomerically pure compound having two chiral centers
will be ntially free of other reomers of the compound. A typical
stereomerically pure compound comprises greater than about 80% by weight of one
stereoisomer of the compound and less than about 20% by weight of other stereoisomers
of the compound, greater than about 90% by weight of one stereoisomer of the compound
and less than about 10% by weight of the other stereoisomers of the compound, greater
than about 95% by weight of one stereoisomer of the compound and less than about 5% by
weight of the other stereoisomers of the compound, or r than about 97% by weight
of one stereoisomer of the compound and less than about 3% by weight of the other
stereoisomers of the compound. The Diaminopyrimidine nds can have chiral
centers and can occur as racemates, individual enantiomers or diastereomers, and mixtures
thereof. All such isomeric forms are included within the embodiments disclosed herein,
including mixtures thereof.
The use of stereomerically pure forms of such opyrimidine
Compounds, as well as the use of mixtures of those forms, are encompassed by the
embodiments disclosed herein. For e, mixtures comprising equal or unequal
amounts of the enantiomers of a particular Diaminopyrimidine Compound may be used in
methods and compositions disclosed herein. These isomers may be asymmetrically
synthesized or ed using standard techniques such as chiral columns or chiral
resolving agents. See, e. g., Jacques, J et al., Enantiomers, tes and Resolutions
(Wiley-Interscience, New York, 1981); Wilen, S. H., et al., edron 33 :2725 (1977);
Eliel, E. L., Stereochemistry ofCarbon Compounds (McGraw-Hill, NY, 1962); and Wilen,
S. H., Tables ofResolving Agents and Optical Resolutions p. 268 (EL. Eliel, Ed., Univ. of
Notre Dame Press, Notre Dame, IN, 1972).
ATI—25 14175v1
WO 45569
It should also be noted the Diaminopyrimidine Compounds can include E
and Z isomers, or a mixture thereof, and cis and trans isomers or a mixture f. In
certain embodiments, the Diaminopyrimidine Compounds are isolated as either the E or Z
isomer. In other embodiments, the Diaminopyrimidine nds are a mixture of the E
and Z isomers.
"Tautomers" refers to isomeric forms of a compound that are in equilibrium
with each other. The concentrations of the isomeric forms will depend on the environment
the nd is found in and may be different depending upon, for example, whether the
compound is a solid or is in an organic or aqueous solution. For e, in aqueous
solution, pyrazoles may exhibit the ing isomeric forms, which are referred to as
tautomers of each other:
IN\ IN
/ N\ |
As readily understood by one skilled in the art, a wide variety of functional
groups and other stuctures may exhibit tautomerism and all tautomers of compounds of
formula (I) are within the scope of the present invention.
It should also be noted the Diaminopyrimidine Compounds can n
unnatural proportions of atomic isotopes at one or more of the atoms. For example, the
compounds may be radiolabeled with radioactive isotopes, such as for example tritium
(3H), iodine-125 (1251), sulfur-35 (358), or carbon-l4 (14C), or may be ically enriched,
such as with deuterium (2H), carbon-l3 (13C), or nitrogen-15 (UN). As used herein, an
“isotopologue” is an isotopically ed compound. The term “isotopically enriched”
refers to an atom having an isotopic composition other than the natural isotopic
composition of that atom. “Isotopically enriched” may also refer to a compound
containing at least one atom having an isotopic composition other than the natural isotopic
composition of that atom. The term “isotopic composition” refers to the amount of each
isotope present for a given atom. Radiolabeled and isotopically encriched compounds are
useful as therapeutic agents, e.g., cancer and inflammation therapeutic agents, research
reagents, e.g., binding assay reagents, and diagnostic , e. g., in vivo imaging agents.
All isotopic variations of the Diaminopyrimidine Compounds as described , r
radioactive or not, are intended to be encompassed within the scope of the embodiments
ATI—2514l75v1
provided herein. In some embodiments, there are provided isotopologues of the
Diaminopyrimidine Compounds, for example, the isotopologues are deuterium, carbon-l3,
or en-15 enriched Diaminopyrimidine Compounds.
“INK” means a protein or an isoform thereof expressed by a INKl, INK2,
or INK3 gene (Gupta, S., Barrett, T., Whitmarsh, A.I., Cavanagh, I
., Sluss, H.K., Derijard,
B. and Davis, RI. The EMBO J. 0-2770 (1996)).
“Treating” as used herein, means an alleviation, in whole or in part, of a
disorder, disease or condition, or one or more of the symptoms associated with a disorder,
disease, or condition, or g or halting of further progression or worsening of those
symptoms, or alleviating or eradicating the cause(s) of the disorder, disease, or condition
itself. In one embodiment, the er is a liver f1brotic disorder, such as non-alcoholic
steatohepatitis, steatosis (i.e. fatty , cirrhosis, y sclerosing cholangitis, primary
biliary cirrhosis, hepatitis, hepatocellular carcinoma, or liver fibrosis coincident with
chronic or repeated alcohol ingestion (alcoholic hepatitis), with infection (e.g. viral
ion such as HCV), with liver transplant, or with drug induced liver injury
(e.g. acetaminophen ty). In some embodiments, “treating” means an alleviation, in
whole or in part, of a disorder, disease or condition, or symptoms associated with es
or metabolic syndrome leading to liver fibrotic disorders, such as non-alcoholic
steatohepatitis, sis (i.e. fatty liver), hepatitis or sis, or a g, or halting of
further progression or ing of those symptoms. In one embodiment, the symptom is
jaundice. In another embodiment, “treating” means and alleviation, in whole or in part, of
a er, disease or condition, or symptoms ated with a condition, treatable or
preventable by inhibition of a INK y.
“Preventing” as used herein, means a method of delaying and/or precluding
the onset, recurrence or spread, in whole or in part, of a disorder, disease or condition;
barring a subject from acquiring a disorder, disease, or condition; or reducing a subject’s
risk of acquiring a disorder, disease, or condition. In one embodiment, the disorder is a
liver f1brotic disorder, or diabetes or metabolic me leading to liver fibrotic
disorders, as described herein, or symptoms thereof In another, the disorder is a
condition, treatable or preventable by inhibition of a INK pathway.
ATI—2514l75vl
The term “effective amount” in connection with a Diaminopyrimidine
Compound means an amount capable of treating or preventing a disorder, disease or
condition, or symptoms thereof, disclosed herein.
The term “subject” includes an , including, but not limited to, an
animal such a cow, monkey, horse, sheep, pig, chicken, turkey, quail, cat, dog, mouse, rat,
rabbit or guinea pig, in one ment a mammal, in another embodiment a human. In
one embodiment, a subject is a human having or at risk for having liver fibrotic disorders
or diabetes or metabolic syndrome leading to liver fibrotic disorders, or a condition,
treatable or preventable by inhibition of a JNK pathway, or a symptom thereof
DIAMINOPYRIMIDINE COMPOUNDS
Provided herein are compounds having the following formula (I):
N \ NH2
HN N NH
R1 R2
and pharmaceutically acceptable salts, ers, stereoisomers,
enantiomers, isotopologues, and prodrugs thereof,
wherein:
R1 is tuted or unsubstituted C1_g alkyl, substituted or unsubstituted
cycloalkyl, substituted or unsubstituted non-aromatic cyclyl, substituted or
unsubstituted ycloalkyl, or substituted or unsubstituted alkylheterocyclyl, provided
that R1 is not l-aminocyclohexyl; and
R2 is substituted or tituted C1_g alkyl, substituted or tituted
saturated cycloalkyl, substituted or unsubstituted ycloalkyl, or substituted or
unsubstituted non-aromatic heterocyclyl.
In one embodiment, the compound of formula (I) is not:
2-(2-aminoethylamino)(methylamino)pyrimidinecarboxamide
ATI—2514l75v1
H N1*N
H H
2-(2-arnin0pr0py1arnino)(cyclohexylamino)pyrirnidinecarboxarnide
vwN1“H NOH
2-(2-arninooxoethy1amino)(cyclohexylamino)pyrirnidine
carboxarnide
H2N\n/\NJ\N/[\ll/YLNHZH NOH
minoethylamino)—4-(cyc10hexy1arnino)pyrirnidinecarb0xamide
H2N\/\NlYNHZ/
N NO
H H
(S)(2-aminopropylamino)(cyclobutylamino)pyrimidine
carboxarnide
ATI—ZS 14175V1
(R)(l -aminomethyloxobutanylamino)(cyclobutylamino)-
pyrimidine-S-carboxamide
N N/ NH
\N /
N NH
or 2-(l -acetylpiperidinylamino)(cyclopropylamino)pyrimidinecarboxamide
A O
)LN/YkNHZ/
M N N H
In one embodiment, R1 is not
HZND\;
for example,
:e‘ :0 so ~30
H2N HZN‘“ H2N or HZN‘“
9 9 , _
In some embodiments of compounds of formula (I), R1 is a branched
C1_g alkyl, for example, R1 is isopropyl, sec-butyl, isobutyl, tert-butyl, isopentyl,
ylpentyl, or entyl. In others, R1 is isopropyl, tyl, isobutyl, tert-butyl,
2,3-dimethylbutyl, isopentyl, 2-methylpentyl, neopentyl, tert-pentyl, or 3-methylpentyl. In
, R1 is a substituted or unsubstituted cycloalkyl, for example, cyclopropyl,
cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, bicyclo[l.1.l]pentyl, or
bicyclo[2.2.2]octyl. In others, the cycloalkyl is cyclopropyl, cyclobutyl, cyclopentyl,
ATI—ZS 14175Vl
cyclohexyl, cycloheptyl, cyclooctyl, bicyclo[l . l . l]pentyl, bicyclo[2.2. l ]heptyl, or
bicyclo[2.2.2]octyl. In some such embodiments, the cycloalkyl is tuted with one or
more halogen, -(C1_4 alkyl), -NR2, -(C0_3 alkyl)OR, -NRC(O)R’, ’, R2,
-C(O)OR’, or -NRS(O)2R’, n each R is ndently H, or C1_4 alkyl, wherein the
alkyl is optionally fluorinated, and each R’ is independently C1_4 alkyl, wherein the alkyl is
optionally fluorinated. For example, the cycloalkyl is substituted with one or more
methyl, ethyl, t-butyl, -F, -OH, -OCH3, -OCHF2, -OCF3, -OCH2CH3, H2F,
-OCH2CF3, -CH20H, -CH20CH3, )20H, -NH2, -NH(CH3), -NHC(O)CH3,
-C(O)NHCH3, (CH3)2, or -NHSOZCH3. In other embodiments, the cycloalkyl is
substituted with one or more halogen, -CF3, -(C1_4 alkyl), -(C1_6 cycloalkyl), -NR2,
-(C0_3 alkyl)OR, -(C0_3 alkyl)OR”, -NRC(O)R’, -C(O)R’, -C(O)NR2, -C(O)OR’, or
-NRS(O)2R’, wherein each R is independently H, or C1_4 alkyl, wherein the alkyl is
optionally ated, each R’ is independently C1_4 alkyl, wherein the alkyl is optionally
fluorinated, and each R” is independently a C1_6 cycloalkyl, wherein the cycloalkyl is
optionally fluorinated. For example, the cycloalkyl is substituted with one or more
methyl, ethyl, t-butyl, ropyl, -CF3, -F, -OH, -OCH3, -OCHF2, -OCF3, -OCH2CH3,
-OCH2CH2F, -OCH2CF3, -O(cyclopropyl), -CH20H, -CH20CH3, -C(CH3)20H, -NH2,
-NH(CH3), -NHC(O)CH3, -C(O)NHCH3, -C(O)N(CH3)2, or -NHSOZCH3. In some
embodiments, R1 is a substituted or tituted non-aromatic cyclyl, for example,
pyrrolidinyl, tetrahydropyranyl, l,4-dioxaspiro[4.5]decanyl, or piperidyl. In others, the
non-aromatic heterocyclyl is oxetanyl, pyrrolidinyl, tetrahydropyranyl,
l,4-dioxaspiro[4.5]decanyl, or piperidyl. In some such embodiments, the piperidyl is
substituted with —C(O)R’, or -C(O)OR’, wherein R’ is C1_4 alkyl, wherein the alkyl is
optionally fluorinated. In yet other embodiments, R1 is a substituted or unsubstituted
alkylcycloalkyl, for e, (C1_3 alkyl)cyclopropyl, (C1_3 cyclobutyl,
(C1_3 alkyl)cyclopentyl, or (C1_3 alkyl)cyclohexyl. In some such embodiments, R1 is
-(CH2)cyclopropyl, —(CH2)cyclobutyl, —(CH2)cyclopentyl, -(CH2)cyclohexyl,
-CH(CH3)cyclopropyl, —CH(CH3)cyclobutyl, -CH(CH3)cyclopentyl, or
-CH(CH3)cyclohexyl. In , R1 is —(CH2)cyclopropyl, —CH(CH3)cyclopropyl,
-CH(CH3)cyclobutyl,—CH(CH3)cyclohexyl, or -C(CH3)2cyclopropyl. In still other
embodiments, R1 is a substituted or unsubstituted alkylheterocyclyl, for example,
ATI—ZS 14175Vl
-(C1_4 alkyl)tetrahydrofuranyl, -(C1_4 alkyl)dioxolanyl, (C1_4 alkyl)furanyl,
(C1_3 thiophenyl, or -(C1_3 all<yl)pyridyl.
In some embodiments of compounds of formula (I), R1 is selected from
branched C1-8 alkyl,
nfifiee
:98 Q3 “93ija JMQ
wherein
R3, is halogen, -CF3, -(C1_4 alkyl), -(C1_6 lkyl), -NR2, -(C0_3 alkyl)OR,
-(C0_3 alkyl)OR”, -NRC(O)R’, -C(O)R’, -C(O)NR2, -C(O)OR’, or -NRS(O)2R’;
R4, is —C(O)R’, or -C(O)OR’;
each R is independently H, or C1_4 alkyl, wherein the alkyl is optionally
ated;
each R’ is independently C1_4 alkyl, wherein the alkyl is optionally
fluorinated;
each R” is independently a C1_6 cycloalkyl wherein the cycloalkyl is
optionally fluorinated; and
n is 0-2.
In some such embodiments, R3 is methyl, ethyl, t-butyl, cyclopropyl, -CF3,
-F, -OH, -OCH3, -OCHF2, -OCF3, -OCH2CH3, -OCH2CH2F, -OCH2CF3, -O(cyclopropyl),
-CH20H, -CH20CH3, -C(CH3)20H, -NH2, -NH(CH3), -NHC(O)CH3, -C(O)NHCH3,
-C(O)N(CH3)2, or -NHSOZCH3.
[005 7] In some embodiments, R2 is a substituted or unsubstituted C1_g alkyl, for
e, , ethyl, n-propyl, isopropyl, n-butyl, tyl, isobutyl, tert-butyl,
tert-pentyl, isopentyl, or 2-methylpentyl. In other embodiments, R2 is methyl, ethyl,
n-propyl, isopropyl, l, sec-butyl, isobutyl, tert-butyl, 3-methylbutyl,
methylbutyl, 3,3-dimethylbutyl, 2,3,3-trimethylbutyl, tert-pentyl, isopentyl, 3-pentyl,
ATI—2514l75Vl
3-methylpentyl, 2-methylpentyl, or 2,4-dimethylpentyl. In some such embodiments, R2 is
substituted with one or more -(C1_4 alkyl), -(C0_3 alkyl)OR, -C(O)NR2 or -NRCOR’,
wherein each R is ndently H, or C1_4 alkyl, wherein the alkyl is optionally
fluorinated, and each R’ is independently C1_4 alkyl, n the alkyl is optionally
fluorinated. For example, R2 is substituted with one or more -OH, or -CH3. In other
embodiments, R2 is substituted with one or more -OH, -OCH3, or -CH3. In some
embodiments, R2 is a substituted or unsubstituted cycloalkyl, for example, R2 is
cyclopropyl, utyl, cyclopentyl, cyclohexyl, cycloheptyl, or cyclooctyl. In some
such embodiments, R2 is tuted with one or more -(C1_4 , -(C0_3 alkyl)OR,
-(C0_3 C(O)NR2, -NR2, or -NRCOR’, wherein each R is independently H, or
C1_4 alkyl, wherein the alkyl is ally fluorinated, and each R’ is independently
C1_4 alkyl, wherein the alkyl is optionally fluorinated. In other embodiments, R2 is
cyclopropyl, utyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl,
o[l.l.l]pentyl, bicyclo[2. 1.1]hexyl, or bicyclo[2.2.l]heptyl. In some such
embodiments, R2 is substituted with one or more -CF3, -(C1_4 , -(C1_6 cycloalkyl),
-(C0_3 alkyl)OR, -(C0_3 alkyl)C(O)NR2, -NR2, or -NRCOR’, wherein each R is
independently H, or C1_4 alkyl, wherein the alkyl is optionally fluorinated, each R’ is
independently C1_4 alkyl, wherein the alkyl is optionally fluorinated, and wherein the
cycloalkyl is optionally ated. In some such embodiments, R2 is substituted with one
or more methyl, ethyl, isopropyl, -CH20H, -OH, -OCH3, -OCH2CH3, H2, -
NHC(O)CH3, or -NHC(O)CH2CH3. In others, R2 is substituted with one or more methyl,
ethyl, isopropyl, -cyclopropyl, -CF3, -CH20H, -OH, -OCH3, -OCH2CH3, -C(O)NH2, -
NHC(O)CH3, or -NHC(O)CH2CH3. In some embodiments, R2 is a tuted or
unsubstituted alkylcycloalkyl, for example, a substituted or unsubstituted
(C1_3 alkyl)cyclopropyl, (C1_3 alkyl)cyclobutyl, (C1_3 alkyl)cyclopentyl, or
(C1_3 alkyl)cyclohexyl. For example, R2 is —(CH2)cyclopropyl, -(CH2)cyclobutyl,
-CH(CH3)cyclopropyl, -CH(CH3)cyclobutyl, -CH(CH2CH3)cyclopropyl,
-C(CH3)2cyclopropyl, or —CH2CH2cyclobutyl. In some embodiments, R2 is a substituted
or unsubstituted non-aromatic heterocyclyl, for example, tetrahydrofuranyl,
tetrahydropyranyl, piperidyl, piperidinonyl or l,4-dioxaspiro[4.5]decanyl. In others, R2 is
oxetanyl, tetrahydrofilranyl, tetrahydropyranyl, piperidyl, piperidinonyl or
ATI—ZS 14175Vl
l,4-dioxaspiro[4.5]decanyl. In some such embodiments, R2 is substituted with one or
more -(C1_4 alkyl), -(C0_3 alkyl)OR, or -C(O)R’, wherein each R is independently H, or
C1_4 alkyl, wherein the alkyl is optionally fluorinated, and each R’ is independently
C1_4 alkyl, wherein the alkyl is optionally fluorinated.
In some embodiments of compounds of formula (I), R2 is a substituted or
unsubstituted C1_g alkyl,
JEFF“ l \
/ !}L¢ a'fiL E >R5n
9 k 9
R5.“ 9 QR5H
R6' 0
N/ >11; 0
:71 ‘1’.
\R5'n 2.
,Q/ i or 5-
R5'n’ /”7.A R5n. ’ R
R5; “
wherein
R5, IS —CF3, -(C1_4 alkyl), -(C1_6 cycloalkyl), -(C0_3 alkyl)OR,
-(C0_3 alkyl)C(O)NR2, -NR2, or -NRCOR’, wherein the cycloalkyl is ally
fluorinated;
R6, is H, or -C(O)R’;
each R is independently H, or C1_4 alkyl, wherein the alkyl is optionally
fluorinated;
each R’ is independently C1_4 alkyl, wherein the alkyl is ally
ated; and
n is 0-2.
In some such embodiments, R5, is , ethyl, isopropyl, -cyclopropyl,
-CF3, , -OH, -OCH3, -OCH2CH3, -C(O)NH2, )CH3, or -NHC(O)CH2CH3.
In some embodiments, R6’ is H or H3, —C(O)CH2CH3, —C(O)CH(CH3)2, or
-C(O)CH2CH(CH3)2.
In some such embodiments of R2, R1 is a cycloalkyl, optionally substituted
with one or more halogen, -CF3, -(C1_4 alkyl), -(C1_6 cycloalkyl), -NR2, -(C0_3 alkyl)OR,
-(C0_3 alkyl)OR”, -NRC(O)R’, -C(O)R’, -C(O)NR2, -C(O)OR’, or -NRS(O)2R’, wherein
each R is independently H, or C1_4 alkyl, wherein the alkyl is optionally fluorinated, each
ATI—ZS 14175Vl
R’ is independently C1_4 alkyl, wherein the alkyl is optionally fluorinated, and each R” is
independently a C1_6 cycloalkyl., wherein the lkyl is optionally fluorinated.
Further embodiments ed herein include combinations of one or more
of the particular embodiments set forth above.
Representative compounds of formula (I) are set forth in Table l.
In some embodiments, the compound is selected from Table 2.
ed herein are compounds having the following formula (1B):
HN N NH
R3 R4
(13)
and pharmaceutically acceptable salts, tautomers, stereoisomers,
enantiomers, isotopologues, and prodrugs thereof,
wherein:
R3 is substituted or unsubstituted C1_g alkyl, substituted or unsubstituted
cycloalkyl, substituted or unsubstituted omatic heterocyclyl, substituted or unsubstituted
alkylcycloalkyl, or substituted or unsubstituted alkyl-(non—aromatic heterocyclyl); and
R4 is substituted or tituted C1_g alkyl, tuted or unsubstituted
cycloalkyl, or substituted or unsubstituted non-aromatic heterocyclyl.
In one embodiment, the compound is not
4-(isopentylamino)(3 -(2-methylpiperidin- l -yl)propylamino)pyrimidine-
-carbonitrile
WNAN/I A)\
H H
(28,2'S)—dimethyl 2,2'-(5-cyanopyrimidine-2,4-diyl)bis(azanediyl)-
bis(4-methylpentanoate)
ATI—2514l75v1
HN)\ “Y/ N I
N/ ”\V 0\
Mo\ 0
S)—diethy1 2,2'-(5-cyanopyrimidine-2,4-diy1)bis(azanediyl)—
bis(3-methy1butanoate)
\/O 'I NY|[NAN/
O WO
4-(cycloheptylamino)—2-(3-(2-methy1piperidin-1 -y1)propy1amino)-
pyrimidine-5 -carbonitrile
4-(4-methy1cyclohexylamino)(3-(2-methy1piperidiny1)propy1amino)—
pyrimidine-5 -carbonitrile
OCANXN/I N
H H
' 01‘
2-(3-(diethy1amino)propy1amino)—4-(4-methy1cyclohexylamino)pyrimidine-
-carbonitrile
jMMAN/| M
In one embodiment of nds of formula (1B), R3 is a branched
C1_g alkyl, for example, R3 is isopropyl, sec-butyl, isobutyl, tert-butyl, isopentyl,
ATI—ZS 14175V1
2-methylpentyl, or tert-pentyl. In other embodiments, R3 is isopropyl, sec-butyl, isobutyl,
tert-butyl, 2,3-dimethylbutyl, isopentyl, 2-methylpentyl, tyl, tert-pentyl, or
ylpentyl. In some embodiments, R3 is tert-butyl. In other ments, R3 is a
substituted or unsubstituted cycloalkyl, for example, cyclopropyl, cyclobutyl, cyclopentyl,
cyclohexyl, cycloheptyl, cyclooctyl, bicyclo[l.l.l]pentyl, or bicyclo[2.2.2]octyl. In some
such embodiments, R3 is cyclopropyl, cyclobutyl, cyclopentyl, exyl, cycloheptyl,
cyclooctyl, bicyclo[l.l.l]pentyl, bicyclo[2.2. l]heptyl, or bicyclo[2.2.2]octyl. In some
embodiments, R3 is cyclobutyl or cyclohexyl. In some embodiments, the cycloalkyl is
substituted with one or more halogen, -CF3, -(C1_4 alkyl), -(C1_6 cycloalkyl), -NR2,
-(C0_3 alkyl)OR, -(C0_3 OR”, -NRC(O)R’, -C(O)R’, -(C0_3 alkyl)C(O)NR2,
-C(O)OR’, or -NRS(O)2R’, wherein each R is independently H, or C1_4 alkyl, wherein the
alkyl is optionally fluorinated, and each R’ is independently C1_4 alkyl, wherein the alkyl is
optionally fluorinated, and each R” is independently a C1_6 cycloalkyl, n the
cycloalkyl is optionally fluorinated. For example, the cycloalkyl is tuted with one or
more methyl, ethyl, t-butyl, cyclopropyl, -CF3, -F, -OH, -OCH3, -OCHF2, -OCF3,
-OCH2CH3, -OCH2CH2F, F3, -O(cyclopropyl), , -CH20CH3,
-C(CH3)20H, -NH2, -NH(CH3), -NHC(O)CH3, -C(CH3)2C(O)N(CH3)2, -C(O)NHCH3,
-C(O)N(CH3)2, or -NHSOZCH3. In other embodiments, the cycloalkyl is substituted with
one or more halogen, -(C1_4 , -NR2, -(C0_3 alkyl)OR, -NRC(O)R’, -C(O)R’,
-(C0_3 alkyl)C(O)NR2, -C(O)OR’, or -NRS(O)2R’, wherein each R is ndently H, or
C1_4 alkyl, wherein the alkyl is optionally fluorinated, and each R’ is independently
C1_4 alkyl, wherein the alkyl is optionally fluorinated. For example, the cycloalkyl is
substituted with one or more methyl, ethyl, t-butyl, -F, -OH, -OCH3, -OCHF2, -OCF3,
-OCH2CH3, -OCH2CH2F, -OCH2CF3, -O(cyclopropyl), -CH20H, -CH20CH3,
-C(CH3)20H, -NH2, -NH(CH3), -NHC(O)CH3, )2C(O)N(CH3)2, -C(O)NHCH3,
-C(O)N(CH3)2, or CH3. In some embodiments, the cycloalkyl is substituted with
one or more methyl, -F, -OH, -OCH3, -OCH2CH3, -OCHF2, -OCH2CF3, -NH(CH3),
)CH3, -C(O)N(CH3)2, or -C(CH3)2C(O)N(CH3)2. In yet other embodiments, R3
is a substituted or unsubstituted non-aromatic heterocyclyl, for example, idinyl,
tetrahydrofilranyl, tetrahydropyranyl, l,4-dioxaspiro[4.5]decanyl, or piperidyl. In some
embodiments, the non-aromatic heterocyclyl is oxetanyl, tetrahydrofuranyl,
ATI—2514l75vl
ydropyranyl, piperidyl, piperidinonyl or l,4-dioxaspiro[4.5]decanyl. In some
embodiments, R3 is tetrahydropyranyl. In some embodiments, the piperidyl is substituted
with —C(O)R’, or -C(O)OR’, wherein R’ is C1_4 alkyl, n the alkyl is optionally
fluorinated. In some embodiments, R3 is a substituted or unsubstituted alkylcycloalkyl, for
example, (C1_3 alkyl)cyclopropyl, (C1_3 alkyl)cyclobutyl, (C1_3 alkyl)cyclopentyl, or
(C1_3 alkyl)cyclohexyl. In some embodiments, R3 is -(CH2)cyclopropyl, -(CH2)cyclobutyl,
-(CH2)cyclopentyl, -(CH2)cyclohexyl, -CH(CH3)cyclopropyl, -CH(CH3)cyclobutyl,
-CH(CH3)cyclopentyl, or 3)cyclohexyl. In others, R3 is cyclopropyl,
-CH(CH3)cyclopropyl, -CH(CH3)cyclobutyl, 3)cyclohexyl, or
-C(CH3)2cyclopropyl. In some embodiments, R3 is a substituted or unsubstituted alkyl-
(non-aromatic heterocyclyl), for example, -(C1_4 alkyl)tetrahydrofuranyl, or
-(C1_4 alkyl)dioxolanyl.
In some embodiments of nds of formula (1B), R3 is selected from
branched C1_g alkyl,
J?\:nLW5%;5 '2 ‘7 E‘s/Q
C 0
is R33” £1 \RS'; 3, \RSn 39 JR3; ’ R%
wherein
R3, is halogen, -CF3, -(C1_4 , -(C1_6 cycloalkyl), -NR2, -(C0_3 alkyl)OR,
-(C0_3 alkyl)OR”, -NRC(O)R’, -C(O)R’, -C(O)NR2, -C(O)OR’, or )2R’;
R4, is —C(O)R’, or -C(O)OR’;
each R is independently H, or C1_4 alkyl, wherein the alkyl is optionally
fluorinated;
each R’ is independently C1_4 alkyl, wherein the alkyl is optionally
fluorinated;
each R” is independently a C1_6 cycloalkyl, wherein the cycloalkyl is
optionally fluorinated; and
n is 0-2.
ATI—ZS 14175Vl
In some embodiments, R3 is methyl, ethyl, t-butyl, cyclopropyl -CF3, -F,
-OH, -OCH3, -OCHF2, -OCF3, -OCH2CH3, -OCH2CH2F, -OCH2CF3, -O(cyclopropyl),
-CH20H, -CH20CH3, -C(CH3)20H, -NH2, -NH(CH3), )CH3, -C(O)NHCH3,
-C(O)N(CH3)2, or -NHSOZCH3.
In some embodiments of compounds of formula (IB), R3 is ed from
branched C1_g alkyl,
1,11 Q fix 0 0
’,QR3”, / RBIn , ELL \RB'n 21L \RB'n or
’ ’ 3'1LJ
L \RB. , R3'n
R3, is n, -(C1_4 alkyl), -NR2, -(C0_3 alkyl)OR, -NRC(O)R’, -C(O)R’,
-(C0_3 alkyl)C(O)NR2, -C(O)OR’, or )2R’;
each R is independently H, or C1_4 alkyl, n the alkyl is ally
fluorinated, each R’ is independently C1_4 alkyl, wherein the alkyl is optionally fluorinated;
n is 0-2.
In some such embodiments, R3, is methyl, ethyl, t-butyl, -F, -OH, -OCH3,
-OCHF2, -OCF3, -OCH2CH3, -OCH2CH2F, -OCH2CF3, -CH20H, -CH20CH3,
-C(CH3)20H, -NH2, -NH(CH3), -NHC(O)CH3, -C(CH3)2C(O)N(CH3)2, -C(O)NHCH3,
-C(O)N(CH3)2, or CH3
In some embodiments of compounds of formula (IB), R4 is a substituted or
tituted C1_g alkyl, for example, methyl, ethyl, n-propyl, isopropyl, n-butyl,
sec-butyl, isobutyl, tert-butyl, isopentyl, 2-methylpentyl, or tert-pentyl. In some
embodiments, R4 is methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl,
tert-butyl, 3-methylbutyl, 2,3-dimethylbutyl, 3,3-dimethylbutyl, 2,3,3-trimethylbutyl,
tert-pentyl, isopentyl, 3-pentyl, 3-methylpentyl, 2-methylpentyl, or 2,4-dimethylpentyl. In
some embodiments, R4 is isopropyl, isobutyl, isopentyl, tert-butyl, or tert-pentyl. In some
such embodiments, R4 is tuted with one or more -(C1_4 alkyl), -(C0_3 alkyl)OR,
-C(O)NR2 or ’, wherein each R is independently H, or C1_4 alkyl, wherein the
alkyl is optionally fluorinated, and each R’ is independently C1_4 alkyl, wherein the alkyl is
optionally fluorinated. For example, R4 is substituted with one or more -OH, or -CH3. In
ATI—2514l75vl
some other embodiments, R4 is a substituted or unsubstituted cycloalkyl, for example,
ropyl, utyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl,
bicyclo[l.l.l]pentyl, bicyclo[2. l.l]hexyl, or bicyclo[2.2.l]heptyl. In some embodiments,
R4 is cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, or o[l . l .l]pentyl. In some
ments, R4 is substituted with one or more halogen, -CF3, -(C1_4 alkyl),
-(C1_6 cycloalkyl), -(C0_3 alkyl)OR, -(C0_3 alkyl)C(O)NR2, -NR2, or -NRCOR’, n
each R is independently H, or C1_4 alkyl, wherein the alkyl is optionally fluorinated, each
R’ is independently C1_4 alkyl, wherein the alkyl is optionally fluorinated, and wherein the
lkyl is optionally fluorinated. For example, R4 is substituted with one or more
methyl, ethyl, isopropyl, -cyclopropyl, -CF3, -CH20H, -OH, -OCH3, -OCH2CH3,
-C(O)NH2, -NHC(O)CH3, or -NHC(O)CH2CH3. In some embodiments, R4 is substituted
with one or more halogen, -(C1_4 alkyl), -(C0_3 alkyl)OR, -(C0_3 alkyl)C(O)NR2, -NR2, or
-NRCOR’, wherein each R is independently H, or C1_4 alkyl, wherein the alkyl is
optionally fluorinated, and each R’ is independently C1_4 alkyl, wherein the alkyl is
optionally fluorinated. In some such embodiments, R4 is tuted with one or more F,
methyl, ethyl, isopropyl, -CH20H, -OH, -OCH3, -OCH2CH3, -OCHF2, -OCH2CF3,
-C(O)NH2, -C(O)NHCH3, -C(O)N(CH3)2, -CH2C(O)NH2, -CH2C(O)NHCH3,
O)N(CH3)2, -CH(CH3)C(O)NH2, -CH(CH3)C(O)NHCH3, -CH(CH3)C(O)N(CH3)2,
-C(CH3)2C(0)NH2, ) HCH3, -C(CH3) 2C(O)N(CH3)2, -NH(CH3),
-NHC(O)CH3, or -NHC(O)CH2CH3. In some embodiments, R4 is substituted with one or
more methyl, ethyl, -F, -CH20H, or -OH. In some embodiments, R4 is a substituted or
tituted non-aromatic cyclyl, for example, yl, tetrahydrofuranyl,
tetrahydropyranyl, piperidyl, piperidinonyl or l,4-dioxaspiro[4.5]decanyl. In some
embodiments, R4 is tetrahydrofuranyl or tetrahydropyranyl. In some such embodiments,
R4 is substituted with one or more -(C1_4 alkyl), -(C0_3 alkyl)OR, or -C(O)R’, wherein each
R is independently H, or C1_4 alkyl, wherein the alkyl is optionally fluorinated, and each R’
is independently C1_4 alkyl, wherein the alkyl is optionally fluorinated.
ATI—2514l75vl
In some embodiments of compounds of a (IB), R4 is a substituted or
unsubstituted C1_g alkyl,
wherein
R5, is —CF3, -(C1_4 alkyl), -(C1_6 cycloalkyl), -(C0_3 alkyl)OR,
-(C0_3 C(O)NR2, -NR2, or -NRCOR’, wherein the cycloalkyl is optionally
fluorinated;
R6, is H, or -C(O)R’;
each R is independently H, or C1_4 alkyl, wherein the alkyl is ally
fluorinated;
each R’ is independently C1_4 alkyl, wherein the alkyl is ally
fluorinated; and
n is 0-2.
In some such embodiments, R5, is methyl, ethyl, isopropyl, propyl,
-CF3, -CH20H, -OH, -OCH3, -OCH2CH3, -C(O)NH2, -NHC(O)CH3, or -NHC(O)CH2CH3.
In some embodiments, R6’ is H or —C(O)CH3, —C(O)CH2CH3, —C(O)CH(CH3)2, or
-C(O)CH2CH(CH3)2.
In some embodiments of compounds of formula (IB), R4 is a substituted or
unsubstituted C1_g alkyl,
21L \ . O \
a :51 a a
n \R5.n R5
E O
§
L \Rsln or ‘71,
’ R5
wherein
R5, is halogen, -(C1_4 alkyl), -(C0_3 alkyl)OR, -(C0_3 alkyl)C(O)NR2, -NR2, or
_ 28 _
ATI—2514l75vl
-NRCOR’;
each R is independently H, or C1_4 alkyl, n the alkyl is optionally
fluorinated;
each R’ is ndently C1_4 alkyl, wherein the alkyl is optionally fluorinated;
n is 0-2.
In some such embodiments, R5, is F, methyl, ethyl, isopropyl, -CH20H, -OH,
-OCH3, -OCH2CH3, -OCHF2, -OCH2CF3, -C(O)NH2, -C(O)NHCH3, -C(O)N(CH3)2,
-CH2C(O)NH2, -CH2C(O)NHCH3, -CH2C(O)N(CH3)2, -CH(CH3)C(O)NH2,
-CH(CH3)C(O)NHCH3, -CH(CH3)C(O)N(CH3)2, -C(CH3)2C(O)NH2, -C(CH3) 2C(O)NHCH3,
-C(CH3) 2C(O)N(CH3)2, -NH(CH3), -NHC(O)CH3, or -NHC(O)CH2CH3. In some embodiments,
R5’ is F, -OH, -OCH3, -OCH2CH3, -OCHF2, -OCH2CF3, -NH(CH3), -NHC(O)CH3,
-C(O)N(CH3)2, -C(CH3)2C(O)N(CH3)2.
In some embodiments, wherein R4 is a substituted or tituted
cycloalkyl, R3 is a cycloalkyl, optionally substituted with one or more halogen, -CF3,
-(C1_4 alkyl), -(C1_6 cycloalkyl), -NR2, -(C0_3 OR, -(C0_3 alkyl)OR”, -NRC(O)R’,
-C(O)R’, -C(O)NR2, -C(O)OR’, or -NRS(O)2R’, wherein each R is independently H, or
C1_4 alkyl, wherein the alkyl is optionally fluorinated, each R’ is independently C1_4 alkyl,
wherein the alkyl is optionally fluorinated and each R” is independently a C1_6 cycloalkyl,
n the lkyl is optionally fluorinated.
r embodiments provided herein include combinations of one or more
of the particular embodiments set forth above.
Representative compounds of formula (IB) are set forth in Table 3.
Diaminopyrimidine nds set forth in Table 1, Table 2, and Table 3
were tested in the INK inhibitor assays described herein and were found to have activity as
JNK inhibitors. In one ment, the Diaminopyrimidine Compound is a compound as
described , wherein the compound at a concentration of 10 uM inhibits JNK1 by at
least about 50% or more.
ATI—2514l75v1
METHODS FOR MAKING DIAMINOPYRIMIDINE COMPOUNDS
The Diaminopyrimidine nds can be made using conventional
organic syntheses and commercially available starting materials. By way of e and
not limitation, Diaminopyrimidine Compounds of formula (I) can be prepared as outlined
in Schemes 1-9 shown below as well as in the examples set forth . It should be
noted that one skilled in the art would know how to modify the procedures set forth in the
illustrative schemes and examples to arrive at the desired ts.
0 o o o
X X
SkN/NYO’R—» NYINL lYNN lYN/
CI SkN/ NH 8 N/ NH 8 N NH
éx éx R2 éx R2 éx R2
0 0
R‘NJ\N/1 NYN m RX iYN/ NH \5 N N“
H éz (5)m R2
As shown in Scheme 1, compounds of formula (I), wherein R1 and R2 are
as defined herein, can be prepared starting from an appropriately derivatized 4-chloro
alkylthiopyrimidine carboxylate ester (wherein each Rx is independently a C1_2 alkyl), by
treatment with RZNHZ at elevated ature (for example 60-80 c’C) in an organic
solvent (for example, ethanol, methanol, isopropanol, THF, NMP, DMF, DMSO, or
dioxane), in the presence of a base (for example, DIEA, TEA, N—methylmorpholine,
l,8-diazabicyclo[5.4.0]undecene, cesium carbonate, sodium ate, sodium
bicarbonate, potassium carbonate, or potassium phosphate). Hydrolysis of the ester is
achieved by treatment with an aqueous base, such as for example s sodium
hydroxide, potassium hydroxide, or lithium hydroxide, in a cosolvent such as ethanol,
methanol, isopropanol, THF, or dioxane. Amide formation is accomplished by reaction
with NH4Cl in the ce of a coupling agent (such as, for example, HATU, CDI,
HBTU, EDC optionally in combination with HOBt, or ethyl chloroformate), in an organic
solvent, such as NMP, DMF, DMSO, dioxane, THF, DCM, or chloroform, in the presence
of a base (such as DIEA, TEA, or potassium carbonate). Oxidation of the hiol
ATI—2514l75v1
moiety is achieved by ent in an organic solvent (such as, for example, acetone,
DCM, NMP, DMF, or chloroform) with an oxidant such as mCPBA, oxone, hydrogen
peroxide, or 3-phenyl(phenylsulfonyl)-l ,2-oxaziridine. The resulting e of
e (m = l) and sulfoxide (m = 2) is treated at elevated temperature (for example,
80-100 C’C) with RlNHz in a solvent (such as, for example, e, DMSO, NMP, DMF,
THF, or water) in the presence of an organic base, such as DIEA, TEA,
N—methylmorpholine, or 1,8-diazabicyclo[5.4.0]undecene, to afford the compounds of
formula (I).
o o
o o
,R" ,R" N \ o’ N \ OH
N\ 0 Nasr N\ 0 R‘NHz
—> A —> A AY
A / /
N N
CI N/ CI CI N/ S’RX HIT] § HIT] §
R1 Rx R1 Rx
N \ o’ NH4C|
§ N Cl 0
N \ NH
0 0 if 2
HN N/
RZNHz s
N \ NH2 N \ NH2 -1 .X
JL / _ JL / R R
Rx /
HN N NH HN N fi’
R1 R2 R1 (om
Selle—r1162
Alternatively, compounds of formula (I) can be prepared as shown in
Scheme 2 (wherein R1, R2 and RK are as defined above). Treatment of a
2,4-dichloropyrimidinecarboxylate alkyl ester with NaSRX in an organic solvent (for
example THF, DCM, or dioxane) in the presence of a catalyst (for example,
triethylbenzylammonium chloride, tetrabutylammonium chloride, or tetrabutylammonium
bromide), under cooling (for example, at -10 CC) affords a mixture of thioalkyl derivatives.
uent treatment with RINHZ at elevated temperature (e.g. 80 CC) in an organic
solvent (for e, dioxane, THF, NMP, DMF, DMSO, l, methanol, or
isopropanol), in the presence of a base (for example, DIEA, TEA, N—methylmorpholine,
azabicyclo[5.4.0]undecene, cesium carbonate, sodium carbonate, sodium
bicarbonate, potassium carbonate, or potassium phosphate) incorporates the R1 sidechain.
Hydrolysis of the alkyl ester, coupling with NH4Cl and oxidation as above, provides a
mixture of sulfone (m = l) and sulfoxide (m = 2) derivatives, which upon ent with
RZNHZ in a solvent (such as dioxane, NMP, DMF, DMSO, THF, or water), in the presence
_ 31 _
ATI—2514l75v1
of an organic base (such as DIEA, TEA, l,8-diazabicyclo[5.4.0]undecene, or
N—methylmorpholine), at elevated temperature (e.g. 80- 110 oC) provides the compounds
of formula (I).
o o o
X X
)L / —2’C|)\N/RZNH RlNH
NH HN N/ NH —> HNAN/ NH
+ o
1\ 0’ 0
N N/ CI N \ NH2
H JL /
HN N NH
R1 R2
Scheme3
Compounds of a (I) can also be prepared as shown in Scheme 3.
Treatment of 2,4-dichloropyrimidinecarboxylate alkyl ester with RZNHZ in a solvent
(for example, ethyl ether, THF, DCM, toluene, or methyl tert-butyl ether) in the presence
of a base (for example, DIEA, TEA, l,8-diazabicyclo[5.4.0]undecene,
N—methylmorpholine, sodium bicarbonate, cesium carbonate, or potassium phosphate) at
low temperature (for example, -70 CC) provides uction of the R2 sidechain.
Separation of the mixture of regioisomers, and hydrogenation of the remaining chlorine in
a sample allows for eric assignment of the R2 sidechain incorporation. The desired
regioisomer compound is then fithher derivatized. Subsequent treatment with RINHZ in an
c solvent (for example, THF, NMP, DMF, DMSO, dioxane, ethanol, methanol, or
panol) in the presence of a base (for example, DIEA, TEA,
l,8-diazabicyclo[5.4.0]undecene, N—methylmorpholine, sodium carbonate, sodium
bicarbonate, cesium carbonate, or potassium phosphate) at elevated temperature (for
example, 70 oC) es introduction of the R1 sidechain. Hydrolysis of the alkyl ester
and coupling with NH4Cl, as , provides the compounds of formula (I).
ATI—2514l75vl
/N /N
/N / /
/ R NH22 N \ R NH21 N \
N \ H202 \
A / R1 )L /
)L / ‘
CI N NH N N NH R1\NJ\N/NI/jfLNHZNH
CI N CI II?2 H F32 H
(I) éz
RZ‘MJLN/ CI
Scheme 4
An alternative method to the sis of compounds of formula (I) is
shown in Scheme 4. Treatment of 2,4-dichloropyrimidinecarbonitrile with RZNHZ in an
organic solvent (for example, ethanol, ol, isopropanol or THF) in the presence of a
base (for example, DIEA, TEA, l,8-diazabicyclo[5.4.0]undecene, N-methylmorpholine,
sodium carbonate, sodium onate, cesium carbonate, or potassium phosphate) at low
temperature (for example, -60 OC) es introduction of the R2 sidechain. As before,
hydrogenation of the remaining chlorine allows for regioisomeric assignment of the R2
incorporation. Subsequent treatment with RINHZ in an organic solvent (for example,
l-butanol, THF, NMP, DMF, DMSO, dioxane, ethanol, methanol, or isopropanol) in the
presence of a base (for example, cesium ate, ium carbonate, sodium
carbonate, sodium bicarbonate, ium phosphate, l,8-diazabicyclo[5 .4.0]undecene,
N-methylmorpholine, DIEA, or TEA) at elevated temperature (for example, 120 CC)
provides introduction of the R1 sidechain (providing in some instances when R1 = R3 and
R2 = R4, compounds of formula (IB)). Conversion of the e moiety with, for example,
catalytic peroxide, in the presence of a strong aqueous base, such as sodium hydroxide or
potassium hydroxide, in a t, such as, for example, DMSO, NMP, DMF, ethanol or
methanol, provides the compounds of formula (I).
o o O
/N / N
/ / \ \ N \ NH
i\ RZNH N \ N NH2 N NH2 RlNH 2
41/ —»|/ —»Rx\x/ —»2 A/
s N/ N
Cl 8 N NH 177 N NH .3: N NH HN NH
éx lIRX R2 RX R2 (mm R2 R1 R2
Scheme5
0085 Yet r method for the synthesis of com ounds of formulaP I is shown
in Scheme 5. Treatment of 4-chloro(alkylthio)pyrimidinecarbonitrile with RlNHgin
an organic solvent (for example, n-butanol, NMP, DMF, DMSO, dioxane, or ethanol) in
ATI—2514l75v1
the presence of a base (such as, for example, DIEA, TEA, N—methylmorpholine,
l,8-diazabicyclo[5.4.0]undecene, potassium carbonate, sodium carbonate, sodium
bicarbonate, cesium carbonate, or ium phosphate), at a temperature between 50 oC
and 90 oC) introduces the R1 sidechain. Conversion of the carbonitrile to the amide, for
example by treatment with peroxide (H202), in a a solvent (such as, for example, DMSO,
NMP, DMF, ethanol, or methanol), in the presence of a base (such as sodium ide or
potassium hydroxide), and oxidation, (for example using mCPBA, oxone, hydrogen
peroxide, or yl(phenylsulfonyl)-l ,2-oxaziridine, in a solvent such as DCM,
NMP, DMF, or DMA), provides the mixture of e (m=l) and sulfoxide (m = 2) as
before, which can be treated with RZNHZ in a solvent such as (dioxane, DMSO, NMP,
DMF, THF, or n-butanol) in the ce of a base (such as DIEA, TEA,
l,8-diazabicyclo[5.4.0]undecene, or ylmorpholine), optionally at elevated
temperature (for e, between room temperature and 130 0C) to provide compounds
of formula (I).
B N
N\ rR1NH2 N\Br N\// N\ NH2
A / —’ I —>
/ I )L /
Cl N s HN N s )x / HN N s
. I HN N s .1 IX
RX R1 RX F3 ng R R
/N /N
/ /
N \ RZNHZ N \
)L / RX —’ )L /
HN N T3 HN N NH
R1 (O)m R1 i R2
o o
1%“.2R NH2 l\ x
HN N/ NH HN N/ s’R
R1 R2 R1 (0)m
Scheme6
Compounds of formula (I) can also be obtained as shown in Scheme 6.
Treament of 5-bromochloro(alkylthio)pyrimidine with RINHZ in an organic solvent
(for example, n-butanol, NMP, DMF, DMSO, dioxane, or ethanol) in the presence of a
base (such as, for example, DIEA, TEA, ylmorpholine, l,8-diazabicyclo-
[5.4.0]undecene, potassium carbonate, sodium carbonate, sodium bicarbonate, cesium
carbonate, or potassium phosphate), at a temperature between 80 oC and 100 oC,
_ 34 _
ATI—2514l75vl
introduces the R1 sidechain. Introduction of the itrile moiety is achieved by
treatment with zinc and dicyanozinc in a solvent (such as DMF, DMSO, NMP, or DMA)
in the presence of a catalyst such as Pd(O), at elevated temperature (for example, n
80 oC — 100 oC). As before, conversion to the amide moiety by treatment with peroxide,
followed by oxidation to the sulfone/sulfoxide, and treatment with RZNHZ provides the
compounds of formula (1). Alternatively, the alkylthio moiety is oxidized first, followed
by introduction of the R2 sidechain, (providing in some instances when R1 = R3 and
R2 = R4 compounds of formula (IB)), and conversion to the amide moiety, provides
compounds of formula (I).
Alternatively, opyrimidine Compounds of Formula (1B), wherein R3
and R4 are as defined herein, can be made as ed in Schemes 7, 8 and 9 shown below,
as well as in the examples set forth herein. It should be noted that one skilled in the art
would know how to modify the procedures set forth in the illustrative schemes and
examples to arrive at the desired product.
if!»R4—»”“21/ R—W AT
RiMJLN/ CI
Scheme 7
As shown in Scheme 7, treatment of 2,4-dichloropyrimidinecarbonitrile
with R4NH2 in an organic t (for example, ethanol, methanol, isopropanol or THF) in
the presence of a base (for example, DIEA, TEA, l,8-diazabicyclo[5.4.0]undecene,
N—methylmorpholine, sodium carbonate, sodium bicarbonate, cesium carbonate, or
potassium phosphate) provides introduction of the R4 sidechain. Subsequent treatment
with R3NH2 in an organic t (for example, l-butanol, THF, NMP, DMF, DMSO,
e, ethanol, methanol, or isopropanol) in the ce of a base (for example, cesium
carbonate, potassium carbonate, sodium carbonate, sodium bicarbonate, potassium
phosphate, l,8-diazabicyclo[5.4.0]undecene, N—methylmorpholine, DIEA, or TEA) at
elevated temperature (for example, 50 0C to 90 oC) provides compounds of a (1B).
ATI—2514l75v1
ell/TNR3NH2 HNJNL/ij R4NH2 T
(”3)
Scheme 8
Alternatively, the R3 substituent is introduced first, followed by
introduction of the R4 substituent by essentially the same methods, as shown in Scheme 8.
In some embodiments, coupling with R4NH2 is med at a temperature n room
temperature and 110 CC.
WNW /:£/’Omi
—’ 3* RX\3* *N/
RxSiN/ NH
RScheme 9 (GmN/:E:N LNW HNN \UB)
In a third approach, compounds of formula (IB) can be prepared starting
from an appropriately derivatized 4-chloroalkylthiopyrimidine-carbonitrile (wherein
each Rx is independently a C1_2 alkyl), by treatment with R4NH2 at ed temperature
(for example 50 CC - 90 CC) in an organic solvent (for example, n-butanol, NMP, DMF,
DMSO, or dioxane), in the presence of a base (for example, DIEA, TEA,
N-methylmorpholine, l,8-diazabicyclo[5.4.0]undecene, potassium carbonate, sodium
ate, sodium bicarbonate, cesium carbonate or potassium phosphate). Oxidation of
the alkylthiol moiety is achieved by treatment in an organic solvent (such as, for example,
DCM, NMP, DMF, or DMA) with an oxidant such as mCPBA, oxone, hydrogen de,
or 3-phenyl(phenylsulfonyl)-l,2-oxaziridine. The resulting mixture of sulfone (m = l)
and sulfoxide (m = 2) is treated at room temperature or elevated temperature (for e,
CC - 110 CC) with R3NH2 in a solvent (such as, for example, dioxane, DMSO, NMP,
DMF, THF, or n-butanol) in the presence of an c base, such as DIEA, TEA, 1,8-
diazabicyclo[5.4.0]undecene, N-methylmorpholine, to afford the compounds of
formula (1B).
ATI—2514l75vl
In one aspect, provided herein are methods for preparing a compound of
formula (I):
)LN/YLNHZ/
HN N NH
{21 R2
the methods comprising contacting a compound of formula (la)
RKSJLNY
N/ NH
|| '
(O)m R2
(1a) 9
with RINHZ in a solvent, in the presence of an organic base,
wherein:
R1 is substituted or unsubstituted C1_g alkyl, substituted or unsubstituted
cycloalkyl, tuted or unsubstituted non-aromatic heterocyclyl, substituted or
unsubstituted alkylcycloalkyl, or substituted or unsubstituted alkylheterocyclyl, provided
that R1 is not l-aminocyclohexyl;
R2 is substituted or unsubstituted C1_g alkyl, substituted or unsubstituted
saturated cycloalkyl, substituted or unsubstituted alkylcycloalkyl, substituted or
unsubstituted non-aromatic heterocyclyl;
Rx is a C1_2 alkyl; and
m is l or 2.
In one ment, the compound of formula (I) is not 2-(2-aminoethyl-amino)—
hylamino)pyrimidinecarboxamide; 2-(2-aminopropylamino)
hexylamino)pyrimidinecarboxamide; 2-(2-aminooxoethylamino)
(cyclohexylamino)pyrimidinecarboxamide; 2—(2-aminoethylamino)—4-
(cyclohexylamino)pyrimidinecarboxamide; (S)(2-aminopropylamino)
butylamino)pyrimidinecarboxamide; (R)( l -aminomethyloxobutan
ylamino)(cyclobutylamino)pyrimidinecarboxamide; lopentylamino)
ATI—2514l75v1
2012/034349
(methylamino)pyrimidinecarboxamide; or 2-(l-acetylpiperidinylamino)
(cyclopropylamino)pyrimidinecarboxamide.
In one embodiment, the solvent is dioxane, DMSO, NMP, DMF, THF, or
water. In another, the base is DIEA, TEA, l,8-diazabicyclo[5.4.0]undecene, or
N—methylmorpholine. In some ments, the contacting is performed at elevated
temperature, for example, from about 80 °C to about 100 CC.
In some embodiments, the methods fithher comprise ing a compound
of formula (Ia):
Risk NYNH2
N/ NH
|| '
(O)m R2
(1a) 9
the methods comprising oxidizing a compound of formula (Ib)
N \ NH2
)L /
s N NH
RX R2
(1b),
in a solvent by treatment with an oxidant ed from mCPBA, oxone,
hydrogen peroxide, or 3-phenyl(phenylsulfonyl)-l ,2-oxaziridine.
In one embodiment, the solvent is e, DCM, NMP, DMF, or
chloroform. In some embodiments, the method is performed at a temperature between
about 0 0C to about 20 0C.
In some embodiments, the methods fithher comprise preparing a compound
of formula (Ib):
N%NH2
)L /
S N NH
I I
RX R2
(1b),
ATI—2514l75vl
the methods comprising ting a compound of formula (Ic)
N \ OH
)L /
s N NH
RX R2
(Ic),
with NH4Cl, in the presence of a coupling agent and a base, in a solvent.
In some embodiments, the solvent is NMP, DMF, DMSO, dioxane, THF,
DCM, or chloroform. In others, the coupling agent is HATU, CDI, HBTU, EDC/HOBt, or
ethyl chloroformate, and the base is DIEA, TEA, or potassium carbonate.
In some embodiments, the methods fiarther comprise preparing a compound
of formula (Ic)
N \ OH
)L /
s N NH
Flax R2
(10),
the methods sing contacting a compound of formula (Id)
N \ o’R
)L /
s N NH
F'ax R2
(1d),
with an aqueous base, in a cosolvent.
In some embodiments, the aqueous base is aqueous sodium hydroxide,
ium hydroxide, or lithium ide. In other embodiments, the cosolvent is
ethanol, methanol, isopropanol, THF, or dioxane.
ATI—ZS 14175Vl
In some embodiments, the methods fithher comprise preparing a compound
of a (Id)
N \ o’RX
S N NH
RX Fla?
(1d),
the methods comprising contacting a compound of formula (Ie)
(16),
with RZNHZ in an organic solvent, in the ce of a base.
In some embodiments, the organic solvent is ethanol, methanol,
isopropanol, THF, NMP, DMF, DMSO, or dioxane. In others, the base is DIEA, TEA,
N—methylmorpholine, 1,8-diazabicyclo[5.4.0]undecene, cesium carbonate, sodium
carbonate, sodium bicarbonate, potassium carbonate, or potassium phosphate. In some
embodiments, the contacting is performed at ed temperature, for example, from
about 60 0C to about 80 0C.
In some ments, the methods fiarther comprise preparing a compound
of a (Ib)
N \ NH2
)L /
s N NH
RX R2
(1b),
the methods comprising contacting a compound of formula (If)
s N NH
RX R2
ATI—ZS 14175v1
with peroxide, in the presence of a base, in a solvent.
In some embodiments, the solvent is DMSO, NMP, DMF, l, or ol.
In others, the base is sodium ide or potassium hydroxide.
In some embodiments, the methods fiarther comprise preparing a compound of
formula (If)
s N NH
RX R2
(If),
the methods comprising contacting a compound of formula (Ig)
A/NY
S N CI
(1g)
with RZNHZ in an organic solvent, in the presence of a base.
In some ments, the c solvent is n-butanol, NMP, DMF, DMSO,
dioxane, or ethanol. In others, the base is DIEA, TEA, N—methylmorpholine,
1,8-diazabicyclo[5.4.0]undecene, potassium ate, sodium carbonate, sodium
bicarbonate, cesium carbonate, or potassium phosphate. In some embodiments, the contacting is
performed at elevated temperature, for example, from about 50 0C to about 90 0C.
Further provided are methods for preparing a compound of formula (I):
N \ NH2
)L /
HN N NH
IIRl R2
the methods comprising contacting a compound of formula (11a)
HNAN/N1“fig
R1 (O)m
_ 41 _
ATI—ZS 14175v1
(Ha),
with RZNHZ in a solvent, in the presence of an c base,
wherein:
R1 is substituted or tituted C1_g alkyl, substituted or unsubstituted
cycloalkyl, substituted or tituted non-aromatic heterocyclyl, substituted or
unsubstituted ycloalkyl, or substituted or unsubstituted alkylheterocyclyl, provided
that R1 is not 1-aminocyclohexyl;
R2 is substituted or unsubstituted C1_g alkyl, substituted or unsubstituted
ted cycloalkyl, substituted or unsubstituted alkylcycloalkyl, substituted or
unsubstituted non-aromatic heterocyclyl;
Rx is a C1_2 alkyl; and
m is 1 or 2.
In one embodiment, the compound of formula (I) is not 2-(2-aminoethyl-
amino)(methylamino)pyrimidinecarboxamide; 2-(2-aminopropylamino)
(cyclohexylamino)pyrimidinecarboxamide; 2-(2-aminooxoethylamino)
hexylamino)pyrimidinecarboxamide; 2—(2-aminoethylamino)—4-
(cyclohexylamino)pyrimidinecarboxamide; (S)(2-aminopropylamino)
(cyclobutylamino)pyrimidinecarboxamide; (R)( 1 -aminomethyloxobutan
o)(cyclobutylamino)pyrimidinecarboxamide; 4-(cyclopentylamino)
lamino)pyrimidinecarboxamide; or 2-(1-acetylpiperidinylamino)
(cyclopropylamino)pyrimidinecarboxamide.
In one embodiment, the solvent is dioxane, DMSO, NMP, DMF, THF, or
water. In another, the base is DIEA, TEA, 1,8-diazabicyclo[5.4.0]undecene, or
N—methylmorpholine. In some embodiments, the contacting is performed at elevated
temperature, for example, from about 80 °C to about 110 CC.
In some embodiments, the methods fiarther comprise preparing a compound
of formula (11a):
11*:52
HN N S/
{21 (51“
_ 42 _
ATI—ZS 14175v1
(113'):
the methods comprising oxidizing a compound of formula (11b)
(11b),
in a solvent by treatment with an oxidant selected from mCPBA,
oxone,hydrogen peroxide, or 3-phenyl(phenylsulfonyl)-l ,2-oxaziridine.
In one embodiment, the solvent is acetone, DCM, NMP, DMF, or
chloroform. In some embodiments, the ing is performed at low temperature, for
example, at about 0 °C.
In some embodiments, the methods r comprise preparing a compound
of formula (11b):
(11b),
the methods comprising contacting a compound of formula (11c)
(11c),
with NH4Cl in the ce of a coupling agent and a base, in a solvent.
In some embodiments, the solvent is NMP, DMF, DMSO, dioxane, THF,
DCM, or chloroform. In , the coupling agent is HATU, CDI, HBTU, EDC/HOBt, or
ethyl chloroformate, and the base is DIEA, TEA, or potassium carbonate.
ATI—2514l75v1
In some embodiments, the s filrther comprise preparing a compound
of formula (IIc)
(11C):
the methods comprising contacting a compound of formula (IId)
(IId),
with an aqueous base, in a cosolvent.
In some embodiments, the aqueous base is aqueous sodium hydroxide,
potassium hydroxide, or lithium hydroxide. In other embodiments, the cosolvent is
ethanol, methanol, isopropanol, THF, or dioxane.
In some embodiments, the methods filrther comprise preparing a compound
of formula (11d)
N \ o’R
)L /
HI}! N §
R1 RX
(11d),
the methods sing ting a compound of a (He)
N \ o’R
CI N §
(116),
with RINHZ in an organic solvent, in the ce of an organic base.
ATI—ZS 14175Vl
In one embodiment, the organic solvent is dioxane, THF, NMP, DMF,
DMSO, ethanol, methanol, or isopropanol. In another, the base is DIEA, TEA,
N—methylmorpholine, 1,8-diazabicyclo[5.4.0]undecene, cesium carbonate, sodium
carbonate, sodium bicarbonate, potassium carbonate, or ium phosphate. In some
embodiments, the contacting is performed at elevated temperature, for example, from
about 80 0C to about 100 0C.
In some ments, the s r comprise ing a compound
of formula (IIe)
(116):
the s comprising contacting a compound of formula (IIf)
(Hf),
with NaSRX in an organic solvent in the presence of a catalyst.
In one embodiment, the solvent is THF, DCM, or dioxane. In one
embodiment, the catalyst is triethylbenzylammonium chloride, tetrabutylammonium
de, or tetrabutylammonium bromide. In some embodiments, the contacting is
performed under cooling for example, about -10 0C.
In some embodiments, the methods fiarther comprise preparing a compound
of formula (11b):
)LN/YLNHZ/
HI}! N s
R1 RX
(11b),
_ 45 _
ATI—ZS 14175v1
the methods comprising contacting a compound of formula (IIg)
JL / ”Y/ N
HN N S
F'z1 F'zx
(Hg),
with peroxide, in the presence of a base, in a solvent.
In some embodiments, the solvent is DMSO, NMP, DMF, ethanol, or
methanol. In others, the base is sodium hydroxide or potassium hydroxide.
In some embodiments, the methods fiarther comprise preparing a compound
of a (IIg)
)L / ”Y/ N
HN N §
R1 RX
(11g),
the methods comprising ting a nd of a (IIh)
HN N 8
E21 F'ex
(IIh),
with zinc and dicyanozinc, in the presence of a catalyst, in a solvent.
In some embodiments, the st is Pd(0). In some embodiments, the
solvent is DMF, DMSO, NMP, or DMA. In others, the contacting is performed at
elevated temperature, for example at a temperature between about 80 oC and about 100 0C.
In some embodiments, the methods filrther comprise preparing a compound
of formula (IIh)
)L /
HN N S
IIRl F'ex
(11h),
_ 46 _
ATI—25 14175v1
the methods comprising contacting a compound of formula (Hi)
CI N 8
(IIi)
with RINHZ, in the ce of a base, in an organic solvent.
In some embodiments, the organic solvent is n-butanol, NMP, DMF,
DMSO, e, or ethanol. In , the base is DIEA, TEA, N-methylmorpholine,
l,8-diazabicyclo-[5.4.0]undecene, potassium carbonate, sodium ate, sodium
bicarbonate, cesium carbonate, or potassium phosphate. In some embodiments, the
contacting is performed at elevated temperature, for example at a temperature between
about 80 oC and about 100 0C.
Also provided are methods for preparing a compound of formula (I):
N \ NH2
)L /
HN N NH
R1 R2
the methods comprising contacting a compound of formula (IIIa)
)LN/\fko’H/
HN N NH
R1 R2
(IIIa),
with with NH4Cl, in the presence of a coupling agent and a base, in a
solvent, wherein:
R1 is substituted or tituted C1_g alkyl, substituted or unsubstituted
cycloalkyl, substituted or tituted non-aromatic heterocyclyl, substituted or
unsubstituted alkylcycloalkyl, or substituted or unsubstituted alkylheterocyclyl, ed
that R1 is not l-aminocyclohexyl; and
ATI—2514l75v1
R2 is substituted or unsubstituted C1_g alkyl, substituted or unsubstituted
saturated cycloalkyl, tuted or tituted alkylcycloalkyl, tuted or
unsubstituted non-aromatic cyclyl.
In one ment, the compound of formula (I) is not 2-(2-aminoethyl-
amino)(methylamino)pyrimidinecarboxamide; 2-(2-aminopropylamino)
(cyclohexylamino)pyrimidinecarboxamide; 2-(2-aminooxoethylamino)
(cyclohexylamino)pyrimidinecarboxamide; 2-(2-aminoethylamino)
(cyclohexylamino)pyrimidinecarboxamide; (S)(2-aminopropylamino)
butylamino)pyrimidinecarboxamide; (R)( 1 -aminomethyloxobutan
ylamino)(cyclobutylamino)pyrimidinecarboxamide; 4-(cyclopentylamino)
(methylamino)pyrimidinecarboxamide; or 2-(1-acetylpiperidinylamino)
(cyclopropylamino)pyrimidinecarboxamide.
In some ments, the solvent is NMP, DMF, DMSO, dioxane, THF,
DCM, or chloroform. In others, the coupling agent is HATU, CDI, HBTU, EDC/HOBt, or
ethyl chloroformate, and the base is DIEA, TEA, or potassium carbonate.
In some such embodiments, the methods further comprise preparing a
compound of formula (Ma):
N \ o’H
)L /
HN N NH
F'ai F'az
(IIIa),
the methods comprising ting a compound of formula (IIIb)
)L /
HN N NH
FIR] R2
(IIIb),
with an aqueous base, in a cosolvent, wherein Rx is a C1_2 alkyl.
In some embodiments the aqueous base is aqueous sodium hydroxide,
potassium hydroxide, or lithium hydroxide. In other embodiments, the cosolvent is
ethanol, methanol, isopropanol, THF, or dioxane.
ATI—25 14175V1
In some embodiments, the method further comprise preparing a compound
of formula (IIIb):
N \ o’R
)L /
HN N NH
Flil R2
(IIIb),
the method comprising contacting a compound of formula (IIIc)
N \ o’R
CI N NH
F'az
(IIIc),
with RINHZ in the presence of an organic base, in an organic solvent.
In some ments, the organic t is THF, NMP, DMF, DMSO,
e, ethanol, methanol, or isopropanol. In others the organic base is DIEA, TEA,
l,8-diazabicyclo[5.4.0]undecene, N—methylmorpholine, sodium carbonate, sodium
bicarbonate, cesium ate, or ium phosphate. In some embodiments, the
contacting is performed at elevated temperature, for example, about 70 0C.
In some embodiments, the methods fiarther comprise ing a compound
of formula (IIIc)
N \ o’R
CI N NH
(IIIc),
the methods comprising contacting a compound of formula (111d)
N\ o’R
CI N CI
(111d)
with RZNHZ in the presence of an organic base in a solvent.
ATI—2514l75v1
In some embodiments, the solvent is ethyl ether, THF, DCM, toluene, or
methyl tert-butyl ether. In others, the base is DIEA, TEA, 1,8-diazabicyclo[5.4.0]undec
ene, N—methylmorpholine, sodium bicarbonate, cesium carbonate, or potassium ate.
In some embodiments the contacting is performed at low temperature, for example, about
-70 ° C.
Also provided are methods for preparing a compound of formula (I):
)LN/YLNHZ/
HN N NH
R1 R2
the methods comprising contacting a compound of formula (IVa)
RLMJLN/ El:
(IVa),
with catalytic peroxide, in the presence of a strong s base, in a
solvent, wherein:
R1 is substituted or tituted C1_g alkyl, substituted or unsubstituted
cycloalkyl, substituted or tituted non-aromatic heterocyclyl, substituted or
unsubstituted alkylcycloalkyl, or tuted or unsubstituted alkylheterocyclyl, ed
that R1 is not 1-aminocyclohexyl; and
R2 is substituted or unsubstituted C1_g alkyl, substituted or unsubstituted
saturated cycloalkyl, substituted or unsubstituted alkylcycloalkyl, substituted or
unsubstituted non-aromatic heterocyclyl.
In one embodiment, the compound of formula (I) is not 2-(2-aminoethyl-
amino)(methylamino)pyrimidinecarboxamide; 2-(2-aminopropylamino)
(cyclohexylamino)pyrimidinecarboxamide; 2-(2-aminooxoethylamino)
(cyclohexylamino)pyrimidinecarboxamide; minoethylamino)—4-
(cyclohexylamino)pyrimidinecarboxamide; (S)(2-aminopropylamino)
(cyclobutylamino)pyrimidinecarboxamide, (R)(1-aminomethyloxobutan
ATI—ZS 14175v1
ylamino)(cyclobutylamino)pyrimidinecarboxamide; 4-(cyclopentylamino)
lamino)pyrimidinecarboxamide; or 2-( 1 -acetylpiperidinylamino)
(cyclopropylamino)pyrimidinecarboxamide.
In some embodiments, the solvent is DMSO, NMP, DMF, ethanol or
methanol. In others, the strong aqueous base is such as sodium hydroxide or potassium
ide.
In some such ments, the methods further comprise preparing a
compound of formula (IVa):
R \NAN/1 ”Y
(IVa),
the methods comprising contacting a compound of formula (IVb)
CI N NH
F'az
(IVb),
with RINHZ in the presence of a base, in an organic solvent.
] In some embodiments, the organic solvent is 1-butanol, THF, NMP, DMF,
DMSO, dioxane, ethanol, methanol, or isopropanol. In others the base is cesium
carbonate, potassium carbonate, sodium carbonate, sodium bicarbonate, potassium
phosphate, 1,8-diazabicyclo[5.4.0]undecene, ylmorpholine, DIEA, or TEA. In
some embodiments, the contacting is performed at elevated temperature, for example,
about 120 CC.
In some such embodiments, the methods further comprise preparing a
compound of a (IVb):
CI N NH
(IVb),
ATI—ZS 14175v1
WO 45569
the methods comprising contacting a compound of formula (IVc)
CI N CI
(IVc),
with RZNHZ in the presence of a base, in an organic solvent.
In some embodiments, the organic solvent is ethanol, methanol,
isopropanol or THF. In others the base is DIEA, TEA, 1,8-diazabicyclo[5.4.0]undec
ene, N—methylmorpholine, sodium carbonate, sodium bicarbonate, cesium carbonate, or
potassium phosphate. In some ments, the contacting is performed at low
temperature, for example, about -60 0C.
In some embodiments, the s fiarther comprise preparing a compound
of formula (IVa):
JL /
HN N NH
II?1 R2
(IVa),
the methods comprising contacting a compound of formula (IVd)
HNJLN/ RX
Isl.”
R1 (O)m
(IVd),
with RZNHZ in the presence of a base, in an organic t.
In some embodiments, the organic solvent is DCM, NMP, DMF, or DMA.
In others, the base is DIEA, TEA, 1,8-diazabicyclo[5.4.0]undecene, or
N—methylmorpholine. In some embodiments, the contacting is performed at a temperature
between room temperature and about 130 0C.
ATI—ZS 14175v1
] In some embodiments, the methods filrther comprise preparing a compound
of a (IVd):
HNAN/I S’Rx
II?1 (5%
(IVd),
the methods comprising oxidizing a compound of formula (Hg)
JL /
HN N §
R1 RX
(Hg),
in a solvent by treatment with an oxidant selected from mCPBA,
oxone,hydrogen peroxide, or 3-phenyl(phenylsulfonyl)-l ,2-oxaziridine.
In one embodiment, the solvent is DCM, NMP, DMF, or DMA. In some
embodiments, the oxidizing is performed at a temperature from about 0 °C to about room
temperature.
Also provided are methods for preparing a compound of a (IB)
)L /
HN N NH
R3 PE“
(113),
the methods comprising contacting a nd of a (Va)
CI N NH
Fla“
(Va),
with R3NH2 in the presence of a base, in an organic solvent, wherein
R3 is tuted or unsubstituted C1_g alkyl, substituted or unsubstituted
cycloalkyl, substituted or unsubstituted non-aromatic heterocyclyl, substituted or unsubstituted
alkylcycloalkyl, or substituted or unsubstituted alkyl-(non—aromatic heterocyclyl); and
_ 53 _
ATI—2514l75vl
R4 is substituted or unsubstituted C1_g alkyl, tuted or unsubstituted
cycloalkyl, or substituted or unsubstituted non-aromatic heterocyclyl.
] In one embodiment, the compound is not 4-(isopentylamino)(3-(2-
methylpiperidin- l -yl)propylamino)pyrimidine-5 -carbonitrile; (ZS ,2'S)—dimethyl 2,2'-(5 -
cyanopyrimidine-2,4-diyl)bis(azanediyl)bis(4-methylpentanoate); (28,2'S)-diethyl 2,2'-(5-
cyanopyrimidine-2,4-diyl)bis(azanediyl)bis(3-methylbutanoate); 4-(cycloheptylamino)
(3 -(2-methylpiperidin- l -yl)propylamino)pyrimidine-5 nitrile; 4-(4-methylcyclo-
hexylamino)(3-(2-methylpiperidin- l -yl)propylamino)pyrimidine-5 -carbonitrile; or
2-(3-(diethylamino)propylamino)(4-methylcyclohexylamino)-pyrimidinecarbonitrile.
In some embodiments, the organic solvent is l-butanol, THF, NMP, DMF,
DMSO, dioxane, ethanol, methanol, or isopropanol. In others the base is cesium
carbonate, potassium carbonate, sodium carbonate, sodium bicarbonate, potassium
phosphate, l,8-diazabicyclo[5.4.0]undecene, N—methylmorpholine, DIEA, or TEA. In
some embodiments, the contacting is med at elevated temperature, for example,
from about 50 0C to about 90 0C.
] In some such ments, the methods further comprise preparing a
compound of formula (Va):
(V3) 9
the methods comprising contacting a compound of formula (Vb)
CI N CI
(Vb),
with R4NH2 in the presence of a base, in an organic solvent.
] In some embodiments, the organic t is ethanol, methanol,
isopropanol or THF. In others the base is DIEA, TEA, 1,8-diazabicyclo[5.4.0]undec
ene, N—methylmorpholine, sodium carbonate, sodium bicarbonate, cesium carbonate, or
ATI—2514l75v1
potassium phosphate. In some embodiments, the contacting is performed at low
temperature, for example, from about -70 °C to about 20 CC.
Also provided are methods for preparing a nd of formula (IB)
JL /
HN N NH
R3 PE“
(13),
the methods comprising contacting a nd of a (VIa)
HN N CI
(VIa),
with R4NH2 in the presence of a base, in an organic solvent, wherein
R3 is substituted or unsubstituted C1_g alkyl, substituted or unsubstituted
cycloalkyl, substituted or unsubstituted non-aromatic heterocyclyl, substituted or tituted
alkylcycloalkyl, or substituted or unsubstituted alkyl-(non—aromatic heterocyclyl); and
R4 is substituted or tituted C1_g alkyl, substituted or unsubstituted
cycloalkyl, or substituted or unsubstituted non-aromatic heterocyclyl.
In one embodiment, the compound is not 4-(isopenty1amino)(3-(2-
methylpiperidinyl)propylamino)pyrimidine-5 -carbonitrile; (ZS ,2'S)—dimethyl 2,2'-(5 -
yrimidine-2,4-diyl)bis(azanediyl)bis(4-methylpentanoate); (28,2'S)-diethyl 2,2'-(5-
yrimidine-2,4-diyl)bis(azanediyl)bis(3-methylbutanoate); 4-(cycloheptylamino)
(3 thylpiperidinyl)propylamino)pyrimidine-5 -carbonitrile; 4-(4-methylcyclohexylamino
)(3-(2-methylpiperidinyl)propylamino)pyrimidine-5 -carbonitrile; or
2-(3-(diethylamino)propylamino)(4-methylcyclohexylamino)-pyrimidinecarbonitrile.
In some embodiments, the c solvent is 1-butanol, NMP, DMF,
DMSO, or dioxane. In others the base is cesium carbonate, potassium carbonate, sodium
carbonate, sodium bicarbonate, potassium phosphate, 1,8-diazabicyclo[5 .4.0]undecene,
N—methylmorpholine, DIEA, or TEA. In some embodiments, the contacting is performed
at elevated temperature, for example, from about 25 °C to about 110 CC.
ATI—25 14175v1
In some such embodiments, the methods further comprise preparing a
compound of formula (VIa):
HN N CI
(VIa),
the methods comprising ting a compound of formula (Vb)
CI N CI
(Vb),
with R3NH2 in the presence of a base, in an organic solvent.
In some such embodiments, the organic solvent is ethanol, methanol,
isopropanol or THF. In others the base is DIEA, TEA, 1,8-diazabicyclo[5.4.0]undec
ene, N-methylmorpholine, sodium carbonate, sodium bicarbonate, cesium carbonate, or
potassium phosphate. In some embodiments, the contacting is performed at low
ature, for e, from about -70 °C to about 20 CC.
Provided are methods for ing a compound of formula (IB)
)L /
HN N NH
R3 PE“
(113),
the methods comprising contacting a compound of formula (VIIa)
/x |
(O)m R4
(VIIa),
with R3NH2 in the presence of a base, in an organic solvent, wherein
R3 is substituted or tituted C1_g alkyl, substituted or unsubstituted
cycloalkyl, substituted or unsubstituted non-aromatic heterocyclyl, substituted or unsubstituted
ATI—25 14175v1
alkylcycloalkyl, or substituted or unsubstituted alkyl-(non-aromatic heterocyclyl);
R4 is substituted or unsubstituted C1_g alkyl, tuted or unsubstituted
cycloalkyl, or substituted or unsubstituted non-aromatic heterocyclyl;
Rx is C1_2 alkyl and
m is 1 or 2.
In one embodiment, the nd is not 4-(isopentylamino)(3-(2-
methylpiperidinyl)propylamino)pyrimidine-5 -carbonitrile; (ZS ,2'S)—dimethyl 2,2'-(5 -
cyanopyrimidine-2,4-diyl)bis(azanediyl)bis(4-methylpentanoate); (28,2'S)-diethyl 2,2'-(5-
cyanopyrimidine-2,4-diyl)bis(azanediyl)bis(3-methylbutanoate); 4-(cycloheptylamino)
(3 -(2-methylpiperidinyl)propylamino)pyrimidine-5 -carbonitrile; 4-(4-methylcyclohexylamino
)(3-(2-methylpiperidin- 1 opylamino)pyrimidine-5 -carbonitrile; or
2-(3-(diethylamino)propylamino)(4-methylcyclohexylamino)-pyrimidinecarbonitrile.
In one embodiment, the solvent is dioxane, DMSO, NMP, DMF, THF, or
n-butanol. In another, the base is DIEA, TEA, 1,8-diazabicyclo[5.4.0]undecene,
N—methylmorpholine. In some embodiments, the contacting is performed at elevated
temperature, for example, from about 25 °C to about 110 CC.
In some ments, the s fithher comprise preparing a compound
of formula (VIIa):
R\S)\N/ ”Y/ N x |
(O)m [Q4
(VIIa),
the methods comprising oxidizing a compound of formula (VIIb)
(VIIb),
in a solvent by treatment with an t selected from mCPBA, oxone,
en peroxide, or 3-phenyl(phenylsulfonyl)-1,2-oxaziridine.
ATI—25 14175v1
In one ment, the t is DCM, NMP, DMF, or DMA. In some
embodiments, the oxidizing is performed at low temperature, for example, about 0 °C.
In some embodiments, the methods further comprise preparing a
compound of formula (VIIb)
(VIIb),
the methods comprising contacting a compound of formula (VIIc)
RX‘SJLN/ CI
(VIIc),
with R4NH2 in an organic solvent, in the presence of a base.
In one embodiment, the organic t is n-butanol, NMP, DMF, DMSO,
or dioxane. In another, the base is DIEA, TEA, N-methylmorpholine,
1,8-diazabicyclo[5.4.0]undecene, potassium carbonate, sodium carbonate, sodium
bicarbonate, cesium ate or potassium phosphate. In some embodiments, the
contacting is performed at elevated temperature, for e, from about 50 °C to about
90 OC.
METHODS OF USE
The Diaminopyrimidine Compounds have utility as pharmaceuticals to
treat, prevent or improve conditions in animals or humans. Further, the
Diaminopyrimidine Compounds are active against n kinases, particularly JNKl
and/or JNK2. ingly, provided herein are many uses of the Diaminopyrimidine
Compounds, including the ent or prevention of those diseases set forth below. The
methods provided herein comprise the administration of an effective amount of one or
more Diaminopyrimidine Compound(s) to a subject in need thereof
In one aspect provided herein are methods of inhibiting a kinase in a cell
sing said kinase, comprising contacting said cell with an effective amount of a
ATI—ZS 14175v1
2012/034349
Diaminopyrimidine Compound. In one embodiment the kinase is JNKl, JNKZ, or mutants
or isoforms thereof, or a combination thereof. For example, the opyrimidine
Compound is a compound from Table 1, 2 or 3.
In another aspect provided herein are methods for treating or preventing
liver f1brotic disorders, such as non-alcoholic steatohepatitis, steatosis (i.e. fatty ,
cirrhosis, primary sclerosing cholangitis, primary biliary cirrhosis, hepatitis, hepatocellular
carcinoma, and liver fibrosis coincident with chronic or ed alcohol ingestion
(alcoholic hepatitis), with ion (e.g. viral infection such as HCV), with liver
transplant, or with drug induced liver injury (e.g. inophen toxicity), comprising
administering to a subject in need thereof an effective amount of a Diaminopyrimidine
Compound. In some such s, provided herein are methods for treating or preventing
diabetes or metabolic me leading to liver fibrotic disorders, such as non-alcoholic
steatohepatitis, steatosis (i.e. fatty liver), sis, primary sclerosing cholangitis, primary
biliary cirrhosis, and hepatitis, sing administering to a t in need thereof an
effective amount of a Diaminopyrimidine Compound.
In r aspect provided herein are methods for treating or preventing
one ore more disorders selected from interstitial pulmonary fibrosis, systemic sclerosis,
derma, chronic allograft nephropathy, antibody mediated rejection, or lupus,
comprising administering to a subject in need thereof an effective amount of a
Diaminopyrimidine Compound. In some such embodiments, the lupus is lupus
erythematosus (such as d lupus erythematosus, or cutaneous lupus erythematosus) or
ic lupus.
In another aspect provided herein are methods for treating or preventing
conditions treatable or preventable by inhibition of INK1 and/or JNK2, the method
comprising administering to a subject in need thereof an ive amount of a
Diaminopyrimidine Compound. Examples of such conditions include rheumatoid
arthritis; rheumatoid spondylitis; osteoarthritis; asthma, bronchitis; allergic rhinitis;
chronic obstructive pulmonary disease; cystic fibrosis; inflammatory bowel disease;
irritable bowel me; mucous s; ulcerative colitis; Crohn's disease; Huntington's
disease; hepatitis; pancreatitis; nephritis; multiple sclerosis; lupus erythematosus; Type II
diabetes; obesity; atherosclerosis; restenosis following angioplasty; left ventricular
ATI—ZS 14175v1
rophy; myocardial infarction; stroke; ischemic damages of heart, lung, gut, kidney,
liver, pancreas, spleen and brain; acute or chronic organ transplant rejection; preservation
of the organ for transplantation; organ failure or loss of limb (e.g., including, but not
limited to, that resulting from ischemia-reperfusion injury, trauma, gross bodily injury, car
accident, crush injury or lant failure); graft versus host disease; endotoxin shock;
multiple organ failure; psoriasis; burn from exposure to fire, chemicals or radiation;
eczema; dermatitis; skin graft; ia; ischemic conditions ated with surgery or
traumatic injury (e.g., vehicle accident, gunshot wound or limb crush); epilepsy;
Alzheimer's disease; Parkinson's disease; immunological response to bacterial or viral
infection; ia; angiogenic and proliferative diseases; solid tumor; and cancers of a
variety of tissues such as colon, rectum, prostate, liver, lung, bronchus, pancreas, brain,
head, neck, stomach, skin, , cervix, blood, larynx, esophagus, mouth, pharynx,
y bladder, ovary or uterine.
PHARMACEUTICAL COMPOSITIONS AND
ROUTES OF ADMINISTRATION
The opyrimidine Compounds can be administered to a t
orally, topically or parenterally in the conventional form of preparations, such as capsules,
microcapsules, tablets, granules, powder, troches, pills, suppositories, injections,
suspensions, syrups, patches, creams, lotions, ointments, gels, sprays, solutions and
emulsions. Suitable formulations can be ed by methods commonly employed using
conventional, c or inorganic additives, such as an excipient (e.g., sucrose, starch,
mannitol, sorbitol, lactose, glucose, cellulose, talc, calcium phosphate or calcium
carbonate), a binder (e.g, cellulose, methylcellulose, ymethylcellulose,
polypropylpyrrolidone, nylpyrrolidone, n, gum arabic, polyethyleneglycol,
sucrose or starch), a disintegrator (e.g, starch, carboxymethylcellulose,
hydroxypropylstarch, low tuted hydroxypropylcellulose, sodium bicarbonate,
calcium phosphate or calcium citrate), a lubricant (e.g., magnesium stearate, light
anhydrous silicic acid, talc or sodium lauryl sulfate), a ng agent (e.g., citric acid,
menthol, glycine or orange powder), a preservative (e. g, sodium benzoate, sodium
bisulf1te, methylparaben or propylparaben), a stabilizer (e.g., citric acid, sodium citrate or
_ 60 _
ATI—2514l75v1
2012/034349
acetic acid), a suspending agent (e.g, methylcellulose, polyvinyl pyrroliclone or aluminum
stearate), a dispersing agent (e.g., hydroxypropylmethylcellulose), a diluent (e.g., water),
and base wax (e.g., cocoa butter, white petrolatum or polyethylene glycol). The ive
amount of the Diaminopyrimidine nds in the pharmaceutical composition may be
at a level that will exercise the desired effect; for example, about 0.005 mg/kg of a
subject’s body weight to about 10 mg/kg of a subject’s body weight in unit dosage for both
oral and parenteral administration.
The dose of a Diaminopyrimidine Compound to be administered to a
subject is rather widely le and can be subject to the nt of a health-care
practitioner. In general, the Diaminopyrimidine Compounds can be administered one to
four times a day in a dose of about 0.005 mg/kg of a subject’s body weight to about
mg/kg of a subject’s body weight in a subject, but the above dosage may be properly
varied depending on the age, body weight and medical condition of the subject and the
type of stration. In one embodiment, the dose is about 0.01 mg/kg of a subject’s
body weight to about 5 mg/kg of a subject’s body weight, about 0.05 mg/kg of a subject’s
body weight to about 1 mg/kg of a subject’s body weight, about 0.1 mg/kg of a subject’s
body weight to about 0.75 mg/kg of a subject’s body weight or about 0.25 mg/kg of a
subject’s body weight to about 0.5 mg/kg of a subject’s body weight. In one embodiment,
one dose is given per day. In any given case, the amount of the Diaminopyrimidine
Compound administered will depend on such factors as the solubility of the active
component, the formulation used and the route of administration. In one embodiment,
application of a topical concentration provides intracellular exposures or concentrations of
about 0.01 — 10 uM.
In another embodiment, ed herein are methods for the treatment or
prevention of a disease or disorder comprising the stration of about 0.375 mg/day to
about 750 , about 0.75 mg/day to about 375 mg/day, about 3.75 mg/day to about
75 mg/day, about 7.5 mg/day to about 55 mg/day or about 18 mg/day to about 37 mg/day
of a Diaminopyrimidine Compound to a subject in need thereof.
In another embodiment, provided herein are methods for the treatment or
tion of a e or disorder comprising the administration of about 1 mg/day to
about 1200 mg/day, about 10 mg/day to about 1200 mg/day, about 100 mg/day to about
ATI—2514l75vl
1200 mg/day, about 400 mg/day to about 1200 mg/day, about 600 mg/day to about
1200 mg/day, about 400 mg/day to about 800 mg/day or about 600 mg/day to about
800 mg/day of a Diaminopyrimidine Compound to a subject in need thereof. In a
particular embodiment, the methods sed herein comprise the administration of
400 mg/day, 600 mg/day or 800 mg/day of a Diaminopyrimidine Compound to a t
in need thereof.
] In another ment, provided herein are unit dosage formulations that
comprise between about 1 mg and 200 mg, about 35 mg and about 1400 mg, about 125 mg
and about 1000 mg, about 250 mg and about 1000 mg, or about 500 mg and about
1000 mg of a Diaminopyrimidine Compound.
In a particular embodiment, provided herein are unit dosage ations
comprising about 100 mg or 400 mg of a Diaminopyrimidine Compound.
In another embodiment, provided herein are unit dosage formulations that
comprise 1 mg, 5 mg, 10 mg, 15 mg, 20 mg, 30 mg, 35 mg, 50 mg, 70 mg, 100 mg,
125 mg, 140 mg, 175 mg, 200 mg, 250 mg, 280 mg, 350 mg, 500 mg, 560 mg, 700 mg,
750 mg, 1000 mg or 1400 mg of a Diaminopyrimidine Compound.
A Diaminopyrimidine Compound can be administered once, twice, three,
four or more times daily. In a particular embodiment, doses of 600 mg or less are
administered as a once daily dose and doses of more than 600 mg are administered twice
daily in an amount equal to one half of the total daily dose.
A Diaminopyrimidine Compound can be administered orally for reasons of
convenience. In one embodiment, when stered orally, a Diaminopyrimidine
Compound is administered with a meal and water. In another embodiment, the
Diaminopyrimidine Compound is dispersed in water or juice (e.g., apple juice or orange
juice) and administered orally as a suspension.
The Diaminopyrimidine Compound can also be administered intradermally,
intramuscularly, intraperitoneally, percutaneously, intravenously, subcutaneously,
intranasally, ally, sublingually, intracerebrally, aginally, transdermally,
rectally, mucosally, by tion, or topically to the ears, nose, eyes, or skin. The mode
of administration is left to the discretion of the health-care practitioner, and can depend in-
part upon the site of the medical condition.
ATI—25 14175v1
In one embodiment, provided herein are capsules containing a
Diaminopyrimidine Compound without an additional carrier, excipient or vehicle.
In another embodiment, provided herein are compositions comprising an
effective amount of a Diaminopyrimidine Compound and a pharmaceutically able
carrier or vehicle, wherein a pharmaceutically acceptable r or vehicle can comprise
an excipient, t, or a e thereof. In one embodiment, the composition is a
pharmaceutical composition.
The itions can be in the form of tablets, chewable tablets, es,
solutions, parenteral solutions, troches, suppositories and suspensions and the like.
Compositions can be formulated to contain a daily dose, or a convenient fraction of a daily
dose, in a dosage unit, which may be a single tablet or capsule or convenient volume of a
liquid. In one ment, the ons are prepared from water-soluble salts, such as the
hydrochloride salt. In general, all of the compositions are prepared according to known
s in pharmaceutical chemistry. Capsules can be prepared by mixing a
Diaminopyrimidine Compound with a le carrier or diluent and filling the proper
amount of the mixture in capsules. The usual rs and diluents include, but are not
limited to, inert powdered substances such as starch ofmany different kinds, powdered
cellulose, especially crystalline and microcrystalline cellulose, sugars such as fructose,
mannitol and sucrose, grain flours and similar edible powders.
] Tablets can be prepared by direct compression, by wet granulation, or by
dry granulation. Their ations usually incorporate diluents, binders, lubricants and
disintegrators as well as the compound. Typical diluents include, for example, various
types of starch, lactose, mannitol, kaolin, calcium phosphate or sulfate, nic salts
such as sodium chloride and powdered sugar. Powdered cellulose derivatives are also
useful. Typical tablet binders are substances such as starch, n and sugars such as
lactose, fructose, glucose and the like. Natural and synthetic gums are also convenient,
including acacia, alginates, methylcellulose, polyvinylpyrrolidine and the like.
Polyethylene glycol, ethylcellulose and waxes can also serve as binders.
A lubricant might be necessary in a tablet formulation to t the tablet
and s from sticking in the dye. The lubricant can be chosen from such slippery
solids as talc, magnesium and calcium stearate, stearic acid and hydrogenated vegetable
ATI—ZS 14175v1
oils. Tablet disintegrators are substances that swell when wetted to break up the tablet and
e the compound. They include starches, clays, celluloses, algins and gums. More
particularly, corn and potato starches, methylcellulose, agar, bentonite, wood cellulose,
powdered natural sponge, -exchange resins, alginic acid, guar gum, citrus pulp and
carboxymethyl cellulose, for example, can be used as well as sodium lauryl sulfate.
Tablets can be coated with sugar as a flavor and sealant, or with film-forming protecting
agents to modify the dissolution properties of the tablet. The compositions can also be
formulated as chewable tablets, for example, by using substances such as mannitol in the
formulation.
When it is desired to administer a Diaminopyrimidine Compound as a
suppository, typical bases can be used. Cocoa butter is a traditional itory base,
which can be modified by addition of waxes to raise its melting point slightly. Water-
miscible suppository bases comprising, particularly, polyethylene glycols of various
molecular weights are in wide use.
] The effect of the opyrimidine Compound can be delayed or
prolonged by proper formulation. For example, a slowly soluble pellet of the
Diaminopyrimidine nd can be prepared and incorporated in a tablet or capsule, or
as a slow-release implantable device. The technique also includes making pellets of
several ent dissolution rates and filling capsules with a mixture of the pellets.
Tablets or capsules can be coated with a film that resists dissolution for a predictable
period of time. Even the parenteral preparations can be made long-acting, by dissolving or
suspending the Diaminopyrimidine nd in oily or emulsified vehicles that allow it
to disperse slowly in the serum.
EXAMPLES
The following Examples are presented by way of ration, not limitation.
Compounds are named using the automatic name ting tool provided in Chemdraw
Ultra 9.0 (Cambridgesoft), which generates systematic names for chemical structures, with
support for the Cahn-Ingold-Prelog rules for stereochemistry. One skilled in the art can
modify the procedures set forth in the illustrative es to arrive at the desired
products.
ATI—ZS 14175v1
[001 84] Abbreviations used:
DCM Dichloromethane
DEA D1ethylamine
EDC Ethyl-(N ’ ,N ’ hylamino)propylcarbodiimide
hydrochloride
HATU zabenzotriazol- l -yl)-N,N,N',N'-
tetramethyluronium hexafluorophosphate
HOBt l -Hydroxybenzotriazole
HPLC High performance liquid chromatography
HTRF Homogeneous time resolved fluorescence
LCMS Liquid chromatography mass spectrometry
mCPBA Meta-chloroperoxybenzoic acid
MS Mass spectrometry
N-methylpyrrolidone
Nuclear magnetic resonance
Supercritical fluid chromatography
O-benzotriazol- l -yl-N,N,N',N'-tetra-
methyluronium tetrafluoroborate
Triethylamine
Trifluoracetic acid
Tetrahydrofuran
Thin layer tography
ATI—2514l75vl
COMPOUND SYNTHESIS
e 1: 4-((1R,3R)Hydr0xycyclohexylamin0)((1r,4R)—4-
methoxycyclohexylamin0)pyrimidinecarboxamide
4-Chlor0((1r,4r)—4-methoxycyclohexylamino)pyrimidine—5-
carbonitrile. 2,4-Dichloro-pyrimidinecarbonitrile (1.2 g, 6.93 mmol) in anhydrous
ethanol (10 mL) and (1r,4r)methoxycyclohexanamine (893 mg, 6.93 mmol) in
anhydrous ethanol (10 mL) were mixed at -60 CC, then DIEA (1.34 g, 10.4 mmol) was
added drop wise. The mixture was stirred at -60 0C for 1.5 h, then at room temperature
overnight. Volatile fractions were d and the residue was purified on silica gel
(eluting with 9.1%-25% ethyl acetate in petroleum ether and .7% methanol in
DCM) to give the 2 isomers (identified as described below), namely 4-chloro((1r,4r)
methoxycyclohexylamino)-pyrimidinecarbonitrile (560 mg, 2.10 mmol, yield 30%) as a
white solid and 2-chloro((1r,4r)methoxycyclohexylamino)pyrimidinecarbonitrile
(227 mg, 0.85 mmol, yield 12%) as a white solid. MS(ESI): m/z 266.9 [M+l]+.
] Identification of the two isomers was achieved by characterization of the
dehalogenated intermediate. Dehalogenation for the two fractions was achieved as
follows. 4-Chloro((1r,4r)methoxycyclohexylamino)pyrimidinecarbonitrile
(50 mg, 0.18 mmol) and Raney nickel in a ent of THF (10 mL) and aqueous
ammonia (1 mL) was stirred at room temperature under a hydrogen balloon overnight.
The mixture was d and the filtrate was concentrated and purified by reverse-phase
preparatory HPLC (10% to 40% acetonitrile + 0.005% ammonia solution) to give
-(aminomethyl)-N-((1r,4r)methoxycyclohexyl)pyrimidinamine (25 mg, 0.10 mmol,
yield 58%). 1H NMR (CDC13 300 MHz): 5 ppm 8.23 (s, 2H), 4.96 (d, J=10.0 Hz, 1H),
3.85-3.73 (m, 1H), 3.69 (s, 2H), 3.34 (s, 3H), .11 (m, 1H), .04 (m, 4H),
1.44-1.34 (m, 4H); MS(ESI): m/Z 236.9 [M+1]+.
[001 87] Similarly, 2-chloro((1r,4r)methoxycyclohexylamino)pyrimidine
carbonitrile (50 mg, 0.18 mmol) and Raney nickel in a cosolvent of THF (10 mL) and
ATI—25 14175v1
2012/034349
aqueous ammonia (1 mL) was stirred at room temperature under a hydrogen balloon
overnight. The mixture was filtered and the filtrate was concentrated and purified by
reverse-phase preparatory HPLC (10% to 40% acetonitrile + 0.005% a on) to
give 5-(aminomethyl)-N-((1r,4r)methoxycyclohexyl)pyrimidinamine (30 mg,
0.12 mmol, yield 66%). 1H NMR (CDC13 300 MHz): 8 ppm 8.46 (s, 1H), 7.84 (s, 1H),
7.25 (s, 1H), 4.00-3.93 (m, 1H), 3.79 (s, 2H), 3.34 (s, 3H), 3.23-3.14 (m, 1H), 2.14-2.02
(m, 4H), 1.48-1.22 (m, 4H); MS(ESI): m/z 236.9 [M+1]+.
B. 4-((1R,3R)—3-Hydr0xycyclohexylamin0)—2-((1r,4R)—4—meth0xy-
cyclohexylamin0)pyrimidinecarb0nitrile. A mixture of 4-chloro((1r,4r)
methoxycyclohexylamino)pyrimidinecarbonitrile (236 mg, 0.88 mmol),
(1R,3R)aminocyclohexanol (151 mg, 1.32 mmol; prepared as described in
Tetrahedron: Asymmetry 15:2051—2056 (2004)) and cesium carbonate (573 mg,
1.76 mmol) in anhydrous nol (20 mL) was stirred at 120 CC under nitrogen for 3 h.
The mixture was partitioned between water and DCM. The organic layers were combined,
concentrated and purified on silica gel (eluting with 16%-50% ethyl e in petroleum
ether and 3.2%-4.7% methanol in DCM) to give 4-((1R,3R)—3-hydroxycyclohexylamino)-
,4R)—4-methoxycyclohexylamino)-pyrimidinecarbonitrile (140 mg, 0.40 mmol,
yield 46%) as a white solid. MS(ESI): m/z 346.0 [M+1]+.
C. 4-((1R,3R)Hydr0xycyclohexylamin0)((1r,4R)—4-meth0xy-
cyclohexylamin0)pyrimidine—5-carboxamide. 4-((1R,3R)Hydroxycyclohexylamino)-
2-((1r,4R)—4-methoxycyclohexylamino)pyrimidinecarbonitrile (140 mg, 0.40 mmol)
was dissolved in DMSO (10 mL) and ten drops of ted aqueous sodium hydroxide
solution and ten drops of aqueous hydrogen peroxide solution (30%) were added at room
temperature. The reaction mixture was stirred at 50 CC for 6 h. The reaction mixture was
partitioned between water and DCM-isopropanol (5:1). The c layers were
combined, concentrated and d on silica gel (eluting with 50%-75% ethyl acetate in
petroleum ether and 4.76%-9. 1% methanol in DCM) to give 4-((1R,3R)
hydroxycyclohexylamino)((1r,4R)methoxycyclohexylamino)-pyrimidine
carboxamide (103 mg, 0.28 mmol, yield 70%) as a white solid. 1H NMR (DMSO-d6
400 MHz): 8 ppm 9.00 (d, J=5.2 Hz, 1H), 8.33 (s, 1H), 7.54 (brs, 1H), 7.00 (s, 1H), 6.81
ATI—25 14175v1
(s, 1H), 4.47 (s, 1H), 4.28 (s, 1H), 3.81 (s, 1H), 3.63 (s, 1H), 3.22 (s, 3H), 3.08 (s, 1H),
1.98-1.54 (m, 8H), 1.41—1.14 (m, 7H); MS(ESI): m/Z 363.9 [M+1]+.
Example 2: 4-((1S,3S)—3-Hydr0xycyclohexylamin0)((1r,4S)—4-
ycyclohexylamin0)pyrimidinecarboxamide
A. 4-((1 S,3 S)—3-Hydr0xycyclohexylamin0)((1r,4S)—4-meth0xy-
cyclohexylamin0)pyrimidinecarb0nitrile. A mixture of 4-chloro((1r,4r)
methoxycyclohexylamino)pyrimidinecarbonitrile (236 mg, 0.88 mmol, synthesis
described herein), (1S,3S)aminocyclohexanol (209 mg, 1.33 mmol; ed as
described in Tetrahedron: Asymmetry 15: 2051—2056 (2004)) and cesium carbonate (573
mg, 1.76 mmol) in anhydrous n-butanol (20 mL) was stirred at 120 CC under nitrogen for 3
h. The mixture was ioned between water and DCM. The c layers were
combined, concentrated and purified on silica gel (eluting with 16%-50% ethyl acetate in
petroleum ether and 3.2%-4.7% methanol in DCM) to give ,3S)—3-
hydroxycyclohexylamino)((1r,4S)methoxycyclohexylamino)pyrimidine
carbonitrile (140 mg, 0.40 mmol, yield 46%) as a white solid. MS(ESI): m/Z 346.1 [M+l]+.
B. 4-((1 S,3 S)—3-Hydr0xycyclohexylamin0)((1r,4S)—4-meth0xy-
exylamin0)pyrimidinecarboxamide. 4-((1S,3S)Hydroxycyclohexylamino)-
2-((1r,4S)methoxycyclohexylamino)pyrimidinecarbonitrile (140 mg, 0.40 mmol)
was dissolved in DMSO (10 mL) and ten drops of saturated aqueous sodium hydroxide
solution and ten drops of aqueous hydrogen peroxide solution (30%) were added at room
temperature. The reaction mixture was stirred at 50 CC for 6 h. The reaction mixture was
partitioned between water and DCM-isopropanol (5:1). The organic layers were
ed, concentrated and purified on silica gel (eluting with 50%-75% ethyl acetate in
petroleum ether and 4.76%-9.1% methanol in DCM) to give 4-((lS,3S)—3-
hydroxycyclohexylamino)((1r,4S)methoxycyclohexylamino)pyrimidine
carboxamide (102 mg, 0.28 mmol, yield 70%) as a white solid. 1H NMR d6
ATI—2514l75v1
400 MHZ): 8 ppm 9.01 (d, J=6.0 HZ, 1H), 8.34 (s, 1H), 7.56 (brs, 1H), 7.02 (d, J=4.8 HZ,
1H), 6.82 (s, 1H), 4.48 (s, 1H), 4.29 (s, 1H), 3.81 (s, 1H), 3.64 (s, 1H), 3.23 (s, 3H), 3.08
(s, 1H), 2.01-1.55 (m, 8H), 1.41-1.15 (m, 7H); MS(ESI): m/z 363.9 [M+1]+.
Example 3: 2-((1r,4S)Eth0xycyclohexylamin0)((1S,ZS)
hydroxycyclopentylamin0)pyrimidinecarboxamide
V0 N/
l NH2
” N 1ng
A. tert-Butyl (1r,4r)—4-hydr0xycyclohexylcarbamate. To a suspension
of )aminocyclohexanol hydrochloride (25 g, 217 mmol) in e (200 mL) was
added a solution of sodium hydroxide (8.7 g, 217 mmol) in water (150 mL) at room
temperature, followed by addition of di-tert-butyl-dicarbonate (47 g, 270 mmol). The
ing mixture was stirred at room temperature for 15 h. When the ng material was
ed, the volatiles were removed and the residue was diluted with water. The solid
was collected by filtration and dried to give tert-butyl (1r,4r)hydroxycyclohexyl-
carbamate as a white solid (33 g, 0.15 mol, yield 92%). 1H NMR dg, 300 MHZ):
8 ppm 6.65 (d, J=7.5 HZ, 1H), 4.48 (d, J=3.0 HZ, 1H), 3.14 (s, 1H), 1.77 (m, 4H), 1.37
(s, 9H), 1.14 (m, 4H).
B. utyl (1r,4r)—4-eth0xycyclohexylcarbamate. To a solution of tert-
butyl (1r,4r)hydroxycyclohexylcarbamate (20 g, 93 mmol) in ous THF (100 mL)
was added sodium hydride (4 g, 100 mmol, 60% in mineral oil) in portions under nitrogen
at 0 CC. The mixture was warmed to room temperature and stirred for 30 min. A solution
of iodoethane (16 g, 102 mmol) in anhydrous THF (50 mL) was added dropwise to the
mixture at 0 OC and the resulting mixture was heated to 60 0C for 15 h. After being cooled
to room temperature, the mixture was poured into ice-water (100 mL). The aqueous
mixture was extracted with ethyl acetate (100 mL X 3), and the organic phase was washed
with brine, dried over sodium sulfate and filtered. The filtrate was concentrated in vacuo.
The residue was purified on silica gel column (eluting with 5% to 30% ethyl acetate in
petroleum ether) to give tert-butyl (1r,4r)ethoxycyclohexylcarbamate (3.7 g, 15 mmol,
yield 16%). 1H NMR (DMSO-dg, 400 MHZ): 8 ppm 6.70 (d, J=7.6 HZ, 1H), 3.42 (q,
ATI—25 14175v1
J=7.2 Hz, 2H), 3.11-3.17 (m, 2H), 1.92 (m, 2H), 1.74 (m, 2H), 1.37 (s, 9H), 1.21 (m, 4H),
1.07 (t, J=7.2 Hz, 3H).
C. (1r,4r)—4-Eth0xycyclohexanamine hydrochloride. A solution of tert-
butyl (1r,4r)ethoxycyclohexylcarbamate (3.7 g, 15 mmol) in methanolic hydrochloride
solution (2 M, 20 mL) was stirred at room temperature for 2 h. The reaction mixture was
evaporated under reduced re to give (1r,4r)ethoxycyclohexanamine
hydrochloride (2.7 g, yield 100%).
D. (1S,2S)Aminocyclopentanol hydrochloride. To a on of
(1S,2S)—2-(benzyloxy)cyclopentanamine (4.5 g, 22 mmol) and hloric acid (0.5 mL)
in methanol (100 mL) was added 10 wt.% palladium on activated carbon (500 mg). The
mixture was stirred at room temperature under hydrogen atmosphere (40 psi) for 24 h.
The catalyst was filtered off and the e was concentrated under reduced pressure to
give (1S,2S)—2-aminocyclopentanol hydrochloride as a white solid (2.14 g, 15 mmol,
yield 93%).
E. Ethyl 4-((1 S,2S)hydroxycyclopentylamin0)(methylthio)—
dine-S-carboxylate. A e of ethyl 4-chloro(methylthio)pyrimidine
carboxylate (1.4 g, 6.0 mmol), (1S,2S)aminocyclopentanol hydrochloride (0.7 g,
6.9 mmol) and DIEA (1.0 g) in ethanol (20 mL) was heated at 60 0C for 15 h. After being
cooled to room temperature, the reaction solution was concentrated and the residue was
purified on silica gel column (eluting with 0~10% ethyl acetate in petroleum ether) to give
ethyl 4-((1S,2S)hydroxycyclopentylamino)(methylthio)pyrimidinecarboxylate
(1.3 g, 4.37 mmol, yield 73%) as a white solid. MS (ESI): m/z 298.5 [M+1]+.
F. 4-((1 S,2S)Hydr0xycyclopentylamin0)(methylthio)pyrimidine—
-carb0xylic acid. To a solution of ethyl ,2S)—2-hydroxycyclopentylamino)
(methylthio)pyrimidinecarboxylate (1.3 g, 4.37 mmol) in l (15 mL) was added
aqueous sodium hydroxide solution (15 mL, 2 N), and the mixture was stirred for 1 h at
room temperature. When the starting al was consumed, the reaction mixture was
neutralized with saturated aqueous citric acid solution. The solids were collected by
filtration and dried to give 4-((1S,2S)hydroxycyclopentylamino)
(methylthio)pyrimidinecarboxylic acid (1.0 g, 3.7 mmol, yield 85%) as a white solid.
MS (ESI): m/Z 270.6 [M+1]+.
ATI—2514175vl
G. 4-((1 S,2S)Hydr0xycyclopentylamin0)(methylthio)pyrimidine-
-carb0xamide. The e of 4-((1S,2S)—2-hydroxycyclopentylamino)(methylthio)-
pyrimidinecarboxylic acid (1.0 g, 3.7 mmol), ammonium chloride (0.989 g,
18.5 mmol), HATU (2.25 g, 5.92 mmol), DIEA (2.39 g, 18.5 mmol) and l-HOBt (0.80 g,
.92 mmol) in DMF (10 mL) was d at room temperature for 2 h. The reaction
mixture was diluted with water (15 mL), and the aqueous mixture was extracted with ethyl
acetate (20 mL X 3). The combined organic layers were washed with brine, dried over
sodium sulfate and filtered. The filtrate was ated in vacuo. The residue was
purified on silica gel column (eluting with 30~50% ethyl e in petroleum ether) to
give 4-((1 S,2S)—2-hydroxycyclopentylamino)(methylthio)pyramidinecarboxamide
(800 mg, 2.98 mmol, yield 81%) as a white solid. MS (ESI): m/z 269.4 [M+1]+.
H. 4-((1 S,2S)Hydr0xycyclopentylamin0)(methylsulf0nyl)—
pyrimidine—5-carb0xamide. To a mixture of 4-((1S,2S)—2-hydroxycyclopentylamino)
(methylthio)pyrimidinecarboxamide (800 mg, 2.98 mmol) in acetone (10 mL) was
added a solution of potassium peroxymonosulfate (4.66 g, 7.45 mmol) in water (10 mL),
and the resulting mixture was stirred at room temperature for 2 h. When the starting
material was consumed, the reaction mixture was partitioned n ethyl acetate
(20 mL) and water (15 mL). The aqueous layer was extracted with ethyl acetate
(20 mL X 3). The combined organic layers were washed with brine, dried over sodium
sulfate and filtered. The filtrate was evaporated in vacuo to give 4-((lS,2S)—2-
hydroxycyclopentylamino)(methylsulfonyl)pyrimidinecarboxamide (700 mg,
2.3 mmol, yield 78%) as a solid. MS (ESI): m/z 301.2 [M+1]+.
I. ,4S)Ethoxycyclohexylamino)—4-((1S,2S)hydr0xycyclopentylamin0
)pyrimidine—5-carboxamide. A solution of 4-((1S,2S)
hydroxycyclopentylamino)(methylsulfonyl)pyrimidinecarboxamide (700 mg,
2.3 mmol), (1r,4r)ethoxycyclohexanamine hydrochloride (668 mg, 4.66 mmol) and
DIEA (600 mg, 4.66 mmol) in dioxane (10 mL) was heated at 80 0C for 15 h. After being
cooled to room temperature, the on mixture was concentrated and the residue was
dissolved in ethyl acetate (20 mL). The organic solution was washed with water and brine,
dried over sodium sulfate and filtered. The e was evaporated in vacuo. The residue
was purified by a e-phase preparatory HPLC (40-75% acetonitrile + 0.05%
ATI—2514l75vl
ammonium hydroxide in water, 7.5 min.) to give 2-((1r,4S)ethoxycyclohexylamino)
((1S,2S)hydroxycyclopentylamino)pyrimidinecarboxamide (320 mg, 0.88 mmol,
yield 38%, mp. l26.0~l26.6°C) as a solid. 1H NMR (DMSO-dg, 400 MHz): 5 ppm
9.02-8.93 (m, 1H), 8.32 (d, J=9.2 Hz, 1H), 7.60-7.51 (m, 1H), 7.04 (d, J=7.2 Hz, 1H), 6.88
(d, J=7.2 Hz, 1H), 4.82 (s, 1H), 3.99-3.89 (m, 3H), 3.42 (q, J=7.2 Hz, 2H), 3.15 (s,
J=6.0 Hz, 1H), 2.10-2.06 (m, 1H), 1.97-1.77 (m, 5H), 1.66-1.60 (m, 2H), 1.46 (s, 1H),
1.28-1.18 (m, 5H), 1.06 (t, J=7.2 Hz, 3H); MS (ESI): m/z 364.3 [M+l]+.
Example 4: 4-((1R,3S)—3-Hydr0xycyclohexylamin0)((1R,4R)—4-
(methylcarbamoyl)cyclohexylamin0)pyrimidine—5-carboxamide
O 0
We 11*"’N N/ NH
‘\gOH
A. Ethyl ,3S)—3-hydr0xycyclohexylamin0)(methylthi0)—
dine-S-carboxylate. Ethyl 4-chloro(methylthio)pyrimidinecarboxylate
(4.38 g, 18.82 mmol) and (1S,3R)aminocyclohexanol (2.276 g, 19.76 mmol; prepared
as described in Tetrahedron: Asymmetry 1—2056 (2004)) were dissolved in ethanol
(75 mL) before adding DIEA (4.93 ml, 28.2 mmol) and g to 60 CC. After 2 hrs,
LCMS showed the desired t mass was the dominant peak formed. The reaction was
removed from heat and concentrated. The crude material was purified on a 340G SNAP
Biotage column (20-100% ethyl acetate in hexane) to give ethyl ,3S)hydroxycyclohexylamino
)(methylthio)pyrimidinecarboxylate (5 g, 16.06 mmol, 85 % yield)
as a white foam; MS (ESI) m/z 312.1 [M+1]+
B. 4-((1R,3S)—3-Hydr0xycyclohexylamin0)(methylthio)pyrimidine—5-
carboxylic acid. Ethyl 4-((1R,3 S)hydroxycyclohexylamino)(methylthio)-
pyrimidinecarboxylate (5 g, 16.06 mmol) was dissolved in ethanol (50 mL) before
adding sodium hydroxide solution (2 M in water, 20 mL, 40.0 mmol) and stirring at room
temperature. After 30 min, LCMS shows mostly desired product mass. The reaction
mixture was neutralized by addition of saturated aqueous citric acid on. The resulting
precipitate was filtered and dried to give 4-((1R,3S)hydroxycyclohexylamino)
_ 72 _
ATI—2514l75vl
(methylthio)pyrimidinecarboxylic acid (4.5 g, 15.88 mmol, 99 % yield) as a white
solid; 1H NMR (400 MHz, DMSO-d6) 5 ppm 13.21 (br. s., 1H), 8.44 - 8.54 (m, 2H), 4.74
(d, J=3.90 Hz, 1H), 3.97 - 4.12 (m, 1H), 3.56 (d, J=3.12 Hz, 1H), 2.46 (s, 3H), 2.05 - 2.16
(m, 1H), 1.84 (d, J=10.15 Hz, 1H), 1.65 - 1.80 (m, 2H), 1.11 - 1.36 (m, 4H); MS (ESI) m/z
284.1 [M+1]+
C. 4-((1R,3S)—3-Hydr0xycyclohexylamin0)(methylthi0)pyrimidine
amide. 4-((1R,3 S)Hydroxycyclohexylamino)(methylthio)pyrimidine-5 -
carboxylic acid (4.5 g, 15.88 mmol) and HATU (9.06 g, 23.82 mmol) were dissolved in
DMF (75 mL) and allowed to stir for 5 min at room temperature before adding ammonium
chloride (4.25 g, 79 mmol) and DIEA (13.87 mL, 79 mmol). The on was allowed to
stir at room temperature ght. After LCMS showed the d product mass as the
dominant peak, the reaction was partitioned between water and ethyl acetate. The organic
layer was washed once with brine before drying over sodium sulfate, filtering, and
sing. After drying, 4-((1R,3 S)hydroxycyclohexylamino)(methylthio)-
pyrimidinecarboxamide (4.19 g, 14.84 mmol, 93 % yield) was obtained as an off-white
solid; MS (ESI) m/z 283.2 [M+1]+
D. 4-((1R,3S)Hydroxycyclohexylamin0)(methylsulf0nyl)—
pyrimidine—5-carb0xamide. 4-((1R,3S)Hydroxycyclohexylamino)(methylthio)-
pyrimidinecarboxamide (302 mg, 1.070 mmol) was suspended in DCM (10 mL) and
acetone (10 mL). mCPBA (479 mg, 2.139 mmol) was then added and the reaction was
stirred at room temperature. After 90 min, LCMS showed the desired product mass as the
dominant peak. The reaction was quenched by addition of 10 mL of 10% aqueous sodium
lfate solution. After stirring for 5 minutes, the reaction was partitioned between
ethyl acetate and water. The organic layer was then washed with saturated sodium
bicarbonate and brine. The combined s layers were washed with ethyl acetate three
times before combining the organic layers, drying over sodium sulfate, filtering, and
condensing. After drying, 4-((1R,3 S)hydroxycyclohexylamino)(methylsulfonyl)-
pyrimidinecarboxamide (259 mg, 0.824 mmol, 77 % yield) was obtained as a white
solid ; MS (ESI) m/z 315.2 [M+1]+
E. (1R,4R)—4-Amino-N-methylcyclohexanecarboxamide. tert-Butyl
(1R,4R)(methylcarbamoyl)cyclohexylcarbamate (0.411 g, 1.603 mmol) was dissolved
ATI—2514l75vl
WO 45569
in DCM (5 mL), treated with TFA (5.56 mL, 72.1 mmol) and stirred at room temperature
for 1 h. After that the solvent was reduced in vacuo, the residue ved in acetonitrile
and loaded on a Phenomenex Strada-X-C solid phase extraction column and flushed with
300 mL of acetonitrile. The desired compound was released from the column using 2 M
ammonia in methanol. The on containing the desired compound was reduced in
vacuo to afford (1R,4R)amino-N-methylcyclohexanecarboxamide (0.230 g,
1.475 mmol, 92 % yield); MS (ESI) m/Z 157.0 [M+1]+.
F. 4-((1R,3S)—3-Hydr0xycyclohexylamino)—2-((1R,4R)—4-(methyl-
carbamoyl)cyclohexylamino)pyrimidine—5-carboxamide. 4-((1R,3S)Hydroxy-
cyclohexylamino)(methylsulfonyl)pyrimidinecarboxamide (0.231 g, 0.736 mmol),
(1R,4R)amino-N-methylcyclohexanecarboxamide (0.230 g, 1.472 mmol), DIEA
(0.514 mL, 2.94 mmol), and DMSO (4 mL) were combined and heated at 100 CC for 2 h.
The solvent was evaporated under d pressure, the residue dissolved in a minimum
amount of methanol, loaded on a silica gel column and purified (0-15% ammonia saturated
methanol in DCM) to afford 4-((1R,3S)—3-hydroxycyclohexylamino)((1R,4R)
(methylcarbamoyl)-cyclohexylamino)pyrimidinecarboxamide (0.106 g, 0.271 mmol,
36.9 % yield) as a white powder; MS (ESI) m/Z 391.2 [M+1]+; 1H NMR (400 MHz,
DMSO-d6) 8 ppm 9.10 (br. s., 1H), 8.33 (s, 1H), 7.68 (br. s., 1H), 6.92 - 7.29 (m, 3H), 4.67
(br. s., 1H), 3.87 (br. s., 1H), 3.41 = 4.30 Hz, 3H), 1.66
- 3.71 (m, 2H), 2.55 (d, J - 2.16 (m,
9H), 1.00 - 1.47 (m, 8H).
Example 5: 4-((1R,3S)—3-Hydr0xycyclohexylamino)—2-((1r,4R)—4-
lamin0)cyclohexylamin0)pyrimidinecarboxamide hydrochloride
/ N \ NH2
., )L /
’N N NH
A. tert-Butyl )—4-(5-carbamoyl—4-((1R,3S)—3-hydr0xycyclohexyl—
amin0)pyrimidinylamin0)cyclohexyl(methyl)carbamate. 4-((1R,3S)Hydroxycyclohexylamino
)(methylsulfonyl)pyrimidinecarboxamide (0.397 g, 1.264 mmol;
synthesis described herein), tert-butyl (1R,4R)aminocyclohexyl-(methyl)carbamate
_ 74 _
ATI—25 14175v1
(0.577 g, 2.53 mmol), DIEA (0.883 mL, 5.05 mmol), and DMSO (4 mL) were combined
and heated at 100 0C for 2 h. The solvent was evaporated under reduced pressure, the
e dissolved in a minimum amount of methanol, loaded on a silica gel column and
purified (0-l5% ammonia saturated methanol in DCM) to afford tert-butyl (lR,4r)—4-(5-
carbamoyl(( l R,3 S)hydroxycyclohexylamino)pyrimidinylamino)cyclohexyl-
(methyl)carbamate (0.210 g, 0.455 mmol, 36 % yield) as a white powder; MS (ESI) m/z
463.3 [M+1]+.
B. 4-((1R,3S)Hydr0xycyclohexylamino)—2-((1R,4R)—4-(methyl-
amino)cyclohexylamin0)pyrimidine—5-carboxamide hydrochloride. tert-Butyl (lR,4r)-
4-(5-carbamoyl((lR,3S)hydroxycyclohexylamino)pyrimidinylamino)-
cyclohexyl(methyl)carbamate (0.150 g, 0.324 mmol) was dissolved in DCM (2 mL) and
TFA (2 mL, 26.9 mmol) was added drop wise. The solution was d at room
temperature for l h and then concentrated under reduced pressure. The residue was
purified via preparative HPLC (5-40% acetonitrile/water, 20mL/min.) to afford the title
compound as the corresponding TFA-salt. The fractions containing the desired compound
were concentrated under reduced pressure, the residue dissolved in methanol and hydrogen
chloride (4N in dioxane; 3 mL) was added. The resulting solution was concentrated under
reduced pressure and this ure was ed twice to afford 4-((lR,3S)hydroxy-
cyclohexylamino)((lr,4R)(methylamino)cyclohexylamino)pyrimidine
amide hydrochloride (0.063 g, 0. 158 mmol, 48.7 % . MS (ESI) m/z 363.5
[M+l]+; 1H NMR (400 MHz, DMSO-d6) 8 ppm 9.94 (br. s., 1H), 8.83 - 9.01 (m, 1H), 8.38
- 8.49 (m, 2H), 8.15 (br. s., 1H), 7.64 (br. s., 1H), 3.96 (br. s., 1H), 3.69 (d, J = 13.67 Hz,
2H), 3.49 (d, J = 11.32 Hz, 3H), 2.97 (br. s., 1H), 2.52 (br. s., 2H), 1.69 - 2.17 (m, 7H),
3(nn8H)
ATI—2514l75vl
Example 6: 2-(4,4-Diflu0r0cyclohexylamin0)—4-((1R,3S)—3-
hydroxycyclohexylamin0)pyrimidinecarboxamide
] 4-((1R,3 S)—3-Hydroxycyclohexylamino)(methylsulfonyl)pyrimidine-5 -
carboxamide (478 mg, 1.521 mmol; synthesis described herein), 4,4-difluorocyclo-
hexanamine hydrochloride (522 mg, 3.04 mmol), DIEA (1.062 mL, 6.08 mmol), and
DMSO (8 mL) were ed in a round bottom flask and heated at 100 CC for 1 h. The
reaction was removed from heat and condensed in vacuo. The crude material was purified
on a 100G SNAP Biotage column (2-12% ammonia saturated methanol in DCM). The
peak fractions were combined and evaporated. After drying under high ,
2-(4,4-difluorocyclohexylamino)((1R,3 S)hydroxycyclohexylamino)pyrimidine-5 -
carboxamide (325 mg, 0.880 mmol, 58%) was obtained as a slightly yellow powder;
1H NMR (400 MHz, DMSO-d6) 8 ppm 8.93 (d, J=7.42 Hz, 1H), 8.36 (s, 1H), 7.22 (br. s.,
1H), 2.94 - 3.05 (m, 1H), 1.64 - 2.21 (m, 14H), 1.36 - 1.62 (m, 4H), 0.92 - 1.33 (m, 3H);
MS (ESI) m/z 370.2 [M+1]+.
ATI—25 14175V1
Example 7: ,5R)—5-Hydr0xytetrahydr0-2H-pyranylamin0)((1r,4S)
methoxycyclohexylamin0)pyrimidine—5-carb0xamide, 4-((3R,SS)hydroxytetrahydro-ZH-pyranylamin0
)—2—((1r,4R)—4-meth0xycyclohexylamino)pyrimidine—
-carb0xamide, 4-((3S,5S)hydr0xytetrahydr0-2H-pyranylamin0)—2-((1r,4S)
methoxycyclohexylamin0)pyrimidinecarboxamide, 4-((3R,5R)—5-
hydr0xy-tetrahydro-ZH-pyranylamin0)—2-((1r,4R)—4-
methoxycyclohexylamin0)pyrimidine—5-carb0xamide.
o O o
O / \
/ U 1W ”U 1% ”U 1W U 1W
., / "I
'N . .,
N NH "N)\N/ N NH
NH ’N N/ NH n
H i H a H
(Quw oé-,
0 ’OH
OH QOH
A. 0xy-2H-pyran-3(6H)—0ne. Furanylmethanol (17.67 mL,
204 mmol) was dissolved in DCM (500 mL) and cooled to 0 0C before adding
3-chloroperoxybenzoic acid (68.5 g, 306 mmol) portion wise. The reaction was slowly
allowed to warm to room temperature over 6 h, during which time solid m-chlorobenzoic
acid precipitated from solution. The solution was cooled to -78 CC for 15 min and the
solids were filtered off. The e was condensed to give a yellow solid. The crude
material was purified on a 340G SNAP Biotage column (20-100% ethyl acetate in
hexane). The peak fractions were combined and ated to give 6-hydroxy-2H-pyran-
one (15.8 g, 138 mmol, 67.9 % yield) as a pale yellow oil; 1H NMR (400 MHz,
CDC13)5 ppm 6.94 - 7.01 (m, 1H), 6.18 (d, J=10.93 Hz, 1H), 5.61 - 5.68 (m, 1H), 4.56 (s,
1H), 4.17 (s, 1H), 3.61 (br. s., 1H).
B. 6-(tert-Butyldimethylsilyloxy)—2H-pyran-3(6H)—0ne. 6-Hydroxy-2H-
pyran-3(6H)-one (9 g, 79 mmol) was dissolved in DCM (250 mL), placed under a nitrogen
atmosphere, and cooled to -78 oC. 2,6-Lutidine (13.78 mL, 118 mmol) was then added in
one n, followed by slow addition of t-butyldimethylsilyltrifiuoromethanesulfonate
(21.74 mL, 95 mmol). The reaction was allowed to slowly warm to 0 0C over 4 h. The
on was quenched by addition of ~20 mL of water. The solution turned pale yellow
upon quenching. After transferring to a separatory filnnel, the organic phase was washed
successively with 10% citric acid and brine. The organic layer was then dried over sodium
sulfate, filtered and condensed to give a yellow oil. The crude material was purified on a
ATI—25 14175v1
340G SNAP Biotage column (0-20% ethyl acetate in hexane) to give 6-(tert-
butyldimethylsilyloxy)-2H-pyran-3(6H)-one (9.90 g, 43.4 mmol, 55.0 % yield) as a yellow
oil; 1H NMR (400 MHz, CDC13)5 ppm 6.87 (dd, J=10.54, 3.12 Hz, 1H), 6.08 (d,
J=10.15 Hz, 1H), 5.53 (d, J=3.12 Hz, 1H), 4.51 (d, J=16.79 Hz, 1H), 4.08 (d, J=16.79 Hz,
1H), 0.92 (s, 9H), 0.17 (s, 6H).
C. 6-(tert—Butyldimethylsilyloxy)—3,6-dihydro-ZH-pyranol. To a
cooled (-20 oC) solution of 6-(tert-butyldimethylsilyloxy)-2H-pyran-3(6H)-one (9.9 g,
43.4 mmol) and cerium(IH) chloride heptahydrate (16.15 g, 43.4 mmol) in methanol
(173 mL) was added n wise sodium borohydride(1.640 g, 43.4 mmol). Intense
bubbling was observed upon addition. After the e was stirred for 30 min at -20 0C,
the reaction was quenched with acetone (~20 mL) and stirred at room temperature for 1 h.
Most of the volatile solvents were then evaporated. Brine was added and the slurry was
transferred to a separatory . The mixture was extracted with DCM (thick emulsion
formed) three times. The combined organic layers were dried over sodium sulfate, d
and condensed to give crude 6-(tert-butyldimethylsilyloxy)-3,6-dihydro-2H-pyranol
(5.6 g, 24.31 mmol, 56.1 % yield) as a tan colored oil; 1H NMR (400 MHz, CDClg) 5 ppm
.95 (dd, 5, 2.34 Hz, 1H), 5.75 (d, 5 Hz, 1H), 5.25 (s, 1H), 4.15 (d,
J=9.37 Hz, 1H), 3.72 - 3.82 (m, 2H), 1.74 (d, J=8.98 Hz, 1H), 0.86 - 0.95 (m, 9H), 0.13 (s,
6H).
D. 6-(tert—Butyldimethylsilyloxy)—3,6-dihydr0-2H-pyranyl e.
To a solution of 6-(tert-butyldimethylsilyloxy)-3,6-dihydro-2H-pyranol (13.3 g,
57.7 mmol) and TEA (16.09 mL, 115 mmol) in DCM (200 mL) was added acetic
anhydride (27.2 mL, 289 mmol), and the mixture was stirred at room temperature
ght. Methanol (~3 mL) was added and the mixture was stirred for 30 min at room
temperature before adding water and transferring to a separatory funnel. The organic layer
was washed with water and brine, dried over sodium sulfate, filtered and condensed. The
crude material was purified on a 340G SNAP Biotage column (0-50% ethyl acetate in
hexane) to give 6-(tert-butyldimethylsilyloxy)-3,6-dihydro-2H-pyranyl acetate (13.6 g,
49.9 mmol, 86 % yield) as a pale yellow oil; 1H NMR (400 MHz, CDClg) 5 ppm
.84 - 5.88 (m, 2H), 5.26 - 5.28 (m, 1H), 5.20 - 5.25 (m, 1H), 3.84 (dd, J=6.25, 1.95 Hz,
2H), 2.08 (s, 3H), 0.91 (s, 9H), 0.13 (d, J=1.17 Hz, 6H).
ATI—25 14175v1
E. 3,6-Dihydr0-2H-pyranyl acetate. 6-(tert-Butyldimethylsilyloxy)-
hydro-2H-pyranyl acetate (13.6 g, 49.9 mmol) was dissolved in DCM (250 mL),
placed under a nitrogen atmosphere, and cooled to -30 oC (dry ice/acetone, until
temperature was reached). Triethylsilane (15.95 mL, 100 mmol) was then added slowly
via e, followed by drop wise addition of boron ride etherate (7.59 mL,
59.9 mmol). The reaction was kept under nitrogen and slowly allowed to warm. After
1 h, the on mixture was quenched by additions of saturated sodium onate.
After transferring to a separatory filnnel, the organic layer was washed with water and
brine, dried over sodium sulfate, filtered and condensed. The crude material was purified
on a 340G SNAP Biotage column (0-80% ethyl acetate in hexane). Evaporation of clean
fractions gave hydro-2H-pyranyl acetate (5.5 g, 38.7 mmol, 77 % yield) as a
colorless oil; 1H NMR (400 MHz, CDClg) 8 ppm 5.09 (dtt, J=5.73, 2.21, 2.21, 1.17,
1.17 Hz, 1H), 4.19 - 4.28 (m, 1H), 4.04 - 4.15 (m, 1H), 3.89 - 3.98 (m, 1H), 3.76 - 3.84 (m,
1H), 2.10 (s, 3H).
F. 3,6-Dihydr0-2H-pyranol. To a solution of 3,6-dihydro-2H-pyran
yl acetate (5.5 g, 38.7 mmol) in methanol (130 mL) was added 10 drops of 25% sodium
methoxide in ol. The solution was allowed to stir at room temperature. After
min, TLC (10% ethyl e in hexane; permanganate stain) shows ~1 :1 ratio of
starting material to product. An additional 10 drops of 25% sodium methoxide in
methanol was added. After 30 min, TLC showed ~3:1 ratio of product to starting material.
An additional 10 drops of 25% sodium methoxide in methanol were added. After 30 more
min, TLC showed complete conversion to product. Amberlist 15 was added and stirring
was continued for 15 min before filtering off. Evaporation of the solvent gave
hydro-2H-pyranol (3.8 g, 38.0 mmol, 98 % yield) as a colorless oil; 1H NMR
(400 MHz,CDC13)8 ppm 5.90 - 6.02 (m, 2H), 4.19 (dt, J=2.83, 1.51 Hz, 1H), 4.15 (dt,
J=2.83, 1.51 Hz, 1H), 4.09 (q, J=1.95 Hz, 1H), 4.05 (q, J=1.95 Hz, 1H), 3.96 - 4.00 (m,
1H), 1.92 (br. s., 1H).
G. 2H-Pyran-3(6H)—0ne. 3,6-Dihydro-2H-pyranol (2.44 g,
24.37 mmol) was dissolved in DCM (100 mL) and cooled to 0 0C before slowly adding
Dess-Martin periodinane (10.34 g, 24.37 mmol). The reaction was allowed to slowly
warm to room temperature over 5 h. The reaction was then filtered through celite. After
ATI—25 14175v1
WO 45569
concentrating the filtrate, the crude al was purified on a 100G SNAP Biotage
column (0-80% ethyl acetate in hexane) to give 2H-pyran-3(6H)-one (2.33 g, 23.75 mmol,
97 % yield) as a colorless oil; 1H NMR (400 MHz, CDClg) 5 ppm 7.07 - 7.17 (m, 1H),
6.15 - 6.25 (m, 1H), 4.39 (t, J=2.54 Hz, 2H), 4.19 (s, 2H).
H. Benzyl 5-0x0tetrahydr0-2H-pyranylcarbamate. 2H-pyran-3(6H)-
one (2.33 g, 23.75 mmol), benzyl carbamate (4.31 g, 28.5 mmol), and DCM (2.375 mL)
were added to a small vial and stirred usly. To the thick syrup was added
bismuth(III) nitrate pentahydrate (1.728 g, 3.56 mmol). The vial was capped and the
reaction was stirred vigorously overnight. The reaction was diluted with DCM and filtered
through a pad of celite. The filtrate was condensed and purified on a 100G SNAP Biotage
column (10-100% ethyl acetate in hexane) to give benzyl etrahydro-2H-pyran
ylcarbamate (4.35 g, 17.45 mmol, 73.5 % yield) as a pale yellow oil; 1H NMR (400 MHz,
CDCh)8pmn728-741Gm5HL520-528Gm1H)505-515&m2H)424-435
(m, 1H), 4.01 - 4.06 (m, 1H), 3.89 - 3.95 (m, 1H), 3.80 - 3.87 (m, 1H), 2.73 (d, J=5.47 Hz,
11D,264-271(nn1H)
I. Benzyl 5-hydr0xytetrahydr0-2H-pyranylcarbamate. Benzyl 5-
oxotetrahydro-2H-pyranylcarbamate (4.35 g, 17.45 mmol) and cerium(III) chloride
heptahydrate (6.50 g, 17.45 mmol) were dissolved in methanol (100 mL) before cooling to
0 oC. Sodium borohydride (0.660 g, 17.45 mmol) was then added slowly. Intense
bubbling was observed. The reaction was allowed to stir at 0 0C for 30 min before
quenching by addition of acetone (~3 mL) and stirring at room temperature for
additional min. The on was then evaporated to dryness. The material was
ioned between DCM and water and the aqueous layer was washed with DCM (5X).
The organic layers were combined, dried over sodium sulfate, filtered, and condensed to
give impure benzyl 5-hydroxytetrahydro-2H-pyranylcarbamate (2.5 g, 9.95 mmol,
57.0 % yield) as a white solid; 1H NMR (400 MHz, CDClg) 8 ppm 7.28 - 7.39 (m, 5H),
.90 - 6.06 (m, 1H), 5.10 (d, J=4.29 Hz, 2H), 3.59 - 3.97 (m, 6H), 1.77 - 2.06 (m, 3H);
MS (ESI) m/z 252.1 [M+1]+.
J. 5-Amin0tetrahydr0-2H-pyranol. Benzyl oxytetrahydro-2H-
pyranylcarbamate (2.5 g, 9.95 mmol) was dissolved in DCM (20 mL) and methanol
(20.00 mL) before loading catalyst (10% palladium on carbon) and g with a t-joint.
ATI—25 14175v1
The flask was evacuated and flushed with hydrogen (3X), ining a hydrogen
atmosphere with a balloon. The reaction was allowed to stir at room temperature
overnight. Once the al had all been converted to product (as determined by LCMS),
the reaction was filtered through a pad of celite, washing ghly with DCM and
methanol. The filtrate was condensed to give crude 5-aminotetrahydro-2H-pyranol
(1.13 g, 9.65 mmol, 97 % yield) as tan gum. 1H NMR (400 MHz, DMSO-d6) 5 ppm
4.28 - 4.66 (m, 2H), 3.66 (ddd, J=10.93, 3.90, 1.56 Hz, 2H), 3.44 - 3.55 (m, 1H),
2.89 - 3.01 (m, 2H), 2.81 (s, 1H), 2.01 - 2.13 (m, 1H), 1.22 (d, J=12.10 Hz,1H).
K. Ethyl 2-((1r,4r)—4-meth0xycyclohexylamin0)(methylthi0)—
pyrimidine-S-carboxylate. )Methoxycyclohexanamine (4.39 g, 34.0 mmol),
ethyl 2-chloro(methylthio)pyrimidinecarboxylate (3.95 g, 16.98 mmol) DIEA (5.93
mL, 34.0 mmol) and 1,4-dioxane (100 mL) were combined and heated at 80 oC overnight.
The reaction was removed from heat and condensed. The crude material was purified on a
Biotage (20-80% ethyl acetate in hexanes) to give ethyl ,4r)
methoxycyclohexylamino)(methylthio)pyrimidinecarboxylate (3.1 g, 9.53 mmol, 56
% yield) as a pale yellow solid; 1H NMR (DMSO-d6 ,400 MHz) 8 ppm 8.60 (s, 0.35H),
8.54 (s, 0.65H), 8.05 (d, J=7.4 Hz, 0.64H), 7.87 (d, J=8.2 Hz, 0.36H), 4.22 (q, J=7.0 Hz,
2H), 3.69 - 3.90 (m, 1H), 3.23 (s, 3H), 3.00 - 3.20 (m, 1H), 2.40 (s, 2H), 2.38 (s, 1H), 1.79
- 2.12 (m, 4H), 1.09 - 1.44 ppm (m, 7H); MS (ESI) m/z 326.3 [M+1]+.
L. 2-((1r,4r)—4-Meth0xycyclohexylamin0)(methylthi0)pyrimidine
carboxylic acid. Ethyl 2-((1r,4r)methoxycyclohexylamino)(methylthio)pyrimidine-
-carboxylate (3.1 g, 9.53 mmol) was dissolved in ethanol (60 mL) before adding aqueous
sodium hydroxide solution (2 M, 23.81 mL, 47.62 mmol) and ng at room temperature.
After 30 min, LCMS showed mostly d product mass. The reaction mixture was
neutralized by addition of saturated aqueous citric acid solution. The resulting itate
was filtered and dried to give 2-((1r,4r)methoxycyclohexylamino)(methylthio)-
pyrimidinecarboxylic acid (2.76 g, 9.28 mmol, 97 % yield) as a white solid; 1H NMR
(DMSO-d6 ,400 MHz) 8 ppm 12.59 (s, 1H), 8.57 (s, 0.38H), 8.50 (s, 0.62H), 7.94 (d,
J=7.4 Hz, 0.62H), 7.77 (d, J=7.8 Hz, 0.38H), 3.70 - 3.90 (m, 1H), 3.23 (s, 3H), 3.02 - 3.18
(m, 1H), 2.37 (s, 2H), 2.36 (s., 1H), 1.83 - 2.09 (m, 4H), 1.11 - 1.46 ppm (m, 4H);
MS (ESI) m/z 298.2 [M+1]+
ATI—25 14175v1
M. 2-((1r,4r)—4-Meth0xycyclohexylamino)(methylthio)pyrimidine—5-
carboxamide. 2-((lr,4r)methoxycyclohexylamino)(methylthio)pyrimidine
carboxylic acid (2.66 g, 8.94 mmol) and HATU (5.10 g, 13.42 mmol) were dissolved in
DMF (35 mL) and allowed to stir for 5 minutes at room temperature before adding
ammonium chloride (2.392 g, 44.7 mmol) and DIEA (7.81 mL, 44.7 mmol). The reaction
was allowed to stir at room temperature for 30 min. LCMS shows the desired product
mass as dominant and the reaction was partitioned between water and ethyl acetate. The
organic layer was washed once with brine before drying over sodium sulfate, ng, and
condensing. After drying, ,4r)methoxycyclohexylamino)(methylthio)
dinecarboxamide (2.54 g, 8.57 mmol, 96 % yield) was obtained as an white
solid; 1H NMR (DMSO-d6 ,400 MHz) 8 ppm 8.41 (s, 1H), 7.63 (d, J=7.0 Hz, 0.76H), 7.45
(d, J=7.0 Hz, 0.24H), 7.08 (br. s., 1H), 3.66 - 3.85 (m, 1H), 3.23 (s, 3H), 3.11 (br. s., 1H),
2.32 (s, 3H), 1.81 - 2.11 (m, 4H), 1.10 - 1.44 ppm (m, 4H); MS (ESI) m/z 283.2 [M+l]+
N. 2-((1r,4r)—4-Methoxycyclohexylamino)—4-(methylsulfinyl)-
pyrimidine—5-carb0xamide. 2-((lr,4r)Methoxycyclohexylamino)
(methylthio)pyrimidinecarboxamide (3 g, 10.12 mmol) was dissolved in NMP (30 mL).
At 0 CC, mCPBA (2.268 g, 10.12 mmol) was then added portion wise and the on was
d while elevating the reaction temperature to room temperature slowly. After 30 min,
the reaction mixture was diluted with water (200 mL), stirred for 10 min and the resulting
solid was removed by filtration. The filtrate was concentrated in vacuo to afford
,4r)methoxycyclohexylamino)(methylsulf1nyl)pyrimidinecarboxamide as a
clear, slightly yellow solution in NMP (~25mL). This crude product was used in the next
step without further ation. MS (ESI) m/z 3 13.3 [M+l]+.
O. 4-((3S,5R)—5-Hydr0xytetrahydr0-2H—pyranylamin0)—2-((1r,4S)
methoxycyclohexylamin0)pyrimidinecarb0xamide, 4-((3R,SS)hydroxy-
tetrahydr0-2H-pyranylamin0)—2-((1r,4R)—4-meth0xycyclohexylamino)pyrimidine—
-carb0xamide, 4-((3S,5S)hydroxytetrahydro-ZH-pyranylamin0)—2-((1r,4S)
methoxycyclohexylamin0)pyrimidinecarb0xamide, 4-((3R,5R)—5-hydr0xy-
tetrahydr0-2H-pyranylamin0)—2-((1r,4R)—4-meth0xycyclohexylamino)pyrimidine—
0xamide. To 2-((lr,4r)methoxycyclohexylamino)(methylsulf1nyl)-
pyrimidinecarboxamide (3.1 g, 9.92 mmol) in NMP (25 mL)) was added crude
ATI—2514l75vl
otetrahydro-2H-pyranol (1.15 g, 9.82 mmol) as a solution in NMP (20 mL). To
the suspension was added DIEA (8.57 mL, 49.1 mmol) and the reaction was heated to
100 oC overnight. Most of the NMP was removed by evaporation at 70 0C, the residue
was diluted with DCM and purified on a 340G SNAP Biotage column (0-15% methanol in
DCM over 2000 mL). The product fractions were combined and concentrated to give
2.8 g (78%) of material that was ~85% pure. The al was dissolved in DCM and
repurified on a 340G SNAP Biotage column (2-15% ammonia saturated methanol in
dichloromethane). The product fractions were combined and concentrated to afford a
mixture of four products (two diastereomers and their corresponding enantiomers; 1.95 g),
>99% pure. The crude material was separated by chiral SFC using an AD-H column to
afford 4 compounds labeled PEAK 1 to PEAK 4, with PEAK 1 being the first eluting
compound and PEAK 4 being the latest eluting compound.
] PEAK 1: 1H NMR (400 MHz, g) 8 ppm 8.41 (s, 1H), 4.38 (br. s.,
1H), 3.53 - 3.79 (m, 4H), 3.24 (s, 3H), 2.87 - 2.98 (m, 3H), 1.89 - 2.07 (m, 4H), 1.65 - 1.78
(m, 1H), 1.19 - 1.43 (m, 4H); MS (ESI) m/z 366.3 [M+1]+.
PEAK 2: 1H NMR (400 MHz, DMSO-dg) 5 ppm 8.86 - 9.01 (m, 1H), 8.35
(br. s., 1H), 6.91 - 7.18 (m, 1H), 4.91 - 4.99 (m, 1H), 3.49 - 4.13 (m, 4H), 3.23 (s, 3H),
2.85 - 3.15 (m, 3H), 1.79 - 2.28 (m, 5H), 1.08 - 1.41 (m, 5H), 1.04 (d, J=6.25 Hz, 1H); MS
(ESI) m/z 366.3 [M+1]+ .
PEAK 3; 1H NMR (400 MHz, DMSO-dg) 5 ppm 8.86 — 9.02 (m, 1H),
832-8400n,HD,688-7200n,HD,491-5000n,HD,349-4J5(nn5H)322(s
3H), 2.79 - 3.14 (m, 3H), 1.82 (s, 5H), 1.12 (t, J=7.22 Hz, 6H); MS (ESI) m/z 366.3
[M+1]+ .
PEAK 4: 1H NMR (400 MHz, DMSO-dg) 5 ppm 8.99 - 9.24 (m, 1H), 8.36
wrs,1H)679-720&m2H)472-494@m1HL417-446fim1H)343-3770n
4H), 3.23 (s, 4H), 3.03 - 3.13 (m, 1H), 2.73 (s, 1H), 1.98 (br. s., 6H), 1.03 - 1.35 (m, 5H);
MS (ESI) m/z 366.3 .
ATI—25 14175v1
Example 8: 4-(3-Hydr0xymethylbutylamin0)—2-((1r,4r)—4-
methoxycyclohexylamin0)pyrimidinecarboxamide
N \ NH2
., )L/
’N N NH
H >OH
A. 2-((1r,4r)—4-Methoxycyclohexylamin0)(methylsulfinyl)-
pyrimidine—5-carb0xamide. To a d colorless solution of 2-((1r,4r)
methoxycyclohexylamino)(methy1thio)pyrimidinecarboxamide (0.200 g,
0.675 mmol; synthesis described herein) in NMP (2 mL) was added mCPBA (0.151 g,
0.675 mmol) at 0 oC portion wise. The reaction mixture was then stirred at room
temperature for 2 h until completion of the reaction as indicated by LCMS. The reaction
mixture was diluted with water (20 mL) and filtered. The filtrate was concentrated to
afford 2-((1r,4r)methoxycyclohexylamino)(methy1su1finy1)pyrimidine
carboxamide (0.211 g, 100% yield) as a white sticky solid which was used in the next step
without further purification. MS (ESI) m/z 313.1 .
B. 4-(3-Hydr0xymethylbutylamino)—2-((1r,4r)—4-meth0xy-cyclo-
hexylamin0)pyrimidine—5-carb0xamide. To a solution of 2-((1r,4r)methoxy-
cyclohexylamino)(methylsulfiny1)pyrimidinecarboxamide (0.211 g, 0.675 mmol)
and DIEA (0.236 mL, 1.351 mmol) in NMP (2 mL) was added 4-aminomethy1butan
01 (0.105 g, 1.013 mmol) at room ature. The reaction e was stirred for 2 h at
70 oC. Upon completion of the reaction as indicated by LCMS and TLC the reaction
mixture was concentrated and purified by silica gel chromatography (0% - 15% ammonia
saturated ol in DCM). The product fractions were combined and concentrated to
afford 4-(3-hydroxymethy1buty1amino)((1r,4r)methoxycyclohexylamino)-
dinecarboxamide (0.143 g, 60.2 % yield, 95.8% pure) as a pale yellow solid.
1H NMR (400 MHz, DMSO-dg) 8 ppm 8.81 - 9.03 (m, 1H), 8.32 (s, 1H), 6.75 - 7.06 (m,
2H), 4.28 (s, 1H), 3.63 - 3.77 (m, 1H), 3.39 - 3.52 (m, 2H), 3.22 (s, 3H), 3.02 - 3.11 (m,
1H), 1.81 - 2.06 (m, 4H), 1.57 - 1.67 (m, 2H), 1.21 - 1.34 (m, 2H), 1.16 (br. s., 1H), 1.13
(s, 8H). MS (ESI) m/z 352.4 [M+1]+.
ATI—25 14175V1
Example 9: 4-((1R,2S)(Hydroxymethyl)cyclopentylamino)—2-((1r,4R)—4-
ycyclohexylamino)pyrimidine—5-carb0xamide, 4-((1 S,2R)—2-
(Hydroxymethyl)cyclopentylamino)—2-((1r,4S)
methoxycyclohexylamin0)pyrimidinecarboxamide
o 0
”MA“ NH 'I’MAN/ 1ng
m 0%
A. Ethyl 4-(cis—2-(hydroxymethyl)cyclopentylamino)—2-(methylthi0)-
pyrimidine-S-carboxylate. To a stirred solution of ethyl 4-chloro(methylthio)-
pyrimidinecarboxylate (5.00 g, 21.49 mmol) and cis-(2-aminocyclopentyl)-methanol
(2.60 g, 22.56 mmol) in l (85 mL) was added DIEA (5.61 mL, 32.2 mmol) and
heated to 60 0C for 2.5 h. Upon completion of reaction, as indicated by LCMS and TLC,
the reaction was removed from heat and concentrated, then purified by silica gel
chromatography (0-80% ethyl acetate/hexane). The desired product fractions were
combined and concentrated to afford ethyl 4-(cis(hydroxymethyl)cyclopentylamino)
(methylthio)pyrimidinecarboxylate (6.4 g, 96 % yield) as a white solid. MS (ESI)
m/z 312.4 [M+1]+.
B. 4-(cis—2-(Hydr0xymethyl)cyclopentylamin0)(methylthi0)—
pyrimidine-S-carboxylic acid. To a stirred solution of the ethyl 4-(cis(hydroxyl-
methyl)cyclopentylamino)(methylthio)pyrimidinecarboxylate (6.4 g, 20.55 mmol) in
ethanol (100 mL) was added aqueous sodium hydroxide solution (1 M, 51.4 mL,
51.4 mmol) at room temperature. The reaction mixture was stirred at room temperature
for 2 h. Upon tion of reaction as indicated by LCMS and TLC, the reaction
mixture was concentrated, diluted with water (100 mL), then lized while stirring
with aqueous citric acid solution (2 M, 51.4 mL, 103 mmol). The resulting precipitate was
ed, washed with water (2 x 50 mL) and dried to afford 4-(cis(hydroxymethyl)-
entylamino)(methylthio)pyrimidinecarboxylic acid (5.6 g, 96 % yield) as a
white solid. 1H NMR (400 MHz, DMSO-dg) 8 ppm 8 13.17 (br. s., 1H), 8.71 (d,
J: 7.42 Hz, 1H), 8.50 (s, 1H), 4.49 - 4.60 (m, 2H), 3.40 - 3.46 (m, 1H), 3.32 - 3.39 (m,
ATI—25 14175V1
2H), 2.47 (s, 3H), 2.22 (sxt, J: 6.87 Hz, 1H), 1.95 - 2.04 (m, 1H), 1.78 (qd, J= 4.49,
8.00 Hz, 1H), 1.66 - 1.72 (m, 1H), 1.49 - 1.61 (m, 2H). MS (ESI) m/z 284.3 [M+1]+.
C. (Hydr0xymethyl)cyclopentylamino)—2-(methylthi0)-
pyrimidine—5-carb0xamide. A white suspension of the 4-(cis(hydroxymethyl)-
cyclopentylamino)(methylthio)pyrimidinecarboxylic acid (5.6 g, 19.76 mmol) and
HATU (11.27 g, 29.60 mmol) were dissolved in DMF (79 mL) and stirred for 5 min at
room temperature before adding ammonium chloride (5.29 g, 99 mmol) and DIEA
(17.26 mL, 99 mmol). The reaction mixture was stirred at room temperature for 1 h and
then diluted with water (200 mL) and extracted with ethyl acetate (2 x 200 mL). The
combined organic layers were washed with brine (100 mL), dried over sodium e,
filtered, and concentrated. The residual DMF was removed by suspending the white
suspension in 200 mL water and 200 mL hexanes. The biphasic mixture was stirred
vigorously for 30 min, d and washed with hexanes to afford 4-(cis(hydroxyl-
methyl)cyclopentylamino)(methylthio)pyrimidinecarboxamide (4.50 g, 81 % yield)
as a white solid. MS (ESI) m/z 283.4 [M+1]+.
D. 4-(cis(Hydr0xymethyl)cyclopentylamin0)(methylsulf0nyl)—
pyrimidine—5-carb0xamide. To a d suspension of the 4-(cis(hydroxymethyl)-
cyclopentylamino)(methylthio)pyrimidinecarboxamide (3.5 g, 12.40 mmol) in DCM
(62 mL) and acetone (62 mL) was added mCPBA (5.56 g, 24.79 mmol) and stirred at
room ature for 1.5 h. The crude reaction mixture was quenched by addition of
75 mL of 10% aqueous sodium thiosulfate solution, stirred for 5 min, before ating
most of the volatile solvents. The material was partitioned between ethyl acetate (200 mL)
and water (200 mL), and the combined organic layers were washed with saturated sodium
bicarbonate solution and then brine. The combined aqueous layers were then washed with
ethyl acetate (3x), the c layers were combined, dried over sodium sulfate, filtered,
and condensed. After drying under high vacuum, 4-(cis(hydroxymethyl)cyclopentyl-
amino)(methylsulfonyl)pyrimidinecarboxamide (1.2 g, 3.82 mmol, 30.8 % yield)
was ed as a white solid. MS (ESI) m/z 315.2 [M+1]+.
E. 4-((1R,2S)(Hydr0xymethyl)cyclopentylamin0)((1r,4R)—4-
methoxycyclohexylamin0)pyrimidine—5-carboxamide, 4-((1S,2R)—2-(Hydr0xymethyl)—
cyclopentylamino)—2-((1r,4S)methoxycyclohexylamin0)pyrimidine—5-carboxamide.
ATI—25 14175v1
To a stirred suspension of 4-(cis(hydroxymethyl)cyclopentylamino)(methyl-
sulfonyl)pyrimidinecarboxamide (1.2 g, 3.82 mmol) and (1r,4r)methoxycyclo-
mine hydrochloride (1.90 g, 11.46 mmol) in dioxane (40 mL) was added DIEA
(4 mL, 22.92 mmol) and the resulting solution was stirred at 100 0C for 48 h. The crude
reaction mixture was trated, and then purified by silica gel chromatography
(0% - 15% ammonia saturated methanol in DCM). The product fractions were impure and
the d product was precipitated and filtered from the combined fractions using DCM,
methanol and water to afford the title compound as a mixture of two enantiomers (0.420 g,
.3 % yield) as a white solid. The crude material was separated by chiral SFC using an
AD-H column to afford 2 compounds labeled PEAK 1 and PEAK 2, with PEAK 1 being
the first eluting nd and PEAK 2 being the second eluting compound.
PEAK 1. 1H NMR (400 MHz, DMSO-d6) 8 ppm 9.04 - 9.21 (m, 1H), 8.31
- 8.39 (m, 1H), 6.87 - 7.12 (m, 2H), 4.33 - 4.46 (m, 2H), 3.57 - 3.80 (m, 1H), 3.35 - 3.44
(m, 1H), 3.25 - 3.31 (m, 1H), 3.23 (s, 3H), 3.08 (t, .1: 8.20 Hz, 1H), 2.09 - 2.23 (m, 1H),
2.00 (d,J= 11.71 Hz, 2H), 1.80 - 1.94 (m, 3H), 1.63 - 1.78 (m, 2H), 1.50 - 1.61 (m, 2H),
1.44 (br. s., 1H), 1.09 - 1.33 (m, 5H); MS (ESI) m/z 364.5 [M+1]+.
PEAK 2. 1H NMR (400 MHz, DMSO-dg) 5 ppm 9.03 - 9.18 (m, 1H), 8.34
(br. s., 1H), 6.87 - 7.11 (m, 2H), 4.32 - 4.48 (m, 2H), 3.58 - 3.77 (m, 1H), 3.35 - 3.45 (m,
1H), 3.28 (dd, .1: 7.03, 10.15 Hz, 1H), 3.22 (s, 3H), 3.03 - 3.13 (m, 1H), 2.09 - 2.25 (m,
1H), 2.00 (d, .1: 8.59 Hz, 2H), 1.81 - 1.95 (m, 3H), 1.63 - 1.77 (m, 2H), 1.51 - 1.60 (m,
2H), 1.37 - 1.47 (m, 1H), 1.09 - 1.33 (m, 5H); MS (ESI) m/z 364.5 [M+1]+.
ATI—25 14175V1
2012/034349
Example 10: 4-((1R,3R)—3-Hydr0xymethylcyclohexylamin0)((1r,4R)—4-
methoxycyclohexylamin0)pyrimidinecarboxamide, 4-((1R,3S)Hydr0xy
cyclohexylamin0)((1r,4R)—4-meth0xycyclohexylamin0)pyrimidine
carboxamide
o o
”U NYNN "’MAN/ NH ”U YNN”Mk“ NH
) (5%
’OH ’/
A. (1 S,3R)—3-(Dibenzylamin0)cyclohexanol. To a suspension of )-
3-aminocyclohexanol (5 g, 43.4 mmol; prepared as described in Tetrahedron: Asymmetry
: 2051—2056 (2004)) and sodium bicarbonate (12.03 g,143 mmol) in ethanol (100 mL)
was added omethyl)benzene (15.01 mL, 130 mmol) at room temperature. The
reaction mixture was heated at 75 CC overnight. Upon completion of reaction as indicated
by LCMS and TLC the reaction mixture was filtered and the filtrate was concentrated.
The residue was then dissolved in DCM (250 mL) and washed with aqueous sodium
ide solution (1 N, 2 x 100 mL) and brine (1x 100 mL). The combined organic
layers were dried over anhydrous ium sulfate, concentrated, and purified by silica
gel chromatography (0% - 80% ethyl acetate in hexanes) to yield (lS,3R)
(dibenzylamino)cyclohexanol (11.70g, 91%) as a thick yellow oil. 1H NMR (400 MHz,
DMSO-dg) 5 ppm 7.26 - 7.37 (m, 8H), 7.17 - 7.22 (m, 2H), 4.56 (d, .1: 4.30 Hz, 1H), 3.57
(s, 4H), 3.16 - 3.26 (m, 1H), 2.41 (tt, J: 3.17, 11.86 Hz, 1H), 1.99 - 2.06 (m, 1H), 1.72 (d,
.1: 8.20 Hz, 2H), 1.63 - 1.69 (m, 1H), 1.18 - 1.28 (m, 2H), 0.98 (t, 2H); MS (ESI) m/z
296.4 [M+1]+.
B. (R)—3-(Dibenzylamin0)cyclohexanone. Oxalyl chloride (2.70 mL,
.9 mmol) was ved in dry DCM (150 mL) and cooled to -78 oC. DMSO (4.78 mL,
67.3 mmol) in dry DCM (20 mL) was added dropwise to the reaction mixture and the
reaction was stirred for 15 min at -78 CC. Next, (1S,3R)—3-(dibenzylamino)cyclohexanol
(8.287 g, 28.1 mmol) in dry DCM (100 mL) was added drop wise using an addition fiJnnel
and the reaction mixture was stirred at -78 CC for 15 min. TEA (19.55 mL, 140 mmol)
was then added and the reaction was stirred at -78 CC for 1 h. The dry-ice bath was
_ 88 _
ATI—25 14175v1
removed and the reaction e was allowed to warm to room temperature and stirred
overnight. The reaction mixture was washed with brine (100 mL), the organic layer was
separated, dried over magnesium e and concentrated. Upon slow addition of diethyl
ether to the residue the impurities precipitated, and were separated by filtration. Addition
of diethyl ether to the filtrate yielded (R)—3-(dibenzylamino)cyclohexanone (6.05 g, 74%)
as a white solid which was ted by filtration and dried. 1H NMR (400 MHz,
DMSO-dg) 5 ppm 7.26 - 7.39 (m, 8H), 7.17 - 7.25 (m, 2H), 3.56 - 3.70 (m, 4H), 2.71 - 2.81
(m, 1H), 2.60 - 2.69 (m, 1H), 2.25 - 2.42 (m, 2H), 2.04 - 2.11 (m, 1H), 1.88 - 1.99 (m, 2H),
1.69 - 1.82 (m, 1H), 1.18 - 1.33 (m, 1H); MS (ESI) m/z 294.4 [M+1]+.
C. (3R)—3-(Dibenzylamin0)—l-methylcyclohexanol. To a clear ess
solution of (R)(dibenzylamino)cyclohexanone (5.697g, 19.42 mmol) in dry diethyl
ether (300 mL) was added a solution of 3 M methylmagnesium bromide (8.09 mL,
24.27 mmol) dropwise slowly at 0 CC. The reaction mixture was stirred at 0 CC for
min and the ice-bath was then removed. The reaction e was stirred at room
temperature for 2 h. Upon completion of the reaction, as indicated by LCMS and TLC, the
cloudy solution was slowly poured into a saturated aqueous solution of ammonium
chloride (250 mL). The ether layer was separated, and the aqueous layer was re-extracted
with ether (250 mL). The combined ether layers were dried over magnesium sulfate
trated and purified by silica gel chromatography (0% - 80% ethyl acetate in
hexanes) to yield two diastereomeric isomers of (3R)(dibenzylamino)
methylcyclohexanol (isomer 1 and isomer 2). Isomer 1 (2.704g, 45%) was obtained as a
white solid and isomer 2 (1 .866g, 31%) as a colorless oil, which still contained a small
amount of impurities. Isomer 2 was used without r ation in the next step.
Isomer 1: 1H NMR (400 MHz, DMSO-dg) 8 ppm 7.25 - 7.36 (m, 8H),
7.15 - 7.21 (m, 2H), 3.85 (s, 1H), 3.55 (s, 4H), 2.86 (tt, .1: 3.37, 12.06 Hz, 1H),
1.70 - 1.81 (m, 2H), 1.38 - 1.49 (m, 3H), 1.32 (t,J= 12.30 Hz, 1H), 1.15 - 1.27 (m, 2H),
1.12 (s, 3H); MS (ESI) m/z 310.4 [M+1]+.
Isomer 2: MS (ESI) m/z 310.4 [M+1]+.
] D. (3R)—3-Amin0-l-methylcyclohexanol. A solution of isomer 1 (2.704 g,
8.74 mmol) in ethanol (50 mL) was treated with palladium hydroxide on carbon and
stirred under a balloon filled with en gas overnight. Upon completion of the
ATI—25 14175v1
2012/034349
reaction as indicated by LCMS and TLC the reaction mixture was filtered through a pad of
celite and the filtrate was concentrated to yield one diastereomeric isomer of (3R)—3-
aminomethylcyclohexanol (isomer 3, 0.856g, 76%) as a thick yellow oil. Isomer 3:
1H NMR (400 MHz, DMSO-d6) 8 ppm 3.91 (br. s., 1H), 2.73 - 2.84 (m, 1H), 1.61 - 1.72
(m, 2H), 1.54 (tt, J: 3.66,13.13 Hz, 1H), 1.34 - 1.47 (m, 2H), 1.01 - 1.13 (m, 4H), 0.86 -
0.93 (m, 1H), 0.74 - 0.85 (m, 1H); MS (ESI) m/z 130.2 [M+1]]
The same procedure as described above using isomer 2 (1.823 g,
.89 mmol) in ethanol (25 mL) was utilized to access another diastereomeric isomer of
(3R)aminomethylcyclohexanol (isomer 4, 0.162 g, 21%) containing a small amount
of impurities. Isomer 4 was used without r purification in the next step.
E. 2-((1r,4r)—4-Meth0xycyclohexylamin0)—4-(methylsulfinyl)—
dine—5-carb0xamide. To a stirred colorless solution of 2-((1r,4r)
methoxycyclohexylamino)(methylthio)pyrimidinecarboxamide (0.250 g,
0.843 mmol; sis described ) in NMP (2 mL) was added mCPBA (0.189 g,
0.843 mmol) at 0 °C portion wise. The reaction mixture was then stirred at room
temperature for 2 h until completion of the reaction as indicated by LCMS. The reaction
mixture was diluted with water (20 mL) and filtered. The filtrate was concentrated to
afford 2-((1r,4r)methoxycyclohexylamino)(methylsulfinyl)pyrimidine
carboxamide (0.263 g, 100% yield) as a white sticky solid which was used in the next step
without further purification. MS (ESI) m/z 313.1 [M+1] +.
] F. 4-((1R,3R)Hydr0xymethylcyclohexylamino)—2—((1r,4R)—4-
methoxycyclohexylamin0)pyrimidine—5-carboxamide, 4-((1R,3S)Hydr0xy
methylcyclohexylamin0)((1r,4R)—4-meth0xycyclohexylamin0)pyrimidine
carboxamide. To a solution of 2-((1r,4r)methoxycyclohexylamino)
(methylsulfinyl)pyrimidinecarboxamide (0.263 g, 0.842 mmol) and DIEA (0.294 mL,
1.684 mmol) in NMP (3 mL) was added isomer 3 (0.163 g, 1.263 mmol) at room
temperature. The reaction mixture was stirred for 2 h at 70 CC. Upon completion of the
reaction as indicated by LCMS and TLC the reaction mixture was concentrated and
purified by silica gel chromatography (0% - 20% ammonia saturated methanol in DCM).
The product ons were combined and concentrated to afford one diastereomeric
isomer of )hydroxymethylcyclohexylamino)((1r,4R)methoxycyclo-
ATI—25 14175V1
hexylamino)pyrimidinecarboxamide r 5, 0.265 g, 83 % yield) as a white solid.
Isomer 5: 1H NMR (400 MHz, DMSO-d6) 5 ppm 8.79 (d, .1: 7.42 Hz, 1H), 8.32 (s, 1H),
6.76 - 7.05 (m, 2H), 4.12 - 4.32 (m, 1H), 4.07 (s, 1H), 3.57 - 3.82 (m, 1H), 3.23 (s, 3H),
3.04 - 3.16 (m, 1H), 1.81 - 2.05 (m, 6H), 1.60 - 1.74 (m, 2H), 1.42 - 1.54 (m, 2H),
1.15 - 1.35 (m, 6H), 1.12 (s, 4H); MS (ESI) m/z 378.5 [M+1]+.
The same procedure as described above using isomer 4 (0.163 g,
1.263 mmol), 2-((1r,4r)methoxycyclohexylamino)(methylsulfinyl)pyrimidine
carboxamide (0.263 g, 0.842 mmol) and DIEA (0.294 mL, 1.684 mmol) in NMP (3 mL)
was utilized to access r diastereomeric isomer of 4-((1R)-3 -hydroxy
methylcyclohexylamino)((1r,4R)methoxycyclohexylamino)pyrimidine
carboxamide (isomer 6, 0.043 g, 14 % yield) as a white solid. Isomer 6: 1H NMR
(400 MHz, DMSO-dg) 5 ppm 8.99 (d, .1: 4.69 Hz, 1H), 8.32 (s, 1H), 6.69 - 7.08 (m, 2H),
4.45 (s, 1H), 3.95 - 4.13 (m, 1H), 3.59 - 3.71 (m, 1H), 3.22 (s, 3H), 3.04 - 3.16 (m, 1H),
1.86 - 2.05 (m, 5H), 1.62 - 1.83 (m, 2H), 1.43 - 1.57 (m, 1H), 1.23 - 1.40 (m, 5H),
1.09 - 1.21 (m, 7H); MS (ESI) m/z 378.5 [M+1]+.
The stereochemistry of the individual isomers could be determined after
repeating the sis using (1 S,3R)aminomethylcyclohexanol (prepared as
described herein), which provided isomer 6, namely 4-((1R,3S)hydroxy
methylcyclohexylamino)((1r,4R)methoxycyclohexylamino)pyrimidine
carboxamide. Therefore, isomer 5 is 4-((1R,3R)hydroxymethylcyclohexylamino)
((1r,4R)methoxycyclohexylamino)pyrimidinecarboxamide.
Example 11: 2-((1r,4R)—4-Acetamid0cyclohexylamino)—4-((1R,3S)
ycyclohexylamino)pyrimidine—5-carboxamide
O 11*“
"’N N/ NH
‘\gOH
A. utyl (1r,4r)—4—acetamid0cyclohexylcarbamate. To a stirring
solution of tert-butyl (1r,4r)aminocyclohexylcarbamate (1.0 g, 4.67 mmol) in ethyl
acetate (30 mL) was added acetic anhydride (0.485 mL, 5.13 mmol) in one portion. The
_ 91 _
ATI—25 14175v1
resulting mixture was allowed to stir overnight at room temperature. Additional acetic
anhydride (0.162 mL, 1.71 mmol) was added to the mixture and the mixture was stirred
for an additional hour at room temperature. The reaction mixture was then diluted with an
additional 50 mL of ethyl acetate and was washed with 50 mL each of a saturated aqueous
sodium bicarbonate on and ted aqueous sodium chloride solution. The aqueous
layers were combined and extracted with 50 mL ethyl acetate. The ed ethyl acetate
layers were dried over anhydrous magnesium sulfate, filtered, and concentrated to a afford
tert-butyl (1r,4r)acetamidocyclohexylcarbamate (1.04 g, 4.06 mmol, 87 % yield) as a
solid that was used without further purification. 1H NMR (400 MHz, DMSO-d6) 5 ppm
766-7740n,HD,667-677@m1H)340(¢J=742HL1H)311-322@m1HL
1.65 - 1.82 (m, 7H), 1.37 (s, 9H), 1.16 (d, J=8.20 Hz, 4H). MS (ESI) m/z 201.2 [M-tBu]+.
B. N-((1r,4r)—4-Amin0cyclohexyl)acetamide 2,2,2-triflu0roacetate. To a
stirring solution of tert—butyl (1r,4r)acetamidocyclohexylcarbamate (1.04 g, 4.06 mmol)
in DCM (25 mL) was added TFA (25 mL) in one n. The resulting mixture was
allowed to stir at room temperature for 90 min. The reaction mixture was concentrated to
dryness. The resulting oil was triturated with diethyl ether to afford solids that were
filtered, rinsed with additional diethyl ether and then dried in vacuo to afford N—((1r,4r)
yclohexyl)acetamide 2,2,2-trifluoroacetate (1.07 g, 3.96 mmol, 98 % , which
was used without fiarther purification. 1H NMR (400 MHz, 6) 5 ppm 7.82 (br. s.,
3H), 3.42 (ddd, J=15.42, 7.61, 3.90 Hz, 1H), 2.89 - 3.04 (m, 1H), 1.87 - 1.95 (m, 2H), 1.78
- 1.85 (m, 2H), 1.77 (s, 3H), 1.29 - 1.42 (m, 2H), 1.11 - 1.25 (m, 2H). MS (ESI) m/z 157.0
[M+1]+.
C. ,4R)—4-acetamidocyclohexylamin0)((1R,3 S)
ycyclohexylamino)pyrimidine—5-carb0xamide. To a stirring solution of
4-((1R,3 S)—3-hydroxycyclohexylamino)(methylsulfonyl)pyrimidinecarboxamide
(190 mg, 0.604 mmol; synthesis described herein) and N-((1r,4r)aminocyclohexyl)-
acetamide 2,2,2-trifluoroacetate (245 mg, 0.907 mmol) in DMSO (3 mL) was added
DIEA (0.317 mL, 1.813 mmol). The resulting mixture was stirred at 100 CC overnight.
The crude reaction mixture was concentrated and then purified by silica gel
cmpmmpgqmym45%nmmmmHnDCM)Themomwfihwmmswmeammmmhmd
concentrated to afford ,4R)—4-acetamidocyclohexylamino)((1R,3S)hydroxy-
ATI—25 14175V1
cyclohexylamino)pyrimidinecarboxamide (102 mg, 0.261 mmol, 43.2 % yield) as a
solid. 1H NMR (400 MHz, DMSO-d6) 8 ppm 8.29 (s, 1H), 7.69 (d, J=7.81 Hz, 1H), 4.60
(br. s., 1H), 3.36 - 3.62 (m, 2H), 2.00 - 2.17 (m, 1H), 1.60 - 1.97 (m, 10H), 0.93 - 1.35 (m,
10H). MS (ESI) m/z 391.2 [M+1]+.
Example 12A: 4-((1R,3S)Hydr0xycycloheptylamino)—2-((1r,4R)—4-meth0xycyclohexylamino
)—pyrimidine—5-carboxamide, 4-((1R,3R)Hydr0xycycloheptylamin0
)((1r,4R)—4-methoxycyclohexylamin0)-pyrimidine—5-carb0xamide,
4-((1S,3R)—3-Hydr0xycycloheptylamino)—2-((1r,4S)methoxycyclohexylamino)—
pyrimidine-S-carboxamide, 4-((1S,3S)Hydr0xycycloheptylamin0)((1r,4S)
methoxycyclohexylamin0)-pyrimidine—5-carb0xamide
I 0 I 0
., / ., /
’M N NH ’M N NH
| O
| 0
0 o
’N N/ NH "INJ\N/I NH
H : H ?
A. tert-Butyl ycloheptylcarbamate. To a ng mixture of cyclohept—2
enone (26.96 g, 245.0 mmol) and tert-butyl ate (28.7 g, 245 mmol) in DCM (245 mL)
was added bismuth nitrate pentahydrate (22.79 g, 47.0 mmol). The resulting mixture was stirred
at room temperature overnight. The on was diluted reaction with ethyl acetate (500 mL)
and water (300 mL) and the biphasic mixture was filtered through a bed of Celite. The bed of
Celite was washed well with ethyl acetate and water, and layers of the filtrate separated. The
organic layer was concentrated to an oil that was purified by silica gel chromatography (0-40%
ethyl acetate in hexanes). Product containing fractions were concentrated to afford the title
compound (31.09 g, 137 mmol, 55.9 % . 1H NMR (400 MHz, DMSO-d6) 8 ppm 6.92 (d,
J=7.03 Hz, 1 H), 3.60 (d, J=8.59 Hz, 1 H), 2.55 - 2.69 (m, 1 H), 2.26 - 2.45 (m, 2 H), 1.69 - 1.93
ATI—25 14175V1
W0 2012/145569
(m, 3 H), 1.44 - 1.61 (m, 2 H), 1.37 (d, J=5.08 Hz, 11 H). MS (ESI) m/z 228.5 [M+H]+.
B. tert-Butyl (1R,3S)—3-hydr0xycycloheptylcarbamate, tert-butyl (1R,3R)
hydroxycycloheptylcarbamate, utyl (1 S,3S)—3-hydr0xycycloheptylcarbamate, tert-
butyl (1 S,3R)—3-hydr0xycycloheptylcarbamate. To a solution of tert-butyl 3-oxocycloheptyl-
carbamate (31.09 g, 137 mmol) in methanol (454 mL) was added sodium borohydride (15.52 g,
410 mmol) portion-wise over ~ 10 minutes with mixing. The resulting solution was stirred for
2 h at room temperature and then diluted with water (200 mL). The methanol was removed in-
vacuo and the ing aqueous e was diluted fiarther with 500 mL ethyl acetate and
100 mL saturated aqueous sodium bicarbonate. The layers were ted and the aqueous layer
back-extracted with 2 x 1000 mL ethyl acetate. The combined organic layers were dried over
anhydrous magnesium e, filtered and concentrated to an oil that was purified by silica gel
chromatography (0-50% ethyl acetate in hexanes). Product containing fractions were
concentrated to afford tert-butyl 3-hydroxycycloheptylcarbamate (21.1 g, 92 mmol, 67.3 %
. MS (ESI) m/z 230.3 . The above two reactions were repeated starting with
9.52 g cycloheptenone and yielding 9.27 g of utyl oxycycloheptylcarbamate. The
two batches of tert-butyl 3-hydroxycycloheptylcarbamate were then combined. 29.2 g of the
combined material was separated into the 4 constituent stereoisomers (two diastereomers and
their corresponding enantiomers) by preparative chiral SFC utilizing multiple injections over a
series of 3 separate s. First column: ChiralPak IC-H, 250><30 mm I.D., isocratic 15%
ethanol in CO2, 38 oC. Second column: ChiralCel OJ-H, 250><30 mm I.D., tic 10%
isopropanol in CO2, 38 CC. Third column: ChiralPak AD-H, 250><50 mm I.D., isocratic 20%
isopropanol in CO2, 38 oC. The separated isomers were characterized on an analytical scale
Phenomenex Lux e-2 column, 250><4.6 mm I.D., isocratic 15% ethanol in CO2 (10 min
run time) and labeled as Intermediate 1 to Intermediate 4.
Intermediate 1: 5.4 g (23.55 mmol, 18.5 % yield from SFC purification).
Retention time: 4.065 minutes.
Intermediate 2: 5.5 g (23.98 mmol, 18.8 % yield from SFC purification).
Retention time: 3.019 minutes.
Intermediate 3: 7.2 g (31.34 mmol, 24.6 % yield from SFC purification).
Retention time: 3.675 minutes.
Intermediate 4: 4.7 g (20.50 mmol, 16.1 % yield from SFC purification).
_ 94 _
ATI—2514l75vl
Retention time: 3.263 s.
C. (1S,3R)—3-Amin0cycloheptanol, (1R,3R)aminocycloheptanol, (IS,3S)
aminocycloheptanol, (1R,3S)amin0cycloheptanol. 75 mg (0.327 mmol) of each of the
materials corresponding to Intermediate 1 through Intermediate 4 from step B was separately
dissolved in DCM (11.25 mL) and TFA (3.75 mL). Each reaction was allowed to stir overnight
at t temperature. The solvent of each reaction was removed in vacuo and each was then
dissolved in a mixture of 4N hloric acid in dioxane (5 mL) and methanol (5 mL). Each
on was mixed overnight at ambient ature. Each of the 4 on mixtures (each
containing an individual 3-aminocycloheptanol isomer) was concentrated under reduce pressure
and used without further purification. MS (ESI) m/z 130.2 [M+H]+ for each. The nomenclature
of Intermediate 1 to Intermediate 4 was maintained for tracking purposes.
D. 4-((1R,3S)Hydr0xycycloheptylamin0)((1r,4R)—4-meth0xycyclohexyl-
amin0)pyrimidinecarboxamide, 4-((1R,3R)—3-hydr0xycycloheptylamino)—2-((1r,4R)—4-
methoxycyclohexylamin0)pyrimidinecarb0xamide, ,3R)—3-hydr0xycycloheptylamino
)—2-((1r,4R)—4-methoxycyclohexylamin0)pyrimidine—5-carb0xamide, 4-((1 S,3S)
hydroxycycloheptylamin0)((1r,4R)—4-methoxycyclohexylamino)pyrimidine—5-
carboxamide. To each of the concentrates (Intermediate 1 to Intermediate 4) from step C was
added 2-((1r,4r)methoxycyclohexylamino)(methylsulfonyl)pyrimidinecarboxamide
(53.7 mg, .1635 mmol), NMP (2 mL), and DIEA (0.286 mL, 1.635 mmol). The resulting
4 mixtures were stirred at 80 OC overnight. The reaction solutions were condensed separately
under reduced pressure and the products purified by reverse-phase preparative HPLC (5-80%
acetonitrile + 0.1% trifluoroacetic acid in water + 0.1% trifluoroacetic acid, over 30 min).
Fractions containing product were concentrated under reduced pressure. The resulting residues
were tely redissolved in a methanol (5 mL), passed over an Varian StratoSpheres HCO3
resin SPE tube for TFA removal (0.9 mmol bicarbonate equiv), and then concentrated under
reduced re to afford the title compounds as Peak 1 to Peak 4. The te isomers (Peak
1 to Peak 4) were characterized on an analytical scale ChiralPak AD-H column, 250 x 4.6 mm
ID, isocratic 40% methanol + 0.1% diethylamine in C02 (10 minute run time).
PEAK 1: 10.3 mg (0.027 mmol); 1H NMR (400 MHz, DMSO-d6) 8 ppm 9.02 (d,
J=6.64 Hz, 1 H), 8.33 (s, 1 H), 7.04 (d, J=7.42 Hz, 1 H), 4.44 (br. s., 1 H), 4.19 (br. s., 1 H), 3.56
- 3.90 (m, 2 H), 3.23 (s, 3 H), 3.09 (br. s., 1 H), 1.04 - 2.11 (m, 18 H). MS (ESI) m/z 378.3
ATI—25 14175v1
[M+H]+. Retention time: 2.534 minutes.
] PEAK 2: 30.0 mg (0.079 mmol); 1H NMR (400 MHz, DMSO-d6) 8 ppm 8.95 (d,
J=6.25 Hz, 1 H), 8.33 (s, 1 H), 7.06 (d, J=7.03 Hz, 1 H), 4.46 (d, J=3.12 Hz, 1 H), 3.86 - 4.18
(m, 1 H), 3.48 - 3.81 (m, 2 H), 3.23 (s, 3 H), 3.09 (br. s., 1 H), 1.06 - 2.16 (m, 18 H). MS (ESI)
m/z 378.5 [M+H]+. Retention time: 3.848 minutes.
PEAK 3: 22.0 mg (0.058 mmol); 1H NMR (400 MHz, DMSO-dg) 8 ppm 9.02 (d,
J=7.03 Hz, 1 H), 8.33 (s, 1 H), 7.04 (d, J=7.03 Hz, 1 H), 4.45 (d, J=3.12 Hz, 1 H), 4.20 (br. s.,
1 H), 3.56 - 3.91 (m, 2 H), 3.23 (s, 3 H), 3.09 (br. s., 1 H), 1.06 - 2.12 (m, 18 H). MS (ESI) m/z
378.5 [M+H]+. Retention time: 4.557 minutes.
] PEAK 4: 22.5 mg (0.060 mmol); 1H NMR (400 MHz, DMSO-d6) 8 ppm 8.95 (d,
J=6.64 Hz, 1 H), 8.33 (s, 1 H), 6.47 - 7.21 (m, 1 H), 4.46 (d, J=3.12 Hz, 1 H), 3.94 (br. s., 1 H),
3.73 (br. s., 2 H), 3.23 (s, 3 H), 3.09 (br. s., 1 H), 1.04 - 2.18 (m, 18 H). MS (ESI) m/z 378.3
[M+H]+. Retention time: 2.607 minutes.
From the chemical shift of the proton at ~ 4.2 ppm in Peak 1 and Peak 3 versus
that of ~ 3.94 ppm in Peaks 2 and 4 and also of the proton at ~ 9.02 ppm in Peak 1 and Peak 3
versus that of ~ 8.95 ppm in Peaks 2 and 4 in the 1H NMR data given above, the following
assignment was made: Peak 1 and Peak 3 are omers. Peak 2 and Peak 4 are enantiomers.
Alternatively, a chiral synthetic route was used, described below.
Example 12B: 4-((1R,3S)—3-hydr0xycycloheptylamino)—2-((1r,4R)—4-
methoxycyclohexylamin0)pyrimidinecarboxamide
A. Cyclohept-Z-enol. To a solution of cycloheptenone (10 g, 91 mmol) and
cerium(III) chloride heptahydrate (33.8 g, 91 mmol) in methanol (45.5 mL) was added sodium
borohydride (3.43 g, 91 mmol) portion-wise over 10 minutes period with cooling in a water bath.
The reaction mixture was then d for 2.5 hr at room ature. The reaction was quenched
by addition of water (45 mL) and then was extracted with pentane (4 x 100 mL). The combined
organic ts were dried over anhydrous magnesium sulfate, filtered, and concentrated under
ATI—25 14175v1
reduced pressure to afford the title compound (8.30 g, 74.0 mmol, 82 % yield) as an oil that was
used without filrther purification. 1H NMR (400 MHz, DMSO-d6) 8 ppm 5.49 - 5.71 (m, 2 H),
4.66 (d, J=4.29 Hz, 1 H), 4.05 - 4.20 (m, 1 H), 1.07 - 2.14 (m, 8 H).
B. Cyclohept-Z-enyl methyl carbonate. To a solution of cycloheptenol
(8.3 g, 74.0 mmol) in DCM (227 ml) and pyridine (35.9 ml, 444 mmol), was added methyl
formate (14.24 ml, 185 mmol) with cooling in an ice bath at such a rate that T < 10 CC.
Once addition was complete, the reaction was allowed to mix and warm to ambient temperature
overnight. The reaction mixture was washed with 2 x 150 mL 1N aqueous hydrochloric acid.
The combined washes were back-extracted with 100 mL DCM. The combined DCM layers
were then washed with 150 mL of an aqueous saturated sodium bicarbonate solution, dried over
anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure to afford the
title compound (11.95 g, 70.2 mmol, 95 % yield) as an oil that was used without further
purification. 1H NMR (400 MHz, DMSO-d6) 8 ppm 5.83 (dddd, J=11.81, 7.03, 5.17, 2.15 Hz,
1 H), 5.65 (d, J=11.71 Hz, 1 H), 5.17 (d, J=6.64 Hz, 1 H), 4.71 (d, J=4.30 Hz, 1 H), 3.69 (s,
2 H), 1.99 - 2.23 (m, 2 H), 1.79 - 1.94 (m, 2 H), 1.56 - 1.72 (m, 3 H), 1.34 (d, J=3.51 Hz, 1 H).
C. (Cyclohept-Z-enyl)is0indoline—1,3-di0ne. Phthalimide potassium salt
(19.59 g, 106 mmol), allylpalladium chloride dimer (0.477 g, 1.322 mmol), (1S,2S)-(-)-1,2-
diaminocyclohexane-N,N'-bis(2'-diphenylphosphinobenzoyl) (2.74 g, 3.97 mmol),
exylammonium bromide (50.6 g, 116 mmol), and DCM (212 mL) were ed in a
round-bottomed flask. The flask was flushed with nitrogen and then placed in a sonication bath
for 10 minutes. Cycloheptenyl methyl carbonate (9.00 g, 52.9 mmol) was then added to the
flask in one portion and the resulting mixture was stirred under a nitrogen atmosphere at ambient
temperature ght. The reaction was quenched by on of 50 mL water and was then
extracted with 3 x 100 mL diethyl ether. The combined c layers were dried over
anhydrous magnesium sulfate, d, and concentrated to an oil that slowly solidified
overnight. The solids were ated with methanol (50 mL) and filtered to afford 7.6 g of crude
product. The crude solid product was recrystallized from methanol and dried in vacuo to afford
the title compound (6.70 g, 27.8 mmol, 52.5 % yield) as a solid that was determined to have an
% e.e. of 97.2 (the S isomer was ously prepared as a standard using the (1R,2R)-(-)-1,2-
diaminocyclohexane-N,N'-bis(2'-diphenylphosphinobenzoyl) ligand) by analytical chiral SFC
chromatography menex Lux Cellulose-4, 250 x 4.6 mm I.D., 5-50 % isopropanol in C02,
ATI—2514175v1
13 minute gradient). 1H NMR (400 MHz, DMSO-dg) 8 ppm 7.41 - 8.22 (m, 4 H), 5.62 - 5.97 (m,
2 H), 4.77 (d, 2 Hz, 1 H), 2.01 - 2.29 (m, 3 H), 1.87 - 2.00 (m, 1 H), 1.62 - 1.78 (m, 2 H),
1.45 - 1.61 (m, 1 H), 1.17 - 1.32 (m, 1 H). MS (ESI) m/z 242.3 [M+1]+.
] D. 2-((1R,ZS,3S)Br0m0hydr0xycycloheptyl)is0indoline-1,3-di0ne. To a
solution of (R)(Cycloheptenyl)isoindoline-1,3-dione (4.00 g, 16.58 mmol) in chloroform
(40.0 ml) and ethanol (1.400 mL) was added N—bromosuccinimide (3.78 g, 21.22 mmol) as a
solid over 5 minutes at room temperature. After addition was complete, the reaction mixture was
stirred at room temperature overnight under a nitrogen atmosphere. An additional n of
osuccinimide (1.9 g) and 1.4 mL of ethanol were then added and the mixture was
allowed to continue to mix at room temperature overnight under a nitrogen atmosphere. A third
portion ofN—bromosuccinimide (1.0 g) and 1.4 mL onal ethanol were added to the mixture
and it was again mixed at room temperature for a third night under a nitrogen here. The
reaction mixture was then concentrated to dryness. The resulting residue was triturated with
mL fresh chloroform. The solids were d, rinsed with form, and the filtrate
concentrated under reduced pressure to dryness. THF (40 mL) and 1N hydrochloric acid (aq.)
(10 mL) were added to the concentrated filtrate and the resulting mixture was stirred at room
temperature for 90 minutes. The solution was concentrated under reduced pressure to remove
THF. The concentrate was diluted with 125 mL ethyl acetate and 75 mL of a 1:1 mixture of
water:saturated s sodium bicarbonate. The layers were separated and the aqueous was
back extracted with 75 mL ethyl acetate. The combined ethyl acetate layers were washed with
brine, dried over anhydrous magnesium sulfate, filtered and concentrated under reduced pressure
to afford an oil that was purified by silica gel chromatography (0-30% ethyl acetate in hexanes).
Fractions containing the desired product were concentrated under reduced pressure to the title
compound (3.9 g, 11.53 mmol, 69.6 % yield) as a solid. 1H NMR (400 MHz, DMSO-d6) 8 ppm
7.88 (d, J=7.42 Hz, 4 H), 5.48 (d, J=5.47 Hz, 1 H), 4.73 (dd, J=10.54, 6.25 Hz, 1 H), 4.24 - 4.38
(m, 1 H), 3.91 - 3.99 (m, 1 H), 2.32 (br. s., 1 H), 1.67 - 1.96 (m, 5 H), 1.40 - 1.60 (m, 2 H).
MS (ESI) m/z 320.1 [M-18]+. A COSY NMR ment and the 1H NMR data ed above
were used to verify the bromohydrin regiochemistry. An NOE (via NOESY experiment) was
observed between the protons on the amino group carbon and the hydroxyl group carbon. This
verifles a cis relationship between these two fianctional groups (a trans relationship, lacking this
spacial ity, would not show such an effect).
_ 98 _
ATI—25 14175v1
E. 2-((1R,3S)Hydr0xycycloheptyl)is0indoline-1,3-dione. To a solution of
2-((1R,2S,3S)bromohydroxycyclohepty1)isoindoline-1,3-dione (4.2 g, 12.42 mmol) in
toluene (69 mL) and methanol (6.9 mL) was added tributyltin hydride (4.34 mL, 16.14 mmol)
via syringe over 10 minutes under nitrogen followed by zobis(2-methy1propanenitri1e)
(0.204 g, 1.242 mmol) in one portion. The reaction was then heated to reflux overnight under a
nitrogen atmosphere. The reaction mixture was concentrated to dryness under reduced pressure
to afford a e that was purified by silica gel chromatography (0-50% ethyl acetate in
hexanes). Fractions containing the desired product were concentrated under reduced pressure to
afford the title compound (2.6 g, 10.03 mmol, 81 % yield) as a solid. 1H NMR (400 MHz,
DMSO-d6) 5 ppm 7.72 - 7.98 (m, 4 H), 4.58 (d, J=4.29 Hz, 1 H), 4.14 (br. s., 1 H), 3.67 (dt,
J=6.25, 3.90 Hz, 1 H), 2.24 - 2.40 (m, 1 H), 2.04 -2.19 (m, 1 H), 1.81 - 1.95 (m, 2 H), 1.39 - 1.80
(m, 6 H). MS (ESI) m/z 259.9 [M+H]+.
E. (1 3-Aminocycloheptanol. 2-((1R,3S)Hydroxycycloheptyl)-
isoindoline-1,3-dione (1800 mg, 6.94 mmol) was dissolved in ol (86.80 mL). Hydrazine
monohydrate (0.354 mL, 7.29 mmol) was added to the solution and the resulting mixture was
stirred overnight at reflux. An onal 0.2 eq (0.067 mL) of hydrazine was added and the
mixture was refluxed for a second night. The reaction mixture was concentrated to a volume of a
few milliliters and filtered. The solids were rinsed with 50 mL each ofDCM and chloroform and
the resulting filtrate concentrated under reduced pressure to afford the title compound (174 mg,
1.347 mmol, 19.40 % yield) as an oil that was used without fiarther purification. MS (ESI) m/z
130.2 [M+H]+.
F. 4-((1R,3S)Hydr0xycycloheptylamino)—2-((1r,4R)—4—meth0xycyclohexyl-
amin0)pyrimidine—5-carb0xamide. (1S,3R)Aminocycloheptanol (87 mg, 0.672 mmol) and
DIEA (0.235 mL, 1.344 mmol) were added to a solution of ,4r)methoxycyclohexyl-
amino)(methylsulf1ny1)pyrimidinecarboxamide (105 mg, 0.336 mmol) in NMP (1 mL).
The resulting mixture was heated to 80 CC for 4 h and then allowed to cool to ambient
temperature overnight. The on mixture was condensed under reduced re and the
residue purified by e-phase ative HPLC (5-80% acetonitrile + 0.1% TFA in water +
0.1% TFA, over 30 min). Fractions containing product were concentrated under reduced
pressure. The resulting residue was re-dissolved in a methanol (5 mL), passed over a Varian
StratoSpheres HCO3 resin SPE tube for TFA removal (0.9 mmol bicarbonate equiv.), and then
_ 99 _
ATI—25 14175v1
concentrated under reduced pressure. The residue was triturated with acetonitrile and
concentrated under reduced pressure to afford the title compound (67 mg, 0.177 mmol, 52.8 %
yield) as a solid. 1H NMR (400 MHz, DMSO-d6) 8 ppm 8.96 (d, J=5.86 Hz, 1 H), 8.33 (s, 1 H),
7.00 - 7.16 (m, 1 H), 4.46 (d, J=3.90 Hz, 1 H), 3.85 - 4.09 (m, 1 H), 3.56 - 3.81 (m, 2 H), 3.23 (s,
3 H), 2.97 - 3.15 (m, 1 H), 1.71 - 2.14 (m, 7 H), 1.51 (d, J=10.15 Hz, 11H). MS (ESI) m/z
378.3 [M+H]+.
Analytical chiral SFC using a ChiralPak AD-H column (250 x 4.6 mm I.D.,
isocratic 40% ol + 0.1% diethylamine in C02, 10 minute run time) was used to establish
the relationship between the single isomer afforded in this chiral route with that of the preVious
preparation of all four stereoisomers. The material prepared in this chiral route was found to
have an identical retention time (3.848 s) as Peak 2 in Example 12A thus:
PEAK 2 = 4-((1R,3S)hydr0xycycloheptylamin0)((1r,4R)—4-
methoxycyclohexylamin0)pyrimidinecarb0xamide.
Based on 1H NMR, Peak 2 and Peak 4 were found to be an enantiomeric pair in
Example 12A, thus:
PEAK 4 = 4-((1S,3R)—3-hydr0xycycloheptylamin0)((1r,4R)—4-
methoxycyclohexylamin0)pyrimidinecarb0xamide.
] In addition, it follows that Intermediate 2 used to make Peak 2 in Example 12A
can then be assigned as tert-Butyl (1R,3 S)hydroxycycloheptylcarbamate and Intermediate 4
used to make Peak 4 in e 12A can then be assigned as tert-Butyl (1S,3R)—3-
hydroxycycloheptylcarbamate.
In order to identify the absolute stereochemistry of Intermediate 1 and
Intermediate 3 (and thereby the absolute stereochemistry of Peak 1 and Peak 3) in e 12A
the following experiment was performed.
] Mitsunobu reaction of tert-butyl (1R,3R)hydroxycycloheptyl—carbamate to
afford tert-butyl )hydr0xycycloheptylcarbamate.
O NH
ATI—25 14175V1
A. tert-Butyl (1R,3S)—3-hydr0xycycloheptylcarbamate. ediate 3 from
step B in Example 12A, was dissolved in THF (31.700 mL). The mixture was cooled to 0 0C in
an ice bath under a nitrogen atmosphere and chloroacetic acid (261 mg, 2.76 mmol) followed by
triphenylphosphine (723 mg, 2.76 mmol) were both added in one portion. A diethyl
azodicarboxylate solution (0.437 mL, 2.76 mmol) was added ise waiting until the
disappearance of the yellow color before adding the next drop. Once addition was complete, the
solution was stirred at 0 CC under a nitrogen here for 3 h. The reaction was concentrated
under reduced pressure and the resulting oil purified by silica gel chromatography (0-40% ethyl
acetate in hexanes). Pure product containing fractions were ed and concentrated under
d re and then olved in methanol (16 mL). Sodium carbonate (186 mg,
1.755 mmol) was added to the solution and the resulting mixture was stirred at ambient
temperature for 3 h. The reaction mixture was concentrated under reduced re to dryness.
The residue was diluted with 50 mL of a 1:1 mixture of water:saturated aqueous sodium
bicarbonate and 75 mL DCM. The layers were separated and the aqueous back extracted with
50 mL DCM. The combined DCM layers were dried over anhydrous magnesium sulfate,
filtered, and concentrated under reduced re to afford a material that had an identical
retention time by analytical SFC as Intermediate 2 from step B in Example 12A, or tert—butyl
(1R,3S)hydroxycycloheptylcarbamate (417 mg, 1.818 mmol, 72.5 % yield) as a solid.
1H NMR (400 MHz, DMSO-dg) 8 ppm 6.63 - 6.87 (m, 1 H), 4.44 (d, J=3.90 Hz, 1 H), 3.47 - 3.71
(m, 1 H), 0.99 — 1.98 (m, 19 H). MS (ESI) m/z 260.1 .
Intermediate 3 from step B in Example 12A is therefore assigned as tert-butyl
(1R,3R)hydroxycycloheptylcarbamate. Peak 3 from step D derived from Intermediate 3 in
Example 12A is therefore assigned as 4-((1R,3R)hydroxycycloheptylamino)((1r,4R)
methoxycyclohexylamino)pyrimidinecarboxamide.
Because Peak 1 and Peak 3 are enantiomers by 1H NMR as described in e
12A Peak 1 can be assigned as 4-((1S,3S)Hydroxycycloheptylamino)((1r,4S)
methoxycyclohexylamino)pyrimidinecarboxamide. It follows that Intermediate 1 from step B
in Example 12A that was used to prepare Peak 1 in step D of Example 12A can be assigned as
tert-butyl (l S,3 S)hydroxycycloheptylcarbamate.
Example 13: 4-((1R,3S)—3-Hydr0xycyclohexylamin0)((1r,4R)—4-(2,2,2-
trifluoroethoxy) cyclohexylamin0)pyrimidine—5-carboxamide, 4-((1R,3S)
ATI—2514l75vl
ycyclohexylamino)—2-((1s,4S)—4-(2,2,2-triflu0r0eth0xy)—
cyclohexylamin0)pyrimidine—5-carb0xamide
F o F o
FFX/O’" l/YkNHZ F
N/ Fflvo‘"’N)\N/hl/YLNHZ "’N NH NH
H i H i
g ®
OH OH
A. 4-((1R,3S)—3-Hydr0xycyclohexylamin0)((1r,4R)—4-(2,2,2-triflu0r0-
ethoxy)cyclohexylamin0)pyrimidinecarb0xamide and ,3S)—3-hydr0xycyclo-
hexylamin0)((1s,4S)—4-(2,2,2-triflu0r0ethoxy)cyclohexylamino)—pyrimidine
carboxamide. To a stirring solution of 4-((1R,3S)—3-hydroxycyclohexyl-amino)
(methylsulfonyl)pyrimidinecarboxamide (440 mg, 1.400 mmol; synthesis described
herein) and bis(2,2,2-trifiuoroethoxy)-cyclohexanamine trihydrochloride (529 mg,
2.099 mmol) in DMSO (6.964 mL) was added DIEA (0.978 mL, 5.60 mmol). The
resulting mixture was allowed to stir overnight at 100 CC. The crude reaction mixture was
concentrated, purified by silica gel chromatography (0-10% methanol/dichloromethane),
and then purified by reversed-phase silica gel chromatography (methanol/water with 0.1%
formic acid modifier). The product containing fractions were lized and concentrated
to afford 4-((1R,3 S)—3 -hydroxycyclohexylamino)(4-(2,2,2-trifiuoroethoxy)cyclohexyl-
pyrimidinecarboxamide (135 mg, 0.313 mmol, 22.36 % yield) as a mixture of
2 stereoisomers. MS (ESI) m/z 432.2 [M+H]+. This mixture was separated using chiral
fluid chromatography (AD-H colum) to afford 87.8 mg (0.203 mmol) of a single,
faster eluting, stereoisomer (PEAK 1) and 24.2 mg (0.056 mmol) of a second single,
slower eluting, stereoisomer (PEAK 2).
Subsequently the same reaction ce was repeated using (1r,4r)
(2,2,2-trifluoroethoxy)cyclohexanamine, which was prepared as follows.
(1r,4r)—4-(Benzylamin0)cyclohexanol. A mixture of (1r,4r)amino-
cyclohexanol (230 g, 2 mol), benzaldehyde (212 g, 2 mol) and 4A Molecular Sieves in
methanol (2 L) was refluxed under a nitrogen here for 3 h. The mixture was cooled
using an ice-water bath, and sodium borohydride (72 g, 2 mol) was carefully added in
small ns. After the completion of the addition, the reaction was stirred at room
ATI—25 14175V1
temperature overnight. The solvent was evaporated, and the residue was partitioned
between dichloromethane (2 L) and water (1 L). The dichloromethane layer was separated,
washed with a saturated aqueous sodium de solution, and directly used in the next
step.
Benzyl benzyl((1r,4r)—4-hydr0xycyclohexyl)carbamate. To the
dichloromethane solution of (lr,4r)(benzylamino)cyclohexanol obtained in the previous
step was added saturated aqueous sodium bicarbonate (1.5 L), and to this biphasic system
was added benzyl chlorofomate (358.2 g, 2.1 mol) slowly at 0 0C. After completion of
addition, the reaction was stirred at room temperature for another 1 h. Then the organic
phase was separated and evaporated. After concentration, the residue was purified by
silica gel chromatography (0-30% ethyl acetate in hexanes) to give the title nd as a
colorless liquid (400 g, 1.18 mol, 59% yield for two steps). Both steps were repeated, to
afford a total of 800 g of benzyl benzyl((1r,4r)hydroxycyclohexyl)carbamate.
Benzyl benzyl((1r,4r)—4-(2,2,2-triflu0roeth0xy)cyclohexyl)carbamate.
To a solution of benzyl benzyl((1r,4r)hydroxycyclohexyl)carbamate (400 g, 1.18 mol)
in chloroform (2 L) was added a 50% aqueous on of fluoroboric acid (20 mL), and a
stream of diazotrifluoroethane (freshly prepared by mixing trifluoroethaneamine
hydrochloride (1.6 kg, 11.8 mol) and NaNOZ (814 g, 11.8 mol) in water (3 L) and then
bubbling it into the reaction solution . The reaction was monitored by TLC, and
after completion, a saturated aqueous solution of potassium carbonate (300 mL) was
added. The chloroform layer was separated, concentrated under reduced pressure, and
ed by column chromatography (0-10% ethyl acetate in hexanes) to afford benzyl
benzyl ((1r,4r)(2,2,2-trifluoroethoxy)cyclohexyl)carbamate (192 g, 0.456 mol, 38%
yield). This reaction was repeated, and another batch of benzyl benzyl ((lr,4r)(2,2,2-
trifluoroethoxy)cyclohexyl)carbamate (185 g, 0.439 mol) was obtained.
(1r,4r)—4-(2,2,2-Triflu0r0eth0xy)cyclohexanamine. To a solution of
benzyl benzyl((1r,4r)(2,2,2-trifluoroethoxy)cyclohexyl)carbamate (377 g, 0.89 mol) in
ethyl acetate (2 L) was added 20% palladium hydroxide on carbon (50 g), and the e
was stirred under a 55 psi hydrogen atmosphere for 24 h at room temperature. The catalyst
was d by tion, and the te was concentrated under reduced re. The
resulting residue was dissolved in 2N hydrochloric acid (1.5 L) and the on was
ATI—2514l75vl
washed with methyl l ether (300 mL X 5). Solid potassium carbonate was added to
adjust the pH to above 10. The product was ted into dichloromethane (500 mL x 5).
The ed organic phases were dried and concentrated under reduced pressure. The
residue was purified by silica gel chromatography (10-30% methanol in dichloromethane)
to afford (1r,4r)(2,2,2-trifluoroethoxy)cyclohexanamine (115 g, 0.584 mol, 66% yield):
1H NMR (400 MHz, DMSO-d6) 8 ppm 4.01 (q, J: 8.8 Hz, 2H), 3.40-3.33 (m, 1H),
2.56 - 2.53 (m, 1H), 1.94-1.92 (m, 2H), 1.75-1.72 (m, 2H), 1.24-1.15 (m, 2H), 1.08 - 0.97
(m, 2H); MS (ESI) m/z 198.2 [M+l]+.
Using the intermediate above, it was shown that the material obtained as
PEAK 1 ponded to 4-((1R,3S)hydroxycyclohexylamino)((1r,4R)(2,2,2-
trifluoroethoxy)cyclohexylamino)pyrimidinecarboxamide, while the material obtained
as PEAK 2 coresponded to 4-((1R,3S)hydroxycyclohexylamino)((1s,4S)(2,2,2-
trifluoroethoxy)cyclohexylamino)pyrimidinecarboxamide.
] PEAK 1: 4-((1R,3S)—3-hydr0xycyclohexylamino)—2-((1r,4R)—4-(2,2,2-
trifluoroeth0xy)cyclohexylamin0)pyrimidine—5-carb0xamide. 1H NMR (400 MHz,
DMSO-d6) 5 ppm 8.90 (d, J=6.25 Hz, 1H), 8.34 (s, 1H), 7.46 - 7.52 (m, 1H), 7.07 - 7.17
(m, 1H), 6.91 (dd, J=8.59, 2.73 Hz, 1H), 4.60 - 4.76 (m, 1H), 4.02 (q, J=9.63 Hz, 2H),
3.39 — 3.96 (m, 4H), 0.92 — 2.24 (m, 16H). 19F NMR (376 MHz, DMSO-d6) 5 ppm -76.47
— 72.01 (m, 3 F). MS (ESI) m/z 432.0 [M+H]+.
PEAK 2: 4-((1R,3S)—3-hydroxycyclohexylamino)—2-((ls,4S)(2,2,2-
trifluoroeth0xy)cyclohexylamin0)pyrimidine—5-carb0xamide. 1H NMR (400 MHz,
DMSO-d6) 5 ppm 8.90 (d, J=6.64 Hz, 1H), 8.34 (br. s., 1H), 6.79 - 7.50 (m, 2H), 4.64 (br.
s., 1H), 4.00 — 4.12 (m, 2H), 3.42 (d, J=4.69 Hz, 4H), 0.91 — 2.25 (m, 16H). ”P NMR
(376 MHz, DMSO-d6) 5 ppm -73.63 (t, J=9.47 Hz, 3 F). MS (ESI) m/z 432.0 [M+H]+.
—104—
ATI—25 14175Vl
Example 14: 2-((1r,4R)—4-(Diflu0r0meth0xy)cyclohexylamin0)((1R,3S)
hydroxycyclohexylamin0)pyrimidinecarboxamide
FY. 1*
F "’NJ\N/ NH
A. Methyl 2-chlor0((1R,3S)—3-hydr0xycyclohexylamin0)pyrimidine-
-carb0xylate. To a stirring solution of methyl 2,4-dichloropyrimidinecarboxylate
(4.00 g, 19.32 mmol) in THF (85 mL) was added DIEA (3.37 mL, 19.32 mmol). The
resulting mixture was cooled to -78 0C in a dry ice/acetone bath. A solution of (lS,3R)—3-
aminocyclohexanol (2.448 g, 21.25 mmol; prepared as described in Tetrahedron:
Asymmetry 15:205 l—2056(2004)) in 40 mL THF was added at such a rate that the
temperature remained at -78 CC. The resulting mixture was d at -78 CC for 1 h. The
reaction mixture was then concentrated to dryness and diluted with 200 mL ethyl e
and 75 mL of a 1:1 mixture of water and an aqueous saturated sodium bicarbonate
solution. The layers were separated and the s layer back-extracted with 100 mL
ethyl acetate. The combined ethyl acetate layers were washed with 50 mL of a saturated
aqueous sodium chloride solution, dried over ous magnesium sulfate, filtered and
concentrated to an oil that solidified upon standing. The solid was triturated with diethyl
ether (5 mL), d, rinsed with diethyl ether (5 mL) and dried in vacuo to afford methyl
2-chloro((1R,3 S)—3-hydroxycyclohexylamino)pyrimidinecarboxylate (3 .7 g,
12.95 mmol, 67% yield) that was used without further ation. MS (ESI) m/z
286.0 [M+1]+.
B. (1r,4r)(Dibenzylamin0)cyclohexanol. transAminocyclohexanol
hydrochloride (25 g, 217 mmol) was suspended in acetonitrile (500 mL). Benzyl bromide
(54.2 mL, 456 mmol) and ium carbonate (120 g, 868 mmol) were added to the
suspension and the ing mixture was d Vigorously overnight at room
temperature. The reaction mixture was filtered through a plug of celite and the plug was
washed thoroughly with acetonitrile. The filtrate was condensed to give a white solid. The
crude solids were purified by silica gel chromatography (0-60% ethyl acetate in hexanes).
ATI—2514175V1
Pure product containing fractions were combined and concentrated to afford (1r,4r)
(dibenzylamino)cyclohexanol (25 g, 85 mmol, 39.0 % yield) as a white solid. 1H NMR
(400 MHz, DMSO-dg) 5 ppm 7.26 - 7.36 (m, 8H), 7.16 - 7.22 (m, 2H), 4.43 (d, J=4.69 Hz,
1H), 3.55 (s, 4H), 3.27 - 3.33 (m, 1H), 2.28 - 2.40 (m, 1H), 1.69 - 1.88 (m, 4H), 1.40 (qd,
J=12.56, 2.93 Hz, 2H), 0.89 - 1.05 (m, 2H); MS (ESI) m/z 296.3 .
C. (1r,4r)—N,N-Dibenzyl(diflu0romethoxy)cyclohexanamine. (1r,4r)-
4-(Dibenzylamino)cyclohexanol (5 g, 16.93 mmol) and copper(I) iodide (0.645 g,
3.39 mmol) were dissolved in 170 mL acetonitrile and heated to 45 0C under a en
atmosphere. To this mixture was added a on of 2,2-difluoro(fluorosulfonyl)acetic
acid (3.50 mL, 33.9 mmol) in 30 mL acetontrile over 10 min. Once addition was
complete, the mixture was stirred at 45 CC under nitrogen atmosphere for 1 h. An
additional portion of 2,2-difluoro(fluorosulfonyl)acetic acid (2.86 mL, 27.7 mmol)
reagent in 30 mL acetonitirile was then added over 10 min. The reaction mixture was
stirred for an additional 1 h at 45 CC under nitrogen atmosphere. le components
were then removed via evaporation and the residue was diluted with 175 mL ethyl acetate
and 75 mL of a 1:1 mixture of water and saturated aqueous sodium onate. The
resulting biphasic mixture containing solids was filtered through a sintered glass Buchner
funnel. The filtrate layers were separated and the s layer was extracted with 50 mL
ethyl acetate. The combined ethyl acetate layers were washed with 50 mL of a 1:1 mixture
of saturated sodium chloride and water, dried over anhydrous magnesium sulfate, filtered,
and concentrated to an oil. The crude oil was purified by silica gel tography
(0-30% ethyl acetate in hexanes). Product ning fractions were ed and
concentrated to afford (1r,4r)-N,N-dibenzyl(difluoromethoxy)cyclohexanamine (3.12 g,
9.03 mmol, 53.4 % yield) as an oil that solidified to an off-white solid. 1H NMR
(400 MHz, DMSO-d6) 5 ppm 7.26 - 7.38 (m, 8H), 7.17 - 7.23 (m, 2H), 6.66 (s, 1H), 3.97
(t, J=4.49 Hz, 1H), 3.57 (s, 4H), 2.36 - 2.47 (m, 1H), 1.98 (d, 4 Hz, 2H), 1.83 (d,
J=12.10 Hz, 2H), 1.49 (d, J=12.89 Hz, 2H), 1.22 (d, J=12.49 Hz, 2H). ”P NMR
(376 MHz, DMSO-d6) d ppm -79.28 (d, J=73.00 Hz, 2 F). MS(ESI) m/z 346.1 [M+1]+.
D. (1r,4r)—4-(Difluor0meth0xy)cyclohexanamine. (1r,4r)-N,N-Dibenzyl-
4-(difluoromethoxy)cyclohexanamine (1.6 g, 4.63 mmol) was dissolved in ethanol
(23 mL) in a Parr shaker flask and 20 wt% palladium hydroxide on carbon (0.650 g,
ATI—25 14175v1
0.926 mmol) was added. The container was evacuated, placed on a Parr shaker apparatus,
and shaken under a 50 psi hydrogen atmosphere overnight. The palladium hydroxide was
removed by filtration h a pre-wetted (with ethanol) bed of celite. The filter cake
was rinsed well with ethanol. The e was trated to an oil that was dissolved in
100 mL ethyl acetate, dried over anhydrous ium sulfate, filtered, and concentrated
to an oil that solidified, yielding (1r,4r)(difiuoromethoxy)cyclohexanamine (0.621 g,
3.76 mmol, 81 % yield). 1H NMR (400 MHz, DMSO-d6) 8 ppm 6.46 -6.93 (m, 1H), 3.96
(s, 1H), 2.52 - 2.59 (m, 1H), 1.84 - 1.95 (m, 2H), 1.68 - 1.79 (m, 2H), 1.29 - 1.43 (m, 2H),
1.01 — 1.14 (m, 2H). ”P NMR (376 MHz, DMSO-d6) 5 ppm -78.93 (d, J=91.00 Hz, 2 F).
MS(ESI) m/z 166.2 [M+1]+.
E. Methyl 2—((1r,4R)—4-(diflu0r0meth0xy)cyclohexylamin0)—4-((1R,3S)-
3 hydroxycyclohexylamin0)pyrimidine—5-carboxylate. To a stirring mixture of methyl
2-chloro((1R,3 S)—3-hydroxycyclohexylamino)pyrimidinecarboxylate (300 mg,
1.050 mmol) and (1r,4r)(difiuoromethoxy)cyclohexanamine (260 mg, 1.575 mmol) in
DMSO (5mL) was added DIEA (0.550 mL, 3.15 mmol). The resulting mixture was stirred
at 70 CC for 1 h. The crude on mixture was trated and then d by silica
gel chromatography (0-60% ethyl e in s). The product containing fractions
were combined and concentrated to afford methyl 2-((1r,4R)(difiuoro-
methoxy)cyclohexylamino)((1R,3S)hydroxycyclohexylamino)pyrimidine
carboxylate (165 mg, 0.398 mmol, 37.9 % yield). 1H NMR (400 MHz, DMSO-d6) 8 ppm
8.37 - 8.49 (m, 1H), 8.06 (d, J=7.42 Hz, 1H), 7.22 - 7.55 (m, 1H), 6.49 - 6.94 (m, 1H),
4.67 - 4.76 (m, 1H), 3.75 - 4.10 (m, 2H), 3.72 (s, 3H), 3.43 - 3.69 (m, 2H), 1.63 - 2.24 (m,
8H), 1.08 - 1.54 (m, 8H). MS(ESI) m/z 415.5 [M+1]+.
F. 2-((1r,4R)—4-(Diflu0r0meth0xy)cyclohexylamin0)((1R,3S)-3
hydroxycyclohexylamino) pyrimidine-S-carboxylic acid. To a stirring solution of
methyl 2-(( 1 r,4R)—4-(difiuoromethoxy)cyclohexylamino)(( 1 R,3 S)hydroxycyclo-
hexylamino)-pyrimidinecarboxylate (170 mg, 0.410 mmol) in methanol (10 mL) was
added an aqueous solution of sodium hydroxide (1 M, 3.075 mL, 3.075 mmol) in one
portion. The resulting mixture was allowed to stir at 50 CC for 2 days. The reaction
mixture was concentrated to remove methanol, was diluted with additional water (10 mL),
and an aqueous solution of citric acid (2 M, 4.10 mL, 8.20 mmol) was slowly added. The
ATI—25 14175v1
2012/034349
ing precipitate was stirred at room temperature for 30 min, filtered, and the solids
then washed well with water. The solids were dried in vacuo to afford 2-((1r,4R)
(difluoromethoxy)cyclohexylamino)((1R,3 S)hydroxycyclohexylamino)pyrimidine-
-carboxylic acid (117 mg, 0.292 mmol, 71.2 % yield) as a solid that was used without
further purification. MS (ESI) m/z 401.5 [M+1]+.
G. 2-((1r,4R)—4-(Difluorometh0xy)cyclohexylamin0)((1R,3S)—3-
hydroxycyclohexylamino)pyrimidine—5-carb0xamide. To a stirring suspension of 2-
((1r,4R)(difluoromethoxy)cyclohexylamino)((1R,3 S)hydroxycyclohexylamino)-
pyrimidinecarboxylic acid (117 mg, 0.292 mmol) and HATU (167 mg, 0.438 mmol) in
DMF (2 mL) was added ammonium chloride (78 mg, 1.461 mmol) and DIEA (0.255 mL,
1.461 mmol). The resulting e was stirred at room temperature overnight. The crude
reaction mixture was concentrated to remove the le components and then purified by
silica gel chromatography (10-90% ethyl acetate (containing 10% ammonia saturated
ol) in hexanes). The product fractions were combined and concentrated to afford
2-((1r,4R)(difluoromethoxy)cyclohexylamino)((1R,3 S)hydroxycyclohexyl-
amino)pyrimidinecarboxamide (35.3 mg, 0.088 mmol, 30.2 % yield) as a solid.
1H NMR (400 MHz, DMSO-d6) 5 ppm 8.90 (d, J=6.64 Hz, 1H), 8.34 (br. s., 1H),
6.50 — 7.14 (m, 2H), 4.64 (br. s., 1H), 3.42 — 4.11 (m, 4H), 0.87 — 2.23 (m, 16H). ”P NMR
(376 MHz, DMSO-d6) 5 ppm -78.98 (d, J=110.82 Hz, 2 F). MS (ESI) m/z 400.5 [M+1]+.
Example 15: 4-((1R,3S)—3-Meth0xycyclohexylamin0)((1r,4R)—4-
methoxycyclohexylamin0)pyrimidinecarboxamide
/O N\ NH2
.,)'\/
’N N NH
A. utyl (1R,3S)—3-hydr0xycyclohexylcarbamate. To a stirring
solution of (1S,3R)aminocyclohexanol (1.0 g, 8.68 mmol; prepared as bed in
Tetrahedron: Asymmetry 15:2051—2056 (2004)) in dioxane (8.04 mL) was added di-tert-
butyl-dicarbonate (2.369 g, 10.85 mmol). The resulting mixture was stirred at room
temperature for 18 h. The reaction was concentrated, sodium chloride (0.507 g,
ATI—25 14175v1
WO 45569
8.68 mmol) was added, and the resulting solution was diluted with water (20 mL) and
hexanes (20 mL). The suspension was stirred vigorously for 20 min, then filtered and the
solids were rinsed with hexanes and dried under vacuum to afford tert-butyl )—3-
hydroxycyclohexylcarbamate (1.7836 g, 8.28 mmol, 95 % yield) as an off-white solid.
1H NMR (400 MHz, DMSO-d6) 5 ppm 6.74 (d, J=8.20 Hz, 1H), 4.58 (d, J=4.29 Hz, 1H),
3.35 - 3.43 (m, 1H), 3.11 - 3.27 (m, 1H), 1.90 (d, J=11.32 Hz,1H),1.68 - 1.78 (m, 1H),
1.63 (d, J=3.12 Hz, 2H), 1.37 (s, 9H), 0.87 - 1.23 (m, 4H); MS (ESI) m/z 216.3 [M+1]+.
B. tert-Butyl (1R,3S)meth0xycyclohexylcarbamate. To a solution of
tert-butyl (1R,3S)hydroxycyclohexylcarbamate (1.78 g, 8.27 mmol) in anhydrous THF
(8 mL) was added sodium hydride (0.230 g, 9.09 mmol) in ns under nitrogen at 0 oC.
The mixture was warmed to room temperature and stirred for 30 min. A solution of
iodomethane (0.824 mL, 13.23 mmol) in anhydrous THF (4 mL) was added drop wise to
the mixture at 0 CC and the resulting mixture was stirred at room ature for 20 h.
The crude mixture was quenched with water (50 mL) and extracted with ethyl acetate (3 x
50 mL). The combined c layers were washed with brine, dried over sodium sulfate
and filtered. The filtrate was concentrated in vacuo, and then purified by silica gel
chromatography (0 — 50 % ethyl acetate in hexanes). The t fractions were
combined and concentrated to afford tert-butyl (1R,3S)—3-methoxycyclohexylcarbamate
(1.0686 g, 4.66 mmol, 56.4 % yield) as a white solid; MS (ESI) m/z 230.5 [M+1]+.
] C. (1R,3S)Meth0xycyclohexanamine trifluoroacetate. To a solution
of tert-butyl (1R,3S)methoxycyclohexylcarbamate (1.0686 g, 4.66 mmol) in anhydrous
DCM (18.64 mL) was added TFA (3.59 mL, 46.6 mmol) and the resulting solution was
stirred at room temperature for 1 h. After that, the solvents were removed in vacuo, and the
resulting residue was triturated with ethyl ether (2 x 50mL) to afford (1R,3S)
methoxycyclohexanamine trifluoroacetate (1 . 133 g, 4.66 mmol, 100 % yield) as a white
solid. The crude product was used without fiarther purification in the next step.
D. Ethyl 4-((1R,3S)meth0xycyclohexylamin0)—2-(methylthi0)-
dine-S-carboxylate. To a stirring solution of ethyl 4-chloro(methylthio)-
dinecarboxylate (1.084 g, 4.66 mmol) and (1R,3S)—3-methoxycyclohexanamine
trifluoroacetate (1.133 g, 4.66 mmol) in ethanol (18.63 mL) was added DIEA (2.434 mL,
13.97 mmol). The on mixture was heated to 60 CC for 17 h. The reaction was
ATI—25 14175v1
2012/034349
d from heat, cooled to room temperature and concentrated. The crude material was
purified by silica gel chromatography (0-25% ethyl acetate in hexanes) to afford ethyl 4-
((lR,3S)methoxycyclohexylamino)(methylthio)pyrimidinecarboxylate (l .4284 g,
4.39 mmol, 94 % yield) as a clear oil. MS (ESI) m/z 326.2 [M+l]+.
E. 4-((1R,3S)Methoxycyclohexylamin0)(methylthi0)pyrimidine
carboxylic acid. To a stirring solution of ethyl 4-((lR,3S)—3-methoxycyclohexylamino)-
hylthio)pyrimidinecarboxylate (l .4284 g, 4.39 mmol) in ethanol (1254 mL) was
added aqueous sodium hydroxide solution (1 N, 8.78 mL, 8.78 mmol) and the e was
stirred for 2 h. The reaction was concentrated, diluted with water (50mL), and then
neutralized while stirring with aqueous citric acid solution (2 M, 5.49 mL, 10.97 mmol).
The precipitate was filtered, then washed with water (2 x 50 mL) and dried to afford
4-(( l R,3 S)—3 -methoxycyclohexylamino)(methylthio)pyrimidinecarboxylic acid
(1.1679 g, 3.93 mmol, 89% yield) as a white solid. 1H NMR (400 MHz, DMSO-d6) 5 ppm
1322 (s, 1H), 8.65 (d, J=7.03 Hz, 1H), 8.51 (s, 1H), 4.07 - 4.24 (m, 1H), 3.29 - 3.33 (m,
1H), 3.26 (s, 3H), 2.46 (s, 3H), 2.15 (d, J=l2.10 Hz, 1H), 1.63 - 1.88 (m, 3H), 1.21 - 1.48
(m, 4H); MS (ESI) m/z 298.1 [M+1]+.
F. 4-((1R,3S)Meth0xycyclohexylamin0)(methylthio)pyrimidine—5-
amide. 4-(( l R,3 S)—3 -Methoxycyclohexylamino)(methylthio)pyrimidine-5 -
carboxylic acid (1.1662 g, 3.92 mmol) and HATU (2.237 g, 5.88 mmol) were stirred in
DMF (7.84 mL) for 5 min at room temperature, then ammonium chloride (1 .049 g,
19.61 mmol) and DIEA (3.42 mL, 1961 mmol) were added while stirring. The reaction
was allowed to stir at room temperature for l h. The reaction mixture was poured into
water (100 mL) and ted with ethyl acetate (3 x 50mL). The combined organic layers
were washed with water (50 mL), brine (25 mL), dried over sodium sulfate, filtered, and
concentrated. The residual DMF was removed by suspending the oily residue in 100 mL
water and 100 mL hexanes. The biphasic suspension was stirred Vigorously for 30 min,
filtered and washed with hexanes to afford 4-((lR,3S)—3-methoxycyclohexylamino)
(methylthio)pyrimidinecarboxamide (1.1081 g, 3.74 mmol, 95 % yield) as an ite
solid. MS (ESI) m/z 397.2 [M+l]+.
G. 4-((1R,3S)Meth0xycyclohexylamin0)(methylsulf0nyl)—
pyrimidine—5-carb0xamide. To a solution of 4-((lR,3S)—3-methoxycyclohexylamino)
-llO-
ATI—2514l75Vl
(methylthio)pyrimidinecarboxamide (1.1081 g, 3.74 mmol) in DCM (18.69 mL) and
acetone (18.69 mL) at room temperature was added mCPBA (1.676 g, 7.48 mmol) in five
batches over 2 min and stirred at room temperature for 16 h. To the crude reaction mixture
was added 10% s sodium thiosulfate solution (35 mL) and the mixture was stirred
for 5 min before evaporation of the le solvents. The material was partitioned
between ethyl acetate and water, and the organic layer was then washed with saturated
aqueous sodium bicarbonate solution and then brine. The combined s layers were
then washed with ethyl acetate (3x), organic layers were combined, dried over sodium
sulfate, filtered, and condensed. After drying under high , 4-((1R,3S)methoxy-
cyclohexylamino)(methylsulfonyl)pyrimidinecarboxamide (0.9887 g, 3.01 mmol,
81 % yield) was obtained as a white solid. MS (ESI) m/z 329.3 [M+l]+.
H. 4-((1R,3S)Meth0xycyclohexylamin0)((1r,4R)—4-
methoxycyclohexylamin0)pyrimidine—5-carb0xamide. To a stirring solution of
4-((1R,3 ethoxycyclohexylamino)(methylsulfonyl)pyrimidinecarboxamide
(0.3 g, 0.914 mmol) and (1r,4r)methoxycyclohexanamine (0.236 g, 1.827 mmol) in
DMSO (0.914 mL) was added DIEA (0.637 mL, 3.65 mmol) and the reaction mixture was
d at 100 CC for 17 h. The crude reaction e was concentrated and then purified
by silica gel chromatography (0-10% methanol in ethyl acetate). The product fractions
were combined and concentrated to afford 4-((1R,3 S)—3-methoxycyclohexylamino)
((1r,4R)methoxycyclohexylamino)-pyrimidinecarboxamide (0.155 g, 0.411 mmol,
44.9 % yield) as a white solid. 1H NMR (400 MHZ, DMSO-d6) 5 ppm 8.95 (d, J=7.42 Hz,
1H), 8.34 (s, 1H), 7.01 - 7.17 (m, 1H), 6.76 - 6.88 (m, 1H), 3.51 - 4.07 (m, 2H), 2.97 - 3.29
(m, 8H), 1.63 - 2.42 (m, 8H), 0.98 - 1.39 (m, 9H); MS (ESI) m/z 378.4 [M+l]+.
ATI—2514l75vl
Example 16: 2-((1r,4R)—4-Hydroxymethylcyclohexylamino)((1R,3S)—3-
hydroxycyclohexylamino)pyrimidine—5-carboxamide
\‘O N \ NH2
., 9L /
’N N NH
A. )—4-Amino-l-methylcyclohexanol hydrochloride. A solution of
(1r,4r)(dibenzylamino)methylcyclohexanol (15 .3 g, 49.4 mmol; prepared as
described in PCT Int. Appl. publication WO2010/027500 ) in methanol (137 mL) and
ethyl acetate (137 mL) in a 500 mL Parr vessel was degassed by bubbling nitrogen through
the solution for 5 min. To the on was added palladium hydroxide on carbon (6.94 g,
4.94 mmol) and the vessel was placed on a Parr shaker for 6 days at 3 atm hydrogen. The
vessel was removed from the Parr shaker and then the suspension was filtered through
celite. The filtrate was concentrated, the residue was dissolved in 50 mL methanol,
acidified with aqueous hydrochloric acid on (6 M, 9.06 mL, 54.4 mmol) and
concentrated to afford (lr,4r)—4-amin0-l-methylcyclohexanol hydrochloride (8.31 g,
50.2 mmol, 101 % yield) as an off-white solid, which was used without further purification
in the next step.
] B. utyl (1r,4r)—4-hydroxymethylcyclohexylcarbamate. To a
stirring solution of (lr,4r)amino-l-methylcyclohexanol hydrochloride (8.31 g,
50.2 mmol) in an aqueous sodium hydroxide solution (1 N, 100 mL, 100 mmol) was added
di-tert-butyl-dicarbonate (13.68 g, 62.7 mmol) and the reaction mixture was stirred at
room temperature for 2 h. The reaction was concentrated and then purified by silica gel
chromatography % ethyl acetate in hexanes). The product fractions were combined
and concentrated. The material contained ~50% desired product as shown by LCMS, so
the material was repurified twice on silica gel, using 0-50% ethyl e in hexanes as the
mobile phase. The product fractions were combined and concentrated to afford tert-butyl
(lr,4r)hydr0xymethylcyclohexylcarbamate (2.2 g, 9.59 mmol, 19.13 % yield) as a
white solid. MS (ESI) m/z 230.5 [M+1]+.
-ll2-
ATI—2514l75vl
C. (1r,4r)—4-Amin0-l-methylcyclohexanol trifluoroacetate. To a stirring
solution of tert-butyl (1r,4r)hydroxymethylcyclohexylcarbamate (2.04 g, 8.90 mmol)
in DCM (44 mL) was added TFA (13.71 mL, 178 mmol) and the solution was stirred at
room temperature for 22 h. The reaction was concentrated, the residue was triturated
twice with ethyl ether to afford (1r,4r)aminomethylcyclohexanol trifluoroacetate
(2.106 g, 8.66 mmol, 97 % yield) as a white solid. 1H NMR (400 MHz, DMSO-d6) 5 ppm
7.73 (br. s., 3H), 4.39 (br. s., 1H), 3.05 (d, J=3.51 Hz, 1H), 1.27 - 1.97 (m, 8H), 1.11 (s,
3H); MS (ESI) m/z 130.2 [M+1]+.
D. 2-((1r,4R)—4-Hydr0xymethylcyclohexylamino)—4-((1R,3S)
hydroxycyclohexylamino)pyrimidine—5-carb0xamide. To a stirring on of
,3 S)—3-hydroxycyclohexylamino)(methylsulfonyl)pyrimidinecarboxamide
(0.432 g, 1.374 mmol; synthesis described herein) and )aminomethylcyclo-
hexanol trifluoroacetate (0.435 g, 1.786 mmol) in dioxane (2.75 mL) was added DIEA
(0.718 mL, 4.12 mmol) and the resulting solution was stirred at 110 °C for 23 h. The crude
reaction mixture was concentrated and the residue was d by HPLC (20-100%
methanol in water). The product fractions were combined, trated and the residue
was triturated with acetonitrile. The resulting precipitate was collected to afford
2-((1r,4R)—4-hydroxymethylcyclohexylamino)((1R,3 S)hydroxycyclohexylamino
)pyrimidinecarboxamide (0.0483 g, 0.133 mmol, 9.67 % yield) as an off white
solid. 1H NMR (400 MHz, 6) 8 ppm 8.91 (d, J=6.64 Hz, 1H), 8.34 (br. s., 1H),
6.56 - 7.26 (m, 1H), 3.39 - 4.78 (m, 4H), 2.54 (s, 3H), 0.66 - 2.25 (m, 19H); MS (ESI) m/z
364.5 [M+1]+
ATI—25 14175V1
Example 17: 4-((1S,3S,4S)Hydr0xymethylcyclohexylamino)—2-((1r,4S)
methoxy-cyclohexylamin0)pyrimidinecarboxamide; 4-((1R,3R,4R)—3-Hydr0xy
methylcyclohexylamino)—2-((1r,4R)—4-methoxy-cyclohexylamin0)pyrimidine
carboxamide; 4-((1S,3R,4R)—3-Hydr0xymethylcyclohexylamino)—2-((1r,4S)
methoxy-cyclohexylamin0)pyrimidine—5-carboxamide; 4-((1R,3S,4S)Hydr0xy
methylcyclohexylamino)—2-((1r,4R)—4-methoxy-cyclohexylamin0)pyrimidine
carboxamide
o o o
“U 1%“ ”U 11* “O 11*~O o / ‘0 11*“\
/ ll,
’N 'I N NH
N NH I"NJ\N/
NH 'N N/ NH fl
H : H H :
; .II
'OH : ‘OH : 'OH OH
A. 2-((1s,4s)—4-Hydr0xy—4-methylcyclohexyl)is0indoline-1,3-di0ne. To a
stirring on of (1s,4s)aminomethylcyclohexanol (10 g, 77 mmol; prepared as
described in PCT Int. Appl. publication WO2010/027500) and potassium carbonate
(18.72 g, 135 mmol) in water (155 mL) at 0 CC was added N—carbethoxyphthalimide
(18.66 g, 85 mmol) and the on was stirred for 2 h at room temperature. The fine
suspension was filtered, resuspended in 100 mL water, and refiltered to afford 2-((1s,4s)-
4-hydroxymethylcyclohexyl)isoindoline-1,3-dione (11.413 g, 44.0 mmol, 56.9 % yield)
as a white powder. 1H NMR (400 MHz, DMSO-d6) 5 ppm 7.79 — 7.88 (m, 4H), 4.11 (s,
1H), 3.94 (s, 1H), 2.51 - 2.56 (m, 1H), 2.44 - 2.49 (m, 1H), 1.56 - 1.70 (m, 2H), 1.33 - 1.47
(m, 4H), 1.13 (s, 3H); MS (ESI) m/z 260.5 .
B. 2-(4-Methylcyclohexenyl)is0indoline-1,3-di0ne. 2-((1s,4s)
Hydroxymethylcyclohexyl)isoindoline-1,3-dione (4.6568 g, 17.96 mmol) and
potassium hydrogen sulfate (4.89 g, 35.9 mmol) were ed and heated to 140 0C for
min. No on was observed, so water (11.22 mL) and sulfuric acid (7.66 mL,
144 mmol) were added and the reaction mixture was heated to 100 0C for 2 h. The crude
suspension was cooled to room temperature and poured into 200 mL crushed ice/water,
stirred vigorously for 30 min, then filtered to afford the crude product as a white solid.
The white solid was purified by silica gel tography (0-10% ethyl acetate in
hexanes), and the product ons were combined and concentrated to afford
—114—
ATI—25 14175V1
ethylcyclohexenyl)isoindoline-1,3-dione (3.33 g, 13.80 mmol, 77 % yield) as a
white solid. MS (ESI) m/z 242.0 [M+1]+.
C. 4-Methylcyclohexenamine. To a stirring suspension of
2-(4-methylcyclohexenyl)isoindoline-1,3-dione (5.24 g, 21.72 mmol) in methanol
(163 mL) and DCM (54.3 mL) was added hydrazine e (3.69 mL, 76 mmol) and the
reaction was stirred for 15 h. To the crude sion was added 400 mL water, and the
mixture was stirred for 10 min, then extracted with DCM (4 x 400mL). The combined
organic layers were dried over sodium sulfate then concentrated to afford 4-methylcyclohexenamine
(2.415 g, 21.72 mmol, 100 % yield) as a light yellow oil. MS (ESI)
m/z 112.2 [M+1]+.
D. tert-Butyl 4-methylcyclohexenylcarbamate. To a stirring on
of 4-methylcyclohexenamine (2.415 g, 21 .72 mmol) and TEA (3.33 mL, 23.89 mmol)
in DCM (43.4 mL) at 0 CC was added di-tert-butyl-dicarbonate (7.11 g, 32.6 mmol). The
resulting mixture was stirred for 3 days at room temperature. The crude reaction mixture
was concentrated then purified by silica gel chromatography (0-10% ethyl acetate in
hexanes). The product fractions were ed and concentrated to afford tert-butyl 4-
methylcyclohexenylcarbamate (1.65 g, 7.81 mmol, 36.0 % yield) as a white solid.
1H NMR (400 MHz, DMSO-d6) 5 ppm 6.72 (d, J=7.42 Hz, 1H), 5.26 (br. s., 1H),
3.35 - 3.49 (m, 1H), 1.66 - 2.22 (m, 5H), 1.60 (s, 3H), 1.38 (s, 10H); MS (ESI) m/z 212.4
[M+1]+.
E. tert—Butyl 3-hydroxy—4-methylcyclohexylcarbamate. To a ng
solution of tert-butyl 4-methylcyclohexenylcarbamate (1.5844 g, 7.50 mmol) in THF
(94 mL) at 0 0C was added 1M borane THF complex (33.7 mL, 33.7 mmol). The solution
was stirred at 0 CC for 1 h and then at room temperature for 2 h. The reaction was
quenched very slowly with water (40.5 mL, 2249 mmol), diluted with ethanol (39.8 mL,
682 mmol) and basified with aqueous sodium hydroxide solution (5 N, 37.5 mL,
187 mmol). To the stirring biphasic mixture was slowly added hydrogen peroxide
(38.3 mL, 375 mmol) and the ing mixture was heated to 45 0C for 20 h. The crude
reaction was quenched with saturated aqueous sodium sulfite on (70 mL) and
extracted with ethyl acetate (3 x 100mL). The combined organic layers were washed with
brine, dried over sodium sulfate, filtered and concentrated. The crude product was
ATI—2514l75Vl
d by silica gel chromatography % ethyl acetate in hexanes). The product
fractions were combined and trated to afford a mixture of four isomers of tert-butyl
3-hydroxymethylcyclohexylcarbamate (trans relationship between 3-hydroxy and
4-methyl moieties) (0.9608 g, 4.19 mmol, 55.9 % yield) as a white solid. 1H NMR
(400 MHz, DMSO-d6) 5 ppm 6.60 - 6.85 (m, 1H), 4.29 - 4.58 (m, 1H), 3.35 - 3.80 (m,
1H), 2.81 - 3.28 (m, 1H), 1.20 - 1.96 (m, 14H), 0.79 - 1.14 (m, 5H); MS (ESI) m/z 230.5
[M+1]+.
F. 5-Amin0-(trans)—2—methylcyclohexanol hydrochloride. To vigorously
stirring methanol (10.47 mL) at 0 0C was added acetyl de (0.893 mL, 12.57 mmol).
The solution was stirred for 30min, then tert-butyl oxymethylcyclohexyl-
carbamate (0.9608 g, 4.19 mmol) was added and stirring was continued for 22 h at room
temperature. The crude reaction mixture was concentrated, and the residue was triturated
with ethyl ether (2 x 50 mL) to afford 5-amino-(trans)methylcyclohexanol
hydrochloride (0.694 g, 4.19 mmol, 100 % yield) as a white solid. MS (ESI) m/z 112.2
[003 17] G. 2-(trans—4-Methoxycyclohexylamin0)(methylsulfinyl)pyrimidine—
-carb0xamide. To a solution of 2-((1r,4r)methoxycyclohexylamino)(methylthio)-
pyrimidinecarboxamide (1.24 g, 4.18 mmol; synthesis described herein) in NMP
(12.30 mL) at 0 °C was added mCPBA (0.938 g, 4.18 mmol) portion wise and the reaction
mixture was stirred for 1 h, while allowing to reach room temperature slowly. The
reaction mixture was diluted with water (120 mL), stirred for 10 min and the resulting
solids were removed by ion. The filtrate was concentrated in vacuo at less than
CC to afford 2-((1r,4r)methoxycyclohexylamino)(methylsulf1nyl)pyrimidine
amide (1.307 g, 4.18 mmol, 100 % yield) as a white suspension in NMP (~10 mL).
This crude suspension was used in the next step without further purification. MS (ESI)
m/z 313.5 [M+1]+.
H. 4-((1 S,3S,4S)—3-Hydr0xymethylcyclohexylamino)—2—((1r,4S)—4-
methoxycyclohexylamin0)pyrimidine—5-carboxamide, 4-((1R,3R,4R)—3-hydr0xy
methylcyclohexylamin0)((1r,4R)—4-meth0xycyclohexylamin0)pyrimidine
carboxamide, 4-((1S,3R,4R)—3-hydroxymethylcyclohexylamin0)((1r,4S)—4-
methoxycyclohexylamin0)pyrimidine—5-carboxamide, 4-((1R,3S,4S)—3-hydr0xy
ATI—25 14175V1
methylcyclohexylamino)—2-((1r,4R)—4-meth0xycyclohexylamin0)pyrimidine
carboxamide. To the crude on mixture of (2-((1r,4r)methoxycyclohexylamino)-
4-(methylsulfinyl)pyrimidinecarboxamide (1.31 g, 4.19 mmol) in NMP (10 mL) was
added crude 5-amino-(trans)methylcyclohexanol hydrochloride (0.695 g, 4.19 mmol) as
a solution in NMP (15.00 mL). To the sion was added DIEA (3.65 mL,
.97 mmol) and the reaction was heated to 100 0C for 46 h. The NMP was d by
ation at 70 0C, the residue was diluted with DCM and purified by silica gel
tography (0-15% methanol in DCM). The t fractions were combined,
concentrated, and then repurif1ed by silica gel chromatography (0-10% methanol in DCM).
The product fractions were combined and concentrated to afford a mixture of four
products (two diastereomers and their corresponding enantiomers (1.665 g). NMR of
mixture: 1H NMR (400 MHz, DMSO-d6) 5 ppm 8.35 (d, J=5.45 Hz, 1H), 4.50 - 4.71 (m,
1H), 4.34 (br. s., 1H), 3.53 - 3.69 (m, 1H), 3.23 (s, 3H), 3.03 - 3.19 (m, 2H), 1.77 - 2.09
(m, 5H), 1.65 (br. s., 1H), 1.07 - 1.39 (m, 13H), 0.94 (d, J=6.49 Hz, 3H); MS (ESI) m/z
378.0 [M+1]+ The crude material was separated by chiral SFC using an AD-H column to
afford 4 compounds labeled PEAK 1 to PEAK 4, with PEAK 1 being the first eluting
compound and PEAK 4 being the latest eluting compound. Stereochemistry of Peaks 1
through 4 was determined by methods known to one of skill in the art.
PEAK 1: 4-((1S,3S,4S)Hydr0xymethylcyclohexylamino)—2-
((1r,4S)methoxycyclohexylamin0)pyrimidine—5-carb0xamide. 0.3482 g,
0.922 mmol, 22 % yield. 1H NMR (400 MHz, DMSO-d6) 5 ppm 8.88 (d, J=6.64 Hz, 1H),
8.34 (br. s., 1H), 7.07 (d, J=7.03 Hz, 1H), 4.58 (d, J=5.08 Hz, 1H), 4.10 (q, J=5.08 Hz,
1H), 3.51 - 3.92 (m, 1H), 3.44 (dd, J=7.03, 5.08 Hz, 1H), 3.23 (s, 3H), 3.17 (d, J=5.47 Hz,
3H), 3.09 (br. s., 1H), 2.98 (br. s., 1H), 2.55 (d, J=7.03 Hz, 1H), 1.77 - 2.23 (m, 5H), 1.66
(d, J=12.49 Hz, 1H), 1.04 - 1.35 (m, 6H), 0.94 (d, J=5.86 Hz, 3H).
PEAK 2: 4-((1R,3R,4R)—3-hydroxymethylcyclohexylamino)—2-
((1r,4R)—4-methoxycyclohexylamin0)pyrimidine—5-carb0xamide. 0.4146 g,
1.098 mmol, 26.2 % yield. 1H NMR (400 MHz, DMSO-d6) 8 ppm 8.88 (d, J=6.25 Hz,
1H), 8.34 (br. s., 1H), 7.07 (d, J=7.03 Hz, 1H), 4.57 (br. s., 1H), 4.11 (br. s., 1H),
3.50 - 3.67 (m, 1H), 3.23 (s, 2H), 3.17 (br. s., 2H), 3.03 - 3.13 (m, 1H), 2.94 - 3.02 (m,
1H), 2.89 (q, J=7.16 Hz, 4H), 1.60 - 2.22 (m, 4H), 0.87 - 1.37 (m, 13H).
ATI—25 14175V1
PEAK 3: 4-((1 S,3R,4R)—3-hydroxymethylcyclohexylamin0)
((1r,4R)—4-methoxycyclohexylamin0)pyrimidine—5-carb0xamide. 0.3145 g, 0.833
mmol, 19.9 % yield. 1H NMR (400 MHz, DMSO-d6) 8 ppm 9.25 (d, J=7.42 Hz, 1H), 8.35
(br. s., 1H), 7.05 (d, J=6.64 Hz, 1H), 6.76 - 6.92 (m, 1H), 4.53 (d, J=3.90 Hz, 1H), 4.32
(br. s., 1H), 4.03 - 4.17 (m, 1H), 3.52 - 3.84 (m, 1H), 3.40 - 3.50 (m, 1H), 3.13 - 3.26 (m,
4H), 3.00 - 3.12 (m, 1H), 1.77 - 2.12 (m, 5H), 1.10 - 1.69 (m, 9H), 0.94 (d, J=6.64 Hz,
3H).
PEAK 4: 4-((1R,3S,4S)hydr0xymethylcyclohexylamin0)
((1r,4R)—4-methoxycyclohexylamin0)pyrimidine—5-carb0xamide. 0.4715 g, 1.249
mmol, 29.8 % yield. 1H NMR (400 MHz, DMSO-d6) 8 ppm 9.46 - 9.75 (m, 1H), 8.35 (s,
1H), 4.57 (br. s., 1H), 4.35 (br. s., 1H), 3.60 - 3.79 (m, 1H), 3.23 (s, 4H), 3.00 - 3.15 (m,
1H), 2.87 - 2.99 (m, 1H), 1.75 - 2.06 (m, 5H), 1.06 - 1.73 (m, 11H), 0.94 (d, J=6.25 Hz,
3H).
Example 18: 4-((1R,3S)Hydr0xycyclohexylamino)—2-((1r,4R)—4-
methoxycyclohexylamin0)pyrimidinecarboxamide
/O”'
N \ NH2
)L /
A. 2-Cyclohexenyl—is0indole-1,3-di0ne. To a solution of 3-bromo-
cyclohexene (500 g, 3.12 mmol) in DMF (2000 mL) was added potassium phtalimide
(580 g, 3.12 mmol), and the reaction mixture was stirred at room temperature for 30 h.
The reaction mixture was diluted with water (1000 mL), ted with ethyl acetate
(3 times), and the combined organic layers were concentrated to give 2-cyclohexenyl-
ole-1,3-dione (520 g, 2.30 mol) as a gray solid.
B. rom0hydroxy-cyclohexyl)-is0indole-1,3-di0ne. 2-Cyclohex-
2-enyl-isoindole-1,3-dione (520 g, 2.30 mol) and N—bromosuccinimide (416 g, 2.35 mol)
were mixed in a cosolvent of chloroform (3000 mL) and ethanol (120 mL) and stirred at
room temperature for 16 h. When HPLC showed the starting material was ed, the
on mixture was concentrated to give the residue, which was diluted with
ATI—25 14175Vl
hydrochloride solution (450 mL, 2.0 mol) and THF (2000 mL), and the reaction mixture
was stirred at room temperature for 2 h. The reaction mixture was trated to give the
crude product. The crude product was washed with ethanol (2 times) to give 2-(2-bromo-
3-hydroxy-cyclohexyl)-isoindole-1,3-dione (400 g, 1.23 mol) as a white solid. 1H NMR
(CD301), 400 MHz): 5 ppm 7.87 (m, 4H), 4.70 (m, 1H), 4.33 (m, 1H),3.70 (m, 1H), 2.15
(m, 2H),1.88 (m, 2H), 1.53 (m, 2H).
C. 2-(3-Hydr0xy-cyclohexyl)-isoindole-1,3-dione. Tri-n-butyltin hydride
(430 g, 1.48 mol) was added to a stirred solution of 2-(2-bromohydroxy-cyclohexyl)-
isoindole-1,3-dione (400 g, 1.23 mol) and 2,2'-azobis(2-methylpropionitrile) (20 g) in
toluene (4000 mL) and ol (400 mL) and the reaction e was stirred at 80 CC
for 64 h. The reaction mixture was concentrated to give the crude product. The crude
product was washed with eum ether and ethyl acetate (1 :1) to give 2-(3-hydroxy-
cyclohexyl)-isoindole-1,3-dione (240 g, 0.98 mol) as a white solid. 1H NMR (CDgOD,
400 MHz): 5 ppm 7.82 (m, 4H), 4.16 (m, 1H), 3.63 (m, 1H), 2.13 (m, 2H), 1.98 (d, 2H),
1.89 (m, 1H),1.68 (t, 1H), 1.46 (m, 1H),1.31(m, 1H).
D. (1S,3R)(3-Hydroxy-cyclohexyl)-is0indole-1,3-di0ne and (1R,3S)
acetic acid 3-(1,3-di0x0-1,3-dihydr0-isoind0]—2-yl)—cyclohexyl ester. A solution of 2-(3-
hydroxy-cyclohexyl)-isoindole-1,3-dione (240 g, 0.98 mol) and Lipase B (87 g) in THF
(3000 mL) was stirred at room temperature under nitrogen for 1~2 h. Then acetic acid
vinyl ester (252 g, 2.88 mol) was added to the solution, and the reaction mixture was
stirred at rt for 3~5 h. Then the reaction mixture was filtered, and the filtrate was
concentrated to give crude product. The crude product was purified on silica gel (eluting
with petroleum ether/ethyl acetate =10: 1) to give (1S,3R)(3-hydroxy-cyclohexyl)-
isoindole-1,3-dione (Rf:0.6, petroleum ethyl e = 3/1, 90 g, 0.37 mol,
yield: 39%) as a white solid. 1H NMR (CDgOD, 400 MHz): 5 ppm 7.82 (m, 4H), 4.16 (m,
1H), 3.63 (m, 1H), 2.13 (m, 2H), 1.98 (m, 2H), 1.89 (m, 1H), 1.68 (m, 1H), 1.46 (m, 1H),
1.31(m, 1H).
)Acetic acid 3-(l,3-dioxo-l,3-dihydro-isoindolyl)-cyclohexyl
ester 2, petroleum ether/ethyl acetate = 3/ 1, 110 g, 0.38 mol, yield: 39%) as a white
solid. 1H NMR (CD301), 400 MHz): 5 ppm 7.83 (m, 4H), 4.78 (m, 1H), 4.23 (m, 1H),
2.33 (m, 2H), 2.13 (m, 2H), 2.07 (m, 5H), 1.95 (m, 1H), 1.74 (m, 1H), 1.46 (m, 1H).
ATI—25 14175v1
E. (1S,3R)Amin0-cyclohexanol. To a solution of (1S,3R)(3-
hydroxy-cyclohexyl)-isoindole-1,3-dione (90 g, 0.37 mol) in ethanol (1500 mL) was added
hydrazine (90 g, 1.8 mol), and the reaction solution was stirred at 100 CC for 3h. The
reaction solution was filtered, and the filtrate was concentrated to give (1S,3R)amino-
cyclohexanol (25 g, 0.21 mmol) as a yellow solid. 1H NMR (CDgOD, 400 MHz) 5 ppm
3.54 (m, 1H), 2.65 (m, 1H), 2.12 (m, 1H), 1.92 (m, 1H), 1.89 (m, 2H), 1.32 (m, 1H), 1.06
(m, 2H).
F. Ethyl 4-((1R,3S)—3-hydr0xycyclohexylamin0)(methylthi0)-
dine—S-carboxylate. To a stirring solution of ethyl 4-chloro(methylthio)-
pyrimidinecarboxylate (4.38 g, 18.82 mmol) and (1S,3R)aminocyclohexanol
(2.276 g, 19.76 mmol) in ethanol (75 ml) was added DIEA (4.93 ml, 28.2 mmol). The
on mixture was heated to 60 CC for 2h, was removed from heat and concentrated,
then d by silica gel chromatography (20-100% ethyl acetate/hexane). The desired
product fractions were ed and trated to afford ethyl 4-((1R,3S)
hydroxycyclohexylamino)(methylthio)pyrimidinecarboxylate (5 g, 16.06 mmol,
85 % yield) as a white foam. MS (ESI) m/z 312.1 [M+1]+.
G. 4-((1R,3S)—3-hydr0xycyclohexylamin0)(methylthi0)pyrimidine
carboxylic acid. To a stirring solution of ethyl 4-((1R,3S)—3-hydroxycyclohexyl-amino)-
hylthio)pyrimidinecarboxylate (5 g, 16.06 mmol) in ethanol (50 ml) was added
2M sodium hydroxide (20 ml, 40.0 mmol). Stirring was continued at room temperature
for 1h. The reaction e was neutralized by addition of saturated citric acid. The
resulting precipitate was filtered and dried to afford 4-((1R,3S)—3-hydroxycyclohexylamino
)(methylthio)pyrimidinecarboxylic acid (4.5 g, 15.88 mmol, 99 % yield) as a
white solid. 1H NMR (400 MHz, 6) 8 ppm 13.21 (br. s., 1 H), 8.44 - 8.54 (m,
2 H), 4.74 (d, J=3.90 Hz, 1 H), 3.97 - 4.12 (m, 1 H), 3.56 (d, J=3.12 Hz, 1 H), 2.46 (s,
3 H), 2.05 - 2.16 (m, 1 H), 1.84 (d, J=10.15 Hz, 1 H), 1.65 - 1.80 (m, 2 H), 1.11 - 1.36 (m,
4 H). MS (ESI) m/z 284.1 [M+1]+.
H. 4-((1R,3S)Hydr0xycyclohexylamino)—2-(methylthio)pyrimidine—5-
carboxamide. 4-((1R,3 S)—3-hydroxycyclohexylamino)(methylthio)pyrimidine-5 -
carboxylic acid (4.5 g, 15.88 mmol) and HATU (9.06 g, 23.82 mmol) were dissolved in
DMF (75 ml) and allowed to stir for 5 min at room temperature before adding ammonium
ATI—25 14175v1
de (4.25 g, 79 mmol) and DIEA (13.87 ml, 79 mmol). The reaction turned yellow
upon addition of the base. The reaction was allowed to stir at room ature for 1 h
then partitioned between water and ethyl acetate. The c layer was washed once with
brine before drying over sodium sulfate, filtering, and concentrating to afford 4-((1R,3S)-
3-hydroxycyclohexylamino)(methylthio)pyrimidinecarboxamide (4.19 g,
14.84 mmol, 93 % yield) as an off-white solid. MS (ESI) m/z 283.2 .
I. 4-((1R,3S)Hydroxycyclohexylamin0)(methylsulfonyl)—
pyrimidine—5-carb0xamide. To a stirring suspension of 4-((1R,3S)—3-
hydroxycyclohexylamino)(methylthio)pyrimidinecarboxamide (302 mg,
1.070 mmol) in DCM (10 ml) and acetone (10 ml) was added 3-chloroperoxybenzoic acid
(479 mg, 2.139 mmol). The reaction was stirred at room temperature for 1.5 h. The crude
reaction mixture was quenched by addition of 10 mL of 10% sodium thiosulfate solution,
stirred for 5 minutes, then partitioned between ethyl acetate and water. The organic layer
was washed with saturated sodium bicarbonate and brine. The ed aqueous layers
were extracted with ethyl acetate (3x50mL). The combined organic layers were dried over
sodium sulfate, filtered, and trated to afford 4-((1R,3S)—3-hydroxycyclohexyl-
amino)(methylsulfonyl)pyrimidinecarboxamide (259 mg, 0.824 mmol, 77 % yield)
as a white solid. MS (ESI) m/z 315.2 [M+1]+.
] J. 4-((1R,3S)Hydr0xycyclohexylamin0)((1r,4R)—4-meth0xycyclo—
hexylamin0)pyrimidine—5-carb0xamide. To a stirring solution of 4-((1R,3S)hydroxy-
cyclohexylamino)(methylsulfonyl)pyrimidinecarboxamide (0.178 g, 0.566 mmol)
and (1r,4r)methoxycyclohexanamine (0.146 g, 1.132 mmol) in DMSO (1 . 132 ml) was
added DIEA (0.395 ml, 2.265 mmol). The reaction mixture was stirred at 100 CC for 17 h.
The crude reaction mixture was concentrated and purified by silica gel chromatography
(0-15% methanol/ethyl acetate). The product fractions were combined and concentrated to
afford 4-((1R,3 S)hydroxycyclohexylamino)((1r,4R)—4-methoxycyclohexylamino)-
pyrimidinecarboxamide (0.08 g, 0.220 mmol, 38.9 % yield) as a light tan solid.
1H NMR (CDgOD, 400 MHz): 8 ppm 8.29 (s, 1H), 3.99-4.04 (m, 1H), 3.76 (m, 1H),
3.50 - 3.63 (m, 1H), 3.37 (s, 3H), 3.24 (m, 1H), 3.23 (m, 1H), 1.92-2.12 (m, 6H), .87
(m, 1H), 1.19-1.41(m, 8H). MS (ESI) m/z 364.6 [M+1]+.
ATI—25 14175V1
Example 19: 4-((1R,3S)—3-Hydr0xycycloheptylamino)—2-((1r,4R)—4-
methoxycyclohexylamin0)pyrimidine—5-carb0nitrile
/o,,, CN
)L /
N N NH
H OOH
A. 4-Chlor0((1R,4R)—4-methoxycyclohexylamin0)-pyrimidine—5-
carbonitrile. (1r,4r)Methoxycyclohexanamine (6.37 g, 49.3 mmol),
2,4-dichloropyrimidinecarbonitrile (6 g, 34.5 mmol) and DIEA (9.03 mL, 51.7 mmol)
were mixed in THF (180 mL) at -10 CC (salt ice bath) and stirred at the same temperature
for 5 h. The reaction mixture was stirred further overnight while the temperature went up
to room temperature slowly. Analysis of the reaction mixture by LC/MS showed formation
of the ts with the ratio of about 3 :7. The reaction mixture was concentrated under
reduced re, diluted with water (100 mL) and extracted with ethyl acetate (2x). The
combined organic layers were washed with water and brine and dried over magnesium
sulfate. The drying agent was removed by filtration and the solution was concentrated.
The ing crude mixture was purified by flash chromatography (0-20% ethyl acetate in
hexanes) to give 4-chloro((1R,4R)methoxycyclohexylamino)pyrimidine
carbonitrile (5.79 g, 21.71 mmol, 62.9 % yield; 1H NMR (DMSO-d6 ,400 MHz): 5 ppm
8.74 (d, J=8.2 Hz, 1 H), 8.60 - 8.72 (m, 1 H), 3.58 - 3.80 (m, 1 H), 3.18 (d, J=2.0 Hz, 3 H),
2.97 - 3.12 (m, 1 H), 1.96 (d, J=10.9 Hz, 2 H), 1.83 (d, J=10.5 Hz, 2 H), 1.21 - 1.39 (m,
2 H), 1.06 - 1.22 (m, 2 H); MS (ES) m/z 267.2 ) as a white solid and 2-chloro
((1R,4R)—4-methoxycyclohexylamino)pyrimidinecarbonitrile (2.5 g, 9.37 mmol, 27.2 %
yield; 1H NMR (DMSO-d6 ,400 MHz): 5 ppm 8.50 (s, 1 H), 8.31 (d, J=7.8 Hz, 1 H), 3.90
(dtd, J=11.6, 7.6, 4.1 Hz, 1 H), 3.19 (s, 3 H), 2.98 - 3.10 (m, 1 H), 1.98 (d, J=10.5 Hz,
2 H), 1.77 (d, J=11.3 Hz, 2 H), 1.36 - 1.54 (m, 2 H), 1.05 - 1.22 (m, 2 H). MS (ES) m/z
267.1 [M+1]+) as a white solid.
The regiochemistry of the separated s was confirmed in the
following experiments:
] 4-Chloro((1R,4R)methoxycyclohexylamino)pyrimidinecarbonitrile
(50 mg, 0.187 mmol), diacetoxypalladium (42.1 mg, 0.187 mmol) and ammonium
ATI—25 14175v1
formate (59.1 mg, 0.937 mmol) in methanol (1 mL) was stirred at 70 CC for 2 h. The
on mixture was cooled down to room temperature and was filtered through a pad of
celite. The resulting solution was trated and subjected to flash chromatography
(0-15% methanol in DCM) to give 2-((1R,4R)—4-methoxycyclohexyl-amino)pyrimidine
carbonitrile as a white solid. 1H NMR (DMSO-d6 ,400 MHz; measured at room
ature): 8 ppm 8.66 (d, J=2.7 Hz, 1 H), 8.59 (d, J=3.1 Hz, 1 H), 8.22 (d, J=8.2 Hz,
1 H), 3.62 - 3.77 (m, 1 H), 3.18 (s, 3 H), 2.99 - 3.12 (m, 1 H), 1.90 - 2.02 (m, 2 H), 1.84 (d,
J=10.5 Hz, 2 H), 1.21 - 1.37 (m, 2 H), 1.06 - 1.21 (m, 2 H).
1H NMR (DMSO-d6 ,400 MHz; measured at 80 oC): 8 ppm 8.57 (br. s.,
1 H), 7.91 (d, J=7.0 Hz, 1 H), 3.68 - 3.85 (m, 1 H), 3.05 - 3.16 (m, 1 H), 3.02 (s, 3 H), 1.92
- 2.05 (m, 2 H), 1.87 (d, J=10.2 Hz, 2 H), 1.26 - 1.41 (m, 2 H), 1.11 - 1.26 (m, 2 H).
The same method described above was d to 2-chloro((1R,4R)
methoxycyclohexylamino)pyrimidinecarbonitrile to give 4-((1R,4R)methoxy-
exylamino)pyrimidinecarbonitrile as a white solid. 1H NMR (DMSO-dg,
400 MHz; measured at room temperature): 8 ppm 8.56 (d, J=15.2 Hz, 1 H), 7.74 - 7.91 (m,
1 H), 3.86 - 4.11 (m, 2 H), 3.19 (s, 3 H), 3.12 (d, J=5.1 Hz, 1 H), 1.92 - 2.04 (m, 2 H), 1.78
(d, J=10.5 Hz, 2 H), 1.35 - 1.52 (m, 2 H), 1.05 - 1.18 (m, 2 H). 1H NMR (DMSO-d6,
400 MHz; measured at 80 oC): 8 ppm 8.53 (d, J=28.1 Hz, 1 H), 7.47 (br. s., 1 H),
3.93 - 4.08 (m, 1 H), 3.16 (d, J=5.5 Hz, 1 H), 1.91 - 2.07 (m, 2 H), 1.84 (d, J=10.5 Hz,
2 H), 1.37 - 1.54 (m, 2 H), 1.10 - 1.21 (m, 2 H).
B. (1 S,3R)—3-Amin0cycloheptanol hydrochloride. To vigorously stirring
methanol (60 mL) at 0 CC was added acetyl chloride (5.11 mL, 72.0 mmol) and the
resulting mixture was allowed to stir for 30 min. tert-Butyl (1R,3S)—3-hydroxycycloheptylcarbamate
(5500 mg, 23.98 mmol; synthesis described herein) was added and
the resulting mixture was then stirred overnight at room temperature. The reaction
mixture was trated under reduced pressure to an oil that was triturated with ethyl
ether (100 mL) overnight. The solids were filtered, rinsed with diethyl ether, and dried
under reduced pressure for a few hours to afford (1 S,3R)aminocycloheptanol
hydrochloride (3780 mg, 22.82 mmol, 95 % yield) as a white solid. 1H NMR (400 MHz,
DMSO-d6) 5 ppm 7.85 (br. s., 3 H), 4.69 (d, J=7.42 Hz, 1 H), 3.64 (t, J=8.79 Hz, 1 H),
ATI—25 14175v1
3.07 - 3.21 (m, 1 H), 2.05 (d, J=12.89 Hz, 1 H), 1.69 - 1.94 (m, 2 H), 1.28 - 1.68 (m, 7 H).
MS (ESI) m/z 130.1 [M+1]+.
C. 4-((1R,3S)—3-Hydroxycycloheptylamino)—2-((11,4R)
methoxycyclohexylamin0)pyrimidinecarb0nitrile. To a stirring solution of 4-chloro-
2-((1r,4r)methoxycyclohexylamino)pyrimidine-5 -carbonitrile (200 mg, 0.750 mmol)
and (1S,3R)aminocycloheptanol hydrochloride (186 mg, 1.125 11111101) in DMF (4 mL)
was added DIEA (0.458 mL, 2.62 11111101). The resulting mixture was stirred at 70 CC for
4 h and then allowed to cool to ambient ature overnight. DMF was removed under
reduced re and the remaining residue was purified using silica gel chromatography
(0-50% ethyl acetate + 10% 7 N ammonia in ol in hexanes) to afford 4-((1R,3S)
hydroxycycloheptylamino)((1r,4R)methoxycyclohexylamino)pyrimidine
carbonitrile (210 mg, 0.584 mmol, 78 % yield). 1H NMR (400 MHz, DMSO-d6) 5 ppm
8.07 - 8.23 (m, 1 H), 7.06 - 7.61 (m, 2 H), 4.49 - 4.63 (m, 1 H), 4.00 - 4.27 (m, 1 H), 3.55 -
3.82 (m, 2 H), 3.23 (s, 3 H), 3.00 - 3.16 (m, 1 H), 1.07 - 2.08 (m, 18 H). MS (ESI) m/z
360.5 [M+1]+.
Example 20: 2-((1r,4R)—4-Eth0xycyclohexylamin0)((1R,3S)—3-hydroxy
methylcyclohexylamin0)pyrimidine—5-carb0nitrile
”(l “XAxN N N H
H @011
A. (11, 4r)—4—(Tritylamin0)cyclohexanol. To a cooled (0 0C) solution of
(11, 4r)aminocyclohexanol (10 g, 87 mmol) in DCM (250 mL) and TEA (11.2 g,
112 mmol) was added trityl chloride (24.2 g, 87 mmol). The resulting mixture was stirred
at room temperature ght. Saturated aqueous sodium bicarbonate on was added
to quench the reaction and the aqueous layer was extracted with ethyl acetate. The
combined extracts were washed with brine, dried over anhydrous sodium sulfate. Filtration
and concentration under vacuum gave crude product, which was purified by silica gel
column chromatography (50 % ethyl e in DCM) to afford the title compound (24.8 g,
70 mmol, 80 % yield) as a white solid. MS (ESI) m/z 243.2 [M - ocyclohexanol]+.
—124—
ATI—25 14175v1
B. (1r,4r)—4-Ethoxy-N-tritylcyclohexanamine. To a cooled (0 0C) solution
of )(tritylamino)cyclohexanol (15.0 g, 42 mmol) in DMF (100 mL) was added
sodium hydride (3.4 g, 84 mmol, 60 % in mineral oil) and ethyl iodide (7.2 g, 46 mmol) at
0 0C. The resulting mixture was stirred at room temperature overnight under nitrogen
atmosphere. Saturated aqueous ammonia chloride solution was added to quench the
reaction and the aqueous layer was extracted with ethyl e. The combined ts
were washed with brine and dried over anhydrous sodium sulfate. Filtration and
concentration under vacuum gave crude product, which was purified by silica gel column
chromatography (5 % ethyl acetate in petroleum ether) to afford the title compound
(11.9 g, 31 mmol, 79 % yield) as a white solid. 1H NMR (400 MHz, CDClg) 5 ppm
7.56-7.54 (m, 6H), .20 (m, 6H), 7.18-7.14 (m, 3H), 3.42-3.38 (q, 2H), 3.09 - 3.04
(m, 1H), 2.25-2.21 (m, 1H), 1.80-1.78 (m, 2H), 1.38 (s, 1H), 1.27-1.25 (m, 2H), 1.10 (t,
J: 7.2 Hz, 3H), 1.01-0.88 (m, 4H); MS (ESI) m/z 243.2 [M - 4-ethoxycyclohexanamine]+.
C. (1r,4r)—4-Eth0xycyclohexanamine. To a cooled (0 0C) solution of
(1r, ethoxy-N-tritylcyclohexanamine (13.1 g, 34 mmol) in DCM (10 mL) was added
trifluoroacetic acid (18 mL) at 0 0C. The resulting mixture was dark red. Triethylsilane
(5 mL) was added until the resulting mixture was colourless. The reaction was stirred at
0 0C for additional 15 minutes. After removal of all volatiles in vacuo, the residue was
further dried under high vacuum for 2 h to give the crude product as a white solid. The
crude product was dissolved in ethyl acetate and aqueous hydrochloride solution (150 mL,
0.25 mol/L). The c layer was removed and the s layer was washed with ethyl
e twice. tration of the aqueous layer under high vacuum gave the crude
hydrochloride salt of the desired amine (6.1 g, 34 mmol, 100 % yield) as a white solid,
which was used for the next step without further purification. MS (ESI) m/z
144.0 [M+H]+.
D. 4-Chlor0((1r,4r)—4-ethoxycyclohexylamino)pyrimidine—5-
carbonitrile. To a cooled (-60 0C) solution of (1r,4r)ethoxycyclohexanamine (6.82 g,
37.9 mmol) and 2,4-dichloropyrimidinecarbonitrile (6 g, 34.5 mmol) in THF (115 mL)
was added DIEA (15.02 mL, 86 mmol) dropwise. The resulting mixture was stirred at
-60 0C for 1 h and then d to warm to room temperature overnight. The resulting
mixture was concentrated and the residue was purified by silica gel column
ATI—2514175v1
chromatography (14 % ethyl acetate in petroleum ether). The product fractions were
combined and concentrated to afford 2-chloro((1r,4r)ethoxycyclohexylamino)-
pyrimidinecarbonitrile (3.33 g, 11.86 mmol, 34.4 % yield) and 4-chloro((1r,4r)
ethoxycyclohexylamino)pyrimidinecarbonitrile (5.5 g, 19.59 mmol, 56.8 % yield;
1H NMR (400 MHz, DMSO-d6) 5 ppm 8.62 - 8.87 (m, 2 H), 3.61 - 3.86 (m, 1 H), 3.44 (dd,
J=7.03, 2.34 Hz, 2 H), 3.12 - 3.26 (m, 1 H), 1.75 - 2.15 (m, 4 H), 1.13 - 1.44 (m, 4 H), 1.08
(td, J=6.93, 1.76 Hz, 3 H); MS (ESI) m/z 281.1 [M+1]+) as white solids. The
regiochemistry of the major isomer was confirmed by comparison with the proton spectra
of 4-chloro((1r,4r)methoxycyclohexylamino)pyrimidinecarbonitrile (synthesis
described herein).
E. (1 S,3R)(Dibenzylamin0)cyclohexanol. To a suspension of (1S,3R)-
3-aminocyclohexanol (5 g, 43.4 mmol; prepared as described in Tetrahedron: try
(2004) 056) and sodium bicarbonate (12.03 g,143 mmol) in ethanol (100 mL)
was added (chloromethyl)benzene (15.01 mL, 130 mmol) at room temperature. The
on mixture was heated at 75 CC overnight. Upon completion of the reaction as
indicated by LCMS and TLC the reaction mixture was filtered and the e
ammMmmd7mem$mwwwflmnmwdwdeCM(%0mLflmdwwmflwfihmmmm
sodium hydroxide solution (1N, 2 x 100mL) and brine (2 x 100 mL). The combined
organic layers were dried over anhydrous magnesium sulfate, concentrated, and purified
by silica gel chromatography % ethyl e in hexanes) to yield (1S,3R)—3-
(dibenzylamino)cyclohexanol (11.70 g, 91%) as a thick yellow oil . 1H NMR (400 MHz,
DMSO-dg) 5 ppm 7.26 - 7.37 (m, 8H), 7.17 - 7.22 (m, 2H), 4.56 (d, J: 4.30 Hz, 1H), 3.57
(s, 4H), 3.16 - 3.26 (m, 1H), 2.41 (tt, J= 3.17, 11.86 Hz, 1H), 1.99 - 2.06 (m, 1H), 1.72 (d,
J: 8.20 Hz, 2H), 1.63 - 1.69 (m, 1H), 1.18 - 1.28 (m, 2H), 0.98 (t, 2H); MS (ESI) m/z
296.4 [M+1]+.
] F. (R)—3-(Dibenzylamin0)cyclohexanone. Oxalyl chloride (3.81 mL,
43.6 mmol) was dissolved in dry DCM (150 mL) and cooled to -78 oC. DMSO (6.75 mL,
95.0 mmol) in dry DCM (20 mL) was added dropwise to the reaction mixture and the
reaction was stirred for 15 minutes at -78 CC. Next, (1S,3R)(dibenzylamino)—
cyclohexanol (11.7 g, 39.6 mmol) in dry DCM (100 mL) was added dropwise using an
addition fiJnnel and the reaction was stirred at -78 CC for 15 minutes. TEA (27.6 mL,
ATI—25 14175V1
2012/034349
198 mmol) was then added and the reaction was stirred at -78 CC for 1 h. The dry-ice bath
was removed and the on mixture was allowed to warm to room temperature and stir
overnight. The reaction mixture was washed with brine (5 x 500 mL), the organic layer
was separated, dried over magnesium sulfate and concentrated to yield
(R)(dibenzylamino)cyclohexanone (10.2 g, 88%) as a tan solid. 1H NMR (400 MHz,
6) 8 ppm 7.26 - 7.39 (m, 8H), 7.17 - 7.25 (m, 2H), 3.56 - 3.70 (m, 4H), 2.71 - 2.81
(m, 1H), 2.60 - 2.69 (m, 1H), 2.25 - 2.42 (m, 2H), 2.04 - 2.11 (m, 1H), 1.88 - 1.99 (m, 2H),
1.69 - 1.82 (m, 1H), 1.18 - 1.33 (m, 1H); MS (ESI) m/z 294.4 [M+1]+.
G. (3R,5R)—N,N-Dibenzyl—l-oxaspiro[2.5]octanamine and )—
N,N-dibenzyl—1-0xaspir0[2.5]octan-S-amine. To a yellow on of
(R)(dibenzylamino)cyclohexanone (10.2 g, 34.8mmol) and trimethylsulfonium iodide
(14.90 g, 73.0 mmol) in dry DMSO (260 mL) was added sodium tert—butoxide (6.68 g,
69.5 mmol) n wise at room temperature under a nitrogen atmosphere . The reaction
mixture was stirred at room temperature overnight under nitrogen. Upon completion of
the reaction as indicated by LCMS and TLC the reaction was quenched with 1 L of water
and extracted with ethyl acetate (2 x 800 mL). The organic phase was dried over sodium
sulfate, concentrated and dried to yield a mixture of (3R,5R)-N,N—dibenzyl
ro[2.5]octanamine and (3 S,5R)-N,N—dibenzyloxaspiro [2 . 5 ]octanamine
(10.6g, 99%) as a yellow solid. The mixture was used as is in the next step without
further purification. MS (ESI) m/z 308.4 [M+1]+.
H. (1R,3R)(Dibenzylamin0)—l-methylcyclohexanol and (1S,3R)—3-
(dibenzylamino)—l-methylcyclohexanol. To a mixture of solid lithium aluminum hydride
(95% LAH, 3.47 g, 87 mmol) in THF (230 mL) was added very slowly a clear pale yellow
solution of the above described mixture of (3R,5R)—N,N—dibenzyloxaspiro[2.5]octan
amine and (3S,5R)—N,N—dibenzyloxaspiro[2.5]octanamine (10.69 g, 34.8 mmol) in
THF (230 mL) at 0 CC under nitrogen. The reaction mixture was brought to room
temperature and then heated at 65 CC overnight under nitrogen. Upon completion of the
reaction as indicated by LCMS and TLC the reaction mixture was transferred to a round-
bottom flask and then diluted with THF (100 mL), cooled to 0 CC and while stirring a
saturated on of aqueous sodium sulfate was added drop wise until the reaction
stopped ng. The mixture was stirred ght at room temperature and then was
ATI—25 14175v1
filtered through Celite in a coarse fritted funnel into a round-bottom flask. The filter cake
was washed thoroughly with THF and the colorless filtrate was trated under
reduced pressure. The ing crude mixture was purified by silica gel tography
(0%-60% ethyl acetate in hexanes) to yield the faster eluting isomer (1R,3R)
(dibenzylamino)methylcyclohexanol (5.5 g, 50%; 1H NMR (400 MHz, DMSO-dg)
8 ppm 7.25 - 7.36 (m, 8H), 7.15 - 7.21 (m, 2H), 3.85 (s, 1H), 3.55 (s, 4H), 2.86 (tt,
J= 3.37, 12.06 Hz, 1H), 1.70 - 1.81 (m, 2H), 1.38 - 1.49 (m, 3H), 1.32 (t, J: 12.30 Hz,
1H), 1.15 - 1.27 (m, 2H), 1.12 (s, 3H); MS (ESI) m/z 310.4 [M+1]+) as a white solid, and
then the slower eluting isomer (1 S,3R)(dibenzylamino)methylcyclohexanol (5.1 g,
47%; 1H NMR (400 MHz, DMSO-d6) 5 ppm 7.26 - 7.36 (m, 8H), 7.16 - 7.23 (m, 2H), 4.38
(s, 1H), 3.49 - 3.63 (m, 4H), 2.46 (d, J: 8.98 Hz, 1H), 1.67 - 1.80 (m, 2H), 1.59 (d,
J: 9.76 Hz, 1H), 1.33 - 1.47 (m, 2H), 1.17 - 1.30 (m, 2H), 0.98 - 1.13 (m, 1H), 0.89 (s,
3H); MS (ESI) m/z 310.4 [M+1]+) as a thick yellow oil. A COSY NMR experiment and
the 1H NMR data reported above were used to verify the regiochemistry of the amino
alcohols. For the slower eluting isomer an NOE (via NOESY ment) was observed
between the protons on the amino group cyclohexyl-carbon and the methyl group carbon.
This verifies a cis relationship n these two onal groups (a trans relationship,
lacking this spacial proximity, would not show such an effect), which in turn confirms this
isomer to be (1 S,3R)(dibenzylamino)methylcyclohexanol.
I. (1 S,3R)—3-Amin0-l-methylcyclohexanol. A solution of (1S,3R)
(dibenzylamino)methylcyclohexanol (5.0 g, 16.16 mmol) in ethanol (150 mL) was
treated with palladium hydroxide on carbon and stirred under a balloon filled with
hydrogen gas overnight. Upon completion of the on as indicated by LCMS the
reaction mixture was filtered h a pad of celite and the filtrate concentrated to yield
(1R,3R)aminomethylcyclohexanol (1.3g, 62%) as a thick yellow oil. 1H NMR
(400 MHz, DMSO-dg) 5 ppm 2.87 (br. s., 1H), 1.64 - 1.74 (m, 1H), 1.47 - 1.59 (m, 2H),
1.21 - 1.40 (m, 4H), 1.11 - 1.20 (m, 1H), 1.02 (s, 3H); MS (ESI) m/z 130.2 [M+1]+.
J. 2-((1r,4R)—4-Eth0xycyclohexylamino)—4—((1R,3S)—3-hydr0xy
methylcyclohexylamin0)pyrimidinecarb0nitrile. 4-Chloro((1r,4r)
ethoxycyclohexylamino)pyrimidinecarbonitrile (350 mg, 1.247 mmol), (1S,3R)
aminomethylcyclohexanol (242 mg, 1.870 mmol), and DIEA (0.327 mL, 1.870 mmol)
ATI—25 14175v1
2012/034349
were dissolved in DMF (3.5 mL) in a screw-capped vial. The reaction mixture was stirred
at 70 CC for 4 h. After completion of the reaction as indicated by LCMS and TLC the
reaction mixture was condensed and the resulting residue was purified by silica gel
tography using a gradient of 0-100% ethyl e in hexanes. The desired product
fractions were combined and concentrated to give 2-((1r,4R)ethoxycyclohexylamino)-
4-((1R,3S)—3-hydroxymethylcyclohexylamino)pyrimidinecarbonitrile (0.356 g, 76 %
yield, 98.0% pure) as a white solid. 1H NMR (400 MHz, DMSO-d6) 8 ppm 8.09 - 8.24 (m,
1H), 7.28 - 7.63 (m, 2H), 4.71 - 4.90 (m, 1H), 4.21 (d, J: 3.51 Hz, 1H), 3.57 - 3.78 (m,
1H), 3.43 (q, J: 7.03 Hz, 2H), 3.11 - 3.23 (m, 1H), 1.78 - 2.02 (m, 4H), 1.48 - 1.74 (m,
5H), 1.16 - 1.47 (m, 6H), 1.11 - 1.16 (m, 4H), 1.08 (t, 3H); MS (ESI) m/z 374.5 [M+1]+.
Example 21: 2-((1r,4R)—4-Eth0xycyclohexylamin0)—4-((1R,3S)
hydroxycyclohexylamin0)pyrimidine—5-carb0nitrile
\/O/,'(1QCN
N N NH
A. 2-Chlor0((1R,3S)hydroxycyclohexylamino)pyrimidine—5-
carbonitrile and 4-chlor0((1R,3S)hydr0xycyclohexylamin0)pyrimidine
carbonitrile. 2,4-Dichloropyrimidinecarbonitrile (900 mg, 5.17 mmol) in anhydrous
ethanol (5 mL) and (1R,3S)—3-amino-cyclohexanol (624 mg, 5.43 mmol; prepared as
described in edron: Asymmetry 15 (2004) 2051—2056) in anhydrous ethanol (5 mL)
were mixed at -60 OC and then DIEA (1.0 g, 7.75 mmol) was added dropwise. The
mixture was stirred at -60 CC for 1 h and then at room temperature ght. Volatile
fractions were removed and the residue was purified on silica gel ng with 9.1%-33%
ethyl acetate in petroleum ether) to give 4-chloro((1R,3S)hydroxycyclohexylamino)-
pyrimidinecarbonitrile (600 mg, 2.38 mmol, yield 46%) as a white solid and 2-chloro
((1R,3S)hydroxycyclohexylamino)pyrimidinecarbonitrile (270 mg, 1.07 mmol, yield
%; 1H NMR (400 MHz, 6) 5 ppm 8.55 (s, 1 H), 8.46 (d, J=7.81 Hz, 1 H), 4.83
(d, J=3.90 Hz, 1 H), 3.95 - 4.11 (m, 1 H), 3.45 - 3.61 (m, 1 H), 1.93 (d, J=11.71 Hz, 1 H),
ATI—25 14175v1
1.60 - 1.84 (m, 3 H), 1.03 - 1.50 (m, 4 H); MS (ESI) m/z 253.2 ) as a white solid.
mmmydflmmmmmgmwmflwwmmmmwnmmpBMbw
B. (1S,3R)(5-(Amin0methyl)pyrimidinylamin0)cyclohexanol. To a
mixture of 2-chloro((1R,3 S)—3-hydroxycyclohexyl-amino)pyrimidine-5 -carbonitrile
(70 mg, 0.277 mmol) and ammonium hydroxide (500 ul, 12.84 mmol) in ethanol (4 mL)
was added Raney nickel (16.26 mg, 0.277 mmol). The resulting mixture was evacuated
and then stirred under a n of hydrogen at atmospheric pressure and t
temperature overnight. Ethanol was removed in vacuo and the remaining residue was
d using reverse-phased preparative HPLC (5-80% acetonitrile + 0.1% TFA in water
+ 0.1% TFA, over 30 min). Fractions containing product were concentrated under reduced
pressure. The resulting residue was redissolved in methanol (5 mL), passed over a Varian
StratoSpheres HCO3 resin SPE tube for TFA l (0.9 mrnol bicarbonate equiv.), and
then concentrated under reduced pressure to afford the title compound as an oil that was
used for NMR purposes only. The regiochemistry was confirmed by the presence of two
ct aromatic peaks in the 1H NMR spectrum and the observation of an NOE signal
between the C5 methylene hydrogens and only one of these aromatic peaks in the NOESY
spectrum. 1H NMR (400 MHz, DMSO-dg) 8 ppm 8.32 (s, 1 H), 7.92 (s, 1 H), 7.32 (d,
J=7.48 Hz, 1 H), 4.67 (d, J=3.87 Hz, 1 H), 3.88 - 4.01 (m, 1 H), 3.59 (s, 2 H), 3.49 (d,
J=3.61 Hz, 1 H), 2.06 - 2.16 (m, 1 H), 1.99 (br. s., 2 H), 1.81 (t, J=13.28 Hz, 2 H), 1.69 (dt,
J=13.35, 3.51 Hz, 1 H), 1.01 - 1.35 (m, 4 H). MS (ESI) m/z 223.5 [M+1]+.
C. 2-((1r,4R)—4-Eth0xycyclohexylamin0)—4-((1R,3S)
hydroxycyclohexylamin0)pyrimidine—5-carbonitrile. A mixture of 2-chloro((1R,3S)-
3-hydroxycyclohexylamino)pyrimidinecarbonitrile (270 mg, 1.07 mmol), (1r,4r)
ethoxycyclohexanamine hydrochloride (289 mg, 1.60 mmol; synthesis described herein)
and cesium carbonate (698 mg, 2.14 mmol) in anhydrous nol (10 mL) was stirred at
80 CC for 1 day and then at 120 CC for 5 h. The mixture was extracted between water and
DCM. The c layer was combined, concentrated and purified on silica gel (eluting
with 9.1%-33% ethyl acetate in petroleum ether) to give 2-((1r,4R)ethoxycyclohexyl-
amino)((1R,3 S)—3-hydroxycyclohexylamino)pyrimidine-5 -carbonitrile (202 mg,
0.56 mmol, yield 52%) as a white . 1H NMR (400 MHz, DMSO-d6): 5 ppm 8.11
(s, 1H), 7.10 (s, 1H), 6.95 (s, 1H), 4.51 (d, J=3.6, 1H), 4.05 (s, 1H), 3.67 (s, 1H), 3.58-3.55
ATI—25 14175v1
(m,1H), 3.47 (q, J=6.8, 2H), 3.24—3.19 (m, 1H), 2.00—1.90 (m, 5H), 1.73 (s, 3H), 1.47—1.25
(m, 8H), 1.10 (t, J=7.2, 3H); MS(ESI): m/Z 359.9 [M+1]+.
e 22: 2-(Cyclohexylamin0)—4-((1R,3S)—3-hydr0xycyclohexylamin0)—
pyrimidinecarb0nitrile
(1 “i”JL /
N N NH
A. 2-(Cyclohexylamin0)—4-((1R,3S)—3-hydr0xycyclohexyl-
amin0)pyrimidinecarb0nitrile. A solution of cyclohexanamine (0.181 mL,
1.583 mmol) in DMSO (5 mL), 2-chloro((1R,3S)hydroxycyclohexylamino)-
pyrimidinecarbonitrile (0.200 g, 0.791 mmol; synthesis described herein) and DIEA
(0.276 mL, 1.583 mmol) was heated at 70 °C overnight. After completion of reaction as
indicated by LCMS and TLC the reaction mixture was allowed to cool to room
ature and trated. The resulting crude was purified by silica gel
chromatography using a gradient of 0% - 70% ethyl acetate (containing 10% ammonia
saturated methanol) in hexanes. The desired product fractions were combined and
concentrated to yield lohexylamino)((1R,3 S)hydroxycyclohexylamino)-
pyrimidinecarbonitrile (0.220 g, 88 % yield, 98.1% pure) as a pale yellow solid.
1H NMR (400 MHz, 6) 5 8.08 - 8.21 (m, 1H), 7.08 - 7.56 (m, 2H), 4.74 (d,
J: 3.90 Hz, 1H), 3.93 - 4.13 (m, 1H), 3.44 - 3.77 (m, 2H), 1.83 - 2.02 (m, 2H), 1.65 - 1.82
(m, 6H), 1.58 (d, J: 14.84 Hz, 1H), 1.32 - 1.45 (m, 2H), 1.08 - 1.30 (m, 7H); MS (ESI)
m/z 316.4 [M+1]+.
Example 23: 4-((1R,3S)—3-Hydr0xycycloheptylamino)—2—((1R,4R)—4-(2,2,2-
trifluor0ethoxy)cyclohexylamin0)pyrimidinecarb0nitrile
Fscvo/n CN
N N NH
H to.
ATI—2514l75vl
A. 4-((1R,3S)Hydroxycycloheptylamin0)(methylthio)pyrimidine—
-carb0nitrile. To a stirring solution of 4-chloro(methylthio)pyrimidinecarbonitrile
(0.4 g, 2.155 mmol) and )—3-aminocycloheptanol hydrochloride (0.428 g,
2.59 mmol; synthesis described herein) in DMF (3 mL) was added DIEA (1.126 mL,
6.46 mmol) and stirred at 60 0C for 1h. LCMS shows the reaction to be completed. The
reaction mixture was cooled to room temperature, and poured into water (50 mL). The
suspension was stirred for five minutes, then d to afford 4-((1R,3S)
hydroxycycloheptylamino)(methylthio)pyrimidinecarbonitrile (0.404 g, 1.451 mmol,
67.4 % yield) as an off-white solid; 1H NMR (DMSO-d6 ,400 MHz): 8 ppm 8.39 (s, 1 H),
8.00 (d, J=7.4 Hz, 1 H), 4.63 (d, J=3.9 Hz, 1 H), 4.21 (br. s., 1 H), 3.74 (td,J=8.5, 4.1 Hz,
1 H), 2.47 (s, 3 H), 1.66 - 1.97 (m, 5 H), 1.35 -1.66 ppm (m, 5 H); MS (ESI) m/z 138.1
[M+1]+.
B. 4-((1R,3S)Hydr0xycycloheptylamin0)((1r,4r)—4-(2,2,2-
trifluoroethoxy)cyclohexylamin0)pyrimidine—5-carb0nitrile. 4-((1R,3S)
Hydroxycycloheptylamino)(methylthio)pyrimidinecarbonitrile (381 mg,
1.369 mmol) was dissolved in NMP (7 mL). At 0 oC, mCPBA (675 mg, 3.01 mmol) was
then added portionwise and the on was stirred at room temp for 90 min. To the
reaction mixture was added )(2,2,2-trifiuoroethoxy)cyclohexanamine (0.405 g,
2.054 mmol) (prepared as described herein) and DIEA (0.956 mL, 5.48 mmol) and stirred
for 5 min at room temp. The on mixture was further stirred at 80 CC for 30 min after
which LCMS showed the tion of the reaction. The reaction mixture was cooled
down to room temperature and diluted with water (30 mL). The e was let standing
at room temperature for 4 h during which the desired product precipitated out. The product
was filtered and the collected solid was washed with water then hexanes and dried under
vacuum to give 4-((1R,3S)—3-hydroxycycloheptylamino)((1R,4R)—4-(2,2,2-
trifiuoroethoxy)-cyclohexylamino)pyrimidinecarbonitrile (0.444 g, 1.039 mmol, 76 %
yield) as a tan solidng NMR (DMSO-d6 ,400 MHZ): 5 ppm 8.08 - 8.22 (m, 1 H), 7.06 -
7.59 (m, 2 H), 4.51 - 4.60 (m, 1 H), 4.01 - 4.24 (m, 1 H), 3.54 - 3.78 (m, 2 H), 3.44 (q,
J=701h,2H)311-3240n,1H)188-205(m,4HL112-1880n,P4HL108pmn
(t, J=7.0 Hz, 3 H); MS (ESI) m/z 374.2 [M+1]+.
ATI—25 14175v1
Example 24: 4-((1R,3S)Hydr0xycycloheptylamin0)((1r,4R)—4-
hydroxycyclohexylamin0)pyrimidinecarb0nitrile
HO/h
)LN/fiA/CN/
N N NH
H 0..
A. ,3S)Hydr0xycycloheptylamin0)(methylsulfonyl)—
pyrimidinecarb0nitrile. 4-((1R,3S)—3-Hydroxycycloheptylamino)
(methylthio)pyrimidinecarbonitrile (457 mg, 1.642 mmol; synthesis described herein)
was dissolved in NMP (10 mL). At 0 oC, mCPBA (736 mg, 3.28 mmol) was then added
portionwise and the reaction was stirred for 2 h at room temperature. LCMS indicated
consumption of the starting material and formation of sulfone ediate. This reaction
was carried onto the next step without further purification. MS (ESI) m/z 311.1 [M+1]+.
B. 4-((1R,3S)Hydr0xycycloheptylamin0)((1r,4R)—4-
hydroxycyclohexylamino)pyrimidine—5-carbonitrile. To the on mixture of the
previous step was added (1r,4r)aminocyclohexanol hydrochloride (0.374 g,
2.465 mmol) and DIEA (1.435 mL, 8.22 mmol). The reaction mixture was stirred at 80 CC
for 1 h and then the reaction mixture was cooled to room temperature. The solvent was
evaporated under reduced re and the resulting residue was purified by flash
tography (0-10% ammonia saturated methanol in DCM) to afford 4-((1R,3S)
ycycloheptylamino)((1r,4R)hydroxycyclohexylamino)pyrimidine
carbonitrile (0.250 g, 0.724 mmol, 44.0 % yield) as a tan solid. 1H NMR (400 MHz,
DMSO-dg) 5 8.07 - 8.21 (m, 1H), 7.05 - 7.55 (m, 2H), 4.52 - 4.59 (m, 2H), 4.02 - 4.25 (m,
1H), 3.51 - 3.79 (m, 2H), 3.35 - 3.42 (m, 1H), 1.75 - 1.97 (m, 8H), 1.39 - 1.70 (m, 6H),
1.14 - 1.31 (m, 4H); MS (ESI) m/z 346.1 [M+1]+.
ATI—25 14175v1
Example 25: 2-(4-Hydr0xybicyclo[2.2.2]octanylamin0)—4-(is0pr0pylamin0)pyrimidine- 5-
carboxamide
HO\@\ )LN/YkNHZ/
A. Dimethyl cyclohexane—1,4-dicarb0xylate. To a d solution of
cyclohexane-l,4-dicarboxylic acid (100 g, 0.58 mol) in anhydrous methanol (800 mL) was
added sulfurous dichloride (208 g, 1.75 mol) at 0 oC. The reaction mixture was d at
room temperature overnight. The solution was then concentrated and the residue was
poured into water. The mixture was extracted with ethyl e (3 x 200 mL). The
combined organic layers were washed with brine, dried over anhydrous sodium sulfate and
filtered. Concentration under reduced pressure afforded dimethyl cyclohexane-l,4-
oxylate (105 g, 0.53 mol, 90.5 % yield), which was used in the next step without
further purification.
B. Dimethyl 1-(2-chlor0ethyl)cyclohexane—1,4-dicarb0xylate. To a
solution of diisopropylamine (88 mL, 0.62 mol) in anhydrous THF (500 mL) was added
n-butyl lithium (240 mL, 0.6 mol, 2.5 M solution in hexane) over 20 minutes at -78 oC.
The e was stirred at 0 CC under nitrogen for 30 min. To a mixture of dimethyl
exane-l,4-dicarboxylate (100 g, 0.5 mol) and thylphosphoramide (360 mL,
2 mol) in anhydrous THF (800 mL) was added lithium diisopropylamine (freshly prepared
above) over 30 min at -40 CC. After stirring for l h at this temperature, l-bromo
chloroethane (42 mL, 0.5 mol) was added over 1 h. The mixture was stirred for 3 h at
-78 CC, then warmed to room temperature and stirred overnight. To the on mixture
was added aqueous hydrochloric acid (3 N, 420 mL) and the mixture was stirred for
min. The solvent was removed by evaporation under d pressure. The s
layer was extracted with ethyl acetate (3 x 200 mL), and the combined extracts were
washed with brine (2 x 300 mL) and dried over sodium sulfate. Concentration under
reduced pressure afforded dimethyl l-(2-chloroethyl)cyclohexane-l,4-dicarboxylate
(l 16 g, 88 % yield), which was used in the next step without further purificatioan NMR
—134—
ATI—2514l75vl
(400 MHz, CDClg) 5 ppm 3.72 (s, 3H), 3.65 (s, 3H), 3.46-3.42 (m, 2H), 2.33-2.21 (m, 3H),
2.05-1.85 (m, 4H), 1.58-1.42 (m, 2H), 1.25-1.15 (m, 2H).
C. yl bicyclo[2.2.2]octane-1,4-dicarb0xylate. To a solution of
diisopropylamine (77 mL, 0.54 mol) in anhydrous THF (500 mL) was added n-butyl
lithium (210 mL, 0.53 mol, 2.5 M solution in hexane) over 20 min at -78 CC. Then the
mixture was stirred at 0 CC under nitrogen for 30 min. To a mixture of dimethyl 1-(2-
chloroethyl)cyclohexane-1,4-dicarboxylate (116 g, 0.44 mol) and
hexamethylphosphoramide (317 ml, 1.7 mol) in anhydrous THF (800 mL) was added
lithium diisopropylamine (freshly prepared above) over 30 min at -40 CC. The e
was d for 2 h at -78 CC and then stirred overnight allowing warming to room
ature. To the reaction mixture was added saturated aqueous ammonium chloride
(200 mL) and the mixture was stirred for 10 min. The solvent was removed by evaporation
under reduced pressure. The aqueous layer was extracted with ethyl acetate (3 x 200 mL).
The combined extracts were washed with brine (2 x 300 mL) and dried over sodium
sulfate. Concentration under reduced pressure gave crude product, which was purified by
silica gel column chromatography (10 % ethyl acetate in petroleum ether) to afford the
title compound (58 g, 0.25 mol, 50 % yield in two steps). 1H NMR (400 MHz, CDClg)
8 ppm 3.65 (s, 6H), 1.81 (s, 12H).
D. 4-(Methoxycarbonyl)bicyclo[2.2.2]octane-l-carboxylic acid. A
solution of dimethyl bicyclo[2.2.2]octane-1,4-dicarboxylate (58.0 g, 0.25 mol) in ol
(600 mL) was heated under reflux. To this solution was added a solution of potassium
hydroxide (9.8 g, 0.175 mol) in methanol (100 mL) and water (12 mL) over 30 minutes.
The reaction mixture was refluxed for 24 h. The solvent was then removed and the residue
was diluted with water. The s solution was ted with ethyl acetate (2 x
200 mL) to recover starting material (22.0 g), and the s layer was acidified to pH 3
by on of hydrochloric acid. A precipitate was formed and extracted with ethyl acetate
(3 x 300 mL). The combined extracted were washed with brine, dried over sodium sulfate
and concentrated to give the titled product (30.0 g, 0.14 mol, 55 % yield).1H NMR
(400 MHz, CDClg) 5 ppm 3.65 (s, 3H), 1.81 (s. 12H); MS (ESI) m/z 211.3 [M-H]'.
E. Methyl 4-br0m0bicyclo[2.2.2]octane-l-carboxylate. To a sion
of 4-(methoxycarbonyl) bicyclo[2.2.2]octane-l-carboxylic acid (11.0 g, 51.8 mmol) in
ATI—25 14175v1
acetone (80 mL) was added 1 M aqueous sodium hydroxide solution (51.8 mL,
51.8 mmol). Then a solution of silver nitrate (8.8 g, 51.9 mol) in water (10 mL) was added.
The formed precipitate was collected by filtration, washed with water, acetone and diethyl
ether and dried in vacuo at 115 0C for 4 h. The obtained (4-(methoxycarbonyl)-
bicyclo[2.2.2]octanecarbonyloxy)silver (15.3 g, 47.9 mmol) was suspended in hexane
(125 mL), then e (7.7 g, 48.1 mmol) was added to the reaction mixture over
s at room temperature. After the addition was complete, the reaction mixture was
stirred at room ature for another 30 minutes. The reaction mixture was filtered to
remove the solid, and the filter cake was washed with hexane (4 x 150 mL). The
combined organic filtrates were washed with saturated sodium bicarbonate (2 x 150 mL)
andbfine(200nfl),andthmidfiedovernwgnemunimflfifie Concennafionundervamunn
gave crude product, which was purified by silica gel column chromatography (5 % ethyl
e in petroleum ether) to afford the title compound (4.2 g, 0.17 mol, 33 % yield in two
steps). 1H NMR (400 MHz, CDClg) 8 ppm 3.64 (s, 3H), 2.27-2.20 (m, 6H), .94 (m.
] F. 4-Hydr0xybicyclo[2.2.2]octane-l-carboxylic acid. Methyl 4-
bromobicyclo [2.2.2]octane-l-carboxylate (17.0 g, 69.0 mol) was refluxed in aqueous
sodium hydroxide on (1500 mL, 1 %) for 24 h. After cooling, the reaction solution
was acidified with hydrochloric acid (6 N, 100 mL) and extracted with diethyl ether (6 x
500 mL). The combined ether layers were dried over magnesium e and concentrated
to afford the title compound (10.4 g, 61.1 mmol, 89 % yield), which was used in the next
step without further purification. MS (ESI) m/z 169.2 [M-H]'.
G. Benzyl 4-hydr0xybicyclo[2.2.2]octan-l-ylcarbamate. To a solution of
4-hydroxybicyclo[2.2.2]octanecarboxylic acid (10.4 g, 61.1 mmol) in dioxane (150 mL)
was added DIEA (11.8 g, 91.5 mmol), diphenyl phosphoryl azide (25 g, 91.5 mmol) and
benzyl alcohol (131 g, 1.22 mol). The mixture was stirred at 80 CC overnight. Then the
reaction was concentrated under reduce pressure to remove e and benzyl alcohol
(100 oC, 2 mm Hg). The residue was purified by silica gel column chromatography (5 %
methanol in DCM) to give the title product (15.4 g, 54 mmol, yield 91%). 1H NMR
(400 MHz, CDClg) 8 ppm 7.35-7.30 (m, 5H), 5.03 (s. 2H), 4.55 (br s, 1H), 2.01-1.95 (m,
6H), 1.77—1.72 (m, 6H); MS (ESI) m/z 276.3 [M+H]+.
ATI—25 14175v1
H. 4-Aminobicyclo[2.2.2]0ctanol hydrochloride. To a solution of
benzyl 4-hydroxybicyclo[2.2.2]octanylcarbamate (14.8 g, 53 mmol) in methanol
(200 mL) was added palladium on charcoal (0.5 g, 10%). The reaction mixture was stirred
at 50 0C under hydrogen here (50 Psi) overnight and filtered through celite. The
filtrate was concentrated and the residue was added to hloric acid in methanol
(10%, 50 mL). The mixture was stirred for 2 h at room temperature. Then the mixture was
concentrated again and THF (20 mL) was added. The mixture was stirred at room
temperature for 1 h and the precipitate was collected and dried to give the title t
(6.7 g, 36 mmol, 70 % yield).1H NMR dg) 8 8.00 (s, 3H), 4.48 (br s,lH) ,1.76-
1.80 (m, 6H), 1.58-1.61 (m, 6H). MS (ESI) m/z 142.1[M+1] +.
I. Ethyl 4-(isopropylamin0)(methylthio)pyrimidine—5-carboxylate. A
mixture of ethyl 4-chloro(methylthio)pyrimidinecarboxylate (10 g, 43.0 mmol),
propanamine (4.21 mL, 49.4 mmol) and DIEA (9.76 mL, 55.9 mmol) in ethanol
(140 mL) was heated at 60 CC overnight. After g to room temperature, the solvent
was concentrated under reduced pressure and water was added. The aqueous phase was
extracted three times with ethyl acetate and the combined organic phases were dried over
magnesium sulfate, d and evaporated to give ethyl 4-(isopropylamino)
(methylthio)pyrimidinecarboxylate (10.10 g, 39.5 mmol, 92 % yield) as a colorless oil.
MS (ESI) m/z 256.1 [M+1]+.
J. 4-(Isopropylamin0)(methylthio)pyrimidine—5-carboxylic acid. In a
round-bottomed flask ethyl 4-(isopropylamino)—2-(methylthio)pyrimidinecarboxylate
(10.97 g, 43.0 mmol) was dissolved in ethanol (150 mL) ed by the addition of
aqueous sodium hydroxide solution (1M, 129 ml, 129 mmol) . The resulting mixture was
stirred overnight at room ature and then the solvent was evaporated under reduced
pressure. Aqueous citric acid solution (2M, 129 ml, 258 mmol) was slowly added and the
resulting mixture was stirred for 0.5 h at room temperature. The suspension was filtered
and the solids were washed twice with water (2 x 50 mL) and then dried in the vacuum
oven at 45 CC overnight to afford propylamino)(methylthio)pyrimidine
ylic acid (8.38 g, 36.9 mmol, 86 % yield); MS (ESI) m/z 228.4 [M+1]+.
K. 4-(Isopropylamin0)(methylthio)pyrimidine—5-carboxamide.
4-(Isopropylamino)(methylthio)pyrimidinecarboxylic acid (8.38 g, 36.9 mmol) and
ATI—25 14175v1
HATU (21.03 g, 55.3 mmol) were combined in a 250 mL bottomed flask followed
by the addition ofDMF (92 mL). After that ammonia hydrochloride (9.86 g, 184 mmol)
and DIEA (32 mL, 184 mmol) were added and the mixture was stirred at room
temperature overnight. The solvent was concentrated under reduced re and water
(150 mL) was added. The resulting suspension was filtered, washed with water and dried
under high vacuum overnight to afford 4-(isopropylamino)(methylthio)pyrimidine
carboxamide (8 g, 35.4 mmol, 96 % yield); MS (ESI) m/z 227.4 [M+1]+.
L. 4-(Isopr0pylamin0)—2-(methylsulfinyl)pyrimidine—5—carboxamide
and 4-(Isopr0pylamin0)—2-(methylsulfonyl)pyrimidinecarboxamide. To a solution
of 4-(isopropylamino)(methylthio)pyrimidinecarboxamide (641 mg, 2.8 mmol) in
NMP (6 mL) was added mCPBA (852 mg, 4.2 mmol, 85% purity) at 0 CC. The reaction
was stirred for 1 h at room temperature. Then water (25 mL) was added, which dissolved
the suspension for a short time only to form another thick precipitate, which was filtered
off The resulting filtrate was concentrated under reduced re to afford the title
mixture in NMP, which was used in the next step without further purification. MS (ESI)
m/z 2433,2592 [M+1]+.
M. 2-(4-Hydr0xybicyclo [2.2.2] octanylamin0)—4-(is0propylamin0)-
pyrimidine— 5-carb0xamide. To the solution of 4-(isopropylamino)(methylsulfinyl)-
pyrimidine carboxamide and 4-(isopropylamino)(methylsulfonyl)pyrimidine
amide in NMP (from previous step, 2.8 mmol), 4-aminobicyclo[2.2.2]octanol
hydrochloride (500 mg, 2.8 mmol), DIEA (1.1 g, 8.4 mmol) were added and heated at
100 0C for 3 d. The resulting e was concentrated under reduced pressure and the
residue was purified by ative thin layer chromatography to afford the final product
(74.1 mg, 8.2 % . 1H NMR (DMSO-dg) 8 ppm 8.88 (br s, 1H), 8.31 (s, 1H), 7.5-6.5
(br s, 2H), 5.76 (s, 1H), 4.25 (s, 1H), 4.11 (brs, 1H), 2.05-1.97 (m, 6H), 1.61-1.54 (m, 6H),
1.24-1.12(m, 6H); MS (ESI) m/z 320.2 [M+H]+; Purity = 96.5 % at 214 nm, Purity =
97.7 % at 254 nm.
ATI—2514175v1
Example 26: 4-(tert-Butylamin0)—2-((1r,4r)—4-hydr0xycyclohexylamin0)pyrimidine
carboxamide
HO/“Q [VI/\f'kNHZ
A. Ethyl 4-(tert-butylamin0)(methylthi0)pyrimidine—5-carb0xylate.
A mixture of ethyl 4-chloro(methylthio)pyrimidinecarboxylate (3 g, 12.89 mmol),
2-methylpropanamine (1.565 mL, 14.83 mmol) and DIEA (2.93 mL, 16.76 mmol) in
ethanol (20 mL) was heated at 60 CC overnight. After cooling to room temperature, the
solvent was concentrated under reduced pressure and water was added. The aqueous phase
was extracted three times with ethyl e and the combined organic phases were dried
over anhydrous magnesium sulfate, filtered and evaporated to give ethyl 4-(tert-
butylamino)(methylthio)pyrimidinecarboxylate (3.20 g, 11.86 mmol, 92% yield) as a
ess oil. MS (ESI) m/z 269.5 [M+1]+.
B. 4-(tert—Butylamin0)(methylthi0)pyrimidine—5-carb0xylic acid. In
a round-bottomed flask ethyl 4-(tert-butylamino)(methylthio)pyrimidinecarboxylate
(3.2 g, 11.88 mmol) was dissolved in ethanol (40 mL) followed by the addition of 1M
s sodium ide solution (35.6 mL, 35.6 mmol) . The resulting mixture was
stirred overnight at room temperature and then the solvent was ated under reduced
re. After that 2M s citric acid solution (35.6 mL, 71.3 mmol) was slowly
added and the resulting mixture was stirred for 0.5 h at room temperature. The suspension
was filtered and the solids were washed twice with water (2 x 50 mL) and then dried in a
vacuum oven at 45 °C overnight to afford 4-(tert-butylamino)(methylthio)pyrimidine
carboxylic acid (2.83 g, 11.73 mmol, 99% yield). MS (ESI) m/z 242.3 [M+1]+.
C. 4-(tert-Butylamin0)(methylthi0)pyrimidinecarboxamide.
4-(tert-Butylamino)—2-(methylthio)pyrimidinecarboxylic acid (2.83 g, 11.73 mmol) and
[1 ,2,3 ]triazolo [4,5 -b]pyridin-3 -yl)- 1 ,1 ,3 ,3 -tetramethylisouronium hexafluoro-
phosphate(V) (6.69 g, 17.59 mmol) were combined in a 250 mL round-bottomed flask
followed by the addition ofDMF (29 mL). After that ammonia hydrochloride (3.14 g,
58.6 mmol) and DIEA (10.21 mL, 58.6 mmol) were added and the mixture was stirred at
ATI—25 14175v1
room temperature overnight. The solvent was concentrated under reduced re and
water (150 mL) was added. The resulting suspension was filtered, washed with water and
dried under high vacuum overnight to afford 4-(tert-butylamino)(methylthio)-
pyrimidinecarboxamide (2.54 g, 10.57 mmol, 90% yield). MS (ESI) m/z 241.2
[M+1]+.
] D. 4-(tert-Butylamin0)—2-(methylsulfonyl)pyrimidine—5-carb0xamide.
To a ng solution of 4-(tert—butylamino)(methylthio)pyrimidinecarboxamide
(0.6 g, 2.497 mmol) in NMP (5 mL) was added mCPBA (0.839 g, 3.74 mmol) at 0 oC and
stirring was continued at room temperature for 1h. LCMS showed te conversion to
desired product. The reaction mixture was carried on to next reaction without further
purification. MS (ESI) m/z 273.2 [M+1]+.
E. t-Butylamin0)—2-((1r,4r)—4-hydroxycyclohexylamino)—
pyrimidine—5-carb0xamide. To the solution of 4-(tert-butylamino)(methylsulfonyl)-
pyrimidinecarboxamide from the previous step was added DIEA (2.181 mL,
12.49 mmol) and (1r,4r)aminocyclohexanol hydrochloride (0.568 g, 3.75 mmol), and
the reaction was stirred at 90 0C for 16 h. The solvent was evaporated under reduced
pressure and the resulting residue was purified using e-phased preparative HPLC
(0-50% itrile + 0.1% TFA in water + 0.1% TFA, over 30 min). Fractions containing
product were concentrated under reduced pressure. The resulting residue was redissolved
in a methanol (5 mL), passed over an Varian StratoSpheres HCO3 resin SPE tube for TFA
removal (0.9 mmol bicarbonate equiv.), and then concentrated under reduced pressure to
afford 4-(tert-butylamino)((1r,4r)hydroxycyclohexylamino)pyrimidine
carboxamide (0.350 g, 1.139 mmol, 45.6% yield). 1H NMR (DMSO-d6 ,400 MHz) 5 ppm
0.82 - 0.88 (m, 1 H) 1.14 - 1.30 (m, 5 H) 1.42 (s, 9 H) 1.85 (d, J=4.30 Hz, 4 H) 3.38 (br. s,
1 H) 3.59 (d, J=7.42 Hz, 1 H) 4.54 (s, 1 H) 7.02 (d, J=7.81 Hz, 1 H) 8.32 (s, 1 H) 9.18 (s,
1 H); MS(ESI): m/Z 308.1 [M+1]+.
—140—
ATI—25 14175v1
Example 27 : 4-((1R,3R,4R)—3-Hydr0xymethylcyclohexylamin0)
(isopr0pylamin0)pyrimidine—5-carboxamide
A )L /N \ NH2
N N NH
_ OH
A. 4-((1R,3R,4R)—3-Hydr0xymethylcyclohexylamin0)
(methylthi0)pyrimidine—5-carb0nitrile. To a stirring solution of 4-chloro(methylthio)-
pyrimidinecarbonitrile (310 mg, 1.670 mmol) and (1R,2R,5R)aminomethylcyclo-
hexanol hydrochloride (304 mg, 1.837 mmol; synthesis described herein) in DMF
(2.4 mL) was added DIEA (0.873 mL, 5.01 mmol). The resulting mixture was d at
60 0C for 2 h. LCMS showed the reaction to be complete. The solvent was evaporated
under reduced pressure and the residue diluted with 150 mL ethyl e and 50 mL
water. The layers were separated and the aqueous phase was extracted with 75 mL ethyl
acetate. The combined ethyl acetate layers were washed with brine (2 x 50 mL), dried
over anhydrous magnesium sulfate, filtered and concentrated to an oil that solidified upon
standing to afford 4-((1R,3R,4R)hydroxymethylcyclohexylamino)
(methylthio)pyrimidinecarbonitrile (418 mg, 1.503 mmol, 90% yield). MS (ESI) m/z
279.3 [M+1]+.
B. 4-((1R,3R,4R)—3-Hydr0xymethylcyclohexylamin0)
(methylsulfonyl)pyrimidine—5-carb0nitrile. To a solution of 4-((1R,3R,4R)hydroxy-
4-methylcyclohexylamino)(methylthio)pyrimidinecarbonitrile (400 mg, 1.437 mmol)
in NMP (5 mL) at 0 0C was added mCPBA (805 mg, 3.59 mmol) and the on was
stirred for 3 h at room temperature. The resulting solution was used ly in the next
step without further purification. MS (ESI) m/z 311.4 [M+1]+
] C. 4-((1R,3R,4R)—3-Hydr0xymethylcyclohexylamin0)
(isopropylamin0)pyrimidine—5-carb0nitrile. To the on of 4-((1R,3R,4R)—3-
hydroxymethylcyclohexylamino)(methylsulfonyl)pyrimidinecarbonitrile (446 mg,
1.437 mmol) from the preVious step was added propanamine (0.367 mL, 4.31 mmol)
—141—
ATI—25 14175V1
WO 45569
and DIEA (1.004 mL, 5.75 mmol). The reaction was stirred at 80 CC for 4 h and then
allowed to cool to ambient temperature. The solvent was ated under reduced
pressure and the residue was purified by silica gel chromatography (0-90% ethyl acetate in
hexanes) to afford 4-((1R,3R,4R)hydroxymethylcyclohexylamino)
(isopropylamino)pyrimidinecarbonitrile (381 mg, 1.317 mmol, 92% yield). MS (ESI)
m/z 290.2 [M+1]+
D. 4-((1R,3R,4R)—3-Hydr0xymethylcyclohexylamin0)
(isopr0pylamin0)pyrimidine—5-carb0xamide. 4-((1R,3R,4R)—3-Hydroxymethylcyclohexylamino
)(isopropylamino)pyrimidinecarbonitrile (0.38 g, 1.313 mmol) was
dissolved in DMSO (5 mL). To this solution was added a 50% aqueous sodium hydroxide
solution (0.103 ml, 1.970 mmol) and a 30% s hydrogen peroxide solution
(0.101 ml, 0.985 mol) at room temperature. Then the reaction mixture was d at
50 CC for 1 h. After that, the reaction mixture was poured into ice water (15 mL) and the
resulting e was stirred for 1 h. The ing precipitate was filtered and washed
with water to afford 4-((1R,3R,4R)—3-hydroxymethylcyclohexylamino)
(isopropylamino)pyrimidinecarboxamide (0.210 g, 0.683 mmol, 52% yield). 1H NMR
(DMSO-d6 ,400 MHz) 8 ppm 0.94 (d, J=6.40 Hz, 4 H) 1.12 (d, J=5.91 Hz, 9 H) 1.65 (dd,
J=13.29, 2.95 Hz, 1 H) 1.92 (br. s., 1 H) 2.15 (br. s., 1 H) 2.97 (br. s., 1 H) 3.81 - 4.14 (m,
2 H) 4.55 (d, J=5.41 Hz, 1 H) 6.70 - 7.02 (m, 1 H) 8.34 (br. s., 1 H) 8.92 (br. s., 1 H);
MS (ESI) m/z 308.0 [M+1]+.
Example 28: 2-(Bicyclo[1.1.1]pentan-l-ylamino)—4-((1R,3R,4R)—3-hydr0xy
methylcyclohexylamin0)pyrimidine—5-carboxamide
& JL /N \ NH2
N N NH
. OH
A. 2-(Bicyclo[1.1.1]pentan-l-ylamino)—4-((1R,3R,4R)—3-hydr0xy
methylcyclohexylamin0)pyrimidinecarb0nitrile. To a solution of 4-((1R,3R,4R)
hydroxymethylcyclohexylamino)(methylsulfonyl)pyrimidinecarbonitrile (446 mg,
ATI—2514175v1
1.437 mmol; synthesis described herein) in NMP (5 mL) was added bicyclo[1.1.1]pentan-
1-amine hydrochloride (258 mg, 2.155 mmol; prepared according to Org. Lett., 13(17):
4746-4748 (2011)) and DIEA (1.255 mL, 7.18 mmol). The reaction was stirred at 80 °C
for 4 h and then allowed to cool to ambient ature. The solvent was ated under
reduced pressure and the residue was d by flash chromatography (0-90% ethyl
acetate in hexanes) to afford 2-(bicyclo[1.1.1]pentanylamino)((1R,3R,4R)
hydroxymethylcyclohexylamino)pyrimidinecarbonitrile (381 mg, 1.216 mmol, 85%
yield). MS(ESI): m/Z 314.0 .
B. 2-(Bicyclo[1.1.1]pentanylamin0)—4-((1R,3R,4R)—3-hydr0xy
methylcyclohexylamin0)pyrimidine—5-carb0xamide. 2-(Bicyclo[1.1.1]pentan
ylamino)((1R,3R,4R)hydroxymethylcyclohexylamino)pyrimidinecarbonitrile
(0.38 g, 1.213 mmol) was dissolved in DMSO (26.9 mL) and to this solution was added a
50% aqueous sodium hydroxide solution (0.097 ml, 1.213 mmol) and a 30% aqueous
hydrogen peroxide solution 0.137 mL, 1.213 mmol) at room temperature. Then the
reaction e was stirred at 50 0C for 1 h. The reaction was cooled to room ature
and it was poured into 50 mL of ice water. The white precipitate was collected on filter
paper and was washed twice with water. The precipitate was dried to give 2-
(bicyclo[1 . 1 . 1]pentanylamino)((1R,3R,4R)hydroxymethylcyclohexylamino)-
pyrimidinecarboxamide (0.269 g, 0.812 mmol, 67% yield). 1H NMR (DMSO-d6,
400 MHz): 8 ppm 0.94 (d, J=6.25 Hz, 3 H) 1.10 - 1.26 (m, 3 H) 1.68 (d, J=10.54 Hz, 1 H)
1.92 (d, J=10.93 Hz, 1 H) 2.06 (s, 6 H) 2.17 (d, J=9.76 Hz, 1 H) 2.46 (s, 1 H) 2.98 (br. s.,
1 H) 3.82 - 3.95 (m, 1 H) 4.63 (br. s., 1 H) 7.16 (br. s., 1 H) 7.77 (br. s., 1 H) 8.11 (br. s.,
1 H) 8.33 (s, 1 H) 9.24 (br. s., 1 H); MS(ESI): m/z 332.3 [M+1]+.
—143—
ATI—25 14175v1
Example 29: 4-((2-Cyclopropylpr0panyl)amin0)—2-(((1r,4r)—4-
hydroxycyclohexyl)amin0)pyrimidinecarb0xamide
“00 1*)L /
N N NH
H 2%
A. 4-((2-Cyclopropylpropanyl)amin0)(methylthi0)pyrimidine
carbonitrile. To a solution of 4-chloro(methylthio)pyrimidinecarbonitrile (750 mg,
4.0 mmol) in DMF (8 mL) was added 2-cyclopropylpropanamine (400 mg, 4.0 mmol) and
DIEA (1560 mg, 12.0 mmol). The resulting mixture was d at 60 0C for 2 h. Water was
added and the mixture was ted with ethyl acetate. The combined organic layers were
washed with brine, dried over anhydrous sodium sulfate and filtered. The filtrate was
concentrated to give the crude product, which was purified by silica gel column chromatography
(0-30% ethyl acetate in eum ether) to afford the title compound (665 mg, 2.68 mmol, 66%
yield) as a white solid. MS (ESI) m/z = 249.2 [M+H] +.
B. 4-((2-Cyclopr0pylpr0panyl)amin0)(methylthi0)pyrimidine
carboxamide. To a stirring solution of 4-((2-cyclopropylpropanyl)amino)
(methylthio)pyrimidinecarbonitrile (665 mg, 2.68 mmol) in DMSO (4 mL) was added
aqueous hydrogen peroxide solution (0.162 mL, 30%) and aqueous sodium ide (2.2 mL,
6 mol/L) solution. The resulting mixture was stirred at 50 0C for 12 min, and then water was
added. The d product was filtered and dried in vacuo to give the crude product (392 mg,
1.47 mmol, 55% yield) as a white solid. MS (ESI) m/z 267.3 [M+H] +.
[003 85] C. 4-((2-Cyclopropylpr0panyl)amin0)—2-(methylsulfinyl)pyrimidine—5-
carboxamide and 4-((2-cyclopropylpropan-Z-yl)amin0)(methylsulfonyl)pyrimidine
carboxamide. To a cooled (0 0C) solution of 4-((2-cyclopropylpropanyl)amino)
(methylthio)pyrimidine amide (390 mg, 1.46 mmol) in THF (6 mL) was added
mCPBA (447 mg, 2.2 mmol) portion-wise. The reaction mixture was stirred for 0.5 h at 0 0C.
The mixture was concentrated under vacuum and purified by silica gel column chromatography
(2.5%-10% DCM in methanol) to give a mixture of 4-((2-cyclopropylpropanyl)amino)
(methylsulfinyl)pyrimidinecarboxamide and 4-((2-cyclopropylpropanyl)amino)
ATI—25 14175v1
(methylsulfonyl)pyrimidinecarboxamide (382 mg, 1.32 mmol, 90% yield). MS (ESI) m/z
299.1 [M+H] [and 283.1 [M+H]+.
D. 4-((2-Cyclopr0pylpr0panyl)amin0)(((1r,4r)—4-hydr0xycyclohexyl)—
amin0)pyrimidine—5-carb0xamide. A mixture of cyclopropylpropanyl)amino)—2-
(methylsulfinyl)pyrimidinecarboxamide, 4-((2-cyclopropylpropanyl)amino)
(methylsulfonyl)pyrimidinecarboxamide (191 mg, 0.66 mmol), (1r,4r)aminocyclohexanol
(114 mg, 0.99 mmol), DIEA (256 g, 1.98 mmol) and NMP (5 mL) were combined and heated at
100 0C overnight. The resulting mixture was concentrated and the residue was purified by HPLC
(5-95% acetonitrile in water) to afford the title compound (129.5 mg, 0.39 mmol, 59% .
1H NMR (400 MHz, CDClg): 8 ppm 8.96 (s, 1H), 8.09 (s, 1H ), 5.38 (s, 2H), 4.98-4.96 (m, 1H),
3.79-3.77 (m, 1H), 3.69-3.67 (m, 1H), 2.14-2.11 (d, J=11.6Hz, 2H), 2.04-2.01 (m, 2H), 1.48-1.41
(m, 4H), 1.38 (s, 6H), 1.32-1.22 (m, 2H), 0.48-0.39 (m, 4H); MS (ESI) m/z 334.3 [M+H] +.
e 30: 4-Cyclobutylamin0(((1r,4r)—4—methoxycyclohexyl)amin0)pyrimidine-
-carb0xamide
/O, ' N \ NH2
)L /
N N NH
H <>
A. 4-(Cyclobutylamin0)(methylthi0)pyrimidine—5-carbonitrile. To a
ng solution of 4-chloro(methylthio)pyrimidinecarbonitrile (2 g, 10.8 mmol) in DMF
(10 mL) was added DIEA (4.2 g, 32.4 mmol) and cyclobutanamine (2.3 g, 32.4 mol) at 0 CC.
The resulting mixture was stirred at 60 CC for 2 h. The on mixture was poured into
saturated sodium chloride, and extracted with ethyl acetate three times. The ed organic
layers were dried over anhydrous sodium sulfate, filtered and concentrated to afford the crude
product. The crude product was purified Via silica gel column chromatography (10% ethyl
acetate in petroleum ether) to get the desired t as a white solid (1.7 g, 7.7 mmol, 71%
yield). MS (ESI) m/Z = 221 .2[M+H] +.
B. 4-(Cyclobutylamino)—2-(methylsulfinyl)pyrimidine—5-carb0nitrile and 4-
(cyclobutylamin0)(methylsulfonyl)pyrimidine—5-carb0nitrile. 4-(Cyclobutylamino)
(methylthio)pyrimidinecarbonitrile (1.7 g, 7.7 mmol) was dissolved in DCM (30 mL) and
—145—
ATI—25 14175V1
cooled to 0 0C. To this mixture, mCPBA (4.6 g, 23 mmol) was added portionwise and the
reaction was stirred for 1 h. The resulting mixture was poured into a ted aqueous sodium
bicarbonate solution. The aqueous layer was extracted three times with DCM. The combined
organic layers were dried over anhydrous sodium sulfate, filtered and concentrated to afford a
mixture of 4-(cyclobutyl-amino)(methylsulf1nyl)pyrimidinecarbonitrile and
4-(cyclobutylamino) (methyl-sulfonyl)pyrimidinecarbonitrile as a yellow thick oil (1.6 g
crude), which was used in the next step without fithher purification. MS (ESI) m/z =237.2/253.2
[M+H] +.
C. lobutylamin0)(((1r,4r)—4-meth0xycyclohexyl)amin0)pyrimidine—
-carb0nitrile. To the mixture of 4-(cyclobutylamino)(methylsulf1nyl)pyrimidine
carbonitrile and 4-(cyclobutylamino)(methylsulfonyl)pyrimidinecarbonitrile (1.6 g, crude)
from the previous step was added (1r,4r)methoxycyclohexanamine (0.96 g, 7.4 mmol),
1,4-dioxane (100 mL) and DIEA (4.3 g, 33.4 mmol). The resulting mixture was d at 100 CC
overnight. After removal of all volatile solvents under reduced pressure, the residue was purified
by silica gel column chromatography (33.3% ethyl acetate in petroleum ether) to provide the
desired product as a white solid (1.3 g, 57% . MS (ESI) m/z =302.1 [M+H] +.
D. 4-(Cyclobutylamin0)(((1r,4r)—4-meth0xycyclohexyl)amin0)pyrimidine—
-carb0xamide. To the mixture of lobutylamino)(((1r,4r)methoxycyclohexyl)-
amino)pyrimidinecarbonitrile (700 mg, 2.3 mmol) in DMSO (8 mL) was added aqueous
en peroxide solution (1.3 g, 30%, 11.5 mmol), and then aqueous sodium hydroxide
solution (2 mL, 6 mol/L, 11.5 mmol). The mixture was d at 50 CC for 0.5 h, then water
(30 mL) was added to the reaction mixture, the product was collected and dried to give the
desired compound (400 mg, 1.25 mmol, 54% yield). 1H NMR (400 MHz, CDClg) 8 ppm 8.76
(s, 1H), 8.11 (s, 1H), 5.46 (s, 2H), 5.01 (s, 1H), 4.51-4.45 (m, 1H), 3.83-3.81 (m, 1H), 3.36 (s,
3H), 3.21-3.16 (m, 1H), 2.40-2.33 (m, 2H), 2.15-1.96 (m, 6H), 1.78 (s, 2H), 1.43-1.20 (m, 4H);
MS (ESI) m/Z = 319.9 [M+H] +).
ATI—25 14175v1
Example 31: 4-(Cyclobutylamin0)—2-(((1r,4r)—4-hydroxycyclohexyl)amin0)-
pyrimidine-S-carboxamide
A. 4-(Cyclobutylamin0)(methylsulfinyl)pyrimidinecarb0nitrile and 4-
(cyclobutylamin0)(methylsulfonyl)pyrimidinecarb0nitrile. 4-(Cyclobutylamino)
(methylthio)pyrimidinecarbonitrile (889 mg, 4.04 mmol; synthesis described herein) was
ved in DCM (20 mL) and cooled to 0 0C. To this mixture, mCPBA (2.1 g, 12.1 mmol) was
added portion-wise and the reaction was stirred for 1 h. The resulting mixture was poured into a
saturated aqueous sodium bicarbonate solution. The aqueous layer was extracted three times with
DCM. The combined organic layers were dried over anhydrous sodium sulfate, filtered and
concentrated to afford a e of 4-(cyclobutylamino)(methylsulf1nyl)pyrimidine
carbonitrile and 4-(cyclobutylamino)(methylsulfonyl)pyrimidinecarbonitrile as a yellow
thick oil (893 mg crude), which was used in the next step without r purification. MS (ESI)
m/Z =237.2/253.2 [M+H] +.
B. 4-(Cyclobutylamin0)(((1r,4r)—4-hydr0xycyclohexyl)amin0)pyrimidine—
-carb0nitrile. To the mixture of 4-(cyclobutylamino)(methylsulf1nyl)pyrimidine
itrile and 4-(cyclobutylamino)(methylsulfonyl)pyrimidinecarbonitrile (424 mg,
about 1.93 mmol) from the previous step was added (1r,4r)aminocyclohexanol (244 mg,
2.12 mmol), 1,4-dioxane (50 mL) and DIEA (1.2 g, 9.65 mmol). The resulting mixture was
stirred at 100 OC overnight. After removal of all volatile solvents under reduced pressure, the
residue was purified by silica gel column chromatography (50% ethyl acetate in petroleum ether)
to get the desired product as a white solid (305 mg, 1.06 mmol, 55.4% . MS (ESI) m/z
=288.2 [M+H] f
] C. lobutylamin0)—2-(((1r,4r)—4-hydr0xycyclohexyl)amin0)pyrimidine—
-carb0xamide. To a solution of lobutylamino)(((1r,4r)hydroxycyclohexyl)-
amino)pyrimidinecarbonitrile (305 mg, 1.06 mmol) in DMSO (6 mL) was added aqueous
hydrogen peroxide solution (600.1 mg, 30%, 5.3 mmol), and then aqueous sodium hydroxide
—147—
ATI—25 14175v1
solution (1 mL, 6 mol/L, 5.3 mmol). The mixture was stirred at 50 CC for 0.5 h, and then water
was added and the mixture was extracted with ethyl e. The combined organic layers were
washed with brine, dried over anhydrous sodium sulfate and filtered. Concentration under
reduced pressure gave the crude product, which was purified by silica gel column
chromatography (0-10% methanol in DCM) to afford the title compound (248.2 mg, 0.81 mmol,
76.6% yield). 1H NMR (400 MHz, CDClg) 8 ppm 8.74 (s, 1H), 8.12 (s, 1H), 5.46 (brs, 2H), 5.07-
4.96 (m, 1H), 4.53-4.43 (m, 1H), 3.80-3.79 (m, 1H), 3.70-3.65 (m, 1H), 2.40-2.34 (m, 2H), 2.15-
1.97 (m, 6H), 1.91-1.88 (s, 2H), 1.55-1.19 (m, 4H); MS (ESI) m/Z = 306.0 [M+H]+.
Example 32: 2-(tert-Butylamin0)—4-((1R,3R,4R)—3-hydr0xymethylcyclohexylamin0)-
dine-S--carb0xamide
9N1?“
£1...
A. (R)—tert—Butyl 4-methylcyclohex—3-enylcarbamate and (S)-tert-butyl
4-methylcyclohexenylcarbamate. To a stirring solution of a mixture of (R)
methylcyclohexenamine and (S)—4-methylcyclohexenamine (40.2973 g, 359 mmol;
prepared as described in J. Org. Chem. 1992, 5 7, 3454 — 3462) in ethyl ether (498 mL) at
0 0C was added a solution of di-tert-butyl-dicarbonate (81 g, 362 mmol) in ethyl ether
(100 mL) dropwise over 30 min. The reaction was stirred at 0 0C for 1 h, allowed to
slowly reach room ature over 4 h, and then stirred at room temperature for 16 h.
The reaction mixture was concentrated under reduced re to afford the crude residue.
The crude residue was ated with s (500 mL), stirred for 5 min at 0 0C, then
filtered and washed with hexanes (50 mL) to afford a first crop of product (~55 g). The
filtrate was concentrated under d pressure, triturated with hexanes and the
precipitate was filtered to afford a second crop of product (~15 g). This was repeated to
afford a third crop of product (4.25 g). The three crops were combined to afford a mixture
of (R)-tert-butyl 4-methylcyclohexenylcarbamate and (S)-tert—butyl 4-methylcyclohex-
carbamate (74.25 g, 351 mmol, 98% yield) as a white solid. 1H NMR (400 MHz,
ATI—25 14175V1
W0 45569
DMSO-d6) 8 ppm 6.72 (d, J=7.42 Hz, 1 H), 5.26 (br. s., 1 H), 3.35 - 3.47 (m, 1 H), 1.93
(br. s., 5 H), 1.60 (s, 3 H), 1.32 - 1.44 (m, 10 H).
] B. tert-Butyl (1R,3R,4R)—3-hydr0xymethylcyclohexylcarbamate,
tert-butyl (1R,3S,4S)hydr0xymethylcyclohexylcarbamate, tert—butyl
(1 S,3R,4R)—3-hydr0xymethylcyclohexylcarbamate, tert—butyl (1 S,3S,4S)—3-
hydroxymethylcyclohexylcarbamate. To a ng solution of a mixture of rt-
butyl 4-methylcyclohexenylcarbamate and (S)-tert-butyl 4-methylcyclohex
enylcarbamate (13 g, 61.6 mmol) in THF (780 mL) at 0 CC was added 1 M borane THF
complex (277 mL, 277 mmol). The solution was stirred at 0 oC, allowed to reach room
temperature over 1 h, and then stirred at room temperature for 20 h. The reaction was
quenched very slowly with water (330 mL), diluted with ethanol (326 mL) and basified
with 5 N aqueous sodium hydroxide (308 mL, 1.54 mol). To the stirring biphasic mixture
was slowly added 30% hydrogen peroxide (316 mL, 3.08 mol) and the resulting mixture
was heated to 45 0C for 20 h. The crude reaction was quenched with saturated aqueous
sodium sulfite (573 mL) and extracted with ethyl acetate (4 x 1 L). The combined organic
layers were washed with brine, dried over sodium sulfate, filtered, and trated under
reduced pressure to give the crude product. The above reaction was repeated 5 times
(using 3 x 13 g and 2 x 11 g starting material). The combined crude products from all 6
ons were purified by silica gel chromatography % ethyl acetate in hexanes).
The t containing fractions were combined and concentrated under reduced pressure
to afford a mixture of tert-butyl (1R,3R,4R)hydroxymethylcyclohexylcarbamate,
tert-butyl (1 R,3 S ,4S)-3 -hydroxymethylcyclohexyl-carbamate, tert-butyl (1 S,3R,4R)-3 -
hydroxymethylcyclohexylcarbamate, and tert-butyl (1 S,3S,4S)hydroxy
methylcyclohexylcarbamate (55 g, 242 mmol, 72% yield) as a solid. The 4 constituent
stereoisomers were separated by ative chiral SFC utilizing multiple injections over a
series of 3 separate columns. First column: ChiralPak AD-H, 250><50 mm I.D., isocratic
% methanol in CO2. Second column: ChiralPak AD-H, 0 mm I.D., isocratic 25%
methanol in CO2. Third column: Pak AD-H, 250><50 mm I.D., isocratic 15%
ethanol in C02. The separated isomers were characterized on an analytical scale ChiralPak
AD-3 column, 150><4.6 mm I.D., 5-40% methanol (with 0.05% diethylamine) in CO2 (15
min run time) and labeled as ediate 1 to Intermediate 4.
—149—
ATI—25 14175v1
2012/034349
ediate 1: 2.0 g (8.72 mmol, 3.6% yield fiom SFC purification).
Retention time: 4.77 min. MS (ESI) m/z 252.1 [M + 23]+.
Intermediate 2: 1.5 g (6.54 mmol, 2.7% yield from SFC purification).
Retention time: 5.08 min. MS (ESI) m/z 252.1 [M + 23]+.
ediate 3: 16.0 g (69.78 mmol, 29.1% yield from SFC purification).
Retention time: 5.48 min. 1H NMR (400 MHz, DMSO-d6) 5 ppm 6.64 - 6.86 (m, 1 H),
4.43 - 4.60 (m, 1 H), 3.10 - 3.29 (m, 1 H), 2.81 - 2.96 (m, 1 H), 1.84 - 2.01 (m, 1 H), 1.49 -
1.72 (m, 2 H), 1.37 (s, 9 H), 0.98 - 1.14 (m, 3 H), 0.76 - 0.96 (m, 4 H). MS (ESI) m/z
252.1 [M + 23]+.
Intermediate 4: 18.5 g (80.68 mmol, 33.6% yield from SFC purification).
Retention time: 7.79 min. MS (ESI) m/z 252.1 [M + 23]+.
A small le X-ray crystal structure was solved for Intermediate 3 and
the structure was demonstrated to be tert-butyl (1R,3R,4R)—3-hydr0xy
methylcyclohexylcarbamate. The X-ray structure was solved as follows. Single crystal
X-ray diffraction studies were carried out on a Bruker Kappa APEX CCD diffractometer
equipped with Cu Ka radiation (1 = 1.5478). Crystals of the subject compound were
grown by vapor diffilsion of hexanes into a hexanes/THF solution. A 0.21 x 0.05 x
0.03 mm colorless needle was mounted on a Cryoloop with ne oil. Data were
ted in a en gas stream at 120(2) K using (I) and as scans. Crystal-to-detector
distance was 60 mm using variable exposure time (2s-20s) depending on 0 with a scan
width of 1.00. Data tion was 97.0% complete to 68.000 in 6’. A total of 9000
reflections were collected covering the indices, -33<=h<=32, -31<=k<=30, -6<=l<=5.
2554 reflections were found to be symmetry independent, with a Rint of 0.0602. Indexing
and unit cell refinement indicated a rhombohedral, hexagonal lattice. The space group was
found to be R3. The data were integrated using the Bruker SAINT software m and
scaled using the SADABS software program. Solution by direct methods (SHELXS)
produced a complete phasing model consistent with the structure of tert-butyl
(1R,3R,4R)—3-hydr0xymethylcyclohexylcarbamate.
All non-hydrogen atoms were refined anisotropically by atrix least-
squares (SHELXL-97). All hydrogen atoms were placed using a riding model. Their
ATI—2514175v1
positions were constrained relative to their parent atom using the appropriate HFIX
command in SHELXL-97.
C. (1R,2R,5R)—5-Amino-Z-methylcyclohexanol hydrochloride. To
vigorously ng ol (149 mL) at 0 0C was added acetyl chloride (15.87 mL,
223 mmol) and the resulting mixture stirred for 10 min. To this solution was added tert-
butyl (1R,3R,4R)hydroxymethylcyclohexylcarbamate (17.08 g, 74.5 mmol) and the
mixture was stirred for 22 h at room temperature. The crude reaction was concentrated
and then triturated with ethyl ether (2 x 300 mL) to afford (1R,2R,5R)—5-amino
methylcyclohexanol hydrochloride (12.2 g, 73.6 mmol, 99% yield) as a white solid.
1H NMR (400 MHz, DMSO-d6) 8 ppm 8.02 (br. s., 3 H), 4.77 (d, J=5.86 Hz, 1 H), 2.85 -
3.10 (m, 2 H), 2.03 - 2.21 (m, 1 H), 1.83 (d, J=11.71 Hz, 1 H), 1.65 (dd, J=13.47, 3.32 Hz,
1 H), 1.24 (q, J=11.58 Hz, 2 H), 1.12 (dd, J=6.05, 3.32 Hz, 1 H), 0.82 - 1.03 (m, 4 H).
D. 5-Br0m0-N-tert-butyl(methylthi0)pyrimidinamine. To
-bromochloro(methylthio)pyrimidine (3 g, 12.53 mmol) in dioxane (12.53 mL) was
added 2-methylpropanamine (7.93 mL, 75 mmol). The mixture was stirred at 100 CC
overnight in a sealed vessel. The solvent was removed under reduced pressure and the
residue was dissolved in 100 mL ethyl acetate and washed with 50 mL of a 1M aqueous
solution of sodium en ate. The aqueous layer was back-extracted with
50 mL ethyl acetate. The combined organic layers were dried over anhydrous magnesium
sulfate, filtered and concentrated to give 5-bromo-N-tert-butyl(methylthio)pyrimidin
amine (3.4 g, 12.31 mmol, 98% yield) as a solid. 1H NMR (400 MHz, 6) 5 ppm
8.61 - 8.72 (m, 1 H), 8.08 (s, 1 H), 6.95 - 7.17 (m, 1 H), 2.48 (s, 2 H), 1.38 (s, 9 H).
MS (ESI) m/z 276.0 [M+1]+ and 278.2 [M+1]+.
] E. 2-(tert—Butylamin0)(methylthi0)pyrimidine—5-carb0nitrile.
-Bromo-N-tert-butyl(methylthio)pyrimidinamine (3400 mg, 12.31 mmol), zinc dust
(201 mg, 3.08 mmol), zinc cyanide (940 mg, 8.00 mmol), 1,1'-bis-(diphenylphosphino)-
ferrocene (552 mg, 0.985 mmol), tris(dibenzylideneacetone)dipalladium(0) (564 mg,
0.616 mmol), and DMF (20.5 mL) were ed and heated at 90 oC overnight under
nitrogen. The reaction mixture was d with 125 mL ethyl acetate and 50 mL of water
and then filtered through a pad of Celite. The layers of filtrate were separated and the
aqueous layer was ted with 75 mL ethyl acetate. The combined ethyl acetate layers
-l5l-
ATI—25 14175v1
waewwkflwfih2x50mLbmm¢Mmhwmaflwmmmnmgmmmnwflfimjflmmdmm
concentrated to an oil under reduced re. The crude oil was purified by silica gel
chromatography (0-30% ethyl acetate/hexane) to afford 2-(tert-butylamino)
(methylthio)pyrimidinecarbonitrile (2.26 g, 10.17 mmol, 83% yield). 1H NMR
(400 MHz, DMSO-d6) 5 ppm 8.37 - 8.51 (m, 1 H), 7.85 - 8.10 (m, 1 H), 2.53 - 2.62 (m,
3 H), 1.41 (s, 9 H). MS (ESI) m/z 223.1 [M+1]+.
F. 2-(tert-Butylamin0)(methylthi0)pyrimidinecarboxamide. To a
stirring solution of 2-(tert-butylamino)(methylthio)pyrimidinecarbonitrile (0.6 g,
2.70 mmol) in DMSO (7 mL) was added 6M aqueous sodium hydroxide solution
(2.249 mL, 13.49 mmol) and 30% aqueous hydrogen peroxide (1.530 mL, 13.49 mmol)
solution at 0 CC. Then the mixture was stirred at 50 CC for 15 min. The on mixture
was poured into water (40 mL) and extracted with ethyl acetate (3 x 50 mL). The
combined organic layers were washed with brine, dried over anhydrous sodium sulfate and
ed. Concentration of the filtrate under reduced pressure gave the crude product,
which was purified by silica gel column tography (5% methanol in DCM) to afford
2-(tert-butylamino)(methylthio)pyrimidinecarboxamide (0.462 g, 1.922 mmol,
71.2% yield) as a white solid. MS (ESI) m/z 241.0 [M+1]+.
G. 2-(tert-Butylamin0)—4-(methylsulfinyl)pyrimidine—5—carboxamide.
To a stirring solution of 2-(tert—butylamino)(methylthio)pyrimidinecarboxamide
(0.1 g, 0.416 mmol) in chloroform (12 mL) was added portion-wise yl
lsulfonyl)-1,2-oxaziridine (0.130 g, 0.499 mmol). The resulting pale yellow
solution was stirred at ambient temperature overnight. The reaction solution was
concentrated under reduced re to give the crude product as a white solid. Ethyl
acetate (1 mL) was added and the slurry was stirred at room temp for 1 h. The solids were
filtered, washed with ethyl acetate, and dried under vacuum to afford 2-(tert-butylamino)-
4-(methylsulfinyl)pyrimidinecarboxamide (0.092 g, 0.359 mmol, 86% yield).
MS (ESI) m/z 257.3 [M+1]+.
H. 2-(tert-Butylamin0)—4-((1R,3R,4R)—3-hydr0xymethylcyclohexyl-
amino)pyrimidine—5-carboxamide. To a stirring suspension of 2-(tert-butylamino)
(methylsulf1nyl)pyrimidinecarboxamide (0.092 g, 0.359 mmol) and (1R,2R,5R)
aminomethylcyclohexanol hydrochloride (0.065 g, 0.395 mmol) in DMF (2 mL) was
ATI—2514175v1
added N—ethyl-N-isopropylpropanamine (0.157 mL, 0.897 mmol) and the on was
heated to 90 oC overnight. The crude reaction mixture was concentrated under reduced
pressure and then ice-cold water (20 mL) was added to the residue. The resulting mixture
was vigorously stirred for 1 h and then the product was filtered, washed with water and
dried under vacuum to afford 2-(tert-butylamino)((1R,3R,4R)—3-hydroxy
methylcyclohexylamino)pyrimidinecarboxamide (0.074 g, 0.230 mmol, 64.1% .
1H NMR (400 MHz, DMSO-d6) 8 ppm 8.94 (br. s., 1 H), 8.34 (s, 1 H), 6.69 (br. s., 1 H),
4.59 (d, J=5.47 Hz, 1 H), 3.87 (br. s., 1 H), 2.92 - 3.01 (m, 1 H), 2.14 (d, J=10.15 Hz,
1 H), 1.91 (d, J=11.71 Hz, 1 H), 1.67 (dd, J=13.28, 3.12 Hz, 1H), 1.07 - 1.24 (m, 3 H),
0.91 — 0.99 (m, 4 H). MS (ESI) m/z 322.3 [M+1]+.
Example 33: 2-(Cyclopropylamino)—4-((1R,3R,4R)—3-hydr0xy
methylcyclohexylamin0)pyrimidinecarboxamide
N \ NH2
A JL /
N N NH
. OH
A. 2-(Cyclopropylamino)—4-((1R,3R,4R)—3-hydr0xymethylcyclo-
hexylamin0)pyrimidinecarb0nitrile. To a solution of 4-((1R,3R,4R)hydroxy
methylcyclohexylamino)(methylsulfonyl)pyrimidinecarbonitrile (362 mg,
1.166 mmol; synthesis described herein) in NMP (5.832 mL), was added
ropanamine (0.485 mL, 7.00 mmol). The reaction was stirred at 80 0C for 5 h in a
sealed vessel and then allowed to cool to ambient temperature overnight. The reaction
mixture was concentrated under reduced pressure to an oil that was purified by silica gel
chromatography (0-60% ethyl acetate/hexane) to afford 2-(cyclopropylamino)
((1R,3R,4R)—3-hydroxymethylcyclohexylamino)pyrimidinecarbonitrile (265 mg,
0.922 mmol, 79% yield) as a solid. 1H NMR (400 MHz, 6) 8 ppm 6.99 - 8.32 (m,
3 H), 4.54 (d, J=5.08 Hz, 1 H), 3.85 - 4.13 (m, 1 H), 2.80 - 3.03 (m, 1 H), 2.58 - 2.75 (m,
1 H), 1.50 - 2.08 (m, 3 H), 1.03 - 1.42 (m, 3 H), 0.88 (d, J=6.25 Hz, 4 H), 0.29 - 0.68 (m,
4 H). MS (ESI) m/z 288.1 [M + 1]+.
ATI—2514175v1
B. 2-(Cyclopropylamino)—4-((1R,3R,4R)—3-hydr0xymethylcyclo-
hexylamin0)pyrimidinecarb0xamide. 2-(Cyclopropylamino)((lR,3R,4R)
hydroxymethylcyclohexylamino)pyrimidinecarbonitrile (265 mg, 0.922 mmol) was
ved in DMSO (9.222 mL). To the solution was added 10 drops of 50% aqueous
sodium hydroxide followed by 10 drops of 30% aqueous hydrogen peroxide at room
temperature. The resulting on mixture was stirred at 50 CC for 2 h and was then
added slowly to 60 mL of ice water. The resulting precipitate was stirred for 30 min,
filtered, and washed with water. The solids were dried in a vacuum oven overnight at
45 CC to afford 2-(cyclopropylamino)((1R,3R,4R)hydroxymethylcyclohexyl-
amino)pyrimidinecarboxamide (229 mg, 0.750 mmol, 81% yield). 1H NMR (400 MHz,
DMSO-d6) 5 ppm 8.73 - 8.95 (m, l H), 8.18 - 8.42 (m, l H), 7.17 - 7.37 (m, l H), 4.39 -
4.62 (m, l H), 3.75 - 3.99 (m, l H), 2.81 - 3.06 (m, l H), 2.53 - 2.74 (m, l H), 2.09 - 2.34
(m, l H), 1.82 - 2.05 (m, l H), 1.50 - 1.69 (m, l H), 0.99 - 1.24 (m, 3 H), 0.81 - 0.98 (m,
4 H), 0.50 - 0.67 (m, 2 H), 0.26 - 0.47 (m, 2 H). MS (ESI) m/z 306.3 [M + l]+.
Example 34: t-Butylamin0)—4-((1R,3R)—3-hydr0xy-4,4-
dimethylcyclohexylamin0)pyrimidinecarb0xamide
>L )L /N \ NH2
N N NH
A. 4,4-Dimethylcyclohex-Z-enol. Sodium borohydride (5.03 g, 133 mmol)
was added portion-wise to a stirred solution of 4,4-dimethylcyclohexenone (15.0 g,
121 mmol) in ol (403 mL) in a water bath. Once addition was complete, the
solution was allowed to stir under a nitrogen atmosphere at room temperature for 3 h. The
reaction mixture was diluted with water (150 mL) and the majority of the methanol was
d under reduced re. The aqueous layer was extracted with ethyl acetate (2 x
200 mL). The combine ethyl acetate extracts were dried over anhydrous magnesium
sulfate, filtered, and concentrated to an oil under reduced pressure to afford
methylcyclohexenol (13.4 g, 106 mmol, 88% yield). 1H NMR (400 MHz,
—154—
ATI—2514l75v1
6) 8 ppm 5.41 - 5.57 (m, 1 H), 5.24 - 5.42 (m, 1 H), 4.61 (d, J=5.47 Hz, 1 H),
3.82 - 3.99 (m, 1 H), 1.65 - 1.83 (m, 1 H), 1.21 - 1.59 (m, 3 H), 0.93 (d, J=15.23 Hz, 6 H).
B. 2-(4,4-Dimethylcyclohexenyl)isoindoline—1,3-di0ne. Resin
supported nylphosphine (32.7 g, 106 mmol), oline-1,3-dione (17.19 g,
117 mmol), and 4,4-dimethylcyclohexenol (13.4 g, 106 mmol) were combined and
THF (197 mL) was added. The mixture was stirred and cooled to 0 0C, then diisopropyl
arboxylate (21.09 mL, 107 mmol) was added drop-wise over 2 min. The reaction
was stirred and allowed to warm slowly to ambient temperature overnight. The reaction
mixture was filtered and then concentrated to a yellow solid under reduced pressure. Ethyl
acetate (200 mL) was added and the resulting solids were filtered off again. The ethyl
acetate filtrate was washed with water (100 mL), the aqueous layer extracted with ethyl
e (100 mL), the combined organic layers were dried over anhydrous magnesium
sulfate, filtered, and concentrated to an oil that was purified by silica gel chromatography
(0-20% ethyl acetate/hexane) to afford 2-(4,4-dimethylcyclohexenyl)isoindoline-1,3-
dione (11.59 g, 45.4 mmol, 42.8% yield) as an oil. 1H NMR (400 MHz, DMSO-d6) 5 ppm
7.84 (s, 4 H), 5.51 - 5.62 (m, 1 H), 5.43 (d, J=10.15 Hz, 1 H), 4.59 - 4.74 (m, 1H), 2.14 -
2.30 (m, 1 H), 1.67 - 1.81 (m, 1 H), 1.44 - 1.68 (m, 2 H), 1.09 (s, 3 H), 1.01 (s, 3 H);
MS (ESI) m/z 256.2 [M + 1]+.
C. Mixture of 2-((1R,ZS,3S)br0m0hydr0xy-4,4-
dimethylcyclohexyl)is0indoline-1,3-di0ne, 2-((1S,2R,3R)—2-br0m0hydr0xy-4,4-
dimethylcyclohexyl)is0indoline-1,3-di0ne, 2-((1R,2R,3R)—3-br0m0hydr0xy-4,4-
dimethylcyclohexyl)is0indoline-1,3-di0ne, 2-((1S,ZS,3S)br0m0hydr0xy-4,4-
dimethylcyclohexyl)is0indoline-1,3-di0ne. To a solution of 2-(4,4-dimethylcyclohex
enyl)isoindoline-l,3-dione (11.59 g, 45.4 mmol) in chloroform (110 mL) and ethanol
(3.83 mL) was added N—bromosuccinimide (10.34 g, 58.1 mmol) as a solid over a few min
at ambient temperature. After addition was complete, the reaction e was stirred at
ambient temperature ght under nitrogen. The reaction e was washed with
1 M aqueous solution of sodium thiosulfate (100 mL). The aqueous layer was extracted
with chloroform (100 mL) and the ed organic layers were dried over anhydrous
magnesium sulfate, filtered and concentrated to an oil. To this oil was added 150 mL THF
(150 mL) and a 1N aqueous solution of hydrochloric acid (30 mL). The resulting mixture
ATI—25 14175V1
2012/034349
was d at ambient temperature for 2 h. The THF was removed under reduced pressure
and the remaining aqueous layer was d with ethyl e (150 mL) and 75 mL of a
1:1 water:saturated aqueous sodium bicarbonate on e. The layers were
separated and the aqueous was back-extracted aqueous with ethyl acetate (75 mL). The
ed ethyl acetate layers were washed with brine (50 mL), dried over anhydrous
magnesium sulfate, filtered and concentrated to an oil that was purified by silica gel
chromatography (0-25% ethyl acetate/hexane) to afford a mixture of 2-((1R,2S,3S)
bromohydroxy-4,4-dimethylcyclohexyl)isoindoline- 1 ,3-dione, 2-((1 S,2R,3R)—2-bromohydroxy-4,4-dimethylcyclohexyl)isoindoline- 1 ,3 -dione, 2-((1R,2R,3R)bromo
hydroxy-4,4-dimethylcyclohexyl)isoindoline-1,3-dione, and 2-((1S,2S,3S)bromo
hydroxy-4,4-dimethylcyclohexyl)isoindoline-1,3-dione (11.4 g, 32.4 mmol, 71.3% yield).
MS (ESI) m/z 374.5 [M + 11+ and 376.5 [M + 11+.
D. Mixture 2-((1R,3R)—3-hydroxy-4,4-dimethylcyclohexyl)is0indoline-
1,3-di0ne and ,3S)hydroxy-4,4-dimethylcyclohexyl)is0indoline-1,3-di0ne. A
mixture of 2-((1R,2S ,3 S)bromohydroxy-4,4-dimethylcyclohexyl)isoindoline-1 ,3 -
dione, 2-((1 S,2R,3R)—2-bromohydroxy-4,4-dimethylcyclohexyl)isoindoline-1 ,3 -dione,
2-((1R,2R,3R)bromohydroxy-4,4-dimethylcyclohexyl)isoindoline-1 ,3 -dione, and
2-((1S,2S,3S)—3-bromohydroxy-4,4-dimethylcyclohexyl)isoindoline-1,3-dione (5 .7 g,
16.18 mmol) was dissolved in e (90 mL) and methanol (9 mL). To the solution was
added tributyltin hydride (5.66 mL, 21.04 mmol) over 10 min via syringe under nitrogen,
followed by azobisisobutyronitrile (0.266 g, 1.618 mmol) in one portion. The mixture was
allowed to stir at reflux under a nitrogen atmosphere overnight. The reaction mixture was
concentrated under reduced pressure to afford a residue that was purified by silica gel
chromatography (0-50% ethyl acetate/hexane) yielding a mixture of 2-((1R,3R)
hydroxy-4,4-dimethylcyclohexyl)isoindoline-1,3-dione and 2-((1S,3S)hydroxy-4,4-
dimethylcyclohexyl)isoindoline-1,3-dione (0.9 g, 3.29 mmol, 20.35% . 1H NMR
(400 MHz, DMSO-d6) 5 ppm 7.82 (s, 4 H), 4.51 - 4.80 (m, 1 H), 3.80 - 4.03 (m, 2 H), 2.84
- 3.11 (m, 1 H), 1.49 - 1.67 (m, 3 H), 1.37 - 1.47 (m, 1 H), 1.22 - 1.35 (m, 1 H), 1.13 (s,
3 H), 0.80 - 0.93 (m, 3 H). MS (ESI) m/z 274.0 [M + 1]+. The regiochemistry ofthe
product mixture was verified by small molecule X-ray crystal diffraction. The X-ray
structure was solved as follows. The single crystal X-ray diffraction studies were carried
ATI—25 14175v1
out on a Bruker Kappa APEX-II CCD diffiactometer equipped with Mo Kg radiation (7t =
3 A). Crystals were grown by vapor ion of pentane into a DCM solution. A
0.25 x 0.20 x 0.05 mm ess plate was mounted on a Cryoloop with ne oil. Data
were ted in a nitrogen gas stream at 90(2) K using (I) and as scans. Crystal-to-
or distance was 60 mm and exposure time was 20 seconds per frame using a scan
width of 0.50. Data collection was 100% complete to 25.000 in 6’. A total of 10827
reflections were collected covering the indices, -21<=h<=12, -7<=k<=8, -28<=l<=29.
2892 reflections were found to be symmetry ndent, with a Rint of 0.0821. Indexing
and unit cell refinement indicated a ive, orthorhombic lattice. The space group was
found to be Pbcn. The data were integrated using the Bruker SAINT software program
and scaled using the SADABS re m. Solution by direct methods (SHELXS)
produced a complete phasing model consistent with the proposed structure of a mixture of
the enantiomeric pair 2—((1R,3R)—3-hydroxy-4,4-dimethylcyclohexyl)isoindoline-1,3-
dione and 2-((1S,3S)—3-hydr0xy-4,4-dimethylcyclohexyl)is0indoline-1,3-di0ne.
All non-hydrogen atoms were refined anisotropically by full-matrix least-
squares (SHELXL-97). All hydrogen atoms were placed using a riding model. Their
positions were constrained relative to their parent atom using the appropriate HFIX
command in SHELXL-97.
E. Mixture of (1R,5R)—5-amin0-2,2-dimethylcyclohexanol
hydrochloride and (1 S,5S)—5-amin0-2,2-dimethylcyclohexanol hydrochloride. To a
mixture of 2-((1R,3R)—3-hydroxy-4,4-dimethylcyclohexyl)isoindoline-1 ,3-dione and
,3S)hydroxy-4,4-dimethylcyclohexyl)isoindoline-1,3-dione (1.1 g, 4.02 mmol) in
ethanol (50 mL) was added hydrazine hydrate (0.195 mL, 4.02 mmol). The resulting
solution was allowed to stir at reflux overnight under a nitrogen atmosphere. The reaction
was cooled to ambient temperature and then the pH was adjusted to < 2 via addition of
concentrated aqueous hydrochloric acid. The precipitate was filtered off, rinsed with
ethanol, and then the resulting filtrate was concentrated to 20 mL under reduced pressure.
An equal volume of water was added and this mixture was stirred at ambient temperature
for 15 min. The solids were filtered off, rinsed with water, and the filtrate was
concentrated under reduced pressure to give a solid that was dried in a vacuum oven for a
ATI—2514175v1
few hours to afford a mixture of (1R,5R)amino-2,2-dimethylcyclohexanol
hydrochloride and (1S,5S)amino-2,2-dimethylcyclohexanol hydrochloride (835 mg,
4.65 mmol, 115% yield) that was used without further purification. 1H NMR (400 MHz,
DMSO-dg) 5 ppm 7.87 - 8.21 (m, 3 H), 2.98 - 3.23 (m, 1 H), 2.75 - 3.02 (m, 1 H), 1.49 -
1.92 (m, 2H), 1.26 - 1.47 (m, 3 H), 0.96 - 1.16 (m, 1 H), 0.48 - 0.93 (m, 6 H)
F. 2-(tert-Butylamin0)—4-((1R,3R)—3-hydr0xy-4,4-dimethylcyclohexyl-
amin0)pyrimidinecarboxamide and 2-(tert-butylamin0)—4-((1S,3S)hydr0xy-4,4-
dimethylcyclohexylamin0)pyrimidine—5-carb0xamide. To a stirring suspension of
2-(tert-butylamino)(methylsulfinyl)pyrimidinecarboxamide (375 mg, 1.46 mmol)
and a mixture of )amino-2,2-dimethylcyclohexanol hydrochloride and (1S,5S)-
-amino-2,2-dimethylcyclohexanol hydrochloride (342 mg, 1.902 mmol) in DMF
(4.877 mL) was added DIEA (0.767 mL, 4.39 mmol) and the reaction was heated to 90 oC
overnight. The crude reaction mixture was concentrated under reduced pressure and then
purified using reverse-phased semi-preparative HPLC (5-80% acetonitrile + 0.1% TFA in
water + 0.1% TFA, over 30 min). Fractions containing product were concentrated under
reduced pressure and redissolved in a mixture of ethyl acetate (125 mL) and saturated
aqueous sodium bicarbonate solution (50 mL). The layers were separated and the aqueous
layer was extracted with ethyl e (75 mL). The combined ethyl acetate layers were
dried over anhydrous magnesium sulfate, filtered and concentrated under reduced
pressure. The resulting e was redissolved in a methanol (5 mL), passed over an
Varian StratoSpheres HCO3 resin SPE tube for TFA l (0.9 mmol onate
equivalent), and then concentrated under d pressure to afford an oil that was
triturated with diethyl ether and reconcentrated to give solids. The solids were dried for a
few hours in a vacuum oven at 45 CC to afford a mixture of 2-(tert-butylamino)
((1R,3R)—3-hydroxy-4,4-dimethylcyclohexylamino)pyrimidinecarboxamide and 2-(tert-
butylamino)((1 S ,3 ydroxy-4,4-dimethylcyclohexylamino)pyrimidine-5 -
carboxamide (373 mg, 1.112 mmol, 76% yield).
] G. SFC Separation of a mixture of 2-(tert-butylamin0)—4-((1R,3R)
hydroxy-4,4-dimethylcyclohexylamin0)pyrimidine—5-carb0xamide and 2-(tert-
butylamino)—4-((1S,3S)hydroxy-4,4-dimethylcyclohexylamino)pyrimidine—5-
carboxamide. A mixture of the enantiomers 2-(tert-butylamino)((1R,3R)hydroxy-
ATI—25 14175v1
4,4-dimethylcyclohexylamino)pyrimidinecarboxamide and t-butylamino)
((1S,3S)hydroxy-4,4-dimethylcyclohexylamino)pyrimidine-5 -carboxamide (373 mg)
was separated by preparative chiral SFC utilizing a ChiralPak AD-H, 250><30mm ID.
column with an isocratic 32% ethanol + 0.1% ammonium hydroxide in C02 gradient at
50 mL/min flow rate. The faster eluting isomer was denoted as peak 1 and 155 mg
(0.462 mmol) was obtained. The slower eluting isomer was denoted as peak 2 and
170.0 mg (0.502 mmol) was obatined. Peak 1: 1H NMR (400 MHz, DMSO-d6) 5 ppm
8.82 - 9.11 (m, 1 H), 8.34 (s, 1 H), 6.50 - 6.82 (m, 1 H), 4.40 - 4.72 (m, 1 H), 3.72 - 4.01
(m, 1 H), 3.01 - 3.25 (m, 1 H), 1.83 - 1.99 (m, 1 H), 1.65 - 1.81 (m, 1 H), 1.37 (s, 13 H),
0.89 - 0.95 (m, 3 H), 0.72 - 0.88 (m, 3 H). MS (ESI) m/z 336.2 [M+1]+. Peak 2: 1H NMR
(400 MHz, DMSO-dg) 5 8.95 (s, 1H), 8.34 (s, 1H), 6.68 (s, 1H), 4.52 (d, J = 4.9 Hz, 1H),
3.86 (s, 1H), 3.15 (dt, J: 11.3, 4.6 Hz, 1H), 1.90 (d,.]= 11.9 Hz, 1H), 1.72 (s, 1H), 1.40
(s, 1H), 1.36 (s, 9H), 1.34 - 1.05 (m, 3H), 0.91 (s, 3H), 0.82 (s, 3H). MS (ESI) m/z 336.2
[M+1]+. By SAR y comparison with similar compounds ofknown absolute
stereochemistry provided herein, Peak 1 was assigned as 2-(tert-butylamin0)—4-((1S,3S)-
oxy-4,4-dimethylcyclohexylamin0)pyrimidinecarboxamide. Peak 2 was
assigned as 2-(tert-butylamin0)—4-((1R,3R)—3-hydroxy-4,4-dimethylcyclohexylamin0)-
dine-S-carboxamide.
Example 35: 2-((1r,4r)—4-Hydr0xycyclohexylamin0)(isopr0pylamin0)pyrimidine
carboxamide
HO/“O‘ I‘ll/\kaHZ
A. Ethyl 4-(is0propylamin0)(methylthi0)pyrimidinecarboxylate.
Ethyl 4-chloro(methylthio)pyrimidinecarboxylate (900 g, 3.87 mol) ethanol (12 L),
DIEA (876 mL, 5.05 mol), and isopropylamine (379 mL, 4.45 mol) were combined and
mixed at t temperature for 4 h. An onal amount of isopropylamine (50 mL,
0.59 mol) was added and the mixture was stirred overnight at ambient ature. The
reaction was concentrated under reduced pressure and the crude product was diluted with
water (2 L). The aqueous layer was extracted with chloroform (2 x 3 L). The combined
ATI—25 14175v1
organic layers were dried over anhydrous magnesium sulfate, filtered, and concentrated
under reduced re to afford ethyl propylamino)(methylthio)pyrimidine
carboxylate (1042 g, 4.08 mol, >100% yield, inated with trace DIEA) as a pale
brown oil that was used without fiarther purification. MS (ESI) m/z 256.4 [M+1]+.
B. 4-(Isopropylamino)—2-(methylthi0)pyrimidinecarboxylic acid.
Ethyl 4-(isopropylamino)(methylthio)pyrimidinecarboxylate (1042 g, 4.08 mol,
>100%, contaminated with trace DIEA) was dissolved in ethanol (10 L) and to the
resulting solution was added a 2M aqueous sodium hydroxide solution (3.87 L, 7.74 mol).
The resulting mixture was stirred overnight at ambient temperature and then concentrated
under d pressure. The resulting residue was diluted with 2 L of water and then
washed with methyl t-butyl ether (2 x 1.2 L). The pH of the aqueous layer was adjusted to
pH 4.2-4.5 with a 2N aqueous hydrochloric acid solution. The resulting solids were
collected by filtration, washed with water (2 L) and s (2 L) and then dried overnight
in a vacuum oven at 45 ° C to afford 4-(isopropylamino)(methylthio)pyrimidine
carboxylic acid (848 g, 96.5% yield over 2 steps) as an off-white solid. MS (ESI) m/z
228.1 [M+1]+.
C. 4-(Isopr0pylamin0)—2-(methylthi0)pyrimidine—5-carboxamide. To a
solution of 4-(isopropylamino)(methylthio)pyrimidinecarboxylic acid (180 g,
0.792 mol) and HOBt (123 g, 0.911 mol) in anhydrous THF (6.9 L) was added drop-wise a
mixture of EDC (174.6 g, 0.911 mol) in acetonitrile (3.7 L) at ambient temperature. The
mixture was stirred for 1 h at ambient temperature and then an aqueous ammonium
hydroxide solution (989 mL, 28-30% concentrated, 10 eq) was added drop-wise over
min. The resulting mixture was heated to gentle reflux for 3 h and then concentrated
under reduced pressure. The remaining e was diluted with a saturated aqueous
sodium bicarbonate on (5 L) and then extracted twice with ethyl acetate (9 L and 2 L
tively). The combined organic layers were washed with a ted aqueous sodium
bicarbonate solution (4 L), water (4 L), dried over anhydrous sodium sulfate, filtered and
concentrated under reduced pressure to afford 4-(isopropylamino)(methylthio)-
pyrimidinecarboxamide (171.2 g, 95.5% yield) as a solid. MS (ESI) m/z 227.4 [M+1]+.
D. 4-(Is0pr0pylamin0)—2-(methylsulfinyl)pyrimidine—5-carb0xamide.
To a stirring solution of 4-(isopropylamino)(methylthio)pyrimidinecarboxamide
ATI—25 14175v1
(170 g, 0.751 mol) in chloroform (22 L) was added portion-wise 3-phenyl
(phenylsulfonyl)-1,2-oxaziridine (235.6 g, 0.902 mol) and the resulting solution was
stirred at ambient ature overnight. An additional amount of 3-phenyl
(phenylsulfonyl)-1,2-oxaziridine (19.6 g, 0.075 mol) was added and the mixture was then
stirred ght at ambient temperature. The reaction on was concentrated under
reduced pressure to give the crude product as a white solid. The solids were triturated with
ethyl acetate (1.5 L) at ambient temperature for 1 h, filtered, washed with ethyl e
(250 mL), and dried in a vacuum oven overnight at 45 CC to afford 4-(isopropylamino)
(methylsulf1nyl)pyrimidinecarboxamide (167.7 g, 92% yield) as white solid. MS (ESI)
m/z 243.2 [M+1]+.
E. 2-((1r,4r)—4-Hydr0xycyclohexylamin0)(is0pr0pylamin0)—
pyrimidine—5-carb0xamide. A mixture of (1r,4r)aminocyclohexanol (262.4 g,
2.278 mol) and anhydrous DMF (79 mL) was heated to 100 0C. To this mixture was added
portion-wise 4-(isopropylamino)(methylsulf1nyl)pyrimidinecarboxamide (157.7 g,
0.651 mol). The resulting mixture was allowed to stir a under nitrogen atmosphere at
110 OC ght. The reaction mixture was concentrated under reduced pressure to
remove DMF. To the remaining residue was added water (2 L) and the mixture was
extracted with ethyl acetate (3 x 2 L). The combined organic extracts were washed with
water (2 x 2 L), dried over anhydrous sodium sulfate, filtered, and concentrated under
reduced pressure until the remaining volume reached to 500 mL. The ing material
was ed and washed with ethyl acetate (800 mL). The product was dried at 45 CC in a
vacuum oven overnight. The product was triturated with water (2.1 L) for 4.5 h at 50 OC,
filtered and then dried at 45 CC in a vacuum oven overnight to afford 2-((1r,4r)
ycyclohexylamino)(isopropylamino)pyrimidinecarboxamide (134 g, 70%
yield); 1H NMR (499 MHz, DMSO-d6) 8 ppm 8.71 - 9.01 (m, 1 H), 8.33 (br. s., 1 H), 7.42
- 7.70 (m, 1 H), 6.67 - 7.12 (m, 2 H), 4.51 (d, J=3.94 Hz, 1 H), 3.98 - 4.25 (m, 1 H), 3.51 -
3.77 (m, 1 H), 3.34 - 3.41 (m, 1 H), 1.82 (br. s., 4 H), 1.06 - 1.33 (m, 10 H). MS (ESI) m/z
294.1 [M+1]+.
ATI—25 14175v1
Example 36: (1R,4r)—4-(5-Cyan0((1R,3S)hydr0xymethylcyclohexylamin0)—
pyrimidin-Z-ylamino)—N,N-dimethylcyclohexanecarboxamide
\TJLIIQ )NL/jCN
N N NH
A. tert-Butyl )—4-(dimethylcarbamoyl)cyclohexylcarbamate. A mixture
of )(tert-butoxycarbonylamino)cyclohexanecarboxylic acid (7.5 g, 30.8 mmol), EDC
(20.09 g, 105 mmol), HOBt (16.05 g, 105 mmol) in NMP (60 mL) was stirred at room
temperature for 2 h. A solution of dimethylamine (46.2 mL, 92 mmol) (2.0 M in THF) was
added and the reaction mixture was stirred for 2 days. Water and ethyl acetate were added and
the phases separated. The organic phase was washed twice with saturated aqueous potassium
carbonate on, followed by 1M aqueous hydrogen chloride solution and brine. The organic
phase was dried over ous magnesium sulfate, filtered, and the solvent was evaporated to
give the desired product (5.8 g, 19.3 mmol, 96% yield). MS (ESI) m/z 271.4 .
B. (1r,4r)—4-Amin0-N,N-dimethylcyclohexanecarboxamide hydrochloride.
tert-Butyl (1r,4r)(dimethylcarbamoyl)cyclohexylcarbamate (8.27 g, 30.6 mmol) was dissolved
in e (110 mL) and hydrochloric acid (38.5 mL, 1267 mmol) was added. The reaction
mixture was stirred at room temperature for 4 h, toluene was added and the solvent evaporated
to give the product (6.0 g, 29.0 mmol, 95% yield). 1H NMR (400 MHz, DMSO-d6) 5 ppm 8.22
(br. S., 3 H), 3.01 (s, 3 H), 2.86 — 2.98 (m, 1 H), 2.79 (s, 3 H), 1.93 — 2.04 (m, 2 H), 1.72 (d,
J=7.81 Hz, 2 H), 1.31 — 1.48 (m, 4 H). MS (ESI) m/z 171.4 [M+1]+
C. )—4-(5-Br0m0(methylthi0)pyrimidinylamin0)-N,N-
dimethylcyclohexanecarboxamide. To a stirring suspension of 5-bromochloro
(methylthio)pyrimidine (1.5 g, 6.26 mmol) in ethanol (7.5 mL) was added (1r,4r)amino-N,N—
dimethylcyclohexanecarboxamide hloride (1.618 g, 7.83 mmol) and DIEA (3.28 mL,
18.79 mmol). The resulting mixture was stirred at 80 OC overnight. The ethanol was removed
under reduced pressure and the remaining residue was purified using silica gel chromatography
(0-90% ethyl acetate in hexanes) to afford (1r,4r)(5-bromo(methylthio)pyrimidin
ATI—25 14175v1
ylamino)-N,N-dimethylcyclohexanecarboxamide (1085 mg, 2.91 mmol, 46.4% yield). MS (ESI)
m/z 373.0 [M+1]+, 375.2 [M+1]+.
D. (1r,4r)—4-(5-Cyan0-4—(methylthi0)pyrimidinylamin0)-N,N-
dimethylcyclohexanecarboxamide. (1r,4r)(5-Bromo(methylthio)pyrimidinylamino)—
N,N-dimethylcyclohexanecarboxamide (500 mg, 1.339 mmol), zinc dust (21.90 mg,
0.335 mmol), zinc cyanide (102 mg, 0.871 mmol), 1,1'-bis-(diphenylphosphino)-ferrocene
(60.0 mg, 0.107 mmol), tris(dibenzylideneacetone)dipalladium(0) (61.3 mg, 0.067 mmol), and
N,N—dimethylacetamide (2.178 mL) were combined and the resulting mixture was mixed and
heated at 90 CC ght. The reaction mixture was diluted with ethyl acetate (125 mL) and
water (50 mL) and filtered through a pad of Celite. The filtrate layers were separated and the
aqueous layer was extracted with ethyl acetate (75 mL). The combined ethyl acetate layers were
washed with brine (50 mL), dried over anhydrous ium e, filtered, and concentrated
to an oil under reduced pressure. The oil was purified using silica gel chromatography (0-10%
methanol in DCM) to afford (1r,4r)(5-cyano(methylthio)pyrimidinylamino)-N,N—
dimethylcyclohexanecarboxamide (400 mg, 1.252 mmol, 93% yield) as a solid. MS (ESI) m/z
320.2 [M+1]+.
E. (1r,4r)—4-(5-Cyan0(methylsulfonyl)pyrimidinylamin0)-N,N-
dimethylcyclohexanecarboxamide. To a solution of (1r,4r)(5-cyano(methylthio)-
pyrimidinylamino)-N,N-dimethylcyclohexanecarboxamide (400 mg, 1.252 mmol) in NMP
(6.261 mL) at 0 °C was added mCPBA (702 mg, 3.13 mmol). The reaction was stirred for 1 h at
0 CC and then at ambient temperature overnight. The solution was then used ly in the next
step without further purification assuming a theoretical yield of )(5 -cyano
(methylsulfonyl)pyrimidinylamino)-N,N-dimethylcyclohexanecarboxamide (440 mg,
1.25 mmol, 100% yield). MS (ESI) m/z 352.3 [M+1]+.
F. (1R,4r)—4-(5-Cyan0((1R,3S)—3-hydr0xymethylcyclohexylamin0)-
pyrimidin-Z-ylamino)—N,N-dimethylcyclohexanecarboxamide. To a solution of (1r,4r)—4-(5-
cyano(methylsulfonyl)pyrimidinylamino)-N,N-dimethylcyclohexanecarboxamide (440 mg,
1.252 mmol) in NMP (6.261 mL) was added (1S,3R)aminomethylcyclohexanol
hloride (259 mg, 1.565 mmol) and DIEA (1.312 mL, 7.51 mmol). The reaction was
d at 80 CC for 4 h and then allowed to cool to ambient ature overnight The crude
reaction mixture was concentrated under reduced pressure and purified using reverse-phased
ATI—25 14175v1
semi-preparative HPLC (5-60% itrile + 0.1% TFA in water + 0.1% TFA, over 30 min).
Fractions ning product were concentrated under reduced pressure. The resulting residue
was redissolved in a methanol (5 mL), passed over Varian StratoSpheres HCO3 resin SPE tubes
for TFA removal (0.9 mmol bicarbonate equivalent per tube), concentrated under reduced
pressure, and dried overnight in a vacuum oven at 45 0C to afford (1R,4r)(5-cyano
((1R,3S)hydroxymethylcyclohexylamino)pyrimidinylamino)-N,N-dimethyl-
cyclohexanecarboxamide (138 mg, 0.345 mmol, 27.5% yield). 1H NMR (400 MHz, DMSO-d6)
ppm 8.11 (s, 1 H), 7.58 (d, J=7.81 Hz, 2 H), 4.70 - 5.01 (m, 1 H), 4.12 - 4.42 (m, 2 H), 3.52 -
3.79 (m, 1 H), 3.00 (s, 3 H), 2.79 (s, 3 H), 1.21 - 2.07 (m, 16 H), 1.03 - 1.20 (m, 3 H). MS (ESI)
m/z 401.5 [M+1]+.
Example 37: ,4r)—4-Hydr0xycyclohexylamin0)(tert—pentylamin0)pyrimidine
carboxamide
A. 2-(Methylthi0)—4-(tert-pentylamino)pyrimidine—5-carbonitrile. 4-Chloro
(methylthio)pyrimidinecarbonitrile (500 mg, 2.69 mmol) was ved in DMF (5 mL),
ylbutanamine (0.378 mL, 3.24 mmol) and DIEA (1.411 mL, 8.08 mmol) were added
and the reaction was heated at 70 oC overnight. LCMS showed the desired product mass as the
dominant peak and no starting material remaining. The reaction was removed from heat and
partitioned between ethyl acetate and water. The organic layer was washed once with brine
before drying over magnesium e, filtering, and condensing. The crude material was purified
by silica gel chromatography (0-80% ethyl acetate in hexane over 1650 mL; 40 mL/min).
t fractions were combined, evaporated, and dried under high vacuum to afford 2-
(methylthio)(tert-pentylamino)pyrimidinecarbonitrile (359 mg, 1.519 mmol, 56.4% yield)
as a white solid; MS (ESI) m/z 236.9 [M+1]+
B. 2-(Methylsulfonyl)(tert-pentylamin0)pyrimidinecarb0nitrile.
2-(Methylthio)(tert-pentylamino)pyrimidinecarbonitrile (350 mg, 1.481 mmol) was
dissolved in NMP (5 mL), and cooled to 0 0C before adding mCPBA (664 mg, 2.96 mmol)
ATI—2514175v1
portion-wise. The reaction was kept at 0 CC and allowed to slowly warm to room temperature.
After 2 h, LCMS showed the desired product as the dominant peak and no starting material
present. The crude reaction mixture was used directly in the next step assuming theoretical yield
ofthe e; MS (ESI) m/z 269.2 [M+1]+
C. 2-((1r,4r)—4-Hydr0xycyclohexylamin0)(tert-pentylamino)pyrimidine—5-
itrile. To the crude reaction mixture from the previous step was added )
aminocyclohexanol hloride (269 mg, 1.775 mmol) and DIEA (1.034 mL, 5.92 mmol).
The reaction was then heated at 70 oC overnight. LCMS showed the desired t as the
dominant peak and no starting material remaining. The reaction was removed from heat, and
then partitioned between ethyl e and water. The organic layer was washed once with brine
before drying over magnesium sulfate, filtering, and concentrating under reduced pressure. The
material was purified by semi-preparative HPLC (5-80% acetonitrile + 0.1% TFA in water +
0.1% TFA). The product fractions were combined and concentrated under reduced pressure to a
volume <5 mL. The material was then neutralized with saturated sodium bicarbonate and
ted with ethyl acetate (2x). The combined organic layers were dried over magnesium
sulfate, filtered, and concentrated under reduced pressure. The resulting solid was dissolved in
methanol and washed through a StratoSpheres SPE PL-HCO3 MP-Resin column, eluting with
methanol. ation of the solvent under reduced pressure gave 2-((1r,4r)
hydroxycyclohexylamino)(tert—pentylamino)pyrimidinecarbonitrile (200 mg, 0.659 mmol,
45% yield) as a white solid; 1H NMR (400 MHz, DMSO-dg) 5 ppm 8.07 - 8.24 (m, 1 H), 7.24 -
7.63 (m, 1 H), 5.67 - 5.95 (m, 1 H), 4.56 (d, J=4.69 Hz, 1 H), 3.35 - 3.60 (m, 2 H), 1.74 - 1.96
(m, 6 H), 1.09 - 1.43 (m, 10 H), 0.72 - 0.86 (m, 3 H); MS (ESI) m/z 304.1 [M+1]+
D. 2-((1r,4r)—4-Hydr0xycyclohexylamin0)(tert-pentylamino)pyrimidine—5-
carboxamide. 2-((1r,4r)Hydroxycyclohexylamino)(tert-pentylamino)pyrimidine
carbonitrile (141 mg, 0.465 mmol) was dissolved in DMSO (3 mL) and 10 drops of 50%
aqueous sodium hydroxide and 10 drops of 30% aqueous hydrogen peroxide were added at room
ature. The reaction was then heated at 50 0C. After 30 min, LCMS showed the desired
product as the dominant peak and no ng material remaining. The reaction was removed
from heat and slowly added to ~50 mL of ice water. The resulting material was allowed to mix
for 3 h before filtering and drying under high vacuum at 60 CC overnight. 2-((1r,4r)
hydroxycyclohexylamino)(tert—pentylamino)pyrimidinecarboxamide (125 mg, 0.389 mmol,
ATI—25 14175v1
84% yield) was obtained; 1H NMR (400 MHz, DMSO-d6) 5 ppm 9.14 (s, 1 H), 8.31 (s, 1 H),
7.00 (d, J=7.81 Hz, 1 H), 4.53 (d, J=4.29 Hz, 1 H), 3.38 (d, J=3.51 Hz, 2 H), 1.74 - 1.92 (m,
6 H), 1.36 (s, 7 H), 1.13 - 1.31 (m, 4 H), 0.80 (t, J=7.42 Hz, 3 H); MS (ESI) m/z 322.0 [M+1]+.
Example 38: 4-(Bicyclo[1.1.1]pentanylamin0)—2-((1R,4R)—4-
hydroxycyclohexylamino)pyrimidine—5-carboxamide
A. Ethyl 4-(bicyclo[1.1.1]pentanylamin0)—2-(methylthi0)pyrimidine-
0xylate. A mixture of ethyl ro(methylthio)pyrimidinecarboxylate
(200 g, 0.86 mol), bicyclo[l . l.1]pentanamine hydrochloride (171 g, 1.11 mol; prepared
according to Org. Lett., 13(17): 4746-4748 (2011)) and DIEA (278 g, 2.15 mol) in ethanol
(2.4 L) was stirred overnight at room temperature. After completion of the reaction, the
solvents were concentrated under reduced pressure to give the crude product, which was
diluted with water (1 L). The aqueous layer was extracted with chloroform (2 x 1 L) and
the combined organic layers were washed with brine and dried over anhydrous sodium
sulfate. Evaporation of the solvents afforded the d compound (231 g, 0.83 mol, 96%
yield) as a pale brown oil which was contaminated with trace amounts of DIEA. This
product was used in the next reaction without further purification; 1H NMR (400 MHz,
CDClg) 5 ppm 8.61 (s, 2H), 4.30 (q, J: 7.2 Hz, 2H), 2.54 (s, 3H), 2.51 (s, 1H), 2.20 (s,
6H), 1.35 (t, J: 7.2 Hz, 3H).
B. 4-(Bicyclo[1.1.1]pentan-l-ylamin0)—2-(methylthi0)pyrimidine
carboxylic acid. Ethyl 4-(bicyclo[1.1.1]pentanylamino)(methylthio)pyrimidine
carboxylate (120 g, 0.43 mol) was dissolved in ethanol (1.5 L) followed by the addition of
an aqueous sodium hydroxide on (530 mL, 1.06 mol, 2M) and the resulting mixture
was stirred ght at room temperature. After that the solvent was evaporated under
reduced pressure (<42 oC bath ature). The mixture was d with 500 mL of
water and washed with tert-butyl methyl ether (2 x 500 mL). The s layer was
treated with aqueous hydrochloric acid solution (2N) to pH 4.2-4.5. The resulting solids
ATI—2514l75vl
were ted by filtration followed by washing with water (500 mL) and hexanes
(500 mL). The wet cake was dried under reduced pressure overnight at 45 0C to afford the
desired compound (108 g, 0.43 mol, 100% yield) as an off-white solid (116 mg,
0.365 mmol, 54.7% yield); 1H NMR (400 MHz, CDgOD) 8 ppm 8.52 (s, 1H), 2.55 (s, 3H),
2.52 (s, 1H), 2.24 (s, 6H)
C. 4-(Bicyclo[1.1.1]pentanylamin0)(methylthi0)pyrimidine
carboxamide. To a stirring solution of yclo[1.1.1]pentanylamino)
(methylthio)pyrimidinecarboxylic acid (108 g, 0.43 mol) and HOBt (67 g, 0.49 mol) in
anhydrous THF (4 L) was added drop-wise a mixture of EDC (94 g, 0.49 mol) in
acetonitrile (2 L) at room temperature. After the reaction mixture was stirred for 1 hr at
room temperature, aqueous ammonium hydroxide (600 mL, 28-30% concentrated, 10 eq)
was added drop-wise over 30 min and then the mixture was heated to gentle reflux for 3 h
(60::5 0C). After that all solvents were removed under reduced pressure, the residual
paste/solid was diluted with saturated aqueous sodium bicarbonate on (2 L) and the
resulting suspension was filtered to afford the desired compound (100 g, 0.4 mol, 93%
yield) as an off-white fluffy solid; MS(ESI): m/z 251.1 [M+1]+.
D. 4-(Bicyclo[1.1.1]pentanylamin0)(methylsulfinyl)pyrimidine—5-
carboxamide. To a stirring solution of yclo[1.1.1]pentanylamino)
(methylthio)pyrimidinecarboxamide (76 g, 0.304 mol) in form (7 L) was added
3-phenyl(phenylsulfonyl)-1,2-oxaziridine (143 g, 0.547 mol, 1.8 equiv.) and the
resulting pale yellow solution was stirred at ambient temperature overnight. The reaction
solution was concentrated under d re to give the crude product as a white
solid, which was d with ethyl acetate (1.5 L) and the slurry was stirred at room
temperature for 1 h. The resulting suspension was ed, washed with ethyl acetate, and
dried under vacuum to afford the desired compound (73 g, 0.274 mol, 90% yield) as a
white solid; MS(ESI): m/Z 267.0 [M+1]+.
E. 4-(Bicyclo[1.1.1]pentan-l-ylamino)—2-((1r,4r)—4-hydr0xycyclohexyl—
amin0)pyrimidine—5-carb0xamide. A mixture of (1r,4r)aminocyclohexanol (151.4 g,
1.314 mol) and anhydrous DMF (500 mL) was heated at ~100 c’C. To this mixture was
added portion-wise 4-(bicyclo[1.1.1]pentanylamino)(methylsulf1nyl)pyrimidine
carboxamide (100 g, 0.376 mole) under nitrogen atmosphere and the reaction mixture was
ATI—25 14175v1
stirred at 110 CC overnight. The reaction mixture was cooled to ~45 CC and DMF was
removed under reduced pressure followed by addition of water (500 mL) and ethyl acetate
(500 mL). The resulting white slurry was filtered and washed with ethyl acetate (50 mL).
The solid was dried at 55 0C under vacuum for 48 hrs to afford 100 g of the crude product.
In order to get rid of traces of organic solvent the crude product was suspended in water
(1 L) and d for 4.5 h g the internal temperature at 50::1 c’C. The slurry was
filtered at 45—50 0C and rinsed with water (50 mL). The wet cake was dried under vacuum
at 45—50 0C for 48 h to afford the d compound (92 g, 0.289 mol, 77% yield);
1H NMR (CDgOD, 400 MHz): 8 ppm 8.26 (s, 1H), 3.79 (m, 1H), 3.56-3.58 (m, 1H), 2.47
(s, 1H), 2.18 (s, 6H), 1.98-2.06 (m, 4H), 1.32-1.39 (m, 4H); MS(ESI): m/z 318.1 [M+1]+.
Example 39: 2-((1r,4r)—4-Hydr0xycyclohexylamin0)(1-
cyclopropylamin0)pyrimidine—5-carb0xamide
A. (1r,4r)—4-(5-Br0m0(methylthi0)pyrimidinylamin0)-
cyclohexanol. A 3-L, 3-neck, round-bottom flask was equipped with a J-KEM
temperature controller, a mechanical stirrer, and a nitrogen inlet. The flask was charged
with 5-bromochloro(methylthio)pyrimidine (100 g, 417.5 mmol), (1r,4r)
yclohexanol (76.4 g, 663.4 mmol), and ethanol (1 L). DIEA (109 mL,
626.3 mmol) was added, and the mixture was heated to reflux overnight. TLC (1 :1
hexanes/ethyl acetate) analysis after 20 h indicated complete reaction. The reaction was
allowed to cool to room temperature. Water (300 mL) was added, and a precipitate
gradually formed. The solid was filtered and washed with water to give 111.7 g of a white
solid. The filtrate was extracted with ethyl acetate (3 X 300 mL). The combined organic
layers were dried over sodium e, filtered, and concentrated to a semi-solid. The
semi-solid was slurried in 1:1 hexanes/ethyl acetate and d to give an additional
12.1 g of a white solid. The two batches were combined to give 123.8 g (93%) of (1r,4r)-
4-(5 (methylthio)pyrimidinylamino)cyclohexanol as a white solid. MS (ESI)
m/z 318, 320 [M+1]+.
ATI—25 14175v1
WO 45569
B. 2-((1r,4r)—4-Hydr0xycyclohexylamin0)(methylthi0)pyrimidine
itrile. A 2-L, 3-neck, round-bottom flask was equipped with a J-KEM temperature
controller, a mechanical stirrer, and a nitrogen inlet. The flask was charged under nitrogen
with (1r,4r)(5-bromo(methylthio)pyrimidinylamino)cyclohexanol (123 .8 g,
389 mmol), zinc cyanide (29.2 g, 249 mmol), zinc dust (6.36 g, 97 mmol), and
N,N—dimethylacetamide (478 mL). Tris(dibenzylideneacetone)dipalladium(0) (17.8 g,
0.05 equiv) and 1,1'-bis-(diphenylphosphino)-ferrocene (17.25 g, 0.08 equiv) were added,
and the e was purged with nitrogen. The reaction was heated to 100 °C overnight.
TLC (2:1 ethyl acetate/hexanes) analysis after 17 h indicated complete reaction. The
reaction was allowed to cool to room temperature and diluted with ethyl acetate (2 L). The
mixture was filtered through a short Celite-pad, and the pad was washed with ethyl acetate
(3 X 400 mL). The combined organic layers were washed with water (1 L) and brine
(400 mL), dried over sodium sulfate, and filtered. The filtrate was concentrated to remove
most of the solvent, and a beige precipitate formed. The solids were filtered and washed
with ethyl acetate (2 X 50 mL) to give 55 g (54%) of ,4r)hydroxycyclohexyl-
amino)(methylthio)pyrimidinecarbonitrile as a beige solid. MS (ESI) m/z
265 [M + 11+.
C. ,4r)—4-Hydr0xycyclohexylamin0)(methylsulfinyl)—
pyrimidine—5-carb0nitrile and 2-((1r,4r)—4-hydr0xycyclohexylamin0)—4-
(methylsulfonyl)pyrimidine—5-carb0nitrile. To a stirred colorless solution of 2-((1r,4r)-
4-hydroxycyclohexylamino)(methylthio)pyrimidinecarbonitrile (0.700g, 2.65 mmol)
in NMP (10 mL) was added mCPBA (1.306 g, 5.83 mmol) at 0 CC. The reaction mixture
was then stirred at room ature for 2 h until completion of the reaction as indicated
by LCMS. The reaction mixture was carried on to the next step without further
ation. MS (ESI) m/z 281.4 [M+1] + and 297.2 [M+1] 3
D. 2-((1r,4r)—4-Hydr0xycyclohexylamin0)(1-methylcyclopr0pyl-
amin0)pyrimidine—5-carb0nitrile. To the reaction mixture of 2-((1r,4r)
hydroxycyclohexylamino)(methylsulfinyl)pyrimidinecarbonitrile and ,4r)
hydroxycyclohexylamino)(methylsulfonyl)pyrimidinecarbonitrile from the previous
step was added DIEA (2.78 mL, 15.89 mmol) and 1-methylcyclopropanamine
hympchbnde(0627g,583nnnoD.Therawfionwmssfinedat90oCibr16h. Upon
ATI—25 14175v1
completion of reaction as indicated by LCMS and TLC the reaction e was
concentrated and purified by silica gel chromatography using a gradient of 0% - 80% ethyl
e in hexanes. The product fractions were combined and concentrated to afford
2-(( 1 s,4s)hydroxycyclohexylamino)(1 -methylcyclopropylamino)pyrimidine-5 -
carbonitrile (0.147g, 19% yield) as a pale yellow solid. MS (ESI) m/z 288.2 [M+1]+.
E. 2-((1r,4r)Hydr0xycyclohexylamin0)(l-methylcyclopropyl-
pyrimidine—5-carboxamide. ,4r)Hydroxycyclohexylamino)(1-
methylcyclopropylamino)pyrimidinecarbonitrile (0.225 g, 0.783 mmol) was dissolved
in DMSO (15 ml). Sodium hydroxide (50% wt, 175 uL, 0.78 3 mmol) and 30% hydrogen
peroxide (175 uL, 1.543 mmol) were added to the reaction mixture at room temperature.
The reaction mixture was stirred at 50 CC for 1 h. Upon completion of the reaction, as
indicated by LCMS and TLC, the reaction mixture was cooled to room temperature and
was poured into 300 mL of ice water. The aqueous layer was extracted with 20%
isopropanol in form (x3) and the combined organic layers were dried over
anhydrous magnesium sulfate and concentrated. The crude e was purified by
reverse phase silica gel chromatography using a gradient of 0% - 90% methanol in water.
The product fractions were combined and concentrated to afford 2-((1r,4r)
hydroxycyclohexylamino)( 1 lcyclopropylamino)pyrimidinecarboxamide
(0.181 g, 76% yield); 1H NMR (400 MHz, DMSO-d6) 8 ppm 9.10 (s, 1H), 8.33 (s, 1H),
7.06 (d, .1: 7.42 Hz, 1H), 4.53 (d, .1: 4.30 Hz, 1H), 3.59 - 3.70 (m, 1H), 3.35 - 3.46 (m,
1H), 1.96 (d, .1: 9.76 Hz, 1H), 1.85 (d, .1: 9.76 Hz, 2H), 1.40 (s, 3H), 1.20 - 1.34 (m, 4H),
0.81 - 0.89 (m, 1H), 0.58 - 0.71 (m, 4H); MS (ESI) m/z 306.4 [M+1]+
Example 40: 4-((R)Cyclopr0pylethylamin0)((1r,4R)—4-
hydroxycyclohexylamino)pyrimidine—5-carboxamide
A. 2-((1r,4r)—4-Hydr0xycyclohexylamino)(methylthi0)pyrimidine
carboxamide. A 2-L, 3-neck, round-bottom flask was equipped with a J-KEM temperature
ATI—25 14175V1
2012/034349
controller, a mechanical r, and a nitrogen inlet. The flask was charged with 2-((1r,4r)
hydroxycyclohexylamino)(methylthio)pyrimidinecarbonitrile (54 g, 204.3 mmol; synthesis
described herein) and DMSO (270 mL), and the solution was cooled to 0 oC. Sodium hydroxide
solution (170 mL, 1021 mmol, 6 M in water) and en peroxide on (99 mL,
1021 mmol, 35% in water) were slowly added to the reaction mixture. An rm to 30 °C
was observed. The reaction was heated to 50 0C for 15 min. TLC (10% methanol/ethyl acetate)
analysis indicated complete reaction. The mixture was cooled to 10 CC, diluted with water
(800 mL), and stirred for 10 min. The mixture was filtered to give 18 g of a crude solid. To
recover more product, the e was extracted with ethyl acetate (18 X 250 mL). The combined
organic layers were washed with brine (75 mL), dried over sodium sulfate, filtered, and
concentrated to give 33 g of a crude solid. The crude solids were combined and purified on
silica gel g with 0-15% ol/ethyl acetate to give 26 g of an off-white solid. The solid
was slurried in itrile and filtered to give 19.5 g (33%) of 2-((1r,4r)
hydroxycyclohexylamino)(methylthio)pyrimidinecarboxamide as an off-white solid;
MS (ESI) m/z 283.3 [M+1]
B. 2-((1r,4r)—4-Hydr0xycyclohexylamin0)(methylsulfinyl)pyrimidine
carboxamide and 2-((1r,4r)—4-hydroxycyclohexylamino)—4-(methylsulfonyl)pyrimidine—5-
carboxamide. To a stirred yellow solution of 2-((1r,4r)hydroxycyclohexylamino)
(methylthio)pyrimidinecarboxamide (0.400 g, 1.42 mmol) in NMP (5 mL) was added
mCPBA (0.635 g, 2.83 mmol) at 0 CC. The reaction mixture was then stirred at room
temperature for 1.5 h until completion of the reaction as indicated by LCMS. The reaction
mixture was carried on to next step without filrther purification. MS (ESI) m/z 298.0 [M+1] +
and 315.1[M+1]+
C. 4-((R)Cyclopr0pylethylamin0)—2-((1r,4R)—4-hydroxycyclohexylamino)—
pyrimidine—5-carb0xamide. To the reaction mixture of 2-((1r,4r)hydroxycyclohexylamino)-
4-(methylsulfinyl)pyrimidinecarboxamide and 2-((1r,4r)hydroxycyclohexylamino)
(methylsulfonyl)pyrimidinecarboxamide from the previous reaction was added DIEA
(1.56 mL, 8.95 mmol) and (R)cyclopropylethanamine (0.254 g, 2.98 mmol). The reaction was
stirred at 90 °C for 16 h. Upon completion of reaction, as ted by LCMS and TLC, the
reaction mixture was concentrated and purified by revere phase silica gel chromatography using
a gradient of 0% - 90% methanol in water. The desired fractions were purified again by silica
ATI—25 14175v1
gel tography using a gradient of 0% - 15% ol saturated with ammonia in DCM,
ed by reverse-phased semi-preparative HPLC (0-50% acetonitrile + 0.1% TFA in water +
0.1% TFA, over 30 min). Fractions containing product were concentrated under reduced
pressure. The ing residue was redissolved in methanol (5 mL), passed over Varian
StratoSpheres HCO3 resin SPE tubes for TFA l (0.9 mmol bicarbonate equivalent per
tube), and then concentrated under reduced pressure to afford 4-((R)cyclopropylethylamino)-
2-((1r,4R)—4-hydroxycyclohexylamino)pyrimidinecarboxamide (0.104 g, 22% ;
1H NMR (400 MHz, DMSO-dg) 5 ppm 8.87 - 9.10 (m, 1H), 8.32 (br. s., 1H), 6.68 - 7.02 (m, 1H),
4.51 (d, J: 3.94 Hz, 1H), 3.52 - 3.72 (m, 2H), 3.36 (br. s., 1H), 1.82 (br. s., 4H), 1.12 - 1.32 (m,
8H), 0.95 (d, J: 6.89 Hz, 1H), 0.25 - 0.50 (m, 3H), 0.10 - 0.23 (m, 1H); MS (ESI) m/z 320.1
[M+1]+.
Example 41: 4-((1R,3R,4R)—3-Hydr0xymethylcyclohexylamin0)(1-
methylcyclopropylamin0)pyrimidine—5-carb0xamide
A. 5-Br0m0-N-(1-methylcyclopr0pyl)—4-(methylthi0)pyrimidinamine. To a
stirring suspension of 5-bromochloro(methylthio)pyrimidine (1.0 g, 4.18 mmol) in ethanol
(6.0 mL) was added 1-methylcyclopropanamine hydrochloride (0.674 g, 6.26 mmol) and DIEA
(2.188 mL, 12.53 mmol). The mixture was stirred at 90 CC for 16 h. Upon completion of the
reaction as indicated by LCMS and TLC the reaction mixture was concentrated and purified by
silica gel chromatography using a gradient of 0% - 20% ethyl acetate in hexanes. The product
fractions were combined and concentrated to afford 5-bromo-N-(1-methylcyclopropyl)
(methylthio)pyrimidinamine (0.665 g, 58% yield) as a white solid. MS (ESI) m/z 276.2
[M+1]+.
B. 2-(1-Methylcyclopr0pylamin0)—4-(methylthi0)pyrimidine—5-carbonitrile.
A black suspension of 5-bromo-N-(1-methylcyclopropyl)(methylthio)pyrimidinamine
(0.665 g, 2.425 mmol), zinc (0.040 g, 0.606 mmol), zinc e (0.185 g, 1.577 mmol), 1,1'-bis-
ATI—25 14175v1
2012/034349
(diphenylphosphino)-ferrocene (0.109 g, 0.194 mmol), tris(dibenzylideneacetone)dipalladium(0)
(0.111 g, 0.121 mmol), and N, N’ -dimethylacetamide (6 mL) was flushed with nitrogen and
heated at 90 °C for 16 h. Upon completion of reaction, as indicated by LCMS and TLC, the
reaction mixture was diluted with 125 mL ethyl acetate and 50 mL of water and filtered through
a pad of Celite. The layers of the filtrate were separated and the aqueous layer was extracted
with 75 mL of ethyl acetate. The combined ethyl e layers was washed with 2 x 50 mL
brine, dried over anhydrous magnesium sulfate, filtered and concentrated to an oil. The crude oil
was purified by silica gel chromatography using a gradient of 0% - 30% ethyl acetate in hexanes.
The product fractions were combined and concentrated to afford 2-(1-methylcyclopropylamino)-
4-(methylthio)pyrimidinecarbonitrile (0.449 g, 84% yield) as a pale yellow solid. MS (ESI)
m/z 221.2 [M+1]+.
C. 2-(1-Methylcyclopropylamin0)(methylsulf0nyl)pyrimidine—5-
carbonitrile. To a stirred colorless solution of 2-(1-methylcyclopropylamino)(methylthio)-
pyrimidinecarbonitrile (0.449 g, 2.04 mmol) in NMP (6 mL) was added mCPBA (1.142 g,
.10 mmol) at 0 CC. The reaction mixture was then stirred at room temperature for 1 h until
completion of the reaction as indicated by LCMS. The reaction mixture was d on to next
step without further ation. MS (ESI) m/z 253.3 [M+l] +.
D. 4-((3R,4R)—3-Hydr0xymethylcyclohexylamino)—2-(l-methylcyclopropyl-
amin0)pyrimidine—5-carb0nitrile. To the reaction mixture of 2-(1-methylcyclopropylamino)
(methylsulfonyl)pyrimidinecarbonitrile from the preVious step was added DIEA (2.14 mL,
12.22 mmol) and (1R,2R,5R)—5-aminomethylcyclohexanol hydrochloride (0.371 g,
2.241 mmol; synthesis described herein). The reaction was stirred at 90 0C for 16 h. Upon
completion of reaction, as ted by LCMS and TLC, the on mixture was concentrated
and purified by silica gel tography using a gradient of 0% - 60% ethyl e in hexanes.
The product fractions were combined and concentrated to afford 4-((3R,4R)hydroxy
cyclohexylamino)(1-methylcyclopropylamino)pyrimidinecarbonitrile (0.185g, 30%
yield) as a pale yellow solid. MS (ESI) m/z 302.1 [M+1]+
E. 4-((1R,3R,4R)—3-Hydr0xymethylcyclohexylamin0)(1-
methylcyclopropylamin0)pyrimidine—5-carb0xamide. 4-((3R,4R)Hydroxy
methylcyclohexylamino)(1-methylcyclopropylamino)pyrimidinecarbonitrile (0. 1 8 1 g,
0.601 mmol) was ved in DMSO (6 mL). Ten drops of 50% aqueous sodium hydroxide
ATI—25 14175V1
2012/034349
(0.047 mL, 0.901 mmol) and ten drops of 30% aqueous hydrogen peroxide were added at room
temperature. The reaction mixture was stirred at 50 CC for 1 h. Upon completion of reaction, as
indicated by LCMS and TLC, the reaction mixture was cooled to room temperature and was
poured into 300 mL of the ice water. The aqueous layer was extracted with 20%
iPrOH/chloroform (x3) and the combined c layers were dried over anhydrous magnesium
sulfate and trated. The crude mixture was purified by reverse-phased semi-preparative
HPLC (0-50% acetonitrile + 0.1% TFA in water + 0.1% TFA, over 30 min). Fractions
containing product were concentrated under reduced pressure. The resulting residue was
redissolved in methanol (5 mL), passed over Varian StratoSpheres HCO3 resin SPE tubes for
TFA removal (0.9 mmol bicarbonate equiv. per tube), and then trated under reduced
pressure to afford 4-((1R,3R,4R)—3-hydroxymethylcyclohexylamino)(1-
methylcyclopropylamino)pyrimidinecarboxamide (0.069 g, 36% yield); 1H NMR (400 MHZ,
DMSO-dg) 5 ppm 8.79 - 8.92 (m, 1H), 8.28 - 8.39 (m, 1H), 7.32 - 7.48 (m, 1H), 4.56 (s, 1H),
3.83 - 3.97 (m, 1H), 2.89 - 3.08 (m, 1H), 2.18 - 2.31 (m, 1H), 1.97 - 2.08 (m, 1H), 1.61 - 1.74 (m,
1H), 1.35 (s, 4H), 1.05 - 1.26 (m, 1H), 0.94 (d, J: 6.64 Hz, 5H), 0.66 (s, 3H), 0.54 (br. s., 3H);
MS (ESI) m/z 320.2 [M+1]+.
Example 42: 4-(tert-Butylamin0)—2-((1r,4r)—4—cyclopropoxycyclohexylamin0)-
pyrimidine-S-carboxamide
V/O’“ N \ NH2
)L /
N N NH
H /|\
A. 2-((1r,4r)—4-Hydr0xycyclohexyl)is0indoline-1,3-di0ne. To a stirring solution
of isobenzofuran-l, 3-dione (90 g, 0.6 mol) and (1r,4r)aminocyclohexanol (70 g, 0.6 mol) in
toluene (250 mL) and DMF (250 mL) was stirred at 130 oC ght. The reaction was cooled
to room temperature, water was added and the product was filtered, washed with water and dried
under vacuum to give the desired product as a white solid, which was used for the next step
without r purification (119 g, 0.48 mol, yield: 81%). 1H NMR (400 MHz, CDClg) 5 ppm
7.84-7.79 (m, 2H), 7.72-7.68 (m, 2H), 4.18-4.10 (m, 1H), 3.80-3.73 (m, 1H), .29 (qd,
—174—
ATI—25 14175v1
Jl=3.4Hz, J2=l30Hz, 2H), 2.12-2.09 (dd, J=6.2Hz, 2H), 1.78-1.74 (dd, J=6.6Hz, 2H), 1.49-1.39
(qd, Jl=3.3Hz, J2=l25Hz, 2H).
B. 2-((1r,4r)—4-(Vinyloxy)cyclohexyl)is0indoline-1,3-di0ne. Palladium acetate
(ll g, 0.048 mol) in ethoxyethene (500 mL) was stirred at 0 0C for 15 min, followed by the
addition of a on of 2-((lr,4r)hydroxycyclohexyl)isoindoline-l,3-dione (l 18 g, 0.48 mol)
in ethoxyethene (1000 mL). The mixture was stirred at 60 0C for 3 days. After that the mixture
was cooled to room temperature, filtered and washed with ethyl acetate. The resulting filtrate
was concentrated to give the crude product, which was purified by silica gel column
chromatography (l6.7% - 25% ethyl acetate in petroleum ether) to afford the title compound as a
white solid (80 g 0.29 mol, yield: 61%). 1H NMR (400 MHz, CDClg) 8 ppm 7.84-7.80 (m, 2H),
7.72-7.68 (m, 1H), .32 (dd,J=6.4Hz, 1H), 4.34-4.30 (dd,J=l.2Hz, 1H), 4.20-4.12 (m,
lH),4.04-4.02 (dd, z, 1H), 3.89-3.81 (m, 1H), 2.40-2.29 (qd, Hz, J2=l30.6Hz, 2H),
2.2 l -2. 17 (dd, J=64Hz, 2H), 182-1 .78 (dd, J=64Hz, 2H), 153-1 .43 =33Hz, J2=l26.6Hz,
2H).
C. 2-((1r,4r)—4-Cyclopr0p0xycyclohexyl)isoindoline-1,3-dione. To a stirred
mixture of diethyl ether (100 mL) and potassium hydroxide (2.5 N, 50 mL) was added
l-nitrosourea (38 g, 0.37 mol) at 0 CC. After 15 min, the ether phase was collected and carefully
added to the mixture of 2-((lr,4r)(vinyloxy)cyclohexyl)isoindoline-l,3-dione (10 g,
36.9 mmol) and palladium acetate (826 mg, 3.69 mmol) in diethyl ether (100 mL) and DCM
(100 mL). The resulting solution was stirred at 0 CC for 0.5 h. The procedure of generation and
addition of the ethereal solution of diazomethane was then repeated three times. After the
reaction was completed, the solid in the on mixture was filtered off, the filtrate was
collected and concentrated to give the crude product which was purified by silica gel column
chromatography (25% ethyl acetate in petroleum ether, then 33% ethyl e in petroleum
ether) to give 2-((lr,4r)cyclopropoxycyclohexyl)isoindoline-l,3-dione (9.3 g, 32.6 mmol,
yield: 88%). 1H NMR (400 MHz, CDClg) 5 ppm 7.84-7.79 (m, 2H), 7.72-7.67 (m, 1H), 4.18-4.09
(m, 1H), .48 (m, lH),3.37-3.33 (m, lH),2.38-2.27 (qd, Jl=3.6Hz, .6Hz, 2H),2.2l-
2.18 (dd, J=6.4Hz, lH), l.79-l .76 (dd, J=6.4Hz, 2H), l.50-l .33(qd, Jl=35Hz, J2=l26Hz, 2H),
0.60-0.56 (m, 2H), 0.50-0.46 (m, 2H).
D. (1r,4r)—4-Cyclopropoxycyclohexanamine. A mixture of 2-((lr,4r)
ropoxycyclohexyl)isoindoline-l,3-dione (30 g, 0.10 mol) and hydrazine hydrate (l 8.9 g,
-l75-
ATI—2514l75vl
0.31 mol) in ol (600 mL) was heated at 80 0C for 2 h. The reaction was cooled to room
temperature and filtered. The filtrate was collected and concentrated to give the crude t
which was purified by silica gel column chromatography (3.33% methanol in DCM) to afford
(h4)¢wdwmmquwammmmwamemflflOgwfimdeMd6W0lHNMR
(400 MHz, CDClg) 8 ppm 3.40-3.28 (m, 2H), 2.72-2.65 (m, 1H), 2.06-2.03 (dd, J=3.8Hz, 2H),
1.88-1.85 (dd, J=6.2Hz, 2H), .24 (qd, J1=28Hz, J2=123.3Hz, 2H), 1.19-1.09 (qd,
J1=28Hz, J2=123.3Hz, 2H), 0.56-0.51(m, 2H), 0.49-0.44(m, 2H); MS(ESI) m/z = 156.1 [M+1]+.
E. 4-(tert-Butylamin0)—2-(methylsulfonyl)pyrimidine—5-carb0xamide. To a
stirred on of t-butylamino)(methylthio)pyrimidinecarboxamide (0.500 g,
2.081 mmol; synthesis described herein) in NMP (6 mL) was added mCPBA (0.933 g,
4.16 mmol) at 0 CC. The reaction mixture was stirred at room temperature for 1 h until
completion of the reaction as indicated by LCMS. The reaction mixture was carried on to the
next step without further purification. MS (ESI) m/z 273.2 [M+1] +.
F. 4-(tert-Butylamin0)—2-((1r,4r)—4-cyclopr0p0xycyclohexylamin0)—
pyrimidine—5-carb0xamide. To the reaction mixture of 4-(tert-butylamino)(methylsulfonyl)-
pyrimidinecarboxamide from the preVious step was added DIEA (1.5 mL, 8.33 mmol) and
(1r,4r)cyclopropoxycyclohexanamine (0.485 g, 3.12 mmol). The reaction was d at 90 °C
for 16 h. Upon completion of the reaction, as indicated by LCMS and TLC, the reaction mixture
was slowly added to ~ 70 mL of ice water. This product was filtered, washed with water,
followed by a minimum amount of ethanol and diethyl ether and then dried to give the title
nd 4-(tert-butylamino)((1r,4r)cyclopropoxycyclohexylamino)pyrimidine
carboxamide (0.214g, 30% yield); 1H NMR (400 MHz, DMSO-dg) 5 9.18 (s, 1H), 8.32 (s, 1H),
702-708(nn1HL357-3670n,HD,3300“]=293Ph,HHL199-2090nfiHD,L85-
1.94 (m, 2H), 1.41 (s, 11H), 1.28 (br. s., 5H), 0.37 - 0.46 (m, 4H); MS (ESI) m/z 348.3 .
ATI—25 14175Vl
Example 43: 4-((1R,3S)—3-Hydr0xycyclohexylamino)—2-((1r,4R)—4-
hydroxycyclohexylamin0)pyrimidinecarb0nitrile
HOII'Q )LN/jCN/
N N NH
A. 4-((1R,3S)—3-Hydr0xycyclohexylamino)—2-((1r,4R)—4—
hydroxycyclohexylamino)pyrimidine—5-carbonitrile. 2-Chloro((1R,3S)
hydroxycyclohexylamino)pyrimidinecarbonitrile (240 mg, 0.950 mmol; synthesis
described ), (1R,4R)—4-aminocyclohexanol hydrochloride (216 mg, 1.425 mmol),
and cesium carbonate (619 mg, 1.899 mmol) were suspended in 1,4-dioxane (10 mL) and
heated at 80 0C for 3 h. LCMS showed the d product mass as the dominant peak and
no starting material was remaining. The reaction mixture was concentrated and purified by
silica gel column chromatography (10-100% ethyl acetate in hexanes, then 0-15%
methanol in DCM) to give the title compound (159 mg, 0.480 mmol, 50.5% ;
1H NMR (DMSO-d6 ,400 MHz) 5 ppm 8.06 - 8.24 (m, 1 H), 7.09 - 7.57 (m, 2 H), 4.74 (d,
J=4.3 Hz, 1 H), 4.48 - 4.63 (m, 1 H), 3.89 - 4.16 (m, 1 H), 3.34 - 3.74 (m, 3 H), 1.53 - 2.09
(m, 8 H), 0.99 — 1.51 ppm (m, 8 H); MS (ESI) m/Z 332.1 [M+1]+.
Example 44: 4-((1R,3S)—3-Hydr0xycyclohexylamin0)((1r,4R)—4-(2,2,2-
trifluor0ethoxy)cyclohexylamin0)pyrimidinecarb0nitrile
FFflvoh,
QNACCCNN \N NH
” ii
[0045 8] A. 4-((1R,3S)—3-Hydr0xycyclohexylamin0)((1r,4R)—4—(2,2,2-
roethoxy)cyclohexylamin0)pyrimidinecarb0nitrile. To a stirring solution of
2-chloro((1R,3S)—3-hydroxycyclohexylamino)pyrimidinecarbonitrile (113 mg,
0.447 mmol; synthesis described herein) and (1r,4r)(2,2,2-trifluoroethoxy)cyclo-
hexanamine (150 mg, 0.761 mmol; synthesis bed herein) in DMSO (6.0 mL) was
ATI—25 14175V1
added DIEA (0.156 mL, 0.895 mmol). The resulting mixture was stirred at ambient
temperature for 3 d. DMSO was removed under reduced pressure and the remaining
residue was purified using silica gel chromatography (0-40% ethyl acetate + 10% 7 N
ammonia in methanol in s) to afford the title compound (156 mg, 0.378 mmol,
84.6% yield). 1H NMR (400 MHz, DMSO-d6) 5 ppm 8.03 - 8.29 (m, 1 H), 7.10 - 7.62 (m,
2 H), 4.74 (d, J=3.90 Hz, 1 H), 4.05 (q, J=9.37 Hz, 3 H), 3.36 - 3.82 (m, 3 H), 1.55 - 2.13
(m, 8 H), 1.00 — 1.50 (m, 8 H). ”P NMR (376 MHz, DMSO-d6) 5 ppm -73.64 (t,
J=9.19 Hz, 3 F). MS (ESI) m/z 414.2 [M+1]+.
Example 45: ,4R)—4-(Diflu0r0meth0xy)cyclohexylamin0)((1R,3S)—3-
hydroxycyclohexylamin0)pyrimidine—5-carb0nitrile
FYO/l'
F l/jCN
'1‘ N/ NH
H i1...
A. 2-((1r,4R)—4-(Difluorometh0xy)cyclohexylamino)—4—((1R,3S)—3-
hydroxycyclo-hexylamin0)pyrimidinecarb0nitrile. To a stirring solution of 2-
((1R,3 S)hydroxycyclohexylamino)pyrimidine-5 nitrile (100 mg,
0.396 mmol; synthesis described herein) and (1r,4r)(difluoromethoxy)cyclohexanamine
(131 mg, 0.791 mmol; synthesis described herein) in DMSO (4.0 mL) was added DIEA
(0.138 mL, 0.791 mmol). The resulting mixture was stirred at ambient temperature
overnight. DMSO was removed under reduced pressure and the remaining residue was
purified using silica gel chromatography (5-40% ethyl acetate + 10% ammonia saturated
methanol in hexanes) to afford the title nd (130 mg, 0.340 mmol, 86.0% yield).
1H NMR (400 MHz, DMSO-d6) 8 ppm 8.08 - 8.25 (m, 1 H), 7.12 - 7.62 (m, 2 H), 6.47 -
6.94 (m, 1 H), 4.74 (d, J=4.29 Hz, 1 H), 3.88 - 4.18 (m, 2 H), 3.41 - 3.85 (m, 2 H), 1.01 -
2.11 (m, 16 H). ”P NMR (376 MHz, DMSO-d6) 5 ppm —79.21 — -78.76 (m, 2 F). MS
(ESI) m/z 382.3 [M+1]+.
ATI—25 14175v1
Example 46: 4-(tert—Butylamin0)(4-hydr0xybicyclo[2.2.1]heptan-l-ylamin0)pyrimidine—
-carb0xamide
HO\®\ I‘ll/EELNHZ
A. Cyclopentane-l,3-dicarb0xylic acid. A 22-L, 3-neck, round bottom
flask was equipped with a mechanical stirrer, a J-KEM temperature controller, and a
nitrogen inlet. The flask was d with norbornene (200 g, 2.123 mol), ethyl acetate
(1.95 L), and acetonitrile (1.95 L). The reaction mixture was cooled to 5 0C using an
acetone/dry ice bath. Ruthenium trichloride (9.69 g, 46.72 mmol) was added in one
portion followed by the slow addition of a suspension of sodium periodate (1.816 kg,
8.707 mol) in water (2.925 L) over 30 min. The reaction slowly began to exotherm and
was monitored to keep the temperature between 10 OC and 15 0C. After 90 min the
reaction mixture suddenly thickened to the point where stirring was difficult and
exothermed rapidly up to 39 0C (a large amount of dry ice was added to the cooling bath to
control the exotherm). The reaction mixture was allowed to cool to 20 0C, the dry
ice/acetone bath was removed, and the mixture was d at room temperature overnight.
The solids were d by filtration through a pad of celite and the filtrate was
concentrated to a solid which was triturated with hexane (2 L), filtered, and rinsed with
hexane (2 X 500 mL) to yield 195 g (58%) of cyclopentane-l,3-dicarboxylic acid.
1H NMR (500 Hz, DMSO-dg) 8 ppm 12.07 (s, 2H), 2.66-2.73 (m, 2H), 2.06-2.12 (m, 1H),
1.85-1.89 (m, 1H), .85 (m, 4H).
B. Dimethyl cyclopentane—1,3-dicarb0xylate. A 5-L, 3-neck, round
bottom flask was equipped with a mechanical r, a J-KEM temperature controller, and
a reflux condenser. The flask was charged with cyclopentane-l,3-dicarboxylic acid
(357 g, 2.262 mol) and ol (1.75 L). The solution was cooled to 7 0C using an
ice/water bath. Concentrated sulfuric acid (70 mL) was added se over 30 min
resulting in an rm up to 12 CC. The reaction mixture was heated to reflux and
stirred for 16 h when TLC is (10 % methanol/ethyl acetate) indicated that the
reaction was complete. The reaction e was concentrated, redissolved in methyl
ATI—2514175v1
WO 45569
tert—butyl ether, and washed with saturated aqueous sodium bicarbonate (2 X 150 mL) and
brine (2 X 150 mL). The organic layer was dried over sodium sulfate, filtered, and
concentrated. The ing clear oil was dissolved in hexane (2 L) and treated with a 2 N
aqueous sodium hydroxide solution (950 mL) until the pH ~ 10. The layers were
separated and the aqueous layer was extracted with hexane (4 X 1 L). The organic layers
were combined, dried over sodium sulfate, filtered, and concentrated to provide 360 g
(100%) of dimethyl cyclopentane-l,3-dicarboxylate as a clear oil. 1H NMR (500 Hz,
CDClg) 8 ppm 3.67 (s, 6H), 2.75-2.83 (m, 2H), 2.20-2.26 (m, 1H), 2.05-2.12 (m, 1H),
1.90-2.0 (m, 4H).
C. yl bicyclo[2.2.1]heptane—l,4-dicarb0xylate. A 22-L, 3-neck,
round bottom flask was equipped with a J-KEM temperature controller, a mechanical
stirrer, a nitrogen inlet, and an addition fiJnnel. The flask was flushed with nitrogen then
charged with anhydrous THF (5 L) and ropylamine (731 mL, 5.219 mol). The
on was cooled to —20 0C using a dry ice/acetone bath. The stirring mixture was
slowly treated with 1.6 M llithium in s (3.02 L, 4.833 mol) via cannula over
1 h maintaining the temperature between —20 CC and —27 CC. The reaction mixture was
cooled to — 40 OC and hexamethylphosphoramide (2.7 L, 16.317 mol) was slowly added
via on funnel over 40 min. The on mixture was cooled to —73 °C and yl
cyclopentane-l,3-dicarboxylate (360 g, 1.933 mol) dissolved in anhydrous THF (2 L) was
slowly added via addition funnel over 2 h. The reaction mixture was warmed to —10 CC
and stirred at that temperature for 30 min, then cooled to —70 CC and treated with
1-bromochloroethane (267 mL, 3.209 mol) via addition funnel over 4 h. The reaction
mixture was allowed to slowly warm to room temperature over 12 h and then was
quenched with saturated aqueous ammonium chloride (2 L) over 90 min. The reaction
mixture was diluted with hexane (2 L), the layers were separated, and the aqueous layer
was further extracted with hexane (3 X 2 L). The combined organic layers were washed
with brine (2 X 1 L), dried over sodium sulfate, filtered, and concentrated to a brown oil.
The crude product was purified by silica gel purification (0—10 % ethyl acetate/hexane).
The product ning fractions were concentrated to near dryness and diluted with
hexanes. The resulting crystalline solids were filtered and washed with hexane (200 mL)
providing pure product as a clear crystalline solid. Additional batches of product were
ATI—25 14175v1
obtained from the e in a similar manner. All product batches were combined to
provide 208 g (51%) of dimethyl bicyclo[2.2. 1]heptane-1,4-dicarboxylate as a clear
crystalline solid. 1H NMR (500 Hz, CDClg) 5 ppm 3.68 (s, 6H), 2.03 (d, J: 6.4 Hz, 4H),
1.90 (s, 2H), 1.67 (d, J: 7.0, 4H).
D. 4-(Methoxycarbonyl)bicyclo[2.2.1]heptanecarb0xylic acid. A
12-L, 3-neck, round bottom flask was equipped with a ical stirrer, a J-KEM
temperature controller, and a 250 mL addition flannel. The flask was charged with
dimethyl bicyclo[2.2.1]heptane-1,4-dicarboxylate (208 g, 980 mmol) and THF (6.7 L).
The resulting solution was cooled to 15 0C using an ice/water bath. Sodium hydroxide
pellets (39.2 g, 980 mmol) were dissolved in methanol (400 mL) and slowly added to the
stirring solution over 30 min. After the addition was te, white solids began to
precipitate. The reaction mixture was stirred at room temp for 16 h when TLC analysis
(100% ethyl acetate) indicated about 90% conversion. The reaction e was
concentrated to dryness, ed in hexane (2 L), filtered, and washed with hexane (2 X
400 mL). The resulting sodium carboxylate salt was transferred to a 3-L, 3-neck, round
bottom flask equipped with a mechanical stirrer, dissolved in water (1 L), and slowly
treated with 2 N aqueous hydrochloric acid (430 mL) at 10 CC until pH ~ 4. The thick
suspension was diluted with ethyl acetate (1 L) and transferred to a tory funnel. The
layers were separated and the aqueous layer was fiarther extracted with ethyl acetate (2 X
500 mL), washed with brine (200 mL), dried over sodium sulfate, and concentrated to
provide 170 g (87%) of 4-(methoxycarbonyl)bicyclo[2.2. 1]heptanecarboxylic acid.
1H NMR (500 Hz, DMSO-dg) 5 ppm 12.21 (s, 1H), 3.60 (s, 3H), 1.91 (d, J = 6.7 Hz, 4H),
1.75 (s, 2H), .62 (m, 4H).
E. 4-(Benzyloxycarbonylamin0)bicyclo[2.2.1]heptane—l-carboxylic acid.
A 2-L, 3-neck, round bottom flask was equipped with a mechanical stirrer, a J-KEM
temperature controller, a reflux condenser, and a nitrogen inlet. The flask was charged
with 4-(methoxycarbonyl)bicyclo[2.2.1]heptanecarboxylic acid (100 g, 0.504 mol) and
anhydrous e (500 mL). The flask was cooled to 10 OC and DIEA (175 mL,
1.008 mol) was slowly added over 5 min resulting in a mild exotherm up to 14 OC.
Diphenylphosphonic azide (130 mL, 0.605 mol) was slowly added to the reaction mixture.
The mixture was heated to about 60 CC when ssing began. The reaction quickly
ATI—25 14175v1
ted a large amount of gas and exothermed to reflux. The reaction was stirred at
reflux (110 CC) for 2 h, then cooled to 50 CC and slowly treated with benzyl alcohol
(104 mL, 1.008 mol) over 5 min. The reaction was heated again to 110 CC and stirred for
40 h. The reaction mixture was concentrated to an oil in vacuo, dissolved in ethyl acetate
(2 L), washed with brine (500 mL), and the brine layer was extracted with ethyl acetate
(2 X 400 mL). The ed organics were dried over sodium sulfate, filtered, and
amwmmmdmamweMMmmhwwfiwfiflmdwaih3mmkmmmbmwmflwk
equipped with a mechanical stirrer, a J-KEM temperature controller, and a nitrogen inlet.
The flask was charged with methanol (2 L). The mixture was cooled to 10 °C and treated
with 2N sodium ide (500 mL) over 5 min resulting in an exotherm to 16 CC. The
reaction was stirred at 60 CC for 20 h when TLC analysis (20% methanol/ethyl e)
indicated a complete reaction. The reaction was cooled to room temperature and methanol
was removed in vacuo. With cooling, the reaction mixture was acidified using 2 N
hydrochloric acid (480 mL) to pH 2-3. The aqueous mixture was extracted using ethyl
e (2 L, then 500 mL). The combined c layers were washed with brine
(400 mL), dried over sodium sulfate, and concentrated to provide the crude product as a
brown oil. The crude product was purified by silica gel chromatography (20—100% ethyl
acetate/hexane) providing 132 g (91%) of 4-(benzyloxycarbonylamino)-
o[2.2.1]heptanecarboxylic acid. 1H NMR (500 Hz, DMSO- d6) 5 ppm 12.12 (s,
1H), 7.56 (s, 1H), 7.34-7.38 (m, 4H), 7.28-7.32 (m, 1H), 4.98 (s, 2H), 1.80-1.93 (m, 4H),
1.79 (s, 2H), 1.64 (t, J: 9.1 Hz, 2H), 1.57 (t, J: 8.8 Hz, 2H).
F. 4-Amin0bicyclo[2.2.1]heptane—l-carboxylic acid. A 2-L Parr bottle was
charged with 4-(benzyloxycarbonylamino)bicyclo[2.2.1]heptanecarboxylic acid (105 g,
363mmmDnndeoH5mhnLL08Nhymodmnmadd600mLme10%pdbmmnon
carbon (38.6 g, 18.15 mmol, 50% wet with water). The reaction mixture was reacted on a Parr
shaker under 30 gpsi hydrogen for 10 h when TLC is (10% methanol/ethyl e)
indicated a te reaction. The catalyst was removed by filtration through a short plug of
celite and the plug was washed thoroughly with water (4 X 100 mL). The filtrate was
concentrated to provide 4-aminobicyclo[2.2.1]heptanecarboxylic acid (56.3 g, 100%) as a wet
white solid which was used in the next step without any further purification; MS (ESI) m/z
156.2 [M+1]+
ATI—25 14175v1
G. 0xybicyclo[2.2.1]heptane—l-carboxylic acid. A 2-L, 3-neck, round
bottom flask was equipped with a mechanical stirrer, a reflux ser, a J-KEM temperature
controller, and a nitrogen inlet. The flask was charged with 4-aminobicyclo[2.2.1]heptane
carboxylic acid (56.3 g, 363 mmol) and 10% aqueous acetic acid (340 mL). The reaction
mixture was cooled to 10 oC and was slowly treated over 45 min with sodium nitrite (75.0 g,
1.088 mol) in water (125 mL) via addition filnnel. A significant amount of gas evolution was
observed and the on mixture was stirred at 65 oC overnight. The reaction was cooled to
oC and slowly treated over 30 min with potassium hydroxide (183 g, 3.265 mol) in ol
(400 mL) via addition filnnel. The reaction was stirred at 65 CC for 5 h when TLC analysis (10%
methanol/ethyl acetate) indicated a te reaction. The reaction mixture was concentrated to
remove ol and the remaining aqueous mixture was extracted with ethyl acetate (2 X
400 mL). The aqueous layer was acidified to pH 3 using concentrated hydrochloric acid
(210 mL) while cooling in ice/water bath. The resulting solids (impurities) were filtered and
washed with water (2 X 30 mL). The filtrate was extracted with ethyl acetate (10 X 400 mL),
dried over sodium sulfate, and concentrated to s to provide 53 g (94%) of
4-hydroxybicyclo[2.2.1]heptanecarboxylic acid; MS (ESI) m/z 155.2 [M-1]'
H. Benzyl 4-hydr0xybicyclo[2.2.1]heptanylcarbamate. A 3-L, 3-neck,
round bottom flask was equipped with a mechanical stirrer, a J-KEM temperature controller, a
nitrogen inlet, and a 125 mL addition funnel. The flask was flushed with nitrogen and charged
with 4-hydroxybicyclo[2.2.1]heptanecarboxylic acid (53 g, 339 mmol) and ous toluene
(350 mL). The reaction mixture was cooled to 10 CC and treated with benzyl alcohol (175 mL,
1.695 mol). The reaction mixture was then slowly treated with DIEA (118 mL, 678 mmol) and
diphenylphosphonic azide (87.7 mL, 407 mmol). The reaction mixture was slowly heated up to
50 °C when off-gassing began. The heating mantle was d and the reaction mixture
slowly exothermed up to 75 0C while off-gassing considerably. The reaction was heated to
110 CC and stirred for 20 h when TLC is (10% methanol/ethyl acetate) indicated a
complete reaction. The on mixture was concentrated to remove solvent and partitioned
between ethyl acetate (1.2 L) and brine (700 mL). The organic layer was dried over sodium
sulfate, concentrated, and purified by silica gel chromatography (20—60% ethyl e/hexane)
providing 61 g (69%) ofbenzyl 4-hydroxybicyclo[2.2.1]heptanylcarbamate; MS (ESI) m/z
260.1 [M-1]'
ATI—25 14175v1
WO 45569
] I. 4-Amin0bicyclo[2.2.1]heptan-l-ol hloride. A 2-L Parr bottle was
charged with benzyl 4-hydroxybicyclo[2.2.1]heptanylcarbamate (61 g, 233 mmol), methanol
(400 mL), and water (200 mL). The Parr bottle was flushed with nitrogen and charged with
% palladium on carbon (25 g, 11.65 mmol, 50% wet with water). The reaction was run under
gpsi hydrogen on a parr shaker for 3 h when TLC analysis (15% methanol/DCM with 2%
ammonium hydroxide) ted a complete reaction. The reaction was filtered through a celite
plug and concentrated to remove ol. The resulting aqueous mixture was treated with 2 N
hydrochloric acid (115 mL) until it reached pH 1-2. The aqueous mixture was extracted using
ethyl acetate (5 X 400 mL) to remove an ty. The aqueous mixture was concentrated to
dryness and dried in a vacuum oven at 40 oC overnight to provide 36.91 g (97%) of
4-aminobicyclo[2.2.1]heptanol hydrochloride; MS (ESI) m/z 128.1 [M+1]+
J. 4-(tert-Butylamin0)—2-(4-hydroxybicyclo[2.2.1]heptan-l-ylamin0)-
pyrimidine—5-carb0xamide. 4-(tert-Butylamino)(methylsulfonyl)pyrimidinecarboxamide
(0.165 g, 0.606 mmol; synthesis described herein), 4-aminobicyclo[2.2.1]heptanol
hydrochloride (0.105 g, 0.644 mmol) and DIEA (0.337 mL, 1.931 mmol) were mixed in DMF
(8 mL) and heated at 90°C overnight. The t was evaporated and the residue was d
by silica gel column chromatography (0-10% methanol in ethyl acetate) to give the desired
product. (41 mg, 0.127 mmol, 21 %). 1H NMR (400 MHz, DMSO-d6) 5 ppm 9.43 (br. s., 0 H)
8.32 (s, 1 H) 7.07 (br. s., 1 H) 4.88 (br. s., 1 H) 1.94 - 2.14 (m, 2 H) 1.61 - 1.87 (m, 6 H) 1.49 -
1.60 (m, 2 H) 1.42 (s, 9 H). MS (ESI) m/z 320.0 [M+1]+
Example 47: 2-((1r,4r)—4-Hydr0xycyclohexylamin0)(3-methylbicyclo[1.1.1]pentan
ylamin0)pyrimidine—5-carb0xamide
A. 3-Methylbicyclo[1.1.1]pentane—1-carb0xylic acid. To a solution of
1-iodomethylbicyclo[1.1.1]pentane (1.62 g, 7.79 mmol; prepared according to Eur. J.
Org. Chem. 1137-1155 (2000)) in diethyl ether (26 mL), a solution of tert-butyllithium
ATI—25 14175v1
(9.16 mL, 15.57 mmol, 1.7 M in pentane) was added over a period of 40 min at -78 0C.
After stirring the reaction mixture for 1 h at this temperature, carbon e gas was
bubbled through the reaction mixture for 5 min and then the mixture was allowed to warm
to room ature. The reaction mixture was extracted twice with a 5% aqueous sodium
bicarbonate solution. The ed aqueous phases were acidified to pH 2- 3 with
concentrated hydrochloric acid at 0 CC, ted with sodium chloride, and extracted with
diethyl ether. The combined organic phases were dried and, after evaporation of the
solvent under reduced pressure, purified by column chromatography (0-20% ethyl acetate
in hexanes) to afford 3-methylbicyclo[1.1.1]pentanecarboxylic acid (0.5 g, 3.96 mmol,
50.9 % yield); 1H NMR (400 MHz, DMSO-d6) 8 ppm 12.21 (s, 1 H), 1.82 (s, 6 H), 1.14 (s,
3 H).
B. tert-Butyl 3-methylbicyclo[1.1.1]pentanylcarbamate.
Diphenylphosphonic azide (0.340 mL, 1.577 mmol) was added dropwise to a solution of
3-methylbicyclo[1.1.1]pentanecarboxylic acid (0.199 g, 1.577 mmol) and TEA
(0.220 mL, 1.577 mmol) in dry tert-butanol (6 mL). The solution was stirred at room
ature for 4 h and then heated to reflux for 24 h. The solvent was evaporated under
reduced pressure and the residue was extracted three times with tert-butyl methyl ether.
The combined organic phase was washed with saturated aqueous sodium bicarconate
solution and dried over anhydrous magnesium e. After filtration and evaporation of
the solvent under reduced pressure the residue was purified by column chromatography
(0-5% ethyl e in hexanes) to afford tert—butyl 3-methylbicyclo[1.1.1]pentan
ylcarbamate (0.111 g, 0.563 mmol, 35.7 % yield); 1H NMR (400 MHz, 6) 5 ppm
1.74 (s, 6 H), 1.36 (s, 9 H), 1.17 (s, 3 H).
] C. 3-Methylbicyclo[1.1.1]pentanamine hydrochloride. To a solution
of tert-butyl 3-methylbicyclo[1.1.1]pentanylcarbamate (0.1 g, 0.507 mmol) in ethyl
acetate (10 mL) was added hydrochloric acid (0.760 mL, 3.04 mmol, 4M in e) at
room temperature. The reaction was stirred at room temperature for 16 h. The reaction
mixture was concentrated, the resulting solids were washed with diethyl ether and the
ing suspension filtered to give 3-methylbicyclo[1.1.1]pentanamine hydrochloride
(0.04 g, 0.299 mmol, 59.1 % yield). 1H NMR (400 MHz, DMSO-d6) 8 ppm 8.59 (br. s.,
3 H), 1.84 (s, 6 H), 1.22 (s, 3 H).
ATI—25 14175v1
D. ,4r)—4-Hydr0xycyclohexylamin0)(3-
methylbicyclo[1.1.1]pentan-l-ylamin0)pyrimidinecarb0xamide. To a stirring
suspension of 2-((1r,4r)hydroxycyclohexylamino)(methylsulf1nyl)pyrimidine
carboxamide (0.25 g, 0.838 mmol; synthesis bed herein) and 3-methylbicyclo-
[1.1.1]pentanamine hydrochloride (0.123 g, 0.922 mmol) in DMF (3 mL) was added
DIEA (0.366 mL, 2.095 mmol) and the reaction was heated to 80 oC overnight. The crude
reaction mixture was concentrated under reduced pressure and then ice-cold water (20 mL)
was added to the residue. The resulting mixture was usly stirred for 1 h and then the
formed precipitate was d, washed with water and dried under vacuum to afford
2-((1r,4r)hydroxycyclohexylamino)(3-methylbicyclo[1 . 1 . 1]pentan
ylamino)pyrimidinecarboxamide (0.222 g, 0.670 mmol, 80 % . 1H NMR
(400 MHz, DMSO-d6) 5 ppm 1.15 - 1.31 (m, 7 H), 1.81 - 1.93 (m, 4 H), 1.98 (s, 6 H), 3.35
- 3.44 (m, 1 H), 3.54 - 3.63 (m, 1 H), 4.56 (d, J=4.29 Hz, 1 H), 7.12 (d, J=7.81 Hz, 1 H),
8.35 (s, 1 H), 9.35 (s, 1 H); MS (ESI) m/z 332.4 [M+1]+.
Example 48: 4-((1R,3S)Hydr0xycyclohexylamin0)(4-methyltetrahydr0-2H-pyran
ylamin0)pyrimidine—5-carb0xamide
)L /
N N NH
A. 4-((1R,3S)—3-Hydr0xycyclohexylamin0)(4-methyltetrahydr0-2H—
pyranylamin0)pyrimidine—5-carboxamide. 4-((1R,3S)—3-Hydroxycyclohexylamino)-
2-(methylsulfonyl)pyrimidinecarboxamide (0.740 g, 2.354 mmol; synthesis described
herein), 4-methyltetrahydro-2H-pyranamine hydrochloride (0.892 g, 5.88 mmol), DIEA
(1.645 mL, 9.42 mmol) and NMP (20 mL) were combined and heated for 1 h at 180 CC in
a microwave . The solvent was concentrated under reduced pressure and the residue was
purified by column chromatography (0-10% methanol in DCM) to afford 4-((1R,3S)
hydroxycyclohexylamino)(4-methyltetrahydro-2H-pyranylamino)pyrimidine
amide (88 mg, 0.252 mmol, 10.70 % yield). 1H NMR (400 MHz, DMSO-d6) 5 ppm
ATI—25 14175v1
8.96 (br. s., 1H), 8.35 (s, 1H), 6.76 (br. s., 1H), 4.65 (d, .1: 4.69 Hz, 1H), 3.56 (dd,
.1: 3.32, 6.83 Hz, 4H), 3.40 — 3.47 (m, 1H), 2.20 — 2.29 (m, 2H), 2.10 (d, .1: 10.93 Hz,
1H), 1.76 — 1.89 (m, 2H), 1.66 — 1.73 (m, 1H), 1.50 — 1.59 (m, 2H), 1.39 (s, 3H), 1.16 — 1.26
(m, 1H), 1.03 _ 1.12 (m, 3H). MS (ESI)1n/z 350.4 [M+1]+.
Example 49: 4-((1R,3S)—3-Hydroxycyclohexylamino)—2—((1r,4r)—4—[(2H3)methyloxy]-
exylamino) dine-S-carboxamide
/O//
D30 ‘ N \ NH2
N N NH
A. (1r,4r)—4-[(2H3)methyloxy]-N-tritylcyclohexanamine. To a solution of
(1r,4r)(tritylamino)cyclohexanol (2.34 g, 6.55 mmol) in dry THF (15 mL) was added
sodium hydride (524 mg, 13.1 mmol, 60 % in mineral oil) at 0 0C. After the resulting
mixture was stirred for 30 minutes at 0 0C under nitrogen atmosphere, a solution of
iodo(2H3)methane (1.0 g, 6.89 mmol) in THF (5 mL) was added dropwise at 0 0C. The
resulting e was stirred at room temperature ght under nitrogen atmosphere,
then poured into ice water and extracted with ethyl acetate. The combined organic layers
were washed with brine, dried over anhydrous sodium sulfate and filtered. The filtrate was
evaporated under vacuum to give crude product, which was purified by silica gel column
chromatography (5 % ethyl acetate in petroleum ether) to afford the title nd (2.0 g,
.35 mmol, 83 % yield) as a white solid. MS (ESI) m/z 375.0 [M+1] +.
B. (lr,4r)[(2H3)Methyloxy]cyclohexanamine. To a cooled (0 0C)
solution of (1r,4r)[(2H3)methyloxy]-N-tritylcyclohexanamine (2.0 g, 5.35 mmol) in
DCM (10 mL) was added TFA (3 mL) at 0 0C. The resulting mixture was dark red.
Triethylsilane (0.4 mL) was added until the resulting mixture was d to colourless.
The reaction was stirred at 0 0C for additional 15 min. After removal of all volatile
solvents in vacuo, the residue was further dried under high vacuum for 2 h to give the
crude product as a white solid. The crude t was dissolved in ethyl acetate and
aqueous hydrochloride solution (20 mL, 0.25 mol/L) was added. The organic layer was
removed and the inorganic layer was washed with ethyl acetate twice. Aqueous ammonia
ATI—2514l75vl
WO 45569
solution (2 mL) was added to the inorganic layer and the mixture was stirred for 15 min.
Concentration in vacuo gave the crude product as a white solid (706 mg, 5.35 mmol, 100%
yield). MS (ESI) m/z 133.0 [M+1]
C. 4-((1R,3S)—3-Hydr0xycyclohexylamino)—2-((1r,4r)—4-
[(2H3)methyloxy]cyclohexanamin0)pyrimidine—5-carb0xamide. A mixture of 4-
((1 R,3 S)-3 -hydroxycyclohexylamino)(methylsulfonyl)pyrimidine carboxamide
(160 mg, 0.5 mmol; synthesis described herein), )[(2H3)methyloxy]-
cyclohexanamine (132 mg, 1.0 mmol), DIEA (194 mg, 1.5 mmol) and NMP (1 mL) were
combined and heated at 80 0C overnight. The solvent was evaporated under reduced
pressure and the residue was purified by column chromatography (0-15% methanol in
DCM) to give the desired product as a white powder (120 mg, 0.33 mmol, 63 % yield).
1H NMR (400 MHz, CDgOD) 5 ppm 8.17 (s, 1H), 3.93-3.87 (m, 1H), 3.64 (s, 1H), 3.50 (d,
J: 6.0 Hz, 1H), 3.13 (s, 1H), 2.22 (s, 1H), .72 (m, 7H), 1.29-0.99 (m, 8H);
MS (ESI) m/z 367.3 [M+1] i
e 50: 4-(tert-Butylamin0)—2-((1s,4s)—4—hydr0xy
methylcyclohexylamin0)pyrimidine—5-carboxamide
>22V;
A. 4--(tert-Butylamin0)—2-((1s,4s)hydr0xymethylcyclohexyl-
amino)pyrimidine—5-carboxamide. 4-(tert-Butylamino)(methylsulfonyl)pyrimidine
carboxamide (0.110 g, 0.404 mmol; synthesis bed herein), )amino
methylcyclohexanol (0.055 g, 0.429 mmol; prepared according to PCT Int. Appl.
publication No. WO 2010027500) and DIEA (0.225 mL, 1.287 mmol) were mixed in
DMF (5 mL) and heated at 90 OC overnight. The solvent was evaporated and the residue
was purified by silica gel column chromatography (0-10% methanol in ethyl acetate) to
give the desired product. (37 mg, 0.115 mmol, 27%). 1H NMR (400 MHz, DMSO-d6)
8 ppm 9.08 — 9.23 (m, 1 H) 8.25 — 8.37 (m, 1 H) 6.89 — 7.06 (m, 1 H) 3.97 — 4.04 (m, 1 H)
ATI—25 14175v1
3.46 — 3.62 (m, 1 H) 1.48 — 1.71 (m, 6 H) 1.40 (s, 9 H) 1.19 — 1.36 (m, 2 H) 1.10 (s, 4 H).
MS (ESI)m/z 322.4 [M+1]+
Example 51: 4-((1R,3R)Hydr0xy-4,4-dimethylcyclohexylamin0)(1-
methylcyclopropylamin0)pyrimidine—5-carb0xamide
N \ NH2
% JL /N N NH
A. 2-(1-Methylcyclopr0pylamin0)—4-(methylthi0)pyrimidine
carboxamide. To a ng solution of 2-(1-methylcyclopropylamino)
(methylthio)pyrimidinecarbonitrile (0.653 g, 2.96 mmol, synthesis bed herein) in
DMSO (8 mL) was added 6N aqueous sodium hydroxide (2.470 mL, 14.82 mmol)
solution and 30% aqueous hydrogen peroxide solution (1.873 mL, 16.52 mmol) at 0 oC.
Then the e was stirred at 50 CC and for 20 minutes and was then diluted with
100 mL ethyl e and 30 mL water. The layers were separated and the aqueous layer
was back extracted with 50 mL ethyl e. The combined ethyl acetate layers were
dried over anhydrous magnesium sulfate, filtered and trated to solids that were
dried in a vacuum oven at 45 CC to afford 2-(1-methylcyclopropylamino)—4-
(methylthio)pyrimidinecarboxamide (305 mg, 1.280 mmol, 43.2 % yield). 1H NMR
(400 MHz, DMSO-d6) 5 ppm 8.31 - 8.54 (m, 1 H), 7.80 - 8.07 (m, 1 H), 6.97 - 7.77 (m,
1 H), 2.39 (br. s., 3 H), 1.37 (s, 3 H), 0.52 - 0.79 (m, 4 H). MS (ESI) m/z 239.0 [M+1]+.
B. 2-(1-Methylcyclopr0pylamin0)—4-(methylsulfinyl)pyrimidine—5—
carboxamide. To a stirring solution of 2-(1-methylcyclopropylamino)(methylthio)-
pyrimidinecarboxamide (305 mg, 1.280 mmol) in form (25.6 mL) was added
portionwise 3-phenyl(phenylsulfonyl)-1,2-oxaziridine (502 mg, 1.920 mmol). The
resulting pale yellow solution was stirred at ambient temperature overnight. The reaction
solution was concentrated under reduced pressure to give crude product as a white solid.
Ethyl acetate (10 mL) was added and the slurry was stirred at room temperature for 1 h,
filtered, washed with ethyl acetate, and dried in a vacuum oven for a few hours to afford
ATI—25 14175v1
WO 45569
2-(1-methylcyclopropylamino)(methylsulf1nyl)pyrimidinecarboxamide (242 mg,
0.952 mmol, 74.4 % yield). 1H NMR (400 MHz, DMSO-d6) 8 ppm 8.35 - 8.90 (m, 2 H),
788-8140n,1HL728-7590n,1HL274(&31D,L32-1460ng3Hx068-084
(m, 2 H), 0.50 — 0.70 (m, 2 H). MS (ESI) m/z 255.0 [M+1]+.
C. 4-((1R,3R)Hydr0xy-4,4-dimethylcyclohexylamin0)(1-
methylcyclopropylamin0)pyrimidine—5-carb0xamide. To a stirring suspension of
2-(1-methylcyclopropylamino)(methylsulf1nyl)pyrimidinecarboxamide (242 mg,
0.952 mmol) and a mixture of (1R,5R)—5-amino-2,2-dimethylcyclohexanol hydrochloride
and (1S,5S)—5-amino-2,2-dimethylcyclohexanol hydrochloride (222 mg, 1.237 mmol,
synthesis described herein) in DMF (4.543 mL) was added DIEA (0.499 mL, 2.85 mmol)
and the reaction was heated to 90 OC ght. The crude reaction mixture was poured
into 50 mL of ice water. The resulting solids were slurried for ~ 1 h, filtered, rinsed with
water and dried for a few hours in a vacuum oven at 45 CC to afford a mixture of
,3R)hydroxy-4,4-dimethylcyclohexylamino)(1 -methylcyclopropylamino)-
pyrimidinecarboxamide and 4-((1R,3R)—3-hydroxy-4,4-dimethylcyclohexylamino)
(1-methylcyclopropylamino)pyrimidinecarboxamide (169 mg, 0.507 mmol, 53.3 %
yield). This material was separated by preparative chiral SFC utilizing a Pak
AD-H, 250><30 mm ID. column with an isocratic 40% ethanol + 0.1% ammonium
hydroxide in C02 gradient at 60 mL/min flow rate and at 38 CC. The faster eluting isomer
was denoted as peak 1 and 49 mg (0.147 mmol) was obtained. The slower g isomer
was denoted as peak 2 and 51 mg (0.153 mmol) was obatined. Peak 1: 1H NMR
(400 MHz, DMSO-dg) 5 ppm 8.71 - 9.02 (m, 1 H), 8.21 - 8.43 (m, 1 H), 7.03 - 7.54 (m,
1HL444-4580n,1HL381-3990n,1HL307-3250n,1HL174-2080n,1HL
1.35 (s, 8 H), 0.87 - 0.97 (m, 3 H), 0.77 - 0.86 (m, 3 H), 0.62 - 0.70 (m, 2 H), 0.47 - 0.59
(m, 2 H). MS (ESI) m/z 334.2 [M+1]+. Peak 2: 1H NMR (400 MHz, DMSO-dg) 5 ppm
872-9000n,1HL818-8460n,1HL712-7600n,1HL438-4610n,1HL376-
3.98 (m, 1 H), 3.04 - 3.26 (m, 1 H), 1.75 - 2.10 (m, 1 H), 1.35 (s, 8 H), 0.92 (s, 3 H), 0.82
(s, 3 H), 0.61 - 0.72 (m, 2 H), 0.47 - 0.60 (m, 2 H). MS (ESI) m/z 334.2 [M+1]+. By SAR
potency comparison with similar compounds ofknown absolute chemistry, Peak 1
was assigned as 4-((1S,3S)Hydr0xy-4,4-dimethylcyclohexylamin0)(l-methyl-
cwhmmwhmhMmfimmmdfiwflmmmMePwk2wmwmmme4flkflfifi-
ATI—2514l75vl
2012/034349
Hydroxy-4,4-dimethylcyclohexylamino)—2-(1-methylcyclopr0pylamin0)pyrimidine—5-
carboxamide.
Example 52: yclo[1.1.1]pentanylamin0)—2-((1r,4r)—4-
ycyclohexylamino)pyrimidine—5-carboxamide
] A. 2-Phenylbicyclo[1.1.1]pentanol. A stirring solution of
utyl(phenyl)methanone (3.0 g, 18.8 mmol) in 800 ml of benzene was irradiated with
a 1000 W mercury arc lamp for 48 h at room temperature in a nitrogen atmosphere. The
solution was concentrated and the residue (3.1 g) was purified by column chromatography
(10%-25% ethyl acetate in petrolium ether) to give the desired product as a white solid
(0.9 g, 5.6 mmol, yield: 30%). 1H NMR (300 MHz, CDClg) 8 ppm 7.41-7.28 (m, 5 H),
3.04 (s, 2 H), 2.82 (dd, J1= 10.2 Hz, J2= 2.4 Hz, 1 H), 2.09 (s, 1 H), 1.78 (d, J = 2.4 Hz,
1 H), 1.50 (d, J = 3.3 Hz, 1 H), 1.33 (dd, J1= 9.9, J2= 3.3 Hz, 1 H).
B. 2-Phenylbicyclo[1.1.1]pentanyl acetate. To a stirring solution of
2.7 g (16.8 mmol) of ylbicyclo[1.1.1]pentanol in pyridine (15 mL) at 0 CC was
added dropwise acetyl chloride (1.5 mL, 21.0 mmol) in a nitrogen atmosphere. The
reaction mixture was stirred for 0.5 h at 0 CC and for 1 h at room temperature. The solution
was poured onto ice and extracted with 50 mL of diethyl ether twice. The combined
diethyl ether on was washed with saturated aqueous sodium bicarbonate solution and
with saturated aqueous copper sulfate solution. After drying over anhydrous magnesium
sulfate, the solution was concentrated and the crude product was purified by column
chromatography (0-5% ethyl acetate in petrolium ether) to give the desired product (2.7 g,
13.4 mmol, yield: 80%). 1H NMR (400 MHz, CDClg) 5 ppm 7.47-7.26 (m, 5 H), 3.31 (s,
2 H), 2.43 (dd, J1= 10.4 Hz, J2= 2.8 Hz, 1 H), 1.95 (s, 3 H), 1.80 (d, J = 2.8 Hz, 1 H), 1.66
(d, J = 3.2 Hz, 1 H), 1.49 (dd, J1= 10.4, J2= 3.2 Hz, 1 H).
C. 2-Phenylbicyclo[1.1.1]pentane. A solution of 2-phenyl-
bicyclo[1.1.1]pentanyl acetate (2.7 g, 13.4 mol) in 50 mL of anhydrous ether was
ATI—25 14175V1
2012/034349
placed in a three-necked flask. The flask was cooled to -78 oC, and 150 mL of liquid
ammonia was added. To the stirring mixture was added sodium (0.62 g, 27.0 mmol) in
small pieces over a period of 10 minutes. ng was ued until the blue color was
discharged. The reaction was quenched by the addition of saturated aqueous ammonia
chloride solution (5 mL), and the solvent was allowed to evaporate overnight. Pentane
(40 mL) was added to the residue, and the solution was washed with 30 mL saturated
s sodium chloride on, dried over anhydrous magnesium sulfate, and then
concentrated. The crude product was purified by column chromatography (100% pentane)
to give the desired compound as a colorless liquid (1.8 g, 12.5 mmol, yield: 93% ).
1H NMR (300 MHz, CDC13)5 ppm 7.40-7.21 (m, 5 H), 3.48 (d, J = 6.9 Hz, 1 H), 2.81 (s,
2 H), 2.20 (dd, J1= 9.9Hz, J2= 2.7 Hz, 1 H), 2.00 (d, J = 2.1 Hz, 1 H), 1.94-1.85 (m, 2 H).
D. Bicyclo[1.1.1]pentane—2-carb0xylic acid. A mixture of
2-phenylbicyclo[l.l.l]pentane (2.8 g, 19.4 mmol), ruthenium(IV) oxide (0.1 g, 0.75 mmol),
sodium periodate (41.5 g, 194 mmol), water (155 mL), perchloromethane (110 mL), and
acetonitrile (110 mL) was stirred for 4 d. DCM (200 mL) was added to the mixture, and
the solids were removed by filtration. The mother liquid was alkalized with aqueous
sodium hydroxide solution (1 M), and the organic solvent was removed by reduced
pressure. The residue nic layer was extracted with diethyl ether (100 mL x 2) and
the water phase was acidified with aqueous hydrochloric acid (2 M) to pH < 3, then
extracted with diethyl ether (100 mL x 5 ). The organic layers were combined and
concentrated to give the crude acid as a yellow liquid. Then the crude product was purified
by column chromatography (10% ethyl acetate in petrolium ether) to give 400 mg
(3.57 mmol, yield: 18 %) of the desired t. 1H NMR (300 MHz, CDClg) 8 ppm 2.97
(d, J = 7.5 Hz, 1 H), 2.82 (s, 2 H), 2.49 (dd, J1= 7.2 Hz, J2= 3.3 Hz, 1 H), 1.92 (dd,
J1= 7.2Hz, J2= 3.3 Hz, 1 H), 1.79-1.76 (m, 2 H).
E. Bicyclo[1.1.1]pentanamine hydrochloride. To a stirring on of
bicyclo[l.1.1]pentanecarboxylic acid (1.0 g, 8.9 mmol) in anhydrous toluene (25 mL)
and 2-methylpropanol (5 mL) was added DIEA (2.3 g, 17.8 mmol) and diphenyl
phosphorazidate (2.9 g, 10.7 mmol). The e was heated at 90 CC for 16 h under
nitrogen atmosphere. Then the reaction mixture was concentrated and the residue was
purified by column tography (10% ethyl acetate in petrolium ether) to give crude
ATI—2514l75vl
tert-butyl bicyclo[1.1.1]pentanylcarbamate. The crude product was dissolved in 15 mL
hydrochloric acid solution (1 M in methanol) and the solution was stirred at room
temperature for 16 h. The solution was concentrated and the residue was suspended in
50 mL of diethyl ether. The mixture was stirred for 15 min and the itates were
collected and dried to give the title compound (350 mg, yield: 33%). 1H NMR (DMSO-dg)
8 ppm 8.58 (brs, 3H), 3.35 (s, 1H), 2.62 (s, 2H), .57 (m, 1H), 1.90 (t, J: 5.0 Hz, 1H),
1.79 (d, J = 2.4 Hz, 1H), 1.50 (dd, J1= 10.0 Hz, J1= 2.8 Hz, 1H).
F. 4-(Bicyclo[1.1.1]pentan-Z-ylamino)—2-((1r,4r)—4-
hydroxycyclohexylamino)pyrimidine—5-carboxamide. A mixture of 2-((1r,4r)
hydroxycyclohexylamino)(methylsulfonyl)pyrimidinecarboxamide (300 mg,
0.95 mmol; synthesis described herein), bicyclo[1.1.1]pentanamine hydrochloride
(220 mg, 1.84 mmol) and DIEA (300 mg, 2.33 mmol) in NMP (3 mL) was heated at
100 0C for 16 h. The resulting mixture was purified by preparatory high performance
liquid chromatography twice (5-80 % acetonitrile in water) to give the crude product
(105 mg), which was recrystallized from form to give the desired compound
(85.2 mg, 0.27 mmol, yield: 28%). 1H NMR (400 MHz, CDgOD) 8 ppm: 8.33 (s, 1H), 4.19
(d, J = 6.8 Hz, 1H), 3.77-3.74 (m, 1H), 3.60-3.57 (m, 1H), 2.67 (s, 2H), 2.54 (dd,
J1 = 9.6Hz, J2 = 3.2 Hz, 1H), 2.07-1.88 (m, 6H), 1.66 (d, J = 9.6 Hz, 1H), 1.39-1.34 (m,
4H); MS (ESI) m/z 318.1 .
Example 53: 2-((S)-sec-Butylamin0)—4-(((1R,3R,4R)—3-hydr0xy
methylcyclohexyl)amin0)pyrimidine—5-carb0xamide
A. 4-((1R,3R,4R)—3-Hydr0xymethylcyclohexylamin0)
lthi0)pyrimidine—5-carb0xamide. 4-((1R,3R,4R)Hydroxy
methylcyclohexylamino)(methylthio)pyrimidinecarbonitrile (0.335 g, 1.203 mmol;
sis described herein) was dissolved in DMSO (3 mL). Then aqueous sodium
ATI—2514175v1
hydroxide solution (1.003 mL, 6 M, 6.02 mmol) and aqueous en peroxide solution
(0.682 mL, 6.02 mmol, 30 %) were added at room ature. Then the reaction mixture
was stirred at 50 °C for 2 h. The reaction was cooled to room temperature and it was
poured into 100 mL of ice water. The white precipitate was collected and was washed
twice with water. The solid was dried to give 4-((1R,3R,4R)—3-hydroxymethyl-
cyclohexylamino)(methylthio)pyrimidinecarboxamide (0.260 g, 0.877 mmol, 72.9 %
yield); MS (ESI) m/z 297.7 [M+1]+.
] B. 4-((1R,3R,4R)—3-Hydr0xymethylcyclohexylamin0)
(methylsulfonyl)pyrimidine—5-carb0xamide. 4-((1R,3R,4R)Hydroxy
methylcyclohexylamino)(methylthio)pyrimidinecarboxamide (315 mg, 1.063 mmol)
was dissolved in NMP (4 mL) and cooled to 0 0C before adding mCPBA (476 mg,
2.126 mmol) portionwise. After 1 h, 75 mL of ld water was added directly to the
reaction mixture and the slurry was allowed to stir for 2 h before filtering off the white
precipitate. The filtrate was then condensed under reduced pressure to remove water. The
NMP solution was used directly in the next step assuming quantitative conversion to the
desired t; MS (ESI) m/z 329.4 [M+1]+.
C. 2-((S)-sec-Butylamin0)—4-(((1R,3R,4R)—3-hydr0xy
methylcyclohexyl)amin0)pyrimidine—5-carb0xamide. To a stirring suspension of
4-((1R,3R,4R)hydroxymethylcyclohexylamino)(methylsulfonyl)pyrimidine
carboxamide (0.2 g, 0.609 mmol) in DMF (3 mL) was added (S)—(+)—sec-butylamine
(0.305 mL, 3.05 mmol) and the on was heated to 90 oC overnight. The crude reaction
mixture was concentrated under reduced pressure and then purified using reverse-phased
semi-preparative HPLC (5-75% methanol + 0.1% formic acid in water + 0.1% formic acid,
over 26 min). Fractions containing product were concentrated under d pressure and
the ing residue was redissolved in methanol (5 mL), passed over a Varian
StratoSpheres HCO3 resin SPE tube for formic acid removal (0.9 mmol bicarbonate
equiv.), and then concentrated under reduced pressure to afford 2-((S)-sec-butylamino)
(((1R,3R,4R)hydroxymethylcyclohexyl)amino)pyrimidine-5 -carboxamide (0. 129 g,
0.402 mmol, 66 % yield). 1H NMR (400 MHz, DMSO-d6) 5 ppm 0.80 - 1.24 (m, 15 H)
1.35 - 1.45 (m, 1 H) 1.54 (br. s., 1 H) 1.66 (d, J=12.89 Hz, 1 H) 1.92 (br. s., 1 H) 2.14 (br.
—194—
ATI—25 14175v1
s., 1 H) 2.97 (br. s., 1 H) 3.71 — 3.99 (m, 1 H) 4.55 (d, J=5.86 Hz, 1 H) 6.96 (br. s., 1 H)
8.34 (s, 1 H) 8.90 (br. s., 1 H); MS (ESI) m/z 322.5 [M+1]+.
Example 54: ,4r)—4-Hydr0xycyclohexylamin0)(1-
methylcyclobutylamin0)pyrimidine—5-carboxamide
)L /
N N NH
H 6
A. 2-((1r,4r)—4-Hydr0xycyclohexylamin0)—4—(1-methylcyclobutyl-
amino)pyrimidine—5-carboxamide. To a mixture of 2-((1r,4r)hydroxycyclohexyl-
amino)(methylsulf1nyl)pyrimidinecarboxamide and 2-((1r,4r)hydroxycyclohexyl-
amino)(methylsulfonyl)pyrimidinecarboxamide (1.414 mmol total; synthesis
described herein) in NMP (18 mL) was added 1-methylcyclobutanamine hydrochloride
(0.189 g, 1.556 mmol) and DIEA (0.988 mL, 5.66 mmol). The ing solution was
heated at 100 CC overnight. Ethyl acetate and water were added to the reaction mixture and
the resulting layers were separated. The ethyl acetate layer was dried over anhydrous
magnesium sulfate, filtered, and concentrated under reduced pressure to an oil that was
d by silica gel chromatography (0-20% methanol in DCM) to afford 2-((1r,4r)
hydroxycyclohexylamino)( 1 -methylcyclobutylamino)pyrimidinecarboxamide
(0.193 g, 0.604 mmol, 42.7% yield). 1H NMR (400 MHz, DMSO-d6) 8 ppm 9.13 (s, 1 H)
8.33 (s, 1 H) 7.57 (br. s., 1 H) 7.01 (d, J=7.81 Hz, 2 H) 4.53 (d, J=4.69 Hz, 1 H) 3.58 (br.
s., 1 H) 2.32 (d, 4 Hz, 2 H) 1.94 - 2.11 (m, 2 H) 1.84 (d, J=5.08 Hz, 6 H) 1.52 (s,
3 H) 1.05 — 1.36 (m, 4 H). MS (ESI) m/z 320.1 [M+1]+.
ATI—2514l75vl
2012/034349
Example 55: 4-(Bicyclo[2.1.1]hexanylamin0)—2-(((1r,4r)—4-
ycyclohexyl)amin0)pyrimidine—5-carb0xamide
N N NH
H @
A. 2-Methylbicyclo[2.2.1]heptan-Z-ol. To a solution of
bicyclo[2.2. l]heptanone (25 g, 0.23 mol) in diethyl ether (250 mL) was added a
solution of methylmagnesium bromide in THF (3 mol/L, 90 mL, 0.27 mol) over 1 h at
0 CC. The reaction mixture was stirred for an onal 30 min as it was warmed to room
temperature. Then the reaction was quenched with 40 mL saturated aqueous ammonium
chloride solution. The resulting mixture was extracted with l ether (3 x 80 mL).
The c layers were combined and concentrated to give the desired product (26 g,
0.205 mol, yield: 90%). 1H NMR (400 MHz, CDClg) 5 ppm 2.20 (s, l H), 2.01 (s, 1H),
1.94 (s, l H), 1.61-1.49 (m, 3 H), 1.34-1.20 (m, 7H).
] B. 1-Methylbicyclo[2.2.1]heptan-Z-ol. To a solution of 2-methyl-
bicyclo[2.2.l]heptanol (26 g, 0.20 mol) in acetic acid (50 g, 0.83 mol) was added 1 mL
sulfuric acid. The mixture was refluxed for 3 h and then concentrated under reduced
presssure. The e was poured into 100 mL water. The resulting mixture was
extracted with ethyl acetate (3 x 50 mL) and the combined extracts were washed with
saturated aqueous sodium bicarbonate on (100 mL), brine (100 mL) and then dried
over anhydrous sodium sulfate. Removal of the solvent gave l-methyl-
bicyclo[2.2.l]heptanyl acetate (31 g, 0.173 mol, yield: 89%) as a colorless oil, which
was used without fithher purification.
A mixture of l-methylbicyclo[2.2. l]heptanyl acetate (31 g, 0. 17 mol)
and aqueous sodium hydroxide solution (5%, 250 mL) was refluxed for 2 h. After being
cooled to room temperature, the reaction mixture was extracted with diethyl ether (3 x
100 mL) and the combined organic layers were dried over magnesium e and
concentrated to afford the desired compound (21 g, 0.167 mol, yield: 82%), which was
used in the next step without further purificatioan NMR (400 MHz, CDClg) 5 ppm 3.47-
-l96-
ATI—2514l75vl
3.46 (m, 1H), 2.16-2.14 (m, 1H), .75(m, 1H), 1.57-1.52(m, 1H), 1.43-1.30(m, 3H),
1.15(brs, 3H), 1.01-0.97(m, 2H).
C. Methylenebicyclo[2.2.1]heptanyl romethanesulfonate. To a
solution of oxalyl dichloride (31.75 g,0.25 mol) in DCM (300 mL) was added at -78 0C in
consecutive order DMSO (19.5 g, 0.25 mol), a on of 1-methylbicyclo[2.2.1]heptan-
2-ol (21g, 0.167 mol) in DCM (50 mL) and then triethylamine (50 g, 0.5 mol). The
mixture was stirred at room temperature ght and then poured into 200 mL water.
The resulting mixture was extracted with DCM (2 x 100 mL). The combined extracts
were washed with saturated aqueous sodium bicarbonate solution (50 mL), brine (50 mL)
and dried over anhydrous sodium sulfate. Concentration under reduced pressure gave
crude methylbicyclo[2.2.1]heptanone, which was purified by silica gel column
chromatography (10 % ethyl acetate in eum ether) to afford 12.4 g (0.10 mol, yield:
60%) of this compound.
To a solution of methylbicyclo[2.2. 1]heptanone (26 g, 0.209 mol) and
2,6-di-tert-butylmethyl-pyridine (64 g, 0.315 mol) in DCM (300 mL) was added
se trifluoromethanesulfonic anhydride (88 g, 0.315 mol) in DCM (50 mL) at 0 CC.
The on mixture was stirred at room temperature for 24 h. The mixture was poured
into water, and extracted with DCM (2 x 100 mL). The combined extracts were washed
with a 10% hydrochloric acid solution (3 x 100 mL), saturated aqueous sodium
bicarbonate solution (50 mL), brine (50 mL) and dried over sodium sulfate. Concentration
under reduced pressure gave the crude t, which was purified by silica gel column
chromatography (100% n-pentane) to give the desired product (7.6 g, 0.03 mol, 14%).
1H NMR (400 MHz, : 5 ppm 5.15 (brs, 1H), 4.89 (brs, 1H), 2.51-2.39 (m, 2H),
2.26-2.17 (m, 2H), 2.12-2.05 (m, 2H), 1.99-1.85 (m, 2H), 1.53-1.50 (m, 1H).
D. 2-Ox0bicyclo[2.2.1]heptan-l-yl trifluoromethanesulfonate. A
solution of methylenebicyclo[2.2. 1]heptanyl trifluoromethanesulfonate (7.6 g,
0.03 mol) in methanol (100 mL) was cooled to -40°C and an ozone stream was passed
through the reaction mixture. When the color of the mixture turned to blue, the ozone was
eliminated by passing a stream of argon through the solution for 10 min. Dimethyl sulfide
(5 mL) was added to the mixture and the on mixture was allowed to warm to room
temperature. The resulting mixture was poured into water and extracted with DCM (2 x
ATI—2514l75vl
2012/034349
40 mL). The combined extracts were washed with brine ) and dried over
anhydrous sodium sulfate. The solution was concentrated under reduced pressure to give
the crude product, which was purified by silica gel column chromatography (10 % ethyl
acetate in eum ether) to give the desired product (4.6 g, 18.1 mmol, yield: 60%) as a
yellowish oil. 1H NMR (400 MHz, CDClg) 5 ppm rs, 1H), 2.44-2.34 (m, 2H), 2.26-
2.13 (m, 4H), 2.06-2.02(m, 1H), 1.70-1.66 (m, 1H).
E. Bicyclo[2.1.l]hexane-l-carboxylic acid. A mixture of
2-oxobicyclo[2.2. l]heptan-l-yl trifiuoromethanesulfonate (4.6 g,18.1 mmol) in 600 mL
ethanol/water (60% w/w) and TEA (3.7 g 36.2 mmol) was heated at 130 0C for 100 h.
The e was concentrated under reduced pressure and the residue was poured into
aqueous hydrochloric acid solution (1 mol/L, 150 mL) and extracted with diethyl ether
(3 x 100 mL). The combined extracts were washed with brine (100 mL) and dried over
anhydrous sodium sulfate. The solution was concentrated under reduced pressure to give
the crude product which was purified by silica gel column chromatography (10 % ethyl
acetate in petroleum ether) to give the desired product (1.00 g, 8.09 mmol, yield: 45 %).
1H NMR (400 MHz, CDClg) 8 ppm 2.47-2.45(m, 1H), 1.94-1.90 (m, 4H),1.79-1.74 (m,
2H), .35 (m, 2H).
F. Benzyl o[2.l.1]hexan-l-ylcarbamate. To a on of
bicyclo[2.1.1]hexanecarboxylic acid (1.0 g, 8.09 mmol) in dioxane (20 mL) was added
DIEA (2.5g, 12.4 mmol), diphenylphosphorylazide (3.1 g, 11.2 mmol) and
phenylmethanol (1.5 g, 14.2 mmol). The mixture was stirred at 80 °C overnight under
nitrogen atmosphere and concentrated under reduce pressure. The residue was purified by
silica gel column chromatography (10 % ethyl acetate in petroleum ether) to give the
desired product (1.2 g, 5.2 mmol, yield: 65 %). MS (ESI) m/z = 231.2[M+H]+.
G. Bicyclo[2.1.1]hexan-l-amine hydrochloride. To a solution of benzyl
bicyclo[2.1.1]hexanylcarbamate (1.2 g, 5.2 mmol) in methanol (30 mL) was added
palladium on charcoal (10%, 0.1 g). The reaction mixture was stirred at 50 °C under
hydrogen atmosphere (50 Psi) overnight and filtered through . To the filtrate was
added a hydrochloric acid solution (10% in methanol, 20 mL). The mixture was
concentrated and the residue was suspended in THF (20 mL). The mixture was stirred at
room temperature for 1 h. The precipitate was ted and dried to give the desired
ATI—25 14175v1
product (550 mg, 4.13 mmol, yield: 79 %). 1H-NMR (400MHz, DMSO-dg) 8 ppm 8.73
(br. s, 3H), 2.4 (br. s, 1H), 1.71-1.69 (m, 6H), 1.32-1.31 (m, 2H). MS (ESI) m/z = 98.2
[M+H]+.
H. yclo [2. 1.1] hexanylamin0)(methylthio)pyrimidine—5-
carbonitrile. To a stirred solution of 4-chloro(methylthio)pyrimidinecarbonitrile
(427 mg, 2.3 mmol) in 1,4-dioxane (10 mL) was added DIEA (890 mg, 6.9 mmol) and
bicyclo[2.1.1]hexanamine hloride (320 mg, 2.4 mmol). The resulting mixture
was stirred at 60 CC for 2 h. The reaction mixture was poured into a saturated brine
solution and then extracted with ethyl acetate (20 mL) three times. The combined organic
layers were dried over anhydrous sodium e, filtered and concentrated to afford the
crude product, which was purified by silica gel column tography (15 % ethyl
e in petroleum ether) to give the desired product (502 mg, 2.0 mmol, 89% .
MS (ESI) m/Z =247.2 [M+1] +.
] I. yclo[2.1.1] hexanylamin0)—2-(methylthi0)pyrimidine
carboxamide. To a solution of 4-(bicyclo[2.1.1]hexanylamino)
(methylthio)pyrimidinecarbonitrile (502.0 mg, 2.0 mmol) in DMSO (5 mL) was added
aqueous hydrogen peroxide solution (1.2 g, 30%, 10.2 mmol) and aqueous sodium
hydroxide solution (1.7 mL, 6 mol/L, 10.2 mol) at 0 CC. The mixture was stirred at
50 0C for 15 min and then quenched by the addition of water (30 mL). The solid formed
was collected and dried under vacuum to give the desired product (500 mg, 1.9 mmol,
93% yield). MS (ESI) m/Z =265.3 [M+1] +.
J. 4-(Bicyclo[2.1.1] hexan-l-ylamin0)—2-(methylsulfinyl)pyrimidine—5-
carboxamide and 4-(bicyclo[2.1.1]hexanylamin0)—2-(methylsulfonyl)pyrimidine
carboxamide. To a solution of 4-(bicyclo[2.1.1]hexanylamino)(methylthio)-
pyrimidinecarboxamide (500 mg, 1.9 mmol) in THF (10 mL) at 0 °C was added
mCPBA (490 mg, 2.8 mmol) portion-wise. After 1 h, the reaction mixture was
concentrated. The resulting crude material was purified by silica gel column
chromatography (5-10% methanol in DCM) to give 510 mg of the desired mixture.
MS (ESI) m/Z =281.3, 297.3 [M+1] +.
K. yclo[2.1.1]hexanylamin0)—2-(((1r,4r)—4-hydr0xycyclo-
hexyl)amin0)pyrimidine—5-carb0xamide. To the mixture of 4-(bicyclo[2.1.1]hexan
ATI—2514175v1
ylamino)(methylsulfinyl)pyrimidinecarboxamide and 4-(bicyclo[2.1.1]hexan
ylamino)(methylsulfonyl)pyrimidinecarboxamide (200 mg, about 0.71 mmol ) and
(1r,4r)aminocyclohexanol (123.3 mg, 1.02 mmol) in NMP (10 mL) was added DIEA
(183.0 mg, 1.42 mmol). The resulting mixture was stirred at 100 CC overnight. The
reaction mixture was d by preparative HPLC to give the desired product (187.3 mg,
0.56 mmol, 72% yield). 1H NMR (400 MHZ, CDgOD) 5 ppm 8.29(s, 1H), 3.77(m, 1H),
, 1H), 2.43(s, 1H), 2.07-1.93(m, 8H), .77(m, 2H), 1.60(s, 2H), l.4l-l.35(m,
4H). MS (ESI) m/Z =332.2 [M+H] +.
Example 56: 4-(1-Ethylcyclopentylamino)—2-((1r,4r)—4-
ycyclohexylamino)pyrimidine—5-carboxamide
A. Ethyl cyclopentenecarb0xylate. To a stirred solution of cyclopent-
3-enecarboxylic acid (10 g, 89.3 mmol) in anhydrous ethanol (30 mL) was added sulfurous
dichloride (15.9 g, 134 mmol) at 0 0C. The on mixture was stirred at room
temperature overnight and then concentrated. The residue was poured into water. The
resulting mixture was extracted with ethyl acetate (3 x 100 mL). The combined organic
layers were washed with brine, dried over anhydrous sodium sulfate and filtered. The
filtrate was concentrated and the residue was d by silica gel column
chromatography (2.5 % ethyl acetate in petroleum ether) to give the desired product (6.7 g,
47.9 mmol, yield = 54%) as a yellow oil which was used in the next step without further
purification. 1H NMR (400 MHz, CDClg) 5 ppm 5.66 (s, 2H), 4.18-4.10 (m, 2H), 3.16-
3.05(m, 1H), 2.66 (s, 2H), 2.63 (s, 2H), 1.29-1.24 (t, J=9.4, 3H).
B. Ethyl 1-ethylcyclopentenecarboxylate. To a on of
diisopropylamine (10 mL, 72 mmol) in anhydrous THF (50 mL) was added l
lithium (29 mL, 72 mmol, 2.5 M solution in hexane) over 20 min at -78 0C. The mixture
was stirred at 0 0C under nitrogen for 1 h. The freshly prepared lithium diisopropylamide
was added to a mixture of ethyl cyclopentenecarboxylate (6.7 g, 47.9 mmol) in
ATI—2514175v1
anhydrous THF (50 mL) over 20 minutes at -78 0C. After another 1 hour at this
temperature, iodoethane (11.2 g, 72 mmol) was added over 20 min. Then the mixture was
stirred at room temperature for 2 h and quenched with saturated aqueous ammonium
chloride solution. The aqueous layer was extracted with ether (3 x 100 mL). The
combined organic layers were washed with diluted hydrochloric acid (1 N), then washed
with brine, dried over anhydrous sodium e and filtered. Concentration gave the titled
compound (7 g crude) which was used in the next step without fithher purification.
1H NMR (400 MHz, CDClg) 8 ppm 5.60 (s, 2H), 4.21-4.12 (m, 2H), 2.92-2.84 (m, 2H),
2.31-2.25 (m, 2H), 1.75-1.67 (m, 2H), 1.29-1.24 (m, 3H), 0.88-0.82 (m, 3H).
] C. 1-Ethylcyclopent—3-enecarboxylic acid. A solution of ethyl
l-ethylcyclopentenecarboxylate (3.5 g, 20.8 mmol) and aqueous sodium hydroxide
solution (20.8 mL, 2 mol/L) in methanol (30 mL) was stirred at 80 CC for 2 h and then
concentrated. The e was poured into water, and extracted with ether (3 x 100 mL).
The water layer was acidified with 4 mol/L s hydrochloric acid solution to pH < 3,
and extracted with ethyl acetate (3 x 100 mL). The combined organic layers were washed
with brine, dried over anhydrous sodium sulfate and filtered. Concentration under reduced
pressure gave the crude product, which was purified by silica gel column chromatography
(5 % ethyl e in eum ether) to afford the title compound (1.9 g, 13.6 mmol,
65.5 % yield). 1H NMR (400 MHz, CDC13)8 ppm 5.61 (s, 2H), 2.91 (d, J=l4.8, 2H), 2.32
(d, J=l4.4, 2H), 1.78-1.72 (m, 2H), 0.92-0.88 (t, J=7.4, 3H).
D. Benzyl (1-ethylcyclopentenyl)carbamate. To a solution of
l-ethylcyclopentenecarboxylic acid (1.9 g, 13.6 mmol) in dioxane (30 mL) was added
DIEA ( 5.3 g, 41 mmol), diphenyl phosphoryl azide (4.5 g, 16.3 mmol) and benzylalcohol
(2.2 g, 20.4 mmol). The mixture was stirred at 80 CC overnight and then concentrated
under reduced pressure. The residue was purified by silica gel column chromatography
(2.5 % ethyl e in petroleum ether) to give the title product. (1.3 g, 5.3 mmol,
yield: 39 %). MS (ESI) m/Z = 246.2 [M+1] +.
] E. l-Ethylcyclopentanamine hydrochloride. To a on of benzyl
(1-ethylcyclopentenyl)carbamate (1.3 g, 5.3 mmol) in methanol (20 mL) was added
palladium on charcoal (130 mg, 10 %). The reaction mixture was stirred at 50 °C under
hydrogen atmosphere overnight. A solution of hydrochloric acid (20 mL, 1 mol/L in
ATI—2514l75vl
methanol) was added to the reaction and the reaction mixture was filtered through celite.
The filtrate was concentrated under reduced pressure to give the crude product (900 mg),
which was used for the next step without filrther ation. MS (ESI) m/z = 114.2
[M+H]
F. 4-(1-Ethylcyclopentylamin0)(methylthio)pyrimidine—5-
awbmfinfla Toasfiflngsobfionof4£hbny2{nwflwhhmfiwfinnmne5fimbomfifle
(984 mg, 5.3 mmol) in DMSO (10 mL) was added DIEA (2.1 g, 15.9 mmol) and
1-ethylcyclopentanamine hydrochloride (900 mg crude). The resulting mixture was stirred
at 60 CC for 2 h. The reaction mixture was poured into water and extracted with ethyl
e. The combined organic layers were dried over anhydrous sodium sulfate, filtered
and concentrated to afford the crude product. The crude product was purified by silica gel
column tography (5 % ethyl acetate in petroleum ether) to get the desired product
as a yellow oil (830 mg, 3.2 mmol, 53.5 % yield). MS (ESI) m/z = 263.2 [M+H] +.
[0051 1] G. 4-(1-Ethylcyclopentylamin0)(methylthi0)pyrimidine
carboxamide. To a stirred on of 4-(1-ethylcyclopentylamino)(methylthio)-
dinecarbonitrile (830 mg, 3.2 mmol) in DMSO (10 mL) was added aqueous
hydrogen peroxide (1.8 g, 30%, 16 mmol), and aqueous sodium hydroxide solution
(2.7 mL, 6 mol/L, 16 mmol) at 0 CC. The mixture was stirred at 50 CC for 15 min and
diluted with water. The mixture was extracted with ethyl acetate (3 x 100 mL). The
combined organic layers were washed with brine, dried over anhydrous sodium sulfate and
filtered. Concentration under reduced re gave the crude product, which was purified
by silica gel column chromatography (5 % methanol in DCM) to afford the d
product as a white solid (800 mg, 2.9 mmol, 90% yield). MS (ESI) m/z = 281.2 [M+1]
H. 4-(1-Ethylcyclopentylamin0)(methylsulfonyl)pyrimidine—5-
carboxamide. At 0 0C, mCPBA (873 mg, 4.3 mmol) was added portion-wise to a on
of 4-(1-ethylcyclopentylamino)(methylthio)pyrimidinecarboxamide (800 mg,
2.9 mmol) in THF (30 mL). After 1 h, the reaction mixture was concentrated and the
resulting crude was d by silica gel column chromatography (5 % methanol in DCM)
to afford the desired product (800 mg, 2.56 mmol, 90% yield). MS (ESI) m/z = 313.2
[M+1] +.
ATI—25 14175V1
I. 4-(1-Ethylcyclopentylamin0)((1r,4r)—4-hydr0xycyclohexylamin0)-
pyrimidine—5-carb0xamide. To a mixture of 4-(1-ethylcyclopentylamino)(methyl-
sulfonyl)pyrimidinecarboxamide (200 mg, 0.64 mmol) and (1r,4r)aminocyclohexanol
(115 mg, 1 mmol) in NMP (10 mL) was added DIEA (255 mg, 1.98 mmol).
The resulting mixture was stirred at 100 CC ght. The reaction mixture was purified
by preparative HPLC to give the desired product (117.0 mg, 0.34 mmol, yield 51%).
1H NMR (400 MHz, CDgOD) 5 ppm 8.17 (s, 1H), 3.66 (s, 1H), 3.46 (s, 1H), 2.06-2.04 (m,
2H), 1.98-1.89 (m, 6H), 1.66-1.58 (m, 6H), 1.26-1.24 (m, 4H), .73 (t, J=7.2 Hz, 3H);
MS (ESI) m/z = 348.2 [M+1]+.
Example 57: 4-(((1R,3S)Hydr0xycyclohexyl)amin0)((4-meth0xybicyclo[2.2.2]octan-l-
yl)amin0)pyrimidinecarboxamide
A. yl 1-(2-chlor0ethyl)cyclohexane-1,4-dicarb0xylate. To a
stirring solution of cyclohexane-1,4-dicarboxylic acid (100 g, 0.58 mol) in anhydrous
methanol (800 mL) was added sulfiarous dichloride (208g, 1.75 mol) at 0 0C. The reaction
mixture was stirred at room temperature overnight and then concentrated under d
pressure. The residue was poured into water. The ing mixture was extracted with
ethyl acetate (200 mL x 3). The combined organic layers were washed with brine, dried
over anhydrous sodium sulfate and filtered. Concentration gave crude dimethyl
cyclohexane-1,4-dicarboxylate (105 g, 0.53 mol, yield 90.5%) which was used without
further purification.
To a solution of diisopropylamine (88 mL, 0.62 mol) in ous THF
(500 mL) was added n-butyl lithium (240 mL, 0.6 mol, 2.5 M solution in hexane) over
min at -78 0C. The mixture was stirred at 0 0C under nitrogen for 30 min.
] To the above described mixture of crude yl cyclohexane-1,4-
dicarboxylate (100 g, 0.5 mol) and hexamethylphosphoramide (360 mL, 2 mol) in
anhydrous THF (800 mL) was added the freshly prepared lithium diisopropylamide
ATI—25 14175v1
solution (preparation described above) over 30 min at -40 0C. After stirring for l h at this
temperature, l-bromochloroethane (42 mL, 0.5 mol) was added over 1. The mixture
was stirred for 3 h at -78 0C and then stirred ght at room temperature. The reaction
was quenched by the addition of aqueous hydrochloric acid on (3 N, 420 mL). The
solvent was removed under reduced pressure. The aqueous layer was extracted with ethyl
acetate (200 mL x 3). The combined extracts were washed with brine (2x300 mL) and
dried over sodium e. Concentration gave the title nd (1 16 g, yield 88%)
which was used in the next step without further purification; 1H NMR (400 MHz, CDClg)
ppm 3.72 (s, 3H), 3.65 (s. 3H), 3.46-3.42 (m, 2H), 2.33-2.21 (m, 3H), 2.05-l.85(m, 4H),
158-1 .42 (m, 2H), l.25-l.l5(m, 2H).
B. Dimethyl bicyclo[2.2.2]octane-1,4-dicarb0xylate. To a solution of
ropylamine (77 mL, 0.54 mol) in anhydrous THF (500 mL) was added n-butyl
lithium (210 mL, 0.53 mol, 2.5 M solution in hexane) over 20 min at -78 0C. The mixture
was stirred at 0 0C under nitrogen for 30 min.
[005 l 8] To a mixture of dimethyl l-(2-chloroethyl)cyclohexane-l ,4-dicarboxylate
(1 16 g, 0.44 mol) and hexamethylphosphoramide (3 17 mL, 1.7 mol) in anhydrous THF
(800 mL) was added y prepared lithium diisopropylamide (preparation described
above) over 30 min at -40 0C. The e was stirred for 2 h at -78 0C and then stirred
overnight allowing warming to room temperature. To the reaction mixture was added
saturated aqueous ammonium chloride solution (200 mL) and the mixture was stirred for
min. The volatile ts were removed by evaporation under reduced pressure. The
aqueous layer was extracted with ethyl acetate (3 x 200 mL) and the combined extracts
were washed with brine (300 mL x 2) and dried over sodium e. Concentration under
reduced pressure gave crude product, which was purified by silica gel column
chromatography (10 % ethyl acetate in petroleum ether) to afford the title compound
(58.0 g, 0.25 mol, yield 50% over two steps). 1H NMR (400 MHz, CDC13)C 8 ppm 3.65 (s,
6H), 1.81 (s. 12H).
C. 4-(Methoxycarbonyl)bicyclo[2.2.2]octane-l-carboxylic acid. A
solution of dimethyl bicyclo[2.2.2]octane-l,4-dicarboxylate (58.0 g, 0.25 mol) in methanol
(600 mL) was heated to reflux and then a solution of potassium hydroxide (9.8 g,
0. 175 mol) in methanol (100 mL) and water (12 mL) was added over 30 min. The on
—204—
ATI—2514l75vl
mixture was refluxed for 24 h and concentrated. The residue was diluted with water and
ted with ethyl e (200 mL x 2) to recover some starting material (22.0 g). The
rammgammmmwawwadmfimhomfl=3bymMMmufihmeMMmaddmfl
extracted with ethyl acetate (300 mL x 3). The combined organic layers were washed with
brine, dried over sodium sulfate and concentrated to give the titled product (30.0 g,
0.14 mol, yield 55%). 1H NMR (400 MHz, CDClg) 8 ppm 3.65 (s, 3H), 1.81 (s. 12H);
MS (ESI) m/z = 211.3 [M-H]'.
D. Methyl 4-br0m0bicyclo[2.2.2]octane-l-carboxylate. To a sion
of 4-(methoxycarbonyl)bicyclo[2.2.2]octanecarboxylic acid (11.0 g, 51.8 mmol) in
acetone (80 mL) was added aqueous sodium hydroxide solution (1 M, 51.8 mL,
51.8 mmol) and a solution of silver nitrate (8.8 g, 51.9 mol) in water (10 mL). The
precipitate formed was ted by filtration, washed with water, acetone and diethyl
ether and dried in vacuo at 115 0C for 4 h. The obtained ((4-(methoxycarbonyl)-
bicyclo[2.2.2]octanecarbonyl)oxy)silver (15.3 g, 47.9 mmol) was suspended in hexane
(125 mL), followed by addition of bromine (7.7 g, 48.1 mmol) over 30 min at room
temperature. After the addition was completed, the reaction mixture was stirred at room
temperature for another 30 min. The on mixture was filtered to remove the solid, and
the filter cake was washed with hexane (150 mL x 4). The combined organic filtrates were
washed with saturated aqueous sodium bicarbonate solution (150 mL x 2) and brine
(200 mL), then dried over magnesium sulfate. Concentration under reduced pressure gave
the crude product, which was purified by silica gel column chromatography (5 % ethyl
acetate in petroleum ether) to afford the title compound (4.2 g, 0.17 mol, 33 % yield over
two steps). 1H NMR (400 MHz, CDClg): 8 ppm 3.64 (s, 3H), 2.27-2.20 (m, 6H), 1.98-1.94
0n.6H)
E. 4-Hydr0xybicyclo[2.2.2]octane-l-carboxylic acid. Methyl 4-
bromobicyclo [2.2.2]octane-l-carboxylate (17.0 g, 69.0 mmol) was refluxed in 1.5 L of 1%
aqeous sodium hydroxide solution for 24 h. After cooling down, the reaction solution was
acidified with hloric acid (6N, 100 mL) and extracted with l ether (6 x
500 mL). The combined organic layers were dried over magnesium sulfate and
trated to afford the titled compound (10.4 g, 61.1 mmol, yield: 89 %), which was
used in the next step without further purification; MS (ESI) m/z = 169.2 [M-H]'.
ATI—25 14175v1
F. Methyl 0xybicyclo[2.2.2]octane-l-carboxylate. To a solution
of 4-hydroxybicyclo[2.2.2]octane-l-carboxylic acid (14 g, 82.4 mmol) in methanol
(300 mL) was added concentrated sulfuric acid (1 mL). The mixture was refluxed for 10 h
and then concentrated. The reside was dissolved in water (100 mL) and the mixture was
extracted with ethyl acetate (200 mL x 2). The combined organic phases were washed
with saturated aqueous sodium en carbonate solution (100 mL), brine (100 mL) and
dried over sodium sulfate. Concentration gave the title compound (14.5 g, yield 96%).
1H NMR (400 MHz, CDClg) 8 ppm 3.64 (s, 3H), 1.96-1.89 (m, 6H), 1.69-1.64 (m. 6H).
G. Methyl 4-meth0xybicyclo[2.2.2]octane-l-carboxylate. To a solution
of methyl 4-hydroxybicyclo[2.2.2]octane-l-carboxylate (8.9 g, 48 mmol) in anhydrous
THF (150 mL) at -78 CC was added n-butyl lithium (23 mL, 57.5 mmol, 2.5 M solution in
hexane) over 30 min, ed by the slow addition of iodomethane (14 g, 98 mmol).
The mixture was stirred at 60 0C for 3 h and ed by addition of saturated aqueous
ammonium chloride solution (50 mL). The resulting solution was concentrated and the
residue was extracted with ethyl acetate (150 mL x 2). The organic layers were ed
and washed with brine, dried over magnesium sulfate and then concentrated. The residue
was purified by silica gel column chromatography (10% ethyl acetate in petroleum ether)
to give the title product (6.5 g, 67%). 1H NMR (400 MHz, CDClg) 8 ppm3.64 (s, 3H), 3.18
(s, 3H), 1.95-1.89 (m, 6H), 1.70-1.65 (m. 6H).
] H. 0xybicyclo[2.2.2]octane-l-carboxylic acid. Methyl 4-
methoxybicyclo[2.2.2]octane-l-carboxylate (6.5 g, 33 mmol) was refluxed in aqueous
sodium hydroxide solution (5%, 150 mL) for 2 h. After cooling down, the reaction
solution was acidified with hydrochloric acid solution (6 N, 50 mL) and extracted with
ethyl acetate (100 mL x 2). The combined organic layers were dried over magnesium
sulfate and concentrated to afford the title compound (5.9 g, 32 mmol, yield 97%) which
was used in the next step without further purification. MS (ESI) m/z = 183.2 [M-H]'.
I. Benzyl h0xybicyclo[2.2.2]0ctanyl)carbamate. To a solution
of 4-methoxybicyclo[2.2.2]octane-l-carboxylic acid (5.9 g, 32 mmol) in e (80 mL)
was added DIEA (8.3 g, 64.2 mmol), diphenyl oryl azide (13.2 g, 48 mmol) and
methanol (17.3 g, 160 mmol). The mixture was stirred at 80 CC overnight and then
concentrated under reduce pressure. The residue was purified by silica gel column
ATI—2514l75vl
chromatography (5 % methanol in DCM) to give the desired product. (9 g, 31 mmol, yield
96%). MS (ESI) m/Z = 290.2 [M+H]+.
J. 4-Meth0xybicyclo[2.2.2]octan-l-amine hloride. To a on
of benzyl (4-methoxybicyclo[2.2.2]octanyl)carbamate (9 g, 31 mmol) in methanol
(150 mL) was added palladium on charcoal (0.5 g, 10%). The reaction mixture was stirred
at 50 0C under hydrogen atmosphere (50 psi) overnight and then filtered h celite.
The filtrate was concentrated under reduced pressure. The residue was dissolved in
hydrochloric acid solution (10% in methanol, 50 mL) and stirred for 2 h at room
temperature. The mixture was concentrated and the resulting residue was suspended in
THF (20 mL). The mixture was stirred at room temperature for 1 h and the itate was
collected and dried to give the desired product (3.8 g, 20 mmol, yield: 68%). 1H-NMR
(400MHz, ) 8 ppm 8.14 (brs, 3H), 3.04 (s, 3H), 1.83-1.80 (m, 6H), 1.68-1.64 (m,
6H); MS (ESI) m/Z = 156.1[M+1]+.
K. 4-((1R,3S)Hydr0xycyclohexylamin0)(4-meth0xy—
o[2.2.2]octanylamin0)pyrimidine—5-carboxamide. To a solution of 4-((1R,3S)-
3-hydroxycyclohexylamino)(methylsulfonyl)pyrimidinecarboxamide (1.2 g,
3.8 mmol; sis described herein) and 4-methoxybicyclo[2.2.2]octanamine
hydrochloride (600 mg, 3.1 mmol) in NMP (12 mL) was added DIEA (1.03 g, 8 mmol).
Theremflfingnnxunewmssfinedat130°Clnubrnnmowmveinadmfionfor3h.The
resulting mixture was purified by reverse phase column tography to give the
desired product (230 mg, 0.6 mmol, 15.5 % yield). 1H-NMR (400MHz, CDClg) 5 ppm
8.70 (brs, 1H), 8.08 (s, 1H), 5.40 (brs, 2H), 5.01 (br. s, 1H), 3.99-3.96 (m, 1H), 3.75-3.70
(m, 1H), 3.19 (s, 3H), 2.37-2.34 (m, 1H), 2.15-2.11 (m, 6H), 1.99-1.97 (m, 2H), 1.90-1.86
(m, 1H), 1.80-1.76 (m, 6H), 1.38-1.22 (m, 4H). MS (ESI) m/z = 390.2[M+1]+.
ATI—25 14175v1
Example 58: ,4r)—4-Hydr0xycyclohexylamino)—4-(3-
(trifluoromethyl)bicyclo[1.1. 1]pentan-l-ylamin0)pyrimidinecarboxamide
A. 2-((1r,4r)—4-Hydr0xycyclohexylamin0)(3-(triflu0r0methyl)-
bicyclo[1.1.1]pentanylamin0)pyrimidine—5-carb0xamide. To a 5 mL NMP solution
of (2-((1r,4r)hydroxycyclohexylamino)(methylsulfonyl)pyrimidinecarboxamide
(445 mg, 1.416 mmol)) was added 3-(trifluoromethyl)bicyclo[1.1.1]pentanamine
hydrochloride (266 mg, 1.416 mmol) and DIEA (0.494 mL, 2.83 mmol). The reaction was
then heated at 90 oC overnight. LCMS showed the desired product mass as the dominant
peak. The crude reaction was purified directly on a semi-prep HPLC (method: 5-80%
acetonitrile + 0.1% TFA in water + 0.1% TFA). Product fractions were combined and
evaporated under reduced pressure to a volume <5 mL. The material was then neutralized
with saturated sodium bicarbonate and extracted with ethyl acetate (2X). The combined
organic layers were dried over ium sulfate, filtered, and concentrated. The resulting
solid was dissolved in methanol and washed through a StratoSpheres SPE PL-HCO3
in column, g with methanol. ation of solvent under reduced pressure
gave 2-((1r,4r)hydroxycyclohexylamino)(3-(trifiuoromethyl)bicyclo [1 . 1 . 1]pentan
ylamino)pyrimidinecarboxamide. The material was purified by silica gel
chromatography (0-10% methanol in DCM over 1650 mL; 40 mL/min). Product fractions
were ed and evaporated to dryness to afford 2-((1r,4r)hydroxycyclohexyl-
amino)(3-(trifluoromethyl)bicyclo[1 . 1 . anylamino)pyrimidinecarboxamide
(135 mg, 0.35 mmol, 24.8% yield); 1H NMR (400 MHz, DMSO-d6) 5 ppm 9.54 (s, 1H),
8.41 (s, 1H), 7.57 - 7.86 (m, 1H), 7.26 - 7.32 (m, 1H), 6.91 - 7.17 (m, 1H), 4.60 (d,
J=4.29 Hz, 1H), 3.49 - 3.73 (m, 1H), 3.35 - 3.46 (m, 1H), 2.38 (s, 6H), 1.86 (d,
J=11.32 Hz, 4H), 1.26 (br. s., 4H); MS (ESI) m/z 386.0 [M+1]+.
ATI—25 14175v1
Example 59: 4-(tert—Butylamino)—2-(((1R,3S)hydr0xycyclohexyl)amin0)pyrimidine
carboxamide
HO11 1*”*N/ )2
A. 4-(Tert-butylamino)—2-(((1R,3S)hydr0xycyclohexyl)—
amin0)pyrimidinecarb0xamide. To a mixture of 4-(tert-butylamino)
(methylsulfonyl)pyrimidinecarboxamide (250 mg, 0.918 mmol; synthesis bed
herein) and (1S,3R)aminocyclohexanol (138 mg, 1.2 mmol; prepared as described in
Tetrahedron.‘ Asymmetry 15:2051—2056 (2004)) in NMP (10 mL) was added DIEA
(374 mg, 2.9 mmol). The resulting mixture was stirred at 100 CC overnight. The reaction
mixture was purified by preparative HPLC to give the desired product (212.2 mg,
0.69 mmol, yield 75%). 1H NMR (400 MHz, CDClg) 5 ppm 8.86 (brs, 1H), 8.12 (s, 1H),
.53 (brs, 3H), 3.93-3.91 (m, 1H), 3.88-3.82 (m, 1H), 2.27-2.25 (m, 1H), 1.92-1.85 (m,
3H), 1.47 (s, 9H), 1.42-1.25 (m, 4H); MS (ESI) m/z = 308.2 [M+1]+.
Example 60: 4-(Bicyclo[1.1.1]pentanylamin0)((tetrahydro-ZH-pyran
yl)amin0)pyrimidinecarboxamide
o N \ NH2
)L /
N N NH
” <>
A. yclo[1.1.1]pentanylamin0)(methylthi0)pyrimidine
carbonitrile. To a d solution of 4-chloro(methylthio)pyrimidinecarbonitrile
(3.0 g, 16 mmol) in DMSO (20 mL) was added DIEA (6.2 g, 48 mmol) and
bicyclo[1.1.1]pentanamine hydrochloride (1.9 g, 16 mmol; prepared according to Org.
Lett., 13(17): 4746-4748 ). The resulting e was stirred at 60 CC for 2 h and
then poured into water. The mixture was extracted with ethyl acetate and the combined
organic layers were dried over anhydrous sodium sulfate, filtered and concentrated to
afford the crude t, which was purified by silica gel column chromatography (10 %
ATI—25 14175v1
emflawmmmpambmnaMfimgWemewmmdmmmmG5gJ49mmdfl3%
yield). MS (ESI) m/Z = 233.2 [M+1]+.
B. yclo[1.1.1]pentan-l-ylamin0)—2-(methylthi0)pyrimidine
amide. To a solution of yclo[1.1.1]pentan-l-ylamino)—2-(methylthio)-
pyrimidinecarbonitrile (3.45 g, 14.9 mmol) in DMSO (15 mL) was added aqueous
hydrogen peroxide solution (8.4 g, 30%, 74.5 mmol) and aqueous sodium hydroxide
yflufion(124¢nL,6rnoUL,7451nnufl)at0°C.Thennxuuewmssfinedat50OClbr
min and then quenched by the addition of water (30 mL). The solid formed was
collected and dried under vacuum to give the desired product (3.5 g, 14.0 mmol, 94%
yield). MS (ESI) m/Z =251.2 [M+1]+.
C. 4-(Bicyclo[1.1.1]pentanylamin0)—2-(methylsulfinyl)pyrimidine—5-
carboxamide and 4-(bicyclo[1.1.1]pentanylamin0)—2-(methylsulfonyl)pyrimidine—5-
carboxamide. mCPBA (4.3 g, 21 mmol) was added portion-wise to a solution of
4-(bicyclo[1.1.1]pentanylamino)(methylthio)pyrimidinecarboxamide (3 .5 g,
14 mmol) in THF (40 mL) at 0 0C. The reaction was monitored by thin layer
chromatography. After 1 h, the reaction e was concentrated. The resulting crude
mmmdwwpmfiwbywkaghmmmmMmegmm45%mmMmflmDCMflo
afford 3.1 g of the titled mixture. MS (ESI) m/Z =267.2 [M+1] +/283.2 [M+1]+.
D. 4-(Bicyclo[1.1.1]pentanylamin0)((tetrahydro-ZH-pyran
yl)amin0)pyrimidinecarboxamide. To a e of yclo[1 . 1.1]pentan
ylamino)—2-(methylsulf1nyl)pyrimidinecarboxamide, 4-(bicyclo[1 . 1 . 1]pentan
ylamino)(methylsulfonyl)pyrimidinecarboxamide (300 mg) and tetrahydro-2H-
pyranamine hydrochloride (181.5 mg, 1.32 mmol) in NMP (10 mL) was added DIEA
(426rng,331nnnfl) Theremflfingnnxuuewmssfinedat100°C(nwnnght Thenthe
reaction mixture was purified by ative HPLC to give the desired product (221.3 mg,
0.73 mmol, yield 67 %) as a yellow powder. 1H NMR (400 MHz, CDgOD) 8 ppm 8.19 (s,
1H), 3.95-3.88 (m, 3H), 3.44-3.38 (m, 2H), 2.40 (s, 1H), 2.09 (s, 6H), 1.88-1.85 (m, 2H),
1.55—1.45 (m, 2H); MS (ESI) m/z = 304.2 [M+1]+.
ATI—25 14175v1
Example 61: 4-(Bicyclo[1.1.1]pentanylamin0)(((1R,3S)
hydroxycyclohexyl)amin0)pyrimidinecarb0xamide
A. 4-(bicyclo[1.1.1]pentanylamin0)(methylsulfinyl)pyrimidine
carboxamide and 4-(bicyclo[1.1.1]pentanylamin0)(methylsulfonyl)pyrimidine
carboxamide. 3-Chlorobenzoperoxoic acid (4.27 g, 21 mmol) was added portion-wise to
a solution of 4-(bicyclo[l . l . l]pentan-l -ylamino)(methylthio)pyrimidinecarboxamide
(3.50 mg, 14 mmol, synthesis described herein) in THF (40 mL) at 0 CC. The resulting
solution was mixed at 0 0C for l h and then concentrated under reduced pressure to an oil
that was purified by silica gel column chromatography (5 % methanol in DCM) to afford
310 mg of a mixture of 4-(bicyclo[l . l .l]pentan-l-ylamino)(methylsulfinyl)pyrimidine-
-carboxamide and 4-(bicyclo[l . l . l]pentan- l -ylamino)(methylsulfonyl)pyrimidine
carboxamide as a yellow solid. MS (ESI) m/Z =267.2 [M+l] +/283.2 [M+l]+.
B. 4-(Bicyclo[1.1.1]pentanylamin0)(((1R,3S)hydr0xycyclo-
hexyl)amin0)pyrimidinecarb0xamide. To a mixture of 4-(bicyclo[l.l.l]pentan-l-
ylamino)(methylsulfinyl)pyrimidinecarboxamide and 4-(bicyclo[l -
. l . l n- l
ylamino)(methylsulfonyl)pyrimidinecarboxamide (300 mg) and (l 3-
aminocyclohexanol (152 mg, 1.32 mmol; prepared as described in Tetrahedron:
Asymmetry 152051—2056 (2004)) in NMP (10 mL) was added DIEA (426 mg, 3.3 mmol).
The ing e was stirred at 100 CC overnight. The reaction mixture was purified
by preparative HPLC to give the desired t (230.2 mg, 0.73 mmol, yield 66 %).
1H NMR (400 MHz, CDgOD) 5 ppm 8.29 (s, 1H), 3.91-3.89 (m, 1H), .62 (m, 1H),
2.50 (s, 1H), 2.29-2.25 (m, 1H), 2.20 (s, 6H), 1.97-1.83 (m, 3H), 1.41-1.21 (m, 4H); MS
(ESI) m/z = 318.2 [M+1]+.
-2ll-
ATI—2514l75vl
Example 62: 2-(Bicyclo[1.1.1]pentan-l-ylamino)—4-((1R,3R)—3-hydr0xy-4,4-
dimethylcyclohexylamin0)pyrimidinecarb0xamide
3 JL / NH2
N N NH
A. N-(Bicyclo[1.1.1]pentanyl)br0m0(methylthio)pyrimidin-Z-
amine. To a stirring solution of 5-bromochloro(methylthio)pyrimidine (1.0 g,
4.18 mmol) in NMP (10.0 mL) was added bicyclo[1.1.1]pentanamine hydrochloride
(749 mg, 6.26 mmol, prepared according to Org. Lett., 13(17): 4746-4748 (2011)) and
DIEA (2.19 mL, 12.53 mmol). The mixture was stirred at 100 CC for 16 h and then the
solvent was d under reduced pressure. The residue was d in 100 mL ethyl
acetate and 50 mL 1M aquoues solution of sodium hydrogen phosphate. The layers were
separated and the aqueous layer was extracted with 50 mL ethyl acetate. The combined
organic layers were dried over anyhydrous ium sulfate, d and concentrated
under reduced pressure to afford N-(bicyclo[1.1.1]pentan-l-yl)bromo
(methylthio)pyrimidinamine (1250 mg, 4.37 mmol, 105 % yield) as a solid that was
used without further purification. MS (ESI) m/z 286.0 [M+1]+ and 288.0 .
B. 2-(Bicyclo[1.1.1]pentan-l-ylamin0)—4-(methylthi0)pyrimidine
carbonitrile. N-(Bicyclo[1 . 1 . 1]pentanyl)-5 -bromo(methylthio)pyrimidinamine
(1250 mg, 4.37 mmol), zinc dust (71.4 mg, 1.092 mmol), zinc e (333 mg,
2.84 mmol), 1,1'-bis-(diphenylphosphino)-ferrocene (196 mg, 0.349 mmol),
tris(dibenzylideneacetone)dipalladium(0) (200 mg, 0.218 mmol), and DMA (8.35 mL)
were combined and heated overnight at 90 0C under a nitrogen atmosphere. The reaction
mixture was diluted with 125 mL ethyl acetate and 50 mL water and filtered through a pad
of . The layers of the filtrate were separated and the aqueous layer was extracted
with 75 mL ethyl acetate. The combined ethyl acetate layers were washed with 2 x 50 mL
brine, dried over anhydrous magnesium sulfate, filtered and concentrated to an oil. The
crude oil was d by silica gel chromatography (0% - 30% ethyl e in hexanes).
The product containing fractions were combined and concentrated to afford 2-
ATI—2514175v1
lo[1.1.1]pentan-l-ylamino)(methylthio)pyrimidinecarbonitrile (566 mg,
2.436 mmol, 55.8 % yield) as a solid. 1H NMR (400 MHz, DMSO-d6) 8 ppm 8.81 - 9.08
(m, 1 H), 8.31 - 8.57 (m, 1 H), 2.55 - 2.63 (m, 3 H), 2.11 (s, 7 H). MS (ESI) m/z 233.3
[M+1]+.
C. 2-(Bicyclo[1.1.1]pentanylamin0)(methylthio)pyrimidine—5-
carboxamide. To a stirring solution of 2-(bicyclo[1 . 1.1]pentanylamino)—4-
(methylthio)pyrimidinecarbonitrile (566 mg, 2.436 mmol) in DMSO (7 mL) was added
6 M aqueous sodium hydroxide solution (2.030 mL, 12.18 mmol) and 30% aqueous
hydrogen peroxide solution (1.381 mL, 12.18 mol) at 0 CC. The mixture was then stirred
at 50 CC for 30 min and then was poured into ice water (50 mL). The solids that formed
were stirred in an ice bath for 30 min, d, washed with water, and then dried in a
vacuum oven overnight at 45 0C to afford 2-(bicyclo[1.1.1]pentanylamino)
(methylthio)pyrimidinecarboxamide (410 mg, 1.638 mmol, 67.2 % yield). 1H NMR
(400 MHz, DMSO-d6) 8 ppm 8.41 (s, 1 H), 7.03 - 8.34 (m, 2 H), 2.43 - 2.48 (m, 1 H), 2.35
(br. s., 3 H), 2.09 (s, 6 H). MS (ESI) m/z 251.3 [M+1]+.
D. 2-(Bicyclo[1.1.1]pentanylamin0)—4-(methylsulfinyl)pyrimidine—5-
carboxamide. To a stirring solution of 2-(bicyclo[1 . 1.1]pentanylamino)—4-
(methylthio)pyrimidinecarboxamide (410 mg, 1.638 mmol) in chloroform (39.0 mL)
was added portionwise, 3-phenyl(phenylsulfonyl)-1,2-oxaziridine (514 mg,
1.965 mmol). The ing pale yellow solution was stirred at ambient temperature for
two nights under nitrogen. The reaction mixture was trated under reduced pressure
to give the crude product as a white solid. Ethyl acetate (15 mL) was added to these solids
and the slurry was stirred at room temp for 1 h, filtered, washed with ethyl acetate, and
dried in a vacuum oven for a few hours to afford 2-(bicyclo[1.1.1]pentanylamino)—4-
(methylsulf1nyl)pyrimidinecarboxamide (397 mg, 1.491 mmol, 91 % yield) as white
solid. 1H NMR (400 MHz, DMSO-dg) 8 ppm 8.67 - 9.14 (m, 2 H), 7.93 - 8.11 (m, 1 H),
7.41 - 7.54 (m, 1 H), 2.68 - 2.79 (m, 3 H), 2.43 - 2.48 (m, 1 H), 2.02 - 2.21 (m, 6 H). MS
(ESI) m/z 267.0 [M+1]+.
] E. 2-(Bicyclo[1.1.1]pentanylamin0)—4-((1R,3R)—3-hydr0xy-4,4-
dimethylcyclohexylamin0)pyrimidine—5-carb0xamide. To a stirring suspension of
2-(bicyclo[1 . 1 .1]pentanylamino)(methylsulf1nyl)pyrimidinecarboxamide (397 mg,
ATI—2514175v1
1.491 mmol) and and a mixture of (1R,5R)amino-2,2-dimethylcyclohexanol
hydrochloride and (1S,5S)—5-amino-2,2-dimethylcyclohexanol hydrochloride (348 mg,
1.938 mmol, sis bed herein) in DMF (4.88 mL) was added DIEA (0.78 mL,
4.47 mmol) and the reaction was heated to 90 CC overnight. The crude reaction mixture
was poured into 60 mL of ice water. The resulting solids were slurried for ~ 1 h, filtered,
rinsed with water and dried for a few hours in a vacuum oven at 45 CC to afford a mixture
of 2-(bicyclo[1 . 1 . anylamino)((1R,3R)—3-hydroxy-4,4-dimethyl-
cyclohexylamino)pyrimidinecarboxamide and 2-(bicyclo[1.1.1]pentanylamino)
((1S,3S)—3-hydroxy-4,4-dimethylcyclohexylamino)pyrimidinecarboxamide (481 mg,
1.392 mmol, 93 % yield). This material was separated by preparative chiral SFC utilizing
a ChiralPak AD-H, 250><30mm ID. column with an isocratic 40% ethanol + 0.1%
um hydroxide in C02 gradient at 120 mL/min flow rate and at 38 CC. The faster
eluting isomer was denoted as peak 1 and 132 mg (0.382 mmol) was obtained. The slower
g isomer was denoted as peak 2 and 120 mg (0.349 mmol) was obtained.
Peak 1: 1H NMR (400 MHz, DMSO-d6) 8 ppm 8.85 - 9.12 (m, 1H), 8.14 -
8.44 (m, 1H), 7.63 - 7.90 (m, 1H), 4.47 - 4.63 (m, 1H), 3.76 - 3.96 (m, 1H), 3.08 - 3.23 (m,
1H), 2.43 (s, 1H), 2.04 (s, 6H), 1.87 - 1.99 (m, 1H), 1.66 - 1.83 (m, 1H), 1.04 - 1.47 (m,
4H), 0.92 (s, 3H), 0.82 (s, 3H) MS (ESI) m/z 346.3 [M+1]+.
Peak 2: 1H NMR (400 MHz, DMSO-dg) 8 ppm 8.88 - 9.07 (m, 1H), 8.25 -
8.45 (m, 1H), 7.57 - 7.90 (m, 1H), 4.46 - 4.59 (m, 1H), 3.78 - 3.96 (m, 1H), 3.09 - 3.22 (m,
1H), 2.35 - 2.47 (m, 1H), 2.04 (s, 6H), 1.87 - 1.99 (m, 1H), 1.66 - 1.80 (m, 1H), 1.37 - 1.48
(m, 1H), 1.12 - 1.34 (m, 3H), 0.88 - 0.94 (m, 3H), 0.71 - 0.86 (m, 3H). MS (ESI) m/z
346.3 [M+1]+. By SAR potency comparison with similar compounds ofknown absolute
stereochemistry described herein, Peak 1 was assigned as 2—(bicyclo[1.1.1]pentan
ylamino)—4-((1S,3S)hydroxy-4,4-dimethylcyclohexylamino)pyrimidine—5-
carboxamide. Peak 2 was assigned as 2-(bicyclo[1.1.1]pentanylamin0)—4-((1R,3R)—
3-hydroxy-4,4-dimethylcyclohexylamin0)pyrimidinecarboxamide.
—214—
ATI—25 14175v1
ASSAYS
BIOCHEMICAL ASSAYS
A. Time resolved fluorescence assays
JNKl Assay. A 384-well time resolved fluorescence assay was used to
monitor JNKl activity. The JNKl assay was run in the following assay buffer: 50 mM
HEPES, 10 mM MgClz, 1 mM EGTA, 2 mM DTT, and 0.01% Tween 20. To initiate the
reaction 100 nM of ULightTM-labeled 4EBPl peptide (Perkin-Elmer) and 5 [LM ofATP
were mixed with 500 pM of JNKl (Carna Biosciences), for a total assay volume of 20 [LL
in each well. The assay was incubated at room temperature for l h and terminated using a
mixture of 30 mM EDTA and 4 nM i-4EBPl, by adding 20 [LL of stop solution to
each well. Plates were read on a -Elmer Envision Reader.
] JNK2 Assay. A 384-well time ed fluorescence assay was used to
monitor JNK2 activity. The JNK2 assay was run in the following assay buffer: 50 mM
HEPES, 10 mM MgClz, 1 mM EGTA, 2 mM DTT, and 0.01% Tween 20. To initiate the
reaction 100 nM of ULightTM-labeled 4EBPl e (Perkin-Elmer) and 5 [LM ofATP
were mixed with 500 pM 0f JNK2 (Carna Biosciences), for a total assay volume of 20 [LL
in each well. The assay was incubated at room temperature for l h and terminated using a
e of 30 mM EDTA and 4 nM Eu-anti-4EBPl, by adding 20 [LL of stop solution to
each well. Plates were read on a Perkin-Elmer Envision Reader.
B. Z’-LYTE® Cascade Assays
JNKl Assay. The JNKl Z’-LYTE® Cascade kinase assay was run in the
following buffer: 50 mM HEPES at pH 7.5, 0.01% BRlJ-35, 10 mM MgClz, 1 mM EGTA,
and 1 mM DTT. A 10 [LL kinase reaction mixture was prepared containing 1.81 - 7.25 ng
JNKl, 25 ng inactive MAPKAPK2, 100 [LM ATP, and 2 [LM Ser/Thr 04 peptide. The
assay was incubated at room temperature for l h. Next, 5 [LL of a 1:512 dilution of
Development Reagent A (lnvitrogen, PV3295) was added to the reaction e and
incubated at room temperature for an additional hour. The data was then read on a
fluorescence plate reader and analyzed.
JNK2 assay. The JNK2 E® Cascade kinase assay was run in the
following : 50 mM HEPES pH 7.5, 0.01% BRlJ-35, 10 mM MgClz, 1 mM EGTA,
2 mM DTT. A 10 [LL kinase reaction mixture was prepared containing 0.38 - 1.5 ng
ATl—2514l75vl
JNK2, 100 ng inactive MAPKAPK2, 100 uM ATP, and 2 uM Ser/Thr 04 peptide. The
assay was incubated at room temperature for 1 h. Next, 5 uL of a 1:512 dilution of
Development Reagent A (Invitrogen, PV3295) was added to the reaction mixture and
incubated at room temperature for an additional hour. The data was then read on a
fluorescence plate reader and analyzed.
C. Radioactive Assays
JNK1 assay. The radioactive JNK kinase assay was carried out in a 96-well
plate format at a final volume of 100 uL. The final assay concentration was 6.6 uM ATP
(3-fold ATP Km), 2.64 to 5 ug/mL JNKl, and 100 ug/mL cJUN. JNKl was diluted in the
following dilution buffer (20 mM HEPES pH 7.6, 0.1 mM EDTA, 2.5 mM MgC12,
0.004%(w/V) Triton X100, 2 ug/ml Leupeptin, 20 mM B-glycerol phosphate, 0.1 mM
N33VO4 dithiothreitol) and then pre-mixed with cJun diluted in the substrate on
buffer (20 mM HEPES pH 7.6, 50 mM NaCl, 0.1 mM EDTA, 2.5 mM MgClz, 0.05%(w/V)
Triton X100). The JNKl/cJun mix (85 ul) was added to the inhibitor (5 ul) diluted in
100% DMSO to give a final DMSO assay concentration of 5%(V/V). The enzyme,
substrate and inhibitor mixture was allowed to equilibrate at room temperature for
minutes. The reaction was started by the addition of 10[LL of 10X ATP in kinase buffer
(130 mM MgCl; 6 mM dithiothreitol, 150 mM itrophenyl phosphate, 100 uCi/ml
y-[33P]-ATP). Reactions were allowed to proceed for 60 minutes before precipitation of
protein Via trichloroacetic acid (7.2% TCA final). After a 30 minute incubation with TCA,
reaction ts were collected onto glass microfilter 96-well plates pore MAHF
CIH60) using a Packard Filtermate. The precipitate was washed with ate Buffered
Saline and the amount of phosphate incorporated into cJun was quantified by scintillation
counting using a d nt-NXT. All assays were conducted under conditions
where phosphate incorporation was linear with respect to time and enzyme tration.
The IC50 values were calculated as the concentration of the inhibitor at which the c-Jun
phosphorylation was reduced to 50% of the control value.
JNK2 assay. The assay was carried out in a l plate format at a final
volume of 100 uL. The final assay concentrations were 6.6 uM ATP (3-fold ATP Km),
0.2 to 0.53 ug/mL JNK2, and 100 ug/mL cJUN. JNK2 was d in the following
dilution buffer (20 mM HEPES pH 7.6, 0.1 mM EDTA, 2.5 mM MgClz, 0.004%(w/V)
ATI—25 14175v1
2012/034349
Triton X100, 2 ug/ml Leupeptin, 20 mM B-glycerol phosphate, 0.1 mM N33VO4
dithiothreitol) and then pre-mixed with cJun diluted in the substrate on buffer
(20 mM HEPES pH 7.6, 50 mM NaCl, 0.1 mM EDTA, 2.5 mM MgC12, 0.05% (w/v)
Triton X100). The JNK2/cJun mix (85 ul) was added to the inhibitor (5 ul) diluted in
100% DMSO to give a final DMSO assay tration of 5%(V/V). The enzyme,
ate and inhibitor mixture was allowed to equilibrate at room temperature for
minutes. The reaction was started by the addition of 10uL of 10X ATP in kinase buffer
(130 mM MgCl; 6 mM dithiothreitol, 150 mM itrophenyl phosphate, 100 uCi/ml
y-[33P]-ATP). Reactions were allowed to proceed for 60 minutes before precipitation of
protein Via trichloroacetic acid (7.2% TCA final). After a 30 minute incubation with TCA,
reaction ts are collected onto glass microfilter 96-well plates (Millipore MAHF
CIH60) using a Packard mate. The precipitate was washed with Phosphate Buffered
Saline and the amount of phosphate incorporated into cJun was quantified by scintillation
counting using a Packard nt-NXT. All assays were conducted under conditions
where phosphate incorporation was linear with respect to time and enzyme concentration.
The IC50 values were calculated as the tration of the inhibitor at which the c-Jun
phosphorylation was reduced to 50% of the control value.
CELL ASSAYS
RAW264.7 Phosp_ho-cJun Whole Cell Assay. RAW264.7 cells were
purchased from the American Tissue Culture Collection and maintained in growth media
ting of 90% high glucose Dulbecco's Modified Eagle Medium rogen), 10%
fetal bovine serum (Hyclone), and 2 mM L-glutamine (Invitrogen). All cells were cultured
at 37 0C in 95% air and 5% C02. Cells were plated at a density of 1.0 x 105 cells per well
in a 96-well plate in 120 uL of growth media. Diaminopyrimidine Compound stock
(30 mM) was diluted serially in DMSO, fithher diluted in growth media, and was added to
each well as a 10x concentrated solution in a volume of 15 uL, mixed, and allowed to
incubate with cells. The compound vehicle (DMSO) was maintained at a final
concentration of 0.2% in all wells. After 30 minutes, the cells were activated with
lipopolysaccharide (ALEXIS Biochemicals) at a final concentration of 25 ng/mL.
Lipopolysaccharide was added as a 10x concentrated solution in growth media and added
in a volume of 15 uL per well. Cell plates were cultured for 1 h, after which the cell media
ATI—25 14175v1
was d. The level of c-Jun protein which was phosphorylated at serine 63 was
measured according to the manufacturer’s instructions for the Whole Cell Lysate Kit-
Phospho-c-Jun (Ser 63) Assay (Meso Scale Discovery) with the exception that the
concentration ofNaCl in the lysis buffer was increased to a final concentration of
350 mM. The IC50 values were calculated as the concentration of Diaminopyrimidine
Compound at which the level of phosphorylated c-Jun protein was reduced to 50% of the
signal window. Certain compounds of Table l, 2 and 3 have an IC50 value ranging from
0.01 - 30 uM in this assay.
Jurkat T-cell IL-2 Production Assay. Jurkat T cells (clone E6-1) are
purchased from the an Tissue Culture Collection and maintained in growth media
consisting of RPMI 1640 medium containing 2 mM L-glutamine (Mediatech), with 10%
fetal bovine serum (Hyclone) and penicillin/streptomycin. All cells are cultured at 37 °C
in 95% air and 5% C02. Cells are plated at a density of 1 x 105 cells per well in 120 uL of
media in a 96-well plate. opyrimidine Compound stock (20 mM) is diluted in
growth media and added to each well as a 10 x concentrated solution in a volume of
uL, mixed, and allowed to pre-incubate with cells for 30 min. The compound vehicle
(dimethylsulfoxide) is maintained at a final concentration of 0.2% in all samples. After
min the cells are activated with PMA (phorbol myristate acetate; final concentration
50 ng/mL) and PHA (phytohemagglutinin; final tration 1 ug/mL). PMA and PHA
are added as a 10 x concentrated solution made up in growth media and added in a volume
of 15 uL per well. Cell plates are ed for 6 h. Cells are pelleted by centrifilgation and
the media removed and stored at -20 CC. Media aliquots are analyzed according the
manufacturers instructions for the Human IL-2 Tissue Culture Kit (Meso Scale
Discovery). The IC50 values are calculated as the concentration of the Diaminopyrimidine
nd at which the IL-2 production was reduced to 50% of the signal window.
n compounds from Table l, 2 and 3 have an IC50 value ranging from 0.01 - 10 uM in
this assay.
ANIMAL MODELS
Rat or mouse in viva LPS-induced TNF-u tion and chun Assay.
Male CD rats or 6 mice procured from Charles River Laboratories, at 7 weeks of
age or 20 g weight respectively, were allowed to acclimate for one week prior to use. In
ATI—2514l75vl
the rat, the lateral tail vein was cannulated percutaneously with a 22-gage over-the-needle
catheter under brief isoflurane anesthesia and 20 ug LPS (E. Coli 055:BS) and catheters
were flushed with 2.5 mL/kg of normal injectable saline. In the mouse, 1 mg/kg LPS (E.
Coli ) in saline was administered intraperitoneally in a volume of 200 ul. The
animals were administered the Diaminopyrimidine Compound by oral gavage 15 to
180 min prior to injection of LPS. Blood was collected via cardiac puncture 90 s or
2 h after LPS challenge for rats and mice respectively, and the liver and epididymal fat
was ed for chun analysis using the ale Discovery Platform. The plasma was
prepared using lithium heparin tion tubes and frozen at -80 CC until analyzed. The
TNF-u levels were determined using a rat or mouse specif1c TNF-u ELISA kit (Mesoscale
Discovery). The liver and epididymal fat were homogenized and sonicated in Mesoscale
lysis buffer, the protein t was determined (BCA protein determination kit) and the
chun levels were measured (Mesoscale ery). The ED50 values were calculated as
the dose of the Diaminopyrimidine nd at which the TNF-u or chun levels were
d to 50% of the control value. Certain compounds from Table l, 2 and 3 were
shown, or will be shown, to have an ED50 value ranging from 30-100 mg/kg in this assay.
Choline def1cient amino acid supplement induced non-alcoholic
steatohep_atitis g NASH) model in the rat. Male Wistar rats obtained from Charles River
Laboratories at 7 weeks of age are allowed to acclimate for one week prior to use. Rats
are fed Choline Def1cientL Amino Acid Supplemented (CDAA) diet (Dyets Inc) for up to
12 weeks. Rats are administered Diaminopyrimidine Compound by oral gavage once or
twice daily starting at the time of introduction to the diet for between 2 and 12 weeks. At
the termination of the study blood is collected via cardiac puncture and the liver and
epididymal fat isolated. The liver tissue is processed for histology and the amount of
steatosis or fibrosis is quantitated following H&E oxylin and eosin) or picro Sirius
red staining. The liver fianction is ed by is of liver enzymes, for example,
ALT and AST in plasma or serum. In addition, levels of phospho-cJun in the liver were
quantitated by IHC, as described by Ma F. et. al. Lab Invest.; 89(4):470-84 (2009). The
ED50 values are calculated as the dose of Diaminopyrimidine Compound at which the
f1brosis, steatosis, liver enzyme, and/or p-cJun levels are reduced to 50% of the control
-2l9-
ATI—2514l75vl
value. Certain compounds from Table l, 2 and 3 have, or will be shown to have, an
ED50 value ranging from 10-100 mg/kg in this assay.
Bile duct ligation model of Fibrosis. Male BALB/c mice g) were obtained
from Charles River Laboratories, and were d to acclimate for one week prior to surgery.
A ketamine (80-100 mg/kg)/xylazine(8mg/kg) anesthetic delivered IP was used for the bile duct
ligation surgical procedure. An abdominal incision provided access to the bile duct which was
ligated with two 6.0 silk sutures placed rostral to the bile duct connection with the intestines.
3-0 vicryl suture was used to close the abdominal wall, and skin. Following y, mice were
administered 1 mL of lactated s solution sub cutaneous daily as well as wet food for the
on of the study. Test compounds were administered by oral gavage starting the day after
surgery. Studies were terminated 14 days post bile duct ligation. Blood was collected via
cardiac puncture and serum was isolated for clinical chemistry analysis of liver function (ALT,
AST, and bilirubin). Liver tissue was collected and processed histologically, stained with H&E
(hematoxylin and eosin) or Picro Sirius red, and used to assess the amount of ation,
rtal hyperplasia, necrosis and s induced by the bile duct ligation surgical procedure.
In addition, levels of phospho-cJun in the liver were quantitated by IHC, as described by Ma F.
et. al. Lab Invest.; 89(4):470-84 (2009). Certain compounds from Table l, 2 and 3 show, or will
show, statistically significant inhibition of inflammation, periportal hyperplasia, necrosis,
fibrosis, and/or phosphor-cJun levels at dose levels of 10-300 mg/kg QD or BID.
Carbon Tetrachloride Model of Fibrosis. Male C57Bl/6 mice obtained
from Harlan weighing 22-24g at arrival were allowed to acclimate for one week prior to
use. Fibrosis was established via intraperitoneal injection of CCl4 (0.75 mL/kg) in mineral
oil (15% v/v CCl4 in mineral oil) 3 times a week. The animals were administered the
Diaminopyrimidine Compound by oral gavage l h prior to the initial CCl4 injection and
then daily or twice daily through the end of the study, 28 days later. At the termination of
the study blood was ted via cardiac puncture and the liver was isolated. The liver
tissue was processed for histology and the amount of steatosis or fibrosis was quantitated
following H&E (hematoxylin and eosin) or picro Sirius red staining. The liver function
was ed by analysis of liver enzymes, for example, ALT and AST in plasma or
serum. In addition, levels of o-cJun in the liver were tated by IHC, as
described by Ma F. et. al. Lab Invest.; 470-84 (2009). Certain compounds from
ATI—2514l75vl
Table l, 2 and 3 show, or will show, tically significant inhibition of inflammation,
periportal hyperplasia, necrosis, fibrosis, and/or phosphor-cJun levels at dose levels of
-300 mg/kg QD or BID.
Skin Bleomycin model: Male or female DBA/2 mice are obtained from
Harlan weighing 22-24g at arrival and are allowed to acclimate for one week prior to use.
Skin fibrosis is induced by intradermal injections of bleomycin (0.5 mg/mL in a total
volume of 100 uL) every other day for 6 weeks in defined areas of the upper back. The
animals are administered the Diaminopyrimidine Compound by oral gavage l h prior to
the l bleomycin injection and then daily or twice daily through the end of the study,
3 or 6 weeks later. At the termination of the study blood is collected via cardiac puncture
and the skin is isolated. The skin is processed for histology and the dermal thickness is
quantitated following H&E (hematoxylin and eosin) staining. Certain compounds from
Table l, 2 and 3 will show tically significant inhibition of skin thickness at dose
levels of 10-300 mg/kg QD or BID.
Lung Bleomycin model: Male C57Bl/6 mice are obtained from Charles
River tories and animals are allowed to acclimate for at least 5 days. Animals are
kept on a l2-hours light/dark cycle and are approximately 8 weeks old at the beginning of
the study. Mice are lightly anesthetized with isofiurane and the ae exposed. On
Day 0, bleomycin (30 uL; 0.05U) is injected into the trachea. Following injection of
bleomycin, the wound is closed using wound clips and the animal is allowed to recover.
Prednisolone ive control, dosed intraperitoneally), vehicle (dosed orally), or
Diaminopyrimidine Compound (dosed orally) is administered 30 min to 2 hours prior to
bleomycin administration (prophylactic model) or 4 days after bleomycin (therapeutic
. Dosing with vehicle or Diaminopyrimidine Compound is carried out twice daily
hout all studies, dosing with prednisolone is carried out once daily. Mice are
red daily for adverse effects from test article administration, including effect on
body . Mice are euthanized on Day 13. Bronchoalveolar lavage is med using
1 mL phosphate buffered saline (PBS) and total WBC counts are assessed. Results are
expressed as total cells retrieved. Macrophages, eosinophils, neutrophils, and cytes
are quantified in BALF samples. Lung lobes are processed for histology using H&E
(hematoxylin and eosin), Trichrome or TUNEL ng. Trichrome sections are scored
-22l-
ATI—2514l75v1
for fibrosis ty as described previously (Ashcroft et al. J. Clin. Pat/ml. 41 :467-470
(1988)). Certain compounds from Table 1, 2 and 3 will show tically significant
inhibition of lung fibrosis at dose levels of 10-300 mg/kg QD or BID.
Lupus Model: Female NZB/NZW Fl mice are obtained from Jackson
tories between 4-12 weeks of age at l and are allowed to acclimate for one
week prior to use and to develop spontaneous SLE-like disease. The animals are
administered the Diaminopyrimidine Compound by oral gavage at the initiation of the
study and then daily or twice daily through the end of the study up to 6 months later.
Blood is collected throughout the study and serum isolated to measure occurrence of
dsDNA via a standard ELISA method and proteinurea is measured in the urine. Certain
compounds from Table 1, 2 and 3 will show statistically significant inhibition of
nurea or dsDNA at dose levels of 10-300 mg/kg QD or BID.
UUO Model of Kidney Fibrosis: Male CD-IGS rats are obtained from
Charles River Laboratories at a body weight of approximately 150 — 160 g and are allowed
to acclimate for one week prior to tion of the study. Rats are anesthetized using
ketamine/xylazine and the surgical area is sterilized with 70% ethanol and ne. The
ureter is exposed after a midline incision is made and ligated twice using 5.0 silk suture
placed 1 cm apart and cut between the ligations. The on is closed using 3.0 silk
suture and the animal is allowed to recover. The animals are administered the
Diaminopyrimidine Compound by oral gavage 1 h prior to the ureter ligation and then
daily or twice daily through the end of the study 7 days later. At the termination of the
study blood is collected via cardiac puncture and the kidney isolated. The kidney is
processed for histology and the morphology and amount of fibrosis is quantitated
following H&E oxylin and eosin), picro sirius red or alpha-smooth muscle actin
staining. Certain compounds from Table 1, 2 and 3 will show statistically significant
inhibition of fibrosis or alpha-smooth muscle actin staining at dose levels of 10-300 mg/kg
QD or BID.
ACTIVITY TABLES
] Each of the compounds in Tables 1, 2 and 3 was tested in one or more of
the INK1 biochemical assays and was found to have activity therein, with all of the
ATI—25 14175v1
WO 45569
compounds having an IC50 below 10 MM in the assay, with some compounds having an
IC50 below 200 nM (activity level D), some an IC50 between 200 nM and 800 nM ity
level C), some an IC50 between 800 nM and 1 MM (activity level B), and others having an
IC50 between 1 MM and 10 MM (activity level A).
Table 1.
4-(isopropylan1ino)—2-((lr,4r)-
,2-trifluoroethoxy)—
cyclohexylaniino)pyrin1idine-5 -
carboxaniide
2-(tert-butylan1ino)((lR,3S)-
3-hydroxycyclohexylaniino)-
pyrimidine-S-carboxaniide
2—(4,4—
difluorocyclohexylaniino)
(isopropylaniino)pyrin1idine-5 -
carboxaniide
2-((lr,4R) D
(difluoroniethoxy)cyclohexyla
mino)((lR,2R)
hydroxycyclopentylaniino)-
pyrimidine-S-carboxaniide
PM: 2-(4,4- 356.3 D
“jug [\ ] difluorocyclohexylaniino)
:l ]; ((1R,2R)
M NH :3; hydroxycyclopentylaniino)-
NE at pyrimidine-S-carboxaniide
ATI—2514l75vl
Cmpd Structure NAME MH+ Act.
A- Level
6 x49! 2-((1r,4r)(2-hydr0xypropan- 336.2 D
wk] yclohexylamino)
‘T" [\i (isopropylamino)pyrirnidine
carboxamide
r f11:?”
"if «Q.
4-((1R,2R)
hydroxycyclopentylarnino)
(tetrahydro-ZH-pyran
ylarnino)pyrirnidine-5 -
carboxamide
2-((1r,4R)
methoxycyclohexylamino)
((R)-tetrahydr0-2H-pyran
ylarnino)pyrirnidine-5 -
carboxamide
4-(isopr0pylarnino)—2-((1r,4r)-
4-meth0xycyc10hexy1arnino)-
dine-S-carboxamide
2-((1r,4r)—4-
(dimethylcarbarnoyl)cyclohexyl
amino)—4-
(isopropylamino)pyrirnidine-5 -
amide
2-(1,4-dioxaspiro[4.5]decan
ylarnino)—4-
(isopropylamino)pyrirnidine-5 -
carboxamide
—224—
ATI—ZS 14175V1
Cmpd. Structure NAME MH+ Act.
A- Level
12 :9” 2-((1r,4r)(hydr0xymethyl)- 308.3 D
-"‘:‘\I cyclohexylamino)
“T” L?" (isopropylamino)pyrirnidine
arnide
fl ‘1}: *1
Peak 4
Peak 3
Peak 2
Peak 1
One of:
4-(5-hydr0xytetrahydro-2H-
pyrany1arnin0)—2-((1r,4r)
methoxycyclohexylarnino)-
pyrimidine-S-carboxarnide;
4-(5-hydr0xytetrahydro-2H-
pyrany1arnin0)—2-((1r,4r)
methoxycyclohexylarnino)-
pyrimidine-S-carboxarnide;
4-(5-hydr0xytetrahydro-2H-
pyrany1arnin0)—2-((1r,4r)
methoxycyclohexylarnino)-
pyrimidine-S-carboxamide; or
4-(5-hydr0xytetrahydro-2H-
pyrany1arnin0)—2-((1r,4r)
methoxycyclohexylarnino)-
dine-S-carboxarnide
ATI—ZS 14175V1
Cmpd. Structure NAME MH+ Act.
A- Level
17 4-((1R,3S,4S)—3-hydroxy 378 D
[‘T‘m [JR] methylcyclohexylarnino)
3 i ((1r,4R)—4-
methoxycyclohexylamino)-
H “Hafijiky
El pyrimidine-S-carboxamide
4-((1 S ,3R,4R)-3 xy
methylcyclohexylarnino)
(( 1r,4S)
methoxycyclohexylamino)-
pyrimidine-S-carboxamide
4-((1R,3R,4R)hydroxy
methylcyclohexylarnino)
(( 1r,4R)—4-
methoxycyclohexylamino)-
pyrimidine-S-carboxamide
4'((1S,3S,4S)hydroxy—4-
cyclohexylamino)_2-
((1r,4S)-4_
methoxycyclohexylamino)-
pyrimidine-S-carboxamide
2-((1r,4R)
(difluorornethoxy)cyclohexyla
mino)((1R,3 S)-3 -
hydroxycyclohexylamino)-
pyrimidine-S-carboxamide
2-((1r,4R)hydr0xy
methylcyc10hexy1arnino)
(( 1 R, 3 S)-3 -
ycyclohexylamino)-
pyrimidine-S-carboxamide
ATI—ZS 14175V1
Structure NAME
,3R)hydroxy-3 -
methylcyclohexylarnino)
(( 1r,4R)—4-
methoxycyclohexylamino)-
pyrimidine-S-carboxamide
4-((1R,3 ydroxy-3 -
methylcyclohexylarnino)
(( 1r,4R)—4-
methoxycyclohexylamino)-
pyrimidine-S-carboxamide
2-((1r,4S)
methoxycyclohexylamino)
((S)0X0piperidin
no)pyrirnidine-5 -
carboxamide
2-((1r,4R)
methoxycyclohexylamino)
((R)0X0piperidin
ylarnino)pyrirnidine-5 -
carboxamide
2-((1r,4R)
(dimethylcarbamoyl)cyclohexyl
amino)((1R,3 S)—3 -
hydroxycyclohexylamino)-
pyrimidine-S-carboxamide
4-((1R,3 S)-3 -
hydroxycyclohexylarnino)
((1r,4R)—4-(2,2,2-
trifluoroethoxy)cyclohexy1arnin
o)pyrirnidinecarb0xarnide
ATI—ZS 14175V1
Cmpd. Structure NAME MH+ A°t°
A- Level
29 E.T 4-((1R,3S) 432 D
hydroxycyclohexylamino)
1:1” 2”;r
((ls,4S)(2,2,2-
Efibffl'ffixgi trifluoroethoxy)cyclohexyl-
"= ”gr ' w?“ amino)pyrimidine
carboxamide
4—((1R,3S)
w...“ i.
7 hydroxycycloheptylamlno)‘2_
(( 1 1‘,4R)
ycyclohexylamino)-
pyrimidine-S-carboxamide
31 4-((1R,3R)
hydroxycycloheptylarnino)
(( 1r,4R)—4-
ycyclohexylamino)-
pyrimidine-S-carboxamide
32 4-((IS,3R)
‘ ‘ hydroxycycloheptylarnino)
((1r,4S)
ycyclohexylamino)-
pyrimidine-S-carboxamide
33 4-((IS,3S) 378.3 D
hydroxycycloheptylarnino)
((1r,4S)
methoxycyclohexylamino)-
pyrimidine-S-carboxamide
ATI—ZS 14175V1
Structure NAME
4-((1r,4r)—4-
hydroxycyclohexylamino)
(( 1r,4r)
methoxycyclohexylamino)-
pyrimidine-S-carboxamide
4-(4-hydr0xyrnethylbutan
ylamino)((1r,4r)
methoxycyclohexylamino)-
pyrimidine-S-carboxamide
4-((1R,ZS)
(hydroxyrnethyl)cyclopentylarni
n0)((1r,4R)
methoxycyclohexylamino)-
pyrimidine-S-carboxamide
4-((1 S,2R)
(hydroxyrnethyl)cyclopentylarni
n0)((1r,4S)
methoxycyclohexylamino)-
dine-S-carboxamide
4-((1r,4r)—4-
acetamidocyclohexylamino)
((
methoxycyclohexylamino)-
pyrimidine-S-carboxamide
2-((1r,4R)
acetamidocyclohexylamino)
(( 1 R, 3 S)-3 -
hydroxycyclohexylamino)-
dine-S-carboxamide
ATI—ZS 14175V1
Structure NAME
4-((1 S,3S)
hydroxycyclohexylarnino)
(( 1r,4S)
methoxycyclohexylamino)-
pyrimidine-S-carboxamide
4-((1R,3R)-3 -
hydroxycyclohexylarnino)
(( 1r,4R)—4-
methoxycyclohexylamino)-
dine-S-carboxamide
4-(3-hydroxy
butylarnino)((1r,4r)
methoxycyclohexylamino)-
pyrimidine-S-carboxamide
4-((1R,2R)
hydroxycyclohexylamino)
((1r,4R)—4-
methoxycyclohexylamino)-
pyrimidine-S-carboxamide
4-((1R,3 S)-3 -
ycyclohexylamino)
(( 1r,4R)—4-
methoxycyclohexylamino)-
pyrimidine-S-carboxamide
2-(4,4-
difluorocyclohexylamino)
(( 1 R, 3 S)-3 -
hydroxycyclohexylamino)-
pyrimidine-S-carboxamide
ATI—ZS 14175V1
Structure NAME
4-((1R,3 S)-3 -
hydroxycyclopentylarnino)
(( 1r,4R)—4-
methoxycyclohexylamino)-
pyrimidine-S-carboxamide
2-((1r,4R)
methoxycyclohexylamino)
((R)-piperidin
ylarnino)pyrirnidine-5 -
carboxamide
2-((1r,4S)
methoxycyclohexylamino)
((S)-piperidin
no)pyrirnidine-5 -
carboxamide
4-((1R,3 S)-3 -
hydroxycyclohexylarnino)
(( 1r,4R)—4-
(methylarnino)cyclohexylamino
)pyrimidine-S-carb0xarnide
4-((1R,3 S)-3 -
hydroxycyclohexylarnino)
((R)-tetrahydr0-2H-pyran-3 -
no)pyrirnidine-5 -
carboxamide
4-((1R,3 S)-3 -
hydroxycyclohexylarnino)
(isopropylamino)pyrirnidine-5 -
amide
ATI—ZS 14175V1
Cmpd. Structure NAME MH+ Act.
A' Level
52 3.93“. M mm 4-((1R,3S) 336.2 D
LN] {ij hydroxycyclohexylamino)
H EL». E. H ((S)-tetrahydro-2H-pyran-3 -
3f. mm W.
ylarnino)pyrirnidine
My “V1:
fl amide
53 2-(cyclohexylarnino) 334.2 D
.3. "h
‘ ((1R,3S)
ycyclohexylamino)-
pyrimidine-S-carboxamide
54 4-((1R,3S) 350.3 D
‘ hydroxycyclohexylamino)
(( 1r,4R)—4-
hydroxycyclohexylamino)-
pyrimidine-S-carboxamide
55 3 2-((1r,4r)—4- 350.1 C
L“: [H] methoxycyclohexylamino)
“1'” ET“ (tetrahydro-ZH-pyran
menujw ylarnino)pyrirnidine
E NW. carboxamide
(“I 3;. 4-((1R,3S) 391.2 D
3.. m 1.3 hydroxycyclohexylamino)
L331“ 3LT} ((1r,4R)—4-
(methylcarbarnoyl)cyclo-
H m‘hnfiw3 .3.»
“g” hexylamino)pyrimidine
carboxamide
ATI—ZS 14175V1
Cmpd. Structure NAME MH+ Act.
A- Level
57 4-((1R,3S) 336.2 D
hydroxycyclohexylamino)
(tetrahydro-ZH-pyran
ylarnino)pyrirnidine-5 -
carboxamide
2-((1r,4R)
ethoxycyclohexylamino)
(( 1 R, 3 S)-3 -
hydroxycyclohexylamino)-
pyrimidine-S-carboxamide
,4S)
ethoxycyclohexylamino)
(( 1 S ,3R)-3 -
hydroxycyclohexylamino)-
pyrimidine-S-carboxamide
2-((1r,4S)
ethoxycyclohexylamino)
etrahydro-2H-pyran-3 -
ylarnino)pyrirnidine-5 -
carboxamide
,3R)
hydroxycyclohexylarnino)
(( 1r,4S)
methoxycyclohexylamino)-
pyrimidine-S-carboxamide
2-((1 s,4R)
ethoxycyclohexylamino)
(( 1 S ,2 S)
hydroxycyclopentylamino)-
pyrimidine-S-carboxamide
ATI—ZS 14175V1
Cmpd. Structure NAME MH+ Act.
A- Level
63 2-((1r,4S) 364.3 C
ethoxycyclohexylamino)
\a—5LI‘1,1. UP«.7.‘ ~ H§V€ ' N
((18,2R)
1: ‘r' hydroxycyclopentylamino)-
pyrimidine-S-carboxamide
2-((1 S,3S)
ethoxycyclopentylarnino)
(( 1 S ,2 S)
hydroxycyclopentylarnino)-
pyrimidine-S-carboxamide
,2R)
ycyclopentylarnino)
(( 1r,4R)—4-
methoxycyclohexylamino)-
pyrimidine-S-carboxamide
2-((1r,4R)
ethoxycyclohexylamino)
(( 1 R,2R)
hydroxycyclopentylarnino)-
pyrimidine-S-carboxamide
,4R)
ethoxycyclohexylamino)
((R)hydr0xypropyl-
amino)pyrimidine-5 -
carboxamide
4-((ls,3s)
hydroxycyclobutylarnino)(1 -
(3 -rnethy1butanoy1)piperidin
ylarnino)pyrirnidine-5 -
carboxamide
—234—
ATI—ZS 14175V1
2012/034349
Cmpd. Structure NAME MH+ Act.
A" Level
69 4-((ls,4s)hydroxy 378, 3 D
K r‘juj
methylcyclohexylarnino)
«U ,9 N‘ \L «3:: ((1r,4r)rneth0xycyclohexyl-
:92, \] pyrimidine
carboxamide
2-((1 s,4R)hydroxy
phenylcyclohexylarnino)
((1 S ,2S)hydroxycyclopentylamino
)pyrimidine-5 -
carboxamide
2-((1r,4r)—4-
ethoxycyclohexylarnino)(2-
hydroxyethylarnino)pyrimidine-
oxarnide
2-((1r,4R)
ethoxycyclohexylamino)
((R)-tetrahydr0-2H-pyran
ylarnino)pyrirnidine-5 -
carboxamide
2-((1r,4S)
ethoxycyclohexylamino)
((1 S ,2S)ethoxycyclo-
pentylamino)pyrirnidine-5 -
carboxamide
2-((1r,3S)
ethoxycyclobutylarnino)
((1 S ,2S)hydroxycyclopentylamino
)pyrirnidine-5 -
carboxamide
ATI—ZS 14175V1
Cmpd. Structure NAME MH+ Act.
A- Level
75 2-((1r,4S)(2- 382.3 D
A: ,LATgxi'n‘al fluoroethoxy)cyclohexy1amino)
‘ C “ ‘1; ((1S,2S)hydroxycyclo-
., if”
it; pentylamino)pyrimidine
carboxamide
2-((1R,3R)-3 -
ethoxycyclopentylarnino)
((1 S ,2S)hydroxycyclopentylamino
)pyrirnidine-5 -
carboxamide
2-((1r,4S)
ethoxycyclohexylamino)
((1 S -hydroxycyclohexylamino
)pyrimidine-5 -
carboxamide
4-( 1 -
(hydroxyrnethyl)cyclopentylarni
((1r,4r)methoxycyclohexylamino
)pyrimidine-5 -
carboxamide
2-((1r,4r)—4-
hydroxycyclohexylamino)(4-
methyltetrahydro-2H-pyran
ylarnino)pyrirnidine-5 -
carboxamide
4-((1S,3R)
hydroxycyclopentylarnino)
((1r,4S)rnethoxycyclohexylamino
idine-5 -
carboxamide
ATI—ZS 14175V1
2012/034349
Cmpd. Structure NAME MH+ Act.
A- Level
81 i am 2—((1s,3S)—3— 350.3 D
"I :11 :1 hydroxycyclopentylarnino)
((ls,4R)methoxycyclo-
\ E:
I: \1 :3 hexylamino)pyrimidine
: My
carboxamide
4-(1 -acety1piperidin
ylamino)((1r,4r)
(methoxymethyl)cyclohexylamino
)pyrimidine-5 -
carboxamide
2-(1 -acety1piperidin
ylamino)((1 s,4s)
(methoxymethyl)cyclohexy1-
amino)pyrimidine-5 -
carboxamide
2-((R)acety1pyrrolidin—3 -
o)((1 s,4S)
(methoxymethyl)cyclohexylamino
)pyrimidine-5 -
carboxamide
4-((S)acety1pyrrolidin-3 -
ylamino)—2-((1r,4S)
(methoxymethyl)cyclohexyl-
amino)pyrimidine
carboxamide
2-((1R,3R)-3 -
hydroxycyclopentylarnino)
(1 -(3 -rnethylbutanoyl)piperidin-
4-ylamino)pyrimidine-5 -
amide
ATI—ZS 14175V1
WO 45569
ure NAME
4-((1S,3R)
hydroxycyclopentylarnino)
(1 -(3 -rnethylbutanoyl)piperidin-
4-ylamino)pyrimidine-5 -
carboxamide
2-((1r,4r)—4-
hydroxycyclohexylamino)
(isobutylarnino)pyrimidine-5 -
carboxamide
4-((1 s,4s)
hydroxycyc10hexy1arnino)—2-(1 -
propionylpiperidin
ylarnino)pyrirnidine-5 -
carboxamide
2-((1r,4r)—4-
hydroxycyc10hexy1arnino)—4-(1 -
propionylpiperidin
ylarnino)pyrirnidine-5 -
carboxamide
4-((1 S ,2S)
hydroxycyclopentylarnino)
((1r,4S)rnethoxycyclo-
hexylamino)pyrimidine-5 -
carboxamide
4-((1 S -
hydroxycyclopentylarnino)
((1r,4S)(rnethoxyrnethyl)—
cyclohexylamino)pyrirnidine-5 -
carboxamide
ATI—ZS 14175V1
Cmpd Structure NAME MH+ Act.
A- Level
93 ‘j ,3S) 364.3 D
Ewing, m hydroxycyclohexylamino)
“(fix ((1r,4R)—4-methoxycyclohexyl-
t: 3R.
, amino)pyrimidine
: carboxarmde.
4-((1 S,3R)
hydroxycyclopentylarnino)
((1r,4S)(rnethoxyrnethyl)—
exylamino)pyrirnidine-5 -
carboxamide
4-((1 s,4S)—4-
ethoxycyclohexylamino)
(( 1 R, 3R)-3 -hydroxycyclopentylamino
)pyrirnidine-5 -
carboxamide
2-((1r,4R)
ethoxycyclohexylamino)
((1R,3 S)—3-hydroxycyclopentylamino
)pyrimidine
amide
2-((1R,3R)-3 -
(hydroxyrnethyl)cyclopentylarni
no)—4-((1s,4S)methoxy-
cyclohexylamino)pyrirnidine-5 -
carboxamide
4-((1 S,3S)
(hydroxyrnethyl)cyclopentylarni
no)—2-((1r,4S)rnethoxycyclohexylamino
)pyrirnidine-5 -
carboxamide
ATI—ZS 14175V1
Cmpd. Structure NAME MH+ Act.
A- Level
99 j W ,3S) 364.3 D
m: :11 4;: hydroxycyclopentylarnino)
:i N E:
((1s,4R)—4-(rnethoxyrnethy1)-
km] a}; cyclohexylamino)pyrimidine
3‘9 carboxamide
2-((1r,4r)—4-
hydroxycyclohexylarnino)
((1 s,4s)meth0xycyclohexylamino
)pyrimidine-5 -
carboxamide
4-((1 s,4s)
hydroxycyclohexylarnino)
((1r,4r)methoxycyclohexylamino
)pyrimidine-5 -
carboxamide
,4S)
ethoxycyclohexylamino)
((S)hydr0xypr0py1—
amino)pyrimidine-5 -
carboxamide
2-((1r,4S)
ethoxycyclohexylamino)
((1 S ,2S)rnethoxycyclo-
pentylamino)pyrirnidine-5 -
carboxamide
2-((1r,4R)
ethoxycyclohexylamino)
(( 1 R,ZS)hydroxycyclopentylamino
)pyrimidine
carboxamide
—240—
ATI—ZS 14175V1
Cmpd. Structure NAME MH+ Act.
A- Level
105 2-((1r,4S) 350.3 D
ethoxycyclohexylamino)
( fng\[j
:11; A x ”:33 ((S)-tetrahydr0fi1ran
ylarnino)pyrirnidine-5 -
carboxamide
4-((1 s,4s)
ethoxycyclohexylamino)(1 -
hydroxy-Z-methylpropan-Z-
ylarnino)pyrirnidine-5 -
carboxamide
4-(cyclobuty1arnino)(1-(3 -
methylbutanoyl)piperidin
ylarnino)pyrirnidine-5 -
carboxamide
4-((ls,4s)
(aminornethyl)cyclohexylamino
etrahydro-2H-pyran—4-
ylarnino)pyrirnidine-5 -
carboxamide
2-((1r,4r)—4-
hydroxycyclohexylarnino)
((1 s,4s)(methoxymethyl)-
cyclohexylamino)pyrirnidine-5 -
carboxamide
2-( 1 -(3 -
methylbutanoyl)piperidin
no)(tetrahydro-2H-
4-y1arnino)pyrirnidine-5 -
carboxamide
—241—
ATI—ZS 14175V1
Structure NAME
4-((1S,4S)(2-hydroxypropan-
2-y1)cyclohexylamino)
(tetrahydro-ZH-pyran
ylarnino)pyrirnidine-5 -
carboxamide
4-((1s,4s)(pyrrolidine
carbonyl)cyclohexylamino)
(tetrahydro-ZH-pyran
no)pyrirnidine-5 -
carboxamide
4-((1 s,4s)
cyclohexylamino)(1 -
propionylpiperidin
ylarnino)pyrirnidine-5 -
carboxamide
4-(Cyc10penty1arnino)-2—(1-
propionylpiperidin_4_
ylarnino)pyrirnidine-5 -
amide
4-((ls,4s)
ethoxycyclohexylamino)
(tetrahydro-ZH-pyran
ylarnino)pyrirnidine-5 -
carboxamide
4-((ls,4s)
(dimethylcarbarnoyl)cyclohexyl
amino)(tetrahydr0-2H-pyran-
4-ylamino)pyrimidine-5 -
carboxamide
—242—
ATI—ZS 14175V1
Cmpd. Structure NAME MH+ Act.
A- Level
117 2-((11@4S) 364-3 D
QM“ ethoxycyclohexylamino)
fT‘I‘I ((IS,ZS)
. .
a \n, v \v ‘3’ hydroxycyc10penty1arn1no)pyr1
midine-S-carboxarnide
4-((1 4-
(dimethylcarbamoyl)cyclohexyl
amino)((1r,4r)—4-
methoxycyclohexylamino)-
pyrimidine-S-carboxamide
4-((ls,4s)
xyrnethyl)cyclohexylami
no)((1r,4r)methoxycyclohexylamino
)pyrimidine-5 -
carboxamide
4-((1 s,4s)
aminocyclohexylamino)
((1r,4r)rneth0xycyclohexylamino
)pyrimidine-5 -
carboxamide
4-(1,4-dioxaspiro[4.5]decan
ylamino)((1r,4r)_4_
methoxycyclohexylamino)-
dine-S-carboxamide
2-((S)
cyclohexylethylamino)
((1 s,4R)—4-(hydroxyrnethyl)—
cyclohexylamino)pyrirnidine-5 -
carboxamide
—243—
ATI—ZS 14175V1
Cmpd. Structure NAME MH+ Act.
A- Level
123 A? methyl 4-(5-carbarnoyl 377.1 D
[3’] (cyclohexylamino)pyrirnidin
f“ x :5; ylarnino)piperidine
“vl‘xf; carboxylate
2-((S)
cyclohexylethylamino)
(( 1 s ,4R)—4-
propionamidocyclohexylarnino)
pyrimidine-S-carboxamide
2-((S)
cyclohexylethylamino)
((1 4-hydr0xycyclohexylamino
)pyrimidine-5 -
amide
4-((1 s,4R)
aminocyclohexylamino)((S)cyclohexylethylamino)-
pyrimidine-S-carboxamide
(1-aC€ty1piperidin-4—
ylamino)(1-
cyclohexylethylarnino)-
pyrimidine-S-carboxamide
2-(Cyclopentylamino)-4_
((1 S,4s)
hydroxycyclohexylamino)-
pyrimidine-S-carboxamide
—244—
ATI—ZS 14175V1
2012/034349
Cmpd. Structure NAME MH+ Act.
A- Level
129 2-(cyclopentylamino) 375 .3 C
1 s>
\ihfilr 31'9“ propionarnidocyclohexylarnino)
mf\ pyrimidine-S-carboxamide
2-(cyclopentylarnino)
(( 1 s ,4s)
(methylcarbam0y1)cyclohexy1-
amino)pyrimidine-5 -
carboxamide
4-((1s,4s)(arnin0rnethyl)—
cyclohexylamino)
(cyclopentylarnino)pyrirnidine-
-carboxarnide
2—(cyc10buty1arnino)((1 5,45)-
4-(cyclopropylcarbarnoyl)-
cyclohexylamino)pyrirnidine-5 -
carboxamide
2—(cyc10buty1arnino)((1 5,45)-
4-(piperidine
carbonyl)cyclohexylamino)-
pyrimidine-S-carboxamide
2—(cyc10buty1arnino)((1 5,45)-
(dimethylcarbarnoyl)cyclohexyl
amino)pyrimidine
carboxamide
—245—
ATI—ZS 14175V1
Cmpd. Structure NAME MH+ Act.
A- Level
135 ‘1 2-(cyclobutylamino)((1s,4s)- 334.3 C
D[A]
4-ethoxycyclohexylamino)-
“Rf; pyrimidine-S-carboxamide
2—(cyclopropy1arnino)
(( 1 s ,4s)
(hydroxyrnethyl)cyclohexylamino
)pyrimidine-5 -
carboxamide
2—(cyclopropy1arnino)
(( 1 s ,4s)
(ethylcarbarnoyl)cyclohexylamino
)pyrimidine-5 -
carboxamide
2—(cyclopropy1arnino)
((ls,4s)(3-
methy1butanamido)cyclohexylamino
)pyrimidine-5 -
carboxamide
,4s)
(hydroxyrnethyl)cyclohexylamino
)—2-
(isopropylamino)pyrirnidine-5 -
amide
4-((1s,4s)(2-hydroxypropan-
2-y1)cyclohexylamino)
opylarnino)pyrirnidine-5 -
carboxamide
ATI—ZS 14175V1
Cmpd Structure NAME MH+ Act.
A- Level
141 4-((ls,4s) 349.3 A
:1:U (ethylcarbarnoyl)cyclohexylarni
2?: :r Vt“? no)—2-(isopr0pylarnino)-
w- :1 pyrimidine-S-carboxamide
4-((ls,4s)
isobutyramidocyclohexyl-
amino)—2-
(isopropylamino)pyrirnidine-5 -
carboxamide
2-(isopr0pylarnino)((15,45)-
4-(pyrrolidine
carbonyl)cyclohexylamino)-
pyrimidine-S-carboxamide
4-(cyclohexy1arnino)((1r,4r)-
0xycyc10hexy1arnino)—
pyrimidine-S-carboxamide
,4r)—4-
hydroxycyclohexylamino)
(isopropylamino)pyrirnidine-5 -
carboxamide
4-((ls,4s)
carbamoylcyclohexylamino)
(cyclohexylamino)pyrirnidine-
-carboxarnide
—247—
ATI—ZS 14175V1
Cmpd. Structure NAME MH+ Act.
A- Level
147 if 2-(cyc10hexylarnino)((1s,4s)- 334.2 D
[ j [ \j 4-hydr0xycyc10hexy1arnino)—
\f \T pyrimidine-S-carboxamide
4-(Cyclopentylamino)-2_
(( 1r,4r)-4—
hydroxycyclohexylamino)-
pyrimidine-S-carboxamide
2'(Cy010hexylarnino)—4_
Pentylamino)pyrimidine-
-carboxarnide
4-((1R,3 S)-3 -
hydroxycyclohexylarnino)
((1r,4R)—4-((2H3)rnethyloxy)-
cyclohexylamino)pyrirnidine-5 -
carboxamide
4-((1R,3 S)
hydroxycyclohexylamino)—2-(4-
methyltetrahydro-2H-pyran
ylarnino)pyrirnidine-5 -
carboxamide
4-((R)-3 ,3 -
difluorocyclohexylamino)
R)—4-methoxycyclohexylamino
)pyrimidine-5 -
carboxamide
ATI—ZS 14175V1
Cmpd. ure NAME MH+ Act.
A- Level
153 4-((1R,3 S)-3 - 403.3 D
{it}. xx.
, “LN‘LM hydroxycyclohexylarnino)
NAM; S“ ((1r,4R)(pyrr01idin
fl’VwfiL --'[‘\_lr lohexylarnino)pyrirnidine
carboxarnide
154 4-((S)—3 ,3 - 384.2 D
difluorocyclohexylamino)
((1r,4S)rnethoxycyclohexylamino
)pyrimidine-5 -
carboxamide
155 4-((1R,2S) 364.2 D
ycyclohexylarnino)
((1r,4R)—4-methoxycyclohexylamino
)pyrimidine-5 -
carboxamide
156 4-((1R,2R) 418.2 D
hydroxycyclopentylarnino)
((1r,4R)—4-(2,2,2-
trifluoroethoxy)cyclohexylamino
)pyrimidine
carboxamide
157 i 2-((1r,4R) 392.3 D
ethoxycyclohexylamino)
((1R,3 S)—3-hydroxy-3 -
methylcyclohexylamino)-
pyrimidine-S-carboxamide
—249—
ATI—25 14175V1
Cmpd Structure NAME MH+ Act.
A- Level
158 2-((1r,4R) 392.5 D
{’N‘ng ethoxycyclohexylamino)
2?“ * S)
w?"“1:3“fi‘w’fi hydroxycycloheptylamino)-
pyrimidine-S-carboxamide
yc10[2.2.2]octan
ylamino)((1R,3 S)—3-
hydroxycyclohexylamino)-
pyrimidine-S-carboxamide
4-((1R,3 S)-3 -
hydroxycycloheptylarnino)
((1r,4R)—4-(2,2,2-trifluoroethoxy
)cyclohexylamino)-
pyrimidine-S-carboxamide
4-((1R,3 S)—3-ethy1—3-
ycyclohexylamino)
((1r,4R)—4-
methoxycyclohexylamino)-
pyrimidine-S-carboxamide
4-((1R,3 S)-3 -
hydroxycyclohexylarnino)
((1 S ,4R)—4-methoxy-
cycloheptylamino)pyrirnidine-
-carboxarnide
4-((1R,3 S)-3 -
hydroxycyclohexylarnino)
((1R,4S)—4-methoxycycloheptylamino
)pyrirnidine-
-carboxarnide
ATI—ZS 14175V1
Cmpd. Structure NAME MH+ Act.
A' Level
164 l 319.9 D
7 .3“ 4-(cyclobutylamino)((1r,4r)-
T 4-rneth0xycyc10hexy1arnino)-
w, :JT
pyrimidinecarboxarnide
2-((1r,4R)
(difluorornethoxy)cyclohexyl-
amino)((1R,3 S)hydr0xycycloheptylamino
)pyrirnidine-
-carboxarnide
4-((1R,3 S)-3 -
hydroxycycloheptylarnino)
(tetrahydro-2H-pyran
ylarnino)pyrirnidine-5 -
carboxamide
2-((1r,4R)
ethoxycyclohexylamino)
((R)-tetrahydr0furan-3 -
ylarnino)pyrirnidine-5 -
carboxamide
4-((1R,3 S)—3-hydroxy-3 -
cyclohexylarnino)
((1r,4R)—4-(2,2,2-trifluoro-
ethoxy)cyclohexylamino)-
dine-S-carboxamide
4-((1R,3 S)—3-hydroxy-3 -
methylcyclohexylarnino)
(tetrahydro-2H-pyran
ylarnino)pyrirnidine-5 -
carboxamide
ATI—ZS 14175V1
Cmpd. Structure NAME MH+ Act.
A- Level
170 f; 2—((1r,4R) 413.7 D
(difluorornethoxy)cyclohexyla
mino)((1R,3 ydr0xy-3 -
methylcyclohexylamino)-
pyrimidine-S-carboxamide
171 4-((1R,3 S)-3 - 364 D
hydroxycyc10hepty1arnino)
((1r,4R)—4-hydroxycyclohexylamino
)pyrimidine-5 -
carboxamide
172 2-((1r,4R)—4- 391.8 D
cyclohexylamino)
(( 1 Ra3R,4R)-3 -hydr0xy—4_
methylcyclohexylamino)-
pyrimidine-S-carboxamide
173 2-((1r,4R) 413.7 D
(difluorornethoxy)cyclohexyla
mino)((1R,3R,4R)—3-
hydroxyrnethy1-
exy1amino)pyrirnidine-5 -
carboxamide
174 4- -.»-’ 4-(cyclobuty1amino)((1r,4r)- 387.5 D
,a‘fiik‘w“
if? 1L1x 4-(2,2,2-trifluoroethoxy)—
cyc10hexy1amino)pyrirnidine-5 -
carboxamide
ATI—ZS 14175V1
Structure NAME
4-(cyclopropy1arnino)
((1r,4r)hydr0xycyclohexy1—
pyrimidine-5 -
carboxamide
4-(cyclobutylamino)((1r,4r)-
0xycyc10hexy1arnino)—
pyrimidine-S-carboxamide
4-((1R,3 S)—3-hydroxy-3 -
methylcyclohexylarnino)
((1r,4R)—4-hydroxycyclohexylamino
)pyrimidine-5 -
amide
4-((1R,3R,4R)hydroxy
methylcyclohexylarnino)
((1r,4R)—4-(2,2,2-trifluoroethoxy
)cyclohexylamino)-
pyrimidine-S-carboxamide
4-((1R,3R,4R)hydroxy
methylcyclohexylarnino)
((1r,4R)—4-hydroxycyclohexyl-
amino)pyrimidine
carboxamide
4-((1R,3R)-3 -
hydroxycyclohexylarnino)
((1r,4R)—4-(2,2,2-trifluoroethoxy
)cyclohexylamino)-
pyrimidine-S-carboxamide
ATI—ZS 14175V1
Cmpd. Structure NAME MH+ Act.
A- Level
181 3' ,3S) 364 D
{wanna :13: hydroxycycloheptylarnino)
w. \,**;’m
(4-rnethy1tetrahydro-2H-pyran-
memn" 4-ylamino)pyrirnidine
REM: carboxarnide
2-(tert-butylamino)((1R,3S)hydroxycyc10hepty1arnino)—
pyrimidine-S-carboxamide
,3 S)—3-hydroxy-3 -
methylcycloheptylarnino)
((1r,4R)—4-methoxycyclohexylamino
)pyrimidine-5 -
carboxamide
4-((1 S ,3 S)-3 -hydr0xy-3 -
methylcycloheptylarnino)
((1r,4S)methoxycyclohexylamino
)pyrimidine-5 -
amide
4-((1 S ,3R)—3 -hydroxy-3 -
methylcycloheptylarnino)
((1r,4S)methoxycyclohexyl-
amino)pyrimidine-5 -
carboxamide
4-((1R,3R)hydroxy
methylcycloheptylarnino)
((1r,4R)—4-methoxycyclohexylamino
)pyrimidine-5 -
carboxamide
—254—
ATI—ZS 14175V1
PCT/U82012/034349
Cmpd Structure NAME MH+ Act.
A- Level
187 384.6 D
w =55? 2-(4,4-
difluorocyclohexylamino)
(( 1 R, 3 S)—3 -hydr0xy-3 -rnethy1—
exylamino)pyrirnidine-5 -
carboxamide
4-((R)-tetrahydr0-2H-pyran-3 -
ylarnino)((1r,4R)(2,2,2-
roethoxy)cyclohexylamino
)pyrimidine-5 -
carboxamide
-butylamino)((1r,4R)-
4-hydr0xycyc10hexy1arnino)—
pyrimidine-S-carboxamide
4-(Cyclopentylamino)-2_
((1TAT)rnethoxycyclohexy1—
amino)pyrirnidine_5 _
carboxamide
2-((1r,4r)—4-
(difluorornethoxy)cyclohexylamino
)—4-
(isopropylamino)pyrirnidine-5 -
carboxamide
2-(4,4-
difluorocyclohexylamino)
((1R,3 S)—3-hydroxycycloheptylamino
)pyrimidine-5 -
carboxamide
ATI—ZS 14175V1
WO 45569
Cmpd Structure NAME MH+ Act.
A- Level
193 2-((1r,4R) 336.5 D
l I: [fix] hydroxycyclohexylamino)
T“ \T ((R)-tetrahydr0-2H-pyran
m \ T3»!
f ylarnino)pyrirnidine-5 -
carboxamide
2-((1r,4R)
(dimethylcarbarnoyl)cyclohexyl
amino)((R)-tetrahydro-2H-
pyranylarnin0)pyrirnidine-5 -
carboxamide
4-(sec-butylamino)((1r,4S)—
0xycyc10hexy1arnino)—
pyrimidine-S-carboxamide
4-(tert-buty1arnino)((1r,4r)-
4-hydr0xycyc10hexy1arnino)—
pyrimidine-S-carboxamide
4-(cyclobutylamino)((1r,4r)-
4-ethoxycyclohexylamino)-
pyrimidine-S-carboxamide
2-(4,4-
difluorocyclohexylamino)
(( 1 Ra3R,4R)-3 -hydr0xy—4_
methylcyclohexylamino)-
pyrimidine-S-carboxamide
ATI—ZS 14175V1
Cmpd. Structure NAME MH+ Act.
A- Level
199 m _.o pr0pylarnino)—2—((1r,4r)- 335 .2 D
”Twnxfwat-T 4-(rnethylcarbarnoy1)-
cyclohexylamino)pyrirnidine-5 -
carboxamide
4-((1R,3 S)-3 -
hydroxycyclohexylarnino)
((1 S ,4S)rnethoxycycloheptylamino
)pyrimidine-5 -
carboxamide
4-((1R,3 S)-3 -
hydroxycyclohexylarnino)
((1R,4R)rnethoxycycloheptylamino
idine-5 -
carboxamide
2-(4-
hydroxybicyclo[2.2.2]octan
no)—4-
(isopropylamino)pyrirnidine-5 -
carboxamide
2-((1r,4r)—4-
acetamidocyclohexylamino)
(isopropylamino)pyrirnidine-5 -
carboxamide
2—(tert-butylarnino)-4_
((1R,3R,4R)hydr0xy—4_
methylcyclohexylamino)-
pyrimidine-S-carboxamide
ATI—25 14175V1
Structure NAME
2-((1r,4R)
cyclopropoxycyclohexylarnino)
((1R,3 S)hydroxycyclohexylamino
)pyrirnidine-5 -
carboxamide
4-((1R,3 S)-3 -
hydroxycyclohexylarnino)
((1r,4R)—4-methoxycyclohexylamino
)-N-methylpyrirnidine-5 -
carboxamide
4-((1R,3 S)—3-hydroxy-3 -
methylcyclohexylarnino)
R)—4-((2H3)rnethyloxy)-
cyclohexylamino)pyrirnidine-5 -
carboxamide
,3R,4R)hydroxy
methylcyclohexylarnino)
(tetrahydro-ZH-pyran
ylarnino)pyrirnidine-5 -
amide
2-((1r,4R)
ethoxycyclohexylamino)
((1R,2S)—2-(hydr0xyrnethyl)-
cyclopentylamino)pyrimidine-
-carboxarnide
4-(tert-buty1arnino)((1r,4r)-
4-methoxycyclohexy1-
amino)pyrimidine-5 -
carboxamide
ATI—ZS 14175V1
Cmpd Structure NAME MH+ Act.
A- Level
2 1 1 "xi 4-(tert-buty1arnino)((1r,4r)- 336.4 D
f; 4-ethoxycyclohexylamino)-
xi [TR pyrimidine-S-carboxamide
~55"; ""N‘izf’m
a 53$}ng
4-(tert-buty1arnino)((1r,4r)-
,2-trifluoroethoxy)—
cyclohexylamino)pyrirnidine-5 -
carboxamide
t-butylamino)((1R,3S)-
3-hydr0xyrnethy1cyclohexyl-
amino)pyrimidine-5 -
carboxamide
4-(isopr0pylarnino)—2-((1r,4r)-
4-(rnethylarnino)cyclohexylamino
)pyrimidine-5 -
carboxamide
4-((1R,3 S)—3-hydr0xy- 1 _
methylcyclohexylarnino)
((1r,4R)—4-methoxy-
cyclohexylamino)pyrirnidine-5 -
carboxamide
4-((1R,3 S)-3 -
ycyclohexylarnino)
((1r,4R)—4-rnethoxy-1 -methy1—
cyclohexylamino)pyrirnidine-5 -
carboxamide
ATI—ZS 14175V1
Cmpd Structure NAME MH+ A°t°
A- Level
217 - 342 D
<\F [fl] difluorocyclobutylarnino)
\T‘ ((1r,4r)hydr0xycyclohexy1—
m" {\KT‘M' amino)pyrimidine
H 419%?”
carboxamide
4-(2-cyclopropylethylarnino)
((1r,4r)hydr0xycyclohexy1—
amino)pyrimidine-5 -
carboxamide
4-(2-cyclobutylethylarnino)
((1r,4r)hydr0xycyclohexy1—
amino)pyrimidine-5 -
carboxamide
2-((1r,4r)—4-
hydroxycyclohexylamino)
(isopentylarnino)pyrimidine-5 -
carboxamide
lobutylmethylarnino)
((1r,4r)hydr0xycyclohexy1—
amino)pyrimidine-5 -
amide
4-(isopr0pylarnino)
(tetrahydro-ZH-pyran
ylarnino)pyrirnidine-5 -
carboxamide
ATI—ZS 14175V1
2012/034349
Cmpd Structure NAME MH+ Act.
A- Level
223 WL 4-(bicyclo[1.1.1]pentan 318.6 D
E: 3 ylamino)((1r,4r)
is}:
g» 3 hydroxycyclohexylamino)-
“’11 5 ‘5: .-"N at“:
pyrlmldlne-S-carboxarmde. . . .
H “‘3; 3“
,4r)—4-
ethoxycyclohexylamino)
(isopropylamino)pyrirnidine-5 -
carboxamide
2-((1r,4r)—4-
hydroxycyclohexylamino)
(tert-pentylarnino)pyrimidine-5 -
carboxamide
4-(cyclopropylrnethylarnino)
((1r,4r)hydr0xycyclohexy1—
amino)pyrimidine-5 -
carboxamide
2-(tert-butylarnino)
(isopropylamino)pyrirnidine-5 -
carboxamide
2-((1r,4r)—4-
hydroxycyclohexylamino)
(neopentylarnino)pyrimidine-5 -
carboxamide
ATI—ZS 14175V1
Cmpd. ure NAME MH‘ Act.
A- Level
229 2-(4- 376.2 D
iiifw hydroxybicyclo[2.2.2]octan
1 “‘1‘.
“£19.! ylamino)((1R,3S)—3-
hydroxycyclohexylamino)-
dine-S-carboxamide
230 1-: ~. 2-((ls,4s) 294.1 C
hydroxycyclohexylamino)
(isopropylamino)pyrirnidine-5 -
carboxamide
230 -. ,4s) 306.4 D
‘ hydroxycyclohexylamino)—4-(1-
methylcyclopropylarnino)-
pyrimidine-S-carboxamide
231 4-((1R,3S) 390.2 D
:5.ij hydroxycyclohexylamino)—2-(4-
WAN methoxybicyclo[2.2.2]octan
#J\«”I\SET‘JR 33% ylarnino)pyrirnidine
“= " “C carboxamide
232 N Am 4-(cyc10butylarnino)(4- 332.2 D
mLEEI hydroxybicyclo [2.2 .2]octan
M Mg.” ylarnino)pyrirnidine
‘-'-+“'“xi...4§\.i:;€-“ carboxamide
+1.3 "55*:
233 Hi?
3"”“3 2-((1 S ,4R) 308 D
{\W.-“‘“-‘§* hydroxycycloheptylarnino)
54.5%}. (isopropylamino)pyrirnidine-5 -
-. ":1 .
3 2%"... carboxarmde
““? 3.
ATI—25 14175V1
Cmpd. Structure NAME MH+ Act.
A- Level
234 H5
.~ fan.” 2-((1R,4S) 308 D
hydroxycycloheptylarnino)
(isopropylamino)pyrirnidine-5 -
carboxamide
235 2-((1r,4r)—4- 308.5 D
hydroxycyclohexylamino)
(oxetany1amino)pyrimidine-
-carboxarnide
236 [0001] (R)(tert- 294 C
butylarnino)(tetrahydr0-2H-
pyranylarnin0)pyrirnidine-5 -
carboxamide
237 4-(tert-butylarnino)(4- 334.2
hydroxybicyclo[2.2.2]0ctan
ylarnino)pyrirnidine-5 -
amide
238 2,4-bis(tert- 266.4
butylarnino)pyrimidine-S -
amide
239 2-((1r,4r)—4- 320.2
hydroxycyc10hexy1arnino)—4-(1 -
methylcyclobutylamino)-
pyrimidine-S-carboxamide
ATI—25 14175V1
Cmpd. Structure NAME MH+ Act.
A- Level
240 | 4-((1R,3R,4R)hydroxy 308 D
[1 x} methylcyc10hexy1arnino)
;: (isopropylamino)pyrirnidine
fl 1
7| ‘3“ch carboxamide
H \g
V «,9- N55“:
241 :Kr 2-(4,4-difluorocyclohexy1- 370.6 D
MW E; L. ] amino)((1R,2S)—2-
w! I; (hydroxyrnethyl)cyclopentyl-
amino)-pyrirnidine
E1 1
carboxamide
242 7; 2-((1r,4r)rnethoxy- 334.2
exylamino)(2-
methylcyclobutylamino)-
pyrimidine-S-carboxamide
243 2-((1r,4r)rnethoxycyclo- 334.2
hexylamino)—4-(2-
methylcyclobutylamino)-
pyrimidine-S-carboxamide
244 »~ .. 2-((1r,4r)—4- 320.2
‘ ‘ hydroxycyclohexylamino)—4-(2-
methylcyclobutylamino)-
pyrimidine-S-carboxamide
245 ‘ 320-2
: 2-((1r,4r)—4-
hydroxycyclohexylamino)—4-(2-
cyclobutylamino)-
pyrimidine-S-carboxamide
ATI—25 14175V1
Cmpd. Structure NAME MH+ Act.
A- Level
246 .L 2-((1r,4r)—4- 320.2
ycyclohexylamino)—4-(2-
methylcyclobutylamino)-
pyrimidine-S-carboxamide
247 2-((1r,4r)—4- 320.2
hydroxycyclohexylamino)—4-(2-
methylcyclobutylamino)-
pyrimidine-S-carboxamide
248 lobutylamino)—2-(4_ 320
hydTOXycycloheptylamino)_
pyrimidine-S-carboxamide
249 4-(Cyclobutylamino)—2-(4_ 320
hydroxycycloheptylamino)-
pyrimidine-S-carboxamide
250 4-(tert-butylarnino)(4- 322
hydroxycycloheptylamino)-
pyrimidine-S-carboxamide
4-(tert-butylarnino)(4-
322.5
hydroxycycloheptylamino)-
pyrimidine-S-carboxamide .
ATI—25 14175V1
Cmpd. Structure NAME MH+ Act.
A- Level
’0‘ 4-((1R,ZS) 336 D
m”“5““. l: \l (hydroxyrnethyl)cyclopentyl-
E» ” x I amino)(tetrahydr0-2H-pyran-
H V 4-ylamino)pyrirnidine-5 -
.. 11:?
3T M
carboxarnide
253 .5»qu e * 2-(4-fluorobicyclo[2.2.2]octan- 322.1 D
w” (:33 1 -y1arnino)
.1ng (isopropylarnino)pyrirnidine
LVJLVL carboxamide
{55,
254 2-((1r,4r)—4- 334.2
methoxycyclohexylamino)
(2-rnethy1cyclobutylarnino)-
pyrimidine-S-carboxamide
255 2-((1r,4r)—4- 334.2
methoxycyclohexylamino)
(2-rnethy1cyclobutylarnino)-
pyrimidine-S-carboxamide
256 nethylcyclobutylarnino)- 402.2
,4r)(2,2,2-
trifluoroethoxy)cyclohexyl-
amino)pyrimidine-5 -
carboxamide
257 nethylcyclobutylarnino)- 402.2
2-((1r,4r)(2,2,2-
trifluoroethoxy)cyclohexylamino
)pyrimidine
carboxamide
ATI—25 14175V1
Cmpd. Structure NAME MH+ Act.
A- Level
258 4-(2-rnethylcyclobutylarnino)- 402.2 D
2-((1r,4r)(2,2,2-
trifluoroethoxy)cyclohexylamino
)pyrimidine-5 -
carboxamide
259 J 2-((1r,4R) 3782 D
ethoxycyclohexylamino)
(( 1 R,2R)
(hydroxyrnethyl)cyclopentylamino
)pyrimidine-5 -
carboxamide
260 g“ ,2R) 364.2 D
(hydroxyrnethyl)cyclopentylamino
)((1r,4R)—4-
methoxycyclohexylamino)-
pyrimidine-S-carboxamide
261 3 4—<<R> 320.2 D
cyclopropylethylamino)
(( 1r,4R)—4-
hydroxycyclohexylamino)-
pyrimidine-S-carboxamide
262 2-((1r,4r)—4- 3362 D
hydroxycyclohexylamino)—4-(3-
methylpentan-3 -
no)pyrirnidine-5 -
carboxamide
ATI—25 14175V1
Cmpd. Structure NAME MH+ Act.
A- Level
263 EN —l-cyclopropylethyl- 320.2 D
”‘ '
3-44., 15x...»| am1n0)—2—(( 1 r,4S)
T ycyclohexylam1no)--
T} 2k?“ pyrimidine-S-carboxamide
Hfix _«- 6;?“N
264 ”If 2-(bicyclo[1.1.1]pentan 332.2 D
g 3;” ylarnino)((1R,3R,4R)
m \ hydroxy
4 i :5" RATE»: methylcyclohexylamino)-
Swflkam‘; 7
pyrimidine-S-carboxamide
265 4-(2-rnethylcyclobutylarnino)- 402.2
2-((1r,4r)(2,2,2-
trifluoroethoxy)cyclohexylamino
)pyrimidine
carboxamide
266 4-((1R,ZS)(hydroxyl- 432.2
methy1)cyc10penty1arnino)—2-
((1r,4R)—4-(2,2,2-trifluoroethoxy
)cyclohexylamino)-
pyrimidine-S-carboxamide
267 2-(4-flu0robicyclo [2 .2.2]0ctan- 378.2
1-y1arnino)((1R,3 S)-3 -
hydroxycyclohexylarnino)pyrirn
idine-S-carboxarnide
268 2-((1r,4R)(diflu0r0- 400.2
methoxy)cyclohexylamino)
((1R,2S)—2-(hydr0xyrnethyl)-
entylamino)pyrirnidine-
-carboxarnide
ATI—25 14175V1
Cmpd. ure NAME MH+ Act.
A- Level
4-(ethylamino)((1r,4r) 280.1 D
hydroxycyclohexylamino)-
pyrimidine-S-carboxamide
270 2-((1r,4r)—4- 266.1 C
hydroxycyclohexylamino)
(methylamino)pyrimidine-5 -
carboxamide
271 ;- 2-((1r,4r)—4- 338.3
hydroxycyclohexylamino)—4-(1-
methoxyrnethylpr0pan
ylarnino)pyrirnidine-5 -
carboxamide
272 306 , 3
.V 2-(cyclopropy1arnino)
. ..-
' ’—
((1R,3R,4R)hydroxy
methylcyclohexylamino)-
pyrimidine-S-carboxamide
273 »: 4-(2,3-dirnethylbutan 364.2
i ylamino)((1r,4r)
ethoxycyclohexylamino)-
pyrimidine-S-carboxamide
274 : . 4-(2,3-dirnethylbutan 350.2
3 i 3
ylamino)((1r,4r)
methoxycyclohexylamino)-
pyrimidine-S-carboxamide
ATI—25 14175V1
Cmpd. Structure NAME MH+ Act.
A- Level
275 4-(2,3-dirnethylbutan 336.3 D
MR 15..
Ix F ”I ylamino)((1r,4r)
T it]; ycyclohexylamino)-
*N pyrimidine-S-carboxamide
[ a1
276 i“ =9 4-((S)—3,3-dirnethy1butan 364.2 D
‘i ”Wm-1 ylamino)—2-((1r,4S)
\ffl ethoxycyclohexylamino)-
“ [KL
pyrimidinecarb0xarnide
277 4-((R)-3,3-dimethylbutan 364.2
no)((1r,4R)_4_
ethoxycyclohexylamino)-
pyrimidine-S-carboxamide
278 4-((S)—3,3-dirnethy1butan 350.2
ylamino)—2-((1r,4S)
methoxycyclohexylamino)-
pyrimidine-S-carboxamide
279 4-((R)-3,3-dirnethylbutan 350.2
ylarnino)((1r,4R)
methoxycyclohexylamino)-
pyrimidine-S-carboxamide
280 4-((S)—3,3-dirnethy1butan 336.2
ylamino)—2-((1r,4S)
hydroxycyclohexylamino)-
pyrimidine-S-carboxamide
ATI—25 14175V1
WO 45569 2012/034349
Cmpd. Structure NAME MH+ Act.
A- Level
m! 15:. 4-((R)-3,3-dirnethylbutan 336.2 D
\L L. ylamino)((1r,4R)—4-
'2 ital hydroxycyclohexylamino)-
"‘1- pyrimidine-S-carboxamide
[ a1
282 M .2. 2-((1r,4S) 350.2 D
'i‘iin’fifE’Q}' ethoxycyclohexylamino)
; -rnethylbutan
m [Tel
ylarnino)pyrirnidine-5 -
[IA carboxamide
283 2-((1r,4S) 336.2
methoxycyclohexylamino)
((S)-3 -rnethy1butan
ylarnino)pyrirnidine-5 -
carboxamide
284 2-((1r,4S) 322.2
hydroxycyclohexylamino)
((S)-3 -rnethy1butan
ylarnino)pyrirnidine-5 -
carboxamide
285 2'(Cy010butylarnino)_4- 320.2
(( 1 Ra3R,4R)-3 -hydr0xy—4_
methylcyclohexylamino)-
pyrimidine-S-carboxamide
286 4-((1R,3R,4R)hydroxy 336.2
methylcyclohexylarnino)
(tert-pentylarnino)pyrimidine-5 -
carboxamide
ATI—ZS 14175V1
Cmpd. Structure NAME MH+ Act.
A- Level
287 1 4-((1R,3R,4R)hydroxy 334.1 D
i: \f a“ methy1cyclohexy1arnino)(1-
;; methylcyclobutylamino)-
m FL “I pyrimidine-S-carboxamide
. x?» x
288 1 4-((1R,3R,4R)hydroxy 320.2 D
L].. .m methy1cyclohexy1arnino)(1-
‘f‘w’
«:3 methylcyclopropylarnino)-
fl» :1”
pyrimidine-S-carboxamide
M :1] :31
289 4-(tert-buty1arnino)(4- 336.2
fluorobicyclo[2.2.2]octan
ylarnino)pyrirnidine-5 -
carboxamide
290 2-((1r,4R) 350.2
ethoxycyclohexylamino)
((R)—3-methy1butan—2-
ylarnino)pyrirnidine-5 -
carboxamide
291 ,4R) 336.2
methoxycyclohexylamino)
((R)—3-methy1butan—2-
ylarnino)pyrirnidine-5 -
carboxamide
292 2-((1r,4R)—4- 322.2
hydroxycyclohexylamino)-4_
-rnethylbutan
ylarnino)pyrirnidine-5 -
carboxamide
ATI—25 14175V1
Cmpd. ure NAME MH+ Act.
A- Level
293 H a, 4-((S)— 1 -cyclobutylethylarnino)- 362.2 D
‘S-‘*'l;"»- ”ax M‘wx 2 ((1r,4S) 4
Y - - -
*1 1
”f“ ethoxycyclohexylamino)-
“I: l dine-S-carboxamide
294 4-((R) 362.2 A
cyclobutylethylamino)
((1r,4R)—4-
ethoxycyclohexylamino)-
pyrimidine-S-carboxamide
295 4-((S)— 1 -cyc10butylethylarnino)- 348.2
2-((1r,4S)
methoxycyclohexylamino)-
pyrimidine-S-carboxamide
296 4-<<R> 348.2
cyclobutylethylamino)
(( 1r,4R)—4-
ycyclohexylamino)-
pyrimidine-S-carboxamide
297 4-((S)— 1 -cyc10butylethylarnino)- 334.2
2-((1r,4S)
hydroxycyclohexylamino)-
pyrimidine-S-carboxamide
298 4-<<R> 334.2
cyclobutylethylamino)
(( 1r,4R)—4-
hydroxycyclohexylamino)-
pyrimidine-S-carboxamide
ATI—25 14175V1
PCT/U52012/034349
Cmpd. Structure NAME MH+ Act.
A- Level
299 WT: 4-(tert-butylamino) 308.2 D
N \TEIW‘X’ ((1 R,3R)_3 '
””1”“ hydroxycyclohexyl-
m [a]
amino)pyrimidine-5 -
XE: carboxarnide
300 H94 a «.39 (S)(tert-butylamino) 294. 1 D
' (tetrahydro-2H-pyran
ylarnino)pyrirnidine-5 -
amide
301 .V (R)(tert-buty1arnino) 294.1
(tetrahydro-2H-pyran
ylarnino)pyrirnidine-5 -
carboxamide
302 '
w: 4-(tert-buty1arnino)((1r,4r)- 322.2
4-hydr0xy
methylcyclohexylamino)-
pyrimidine-S-carboxamide
303 5-: '5
: 4-(tert-butylarnino)(oxetan- 266.1
3 -y1arnin0)pyrirnidine-5 -
carboxamide
304 g: 4-(tert-buty1arnino)((1r,4r)- 348.3
4-cyclopropoxycyclohexylamino
)pyrimidine
carboxamide
—274—
ATI—25 14175V1
Cmpd. Structure NAME MH+ Act.
A- Level
305 4-(tert-butylamino)((1S,3S)- 308.1 D
KTRHRI 3-hydr0xycyc10hexy1arnino)—
””1”“ pyrimidine-S-carboxamide
306 .MVD 4-(tert-butylamino)((1S,3R)- 308.2 D
' 3-hydr0xycyc10hexy1arnino)—
pyrimidine-S-carboxamide
307 9‘s 3 4-(tert-butylamino)((1R,3S)- 308.2
3-hydr0xycyc10hexy1arnino)—
pyrimidine-S-carboxamide
308 4-(tert-buty1arnino)((1r,4r)- 363.2
nethylcarbamoyl)-
cyclohexylamino)pyrirnidine-5 -
carboxamide
309 2-((1r,4r)—4- |||||||||||!||||||||||||!||||||||||||!||||||||||||!|353.2 ‘ ethoxycyclohexylarnino)(1-
hydroxymethylpropan
ylarnino)pyrirnidine-5 -
carboxamide
310 4-(1-hydr0xyrnethylpropan- 338.2
2-y1arnino)((1r,4r)
ycyclohexylamino)-
pyrimidine-S-carboxamide
ATI—25 14175V1
Cmpd. ure NAME MH+ Act.
A- Level
3 1 1
1:1: 4-(1-hydr0xyrnethylpropan- 324.2 D
$112» 1* 2-y1arnino)((1r,4r)
b 1L1?!
hydroxycyclohexylamino)-
1- x pyrimidinecarb0xarnide
[.1 L31
312 1 4-((1R,3R,4R)hydr0xy 322.3 D
methylcyc10hexy1arnino)
(oxetany1amino)pyrimidine-
-carboxarnide
313 2-((1r,4r)—4- 348.3
ethoxycyclohexylamino)
(( 1 r, 3r)-3 -
methylcyclobutylamino)-
pyrimidine-S-carboxamide
314 4-(2-cyclopr0pylpropan_2_ 362.2
ylamino)((1r,4r)_4_
ethoxycyclohexylamino)-
pyrimidine-S-carboxamide
315 4-(2-cyclopr0pylpropan_2_ 348.2
ylamino)((1r,4r)_4_
ycyclohexylamino)-
pyrimidine-S-carboxamide
316 4-(2-cyclopr0pylpropan_2_ 334.2
ylamino)((1r,4r)_4_
hydroxycyclohexylamino)-
pyrimidine-S-carboxamide
ATI—25 14175V1
Cmpd. Structure NAME MH+ Act.
A- Level
317 “a. 4-(tert-butylarnino) 294.1 D
:1- ”#3 a 5.. -.
« (tetrahydro-2H-pyran
1";558 ylarnino)pyrirnidine
«11‘ fix carboxamide
L l _
318 m * 4-(tert-butylamino)(4,4- 328.1 D
difluorocyclohexylamino)-
dine-S-carboxamide
319 4-(tert-buty1arnino)((1r,4r)- 358.2
u0rornethoxy)cyclohexylamino
)pyrimidine-5 -
carboxamide
320 4-(bicyclo[1.1.1]pentan 332.1
ylamino)((1r,4r)
methoxycyclohexylamino)
pyrimidine-S-carboxamide
321 2-(4-fluorobicyclo[2.2.2]0ctan- 392.4
1-y1arnino)((3 S)hydroxymethylcyclohexylarnino)
pyrimidine-S-carboxamide
322 2-((1r,4r)—4- 334.2
hydroxycyc10hexy1arnino)—4-(1 -
methylcyclopentylamino)
pyrimidine-S-carboxamide
ATI—25 14175V1
Cmpd. Structure NAME MH+ Act.
A- Level
V, x, w 2-(tert-butylamino)((1 S,3 S)- 336.2 C
R} 3-hydr0xy-4,4-
dimethylcyclohexylamino)
:1 pyrimidine-S-carboxamide
324 2-(tert-butylamino)((1R,3R)- 336.2 D
3-hydr0xy-4,4-
dimethylcyclohexylamino)
dine-S-carboxamide
325 2-((1r,4r)—4- 320.2
hydroxycyclohexylamino)
(( 1 r, 3r)-3 -
methylcyclobutylamino)
pyrimidine-S-carboxamide
326 2-((1r,4r)—4- 348.2
ethoxycyclohexylamino)
(( 1 s ,3 s)-3 -
methylcyclobutylamino)
dine-S-carboxamide
327 ,4r)—4- 320.2
‘ (
hydroxycyclohexylamino)
((1 s,3s)
methylcyclobutylamino)
pyrimidine-S-carboxamide
328 4-((1R,2R) 336.1
‘ (hydroxyrnethyl)cyclopentyl
amino)(tetrahydr0-2H-pyran-
4-ylamino)pyrirnidine
carboxamide
ATI—25 14175V1
Cmpd. Structure NAME MH+ Act.
A- Level
329 9* 9:949 2-((1r,4R)(difluoro- 400.2 D
{“3 ,1: “fl" methoxy)cyclohexy1
”1 amino)((1R,2R)
If [SIX
(hydroxyrnethyl)cyclopentyl-
F 919.“ amino)pyrimidine-5 -
carboxamide
2-(tert-butylamino)((1R,2R)-
r0xyrnethy1)—
cyclopentylamino)pyrirnidine-
-carboxarnide
4-((1R,2R)(hydr0xymethyl)-
cyclopentylamino)—2-((1r,4R)-
4-(2,2,2-trifluoroethoxy)—
cyclohexylamino)pyrirnidine-5 -
carboxamide
2-((1r,4r)—4-
ethoxycyclohexylamino)
(2 , 3 , 3 -trimethylbutan
ylarnino)pyrirnidine-5 -
carboxamide
,4r)—4-
methoxycyclohexylamino)
(2 , 3 , 3 -trimethylbutan
ylarnino)pyrirnidine-5 -
carboxamide
ATI—ZS 14175V1
WO 45569
Cmpd. Structure NAME MH+ Act.
A- Level
m15.. 2-((1r,4r)—4- 350.2 D
\Lx R .m. hydroxycyclohexylamino)
T L1 (2,3,3-trirnethylbutan
ylarnino)pyrirnidine
[Vim carboxamide
335 2-(4-fluorobicyclo[2.2.2]octan- 392.4 D
1-y1arnin0)((1R,3 S)-3 -
ycycloheptylamino)-
pyrimidine-S-carboxamide
336 2-((1r,4r)—4- 334.2
methoxycyclohexylamino)
((1r,3r)-3 -rnethy1cyc10buty1—
amino)pyrimidine-5 -
carboxamide
337 2-((1r,4r)—4- 334.2
methoxycyclohexylamino)
((1 5,3 s)-3 -rnethy1cyclobutylamino
)pyrimidine-5 -
carboxamide
338 4-((1R,3 S)—3-hydroxy 308.2
methylcyc10hexy1arnino)
(isopropylamino)pyrirnidine-5 -
carboxamide
339 2'(Cy010butylarnino)_4- 320.2
((1R93 S)'3 'hYdI'OXycyclo_
heptylamin0)pyrirnidine—5 _
carboxamide
ATI—25 14175V1
Cmpd. Structure NAME MH+ Act.
A- Level
w. ”.3 lobuty1arnino) 320.2 D
3.; g; T: ((1R,3S)—3-hydroxy
I: W] EM]; methylcyclohexylamino)-
w 51: pyrimidine-S-carboxamide
341 lobutylarnino) 306.2 D
M V0
H3 («my iii \. :1: ((1R,3 S)—3-hydr0xycyclohexyl-
Iw] E :1 amino)pyrimidine
carboxamide
H; “
342 _';. - 2-(tert-butylarnino)(2- 336.2
hydroxy-4,4-dirnethy1—
cyclohexylamino)pyrirnidine-5 -
carboxamide
343 1-4 2-(tert-butylarnino)(2- 336.2
hydroxy-4,4-dirnethy1—
cyclohexylamino)pyrirnidine-5 -
carboxamide
344 -. 4-(bicyclo[1.1.1]pentan 346.4
‘ ylamino)((1r,4r)—4-ethoxycyclohexylamino
)pyrirnidine-5 -
carboxamide
345 4-((1R,3R,4R)hydroxy 350.5
methy1cyclohexylarnino)(3-
methylpentan-3 -
ylarnino)pyrirnidine-5 -
carboxamide
ATI—25 14175V1
Cmpd. Structure NAME MH+ Act.
A- Level
346 2-(bicyclo[1.1.1]pentan 332.2 D
ylamino)((1R,3 S)—3 -
hydroxycycloheptylamino)-
pyrimidine-S-carboxamide
347 332.2 D
. 2-(bicyclo[1.1.1]pentan
K F“.
”ask g. {is ylam1no)((1R,3S)—3-_
EM?“ “YE; hydroxymethy1—
513:: “gm: cyclohexylamino)pyrirnidine-5 -
carboxamide
348 2-(bicyclo[1.1.1]pentan 318.1
., _
‘ ylamino)((1R,3S)—3-
hydroxycyclohexylamino)-
dine-S-carboxamide
349 . 4-((1R,3S) 336.2
' hydroxycycloheptylarnino)
(tert-pentylarnino)pyrimidine-5 -
carboxamide
350 4-((1R,3S)—3-hydr0xy 336.2
I \‘
'7 cyc10hexy1arnino)
(tert-pentylarnino)pyrimidine-5 -
carboxamide
351 4-((1R,3S) 332.2
" hydroxycyclohexylamino)
(tert-pentylarnino)pyrimidine-5 -
carboxamide
ATI—25 14175V1
2012/034349
Cmpd. Structure NAME MH+ Act.
A- Level
352 3* 4-((1R,3S) 334.2 D
hydroxycycloheptylarnino)
(1-methylcyclobutylamino
)pyrimidine-5 -
carboxamide
353 4-((1R,3S)—3-hydroxy 334.2 D
methylcyclohexylamino)(1 -
methylcyclobutylamino)-
pyrimidine-S-carboxamide
354 4-((1R,3S) 320.2
.V ‘
hydroxycyc10hexy1arnino)—2-(1 -
cyclobutylamino)-
pyrimidine-S-carboxamide
355 ‘=. 4-(bi(cycloprop)ylarnino) 332,4
a“ 3.
‘ ((118410hydroxycyclohexylamino
)pyrimidine
carboxamide
356 _ 4-(1-ethylcyclopropylarnino) 320.3
((1r,4r)hydr0xycyclohexy1—
amino)pyrimidine-5 -
carboxamide
357 is ;- 2-((1r,4r)hydroxycyclo- 348.2
hexylamino)—4-(1 -
methylcyclohexylamino)-
pyrimidine-S-carboxamide
ATI—25 14175V1
Cmpd. Structure NAME MH+ Act.
A- Level
358 2-((1r,4r)—4- 362.2 D
“34K” ”3%I methoxycyclohexylamino)
L39] N \f“ (1 -rnethylcyclohexy1arnino)-
WT “L pyrimidine-S-carboxamide
Nuax‘u
359 2-((1r,4r)—4- 376.3 D
ethoxycyclohexylamino)(1 -
methylcyclohexylamino)-
dine-S-carboxamide
360 2-((1r,4r)—4- 362.2
ethoxycyclohexylamino)(1 -
ethylcyclobutylamino)-
pyrimidine-S-carboxamide
361 4-(1-ethylcyclobutylarnino) 348.2
((1r,4r)rneth0xycyclohexylamino
)pyrimidine-5 -
carboxamide
362 4-(1-ethylcyclobutylarnino) 334.2
((1r,4r)hydr0xycyclohexy1—
pyrimidine-5 -
carboxamide
363 2-((1r,4r)—4- 322.4
hydroxycyclohexylamino)
(pentany1arnino)pyrirnidine-
-carboxarnide
ATI—25 14175V1
Cmpd. Structure NAME MH+ Act.
A- Level
364 E 2-(cyc10pentylarnino) 334.2 D
[: :] yJJJ
{—3 R,4R)hydroxy
J: methylcyclohexylamino)-
JJ 9?
pyrimidinecarboxarnide
J TI“ :1:
365 2—(tert-butylamino)((1R,2S)- 308.3 D
R‘W‘NJJ a} .4 r0xyrnethy1)cyclopentyl-
:flxfi -J-QN‘S’ amino)pyrimidine
“In, It? carboxarnide
366 2—(2,3-dimethylbutan 350.4
ylarnino)((1R,3R,4R)
hydroxyrnethylcyclohexylamino
)pyrimidine
carboxamide
367 4-((1R,3R,4R)hydroxy 336.2
methylcyclohexylarnino)
(neopentylarnino)pyrimidine-5 -
carboxamide
368 4-(bicyc10[1.1.1]pentan 358.3
ylamino)((1r,4r)
cyclopropoxycyclohexylarnino)
pyrimidinecarboxarnide
369 4-(2,4-dimethylpentan 350.3
ylamino)((1r,4r)
hydroxycyclohexylamino)
dinecarboxarnide
ATI—ZS 14175V1
Cmpd. Structure NAME MH+ Act.
A- Level
370 flew, v
w \ 4-((3 S)—3 -hydr0xy-3 - 404.4 D
m £31 methy1cyclohexylarnino)(4-
N{R :\ methoxybicyclo[2.2.2]octan
“wk“\\ ylamino)pyrirnidine-5 -
31““ H carboxarnide
371 W3N3 4-(tert-buty1arnino)((1 s,4s)- 3222 D
4-hydr0xyrnethy1—
\_ [
i N x};‘ cyclohexylamino)pyrimidine
‘11 7: carboxamide
H :“4 kg,“ x69“
372 4-((S)—1- 348.2
ropylpropylamino)
((1r,4S)rnethoxycyclohexylamino
)pyrirnidine-5 -
amide
373 4-((S) 362.2
cyclopropylpropylamino)
(( 1 r,4S)ethoxycyc10hexy1—
amino)pyrimidine-5 -
carboxamide
374 4-((R) 348.2
cyclopropylpropylamino)
((1r,4R)—4-rnethoxycyclohexyl-
amino)pyrimidine-5 -
carboxamide
375 4—<<R> 362.3
cyclopropylpropylamino)
((1r,4R)—4-eth0xycyclohexy1—
pyrimidine
carboxamide
ATI—25 14175V1
Cmpd. Structure NAME MH+ Act.
A- Level
”WAN t-butylamino)((1R,3S)- 3222 D
S {jifim 3-hydr0xycyc10heptylarnino)—
H)“; ”3““; :3 pyrimidine-S-carboxamide
377 f;- 2-(cyclopropylamino) 306.2 D
:k} m ((1R,3S)—3-hydroxycyclo-
iu-a
_’ “L17
heptylamino)pyrimidine
miga‘u} carboxarnide
378 2-(cyclopropylamino) 306.2
((1R,3 S)—3-hydroxy-3 -
methylcyclohexylamino)-
pyrimidine-S-carboxamide
379 2-(cyclopropy1arnino) 292.1
((1R,3 ydroxycyclohexylamino
)pyrirnidine-5 -
carboxamide
380 4-(tert-butylamino)((1R,3S)- 322.2
3-hydr0xyrnethy1cyclohexyl-
amino)pyrimidine
carboxamide
381 2-((1r,4r) 336.2
methoxycyclohexylamino)
(tert-pentylarnino)pyrimidine-5 -
carboxamide
ATI—25 14175V1
Cmpd. Structure NAME MH+ Act.
A- Level
382 fig 2-((1r,4r) 362.3 D
W; cyclopropoxycyclohexylarnino)
LY: LY] (tert-pentylarnino)-
W pyrimidinecarb0xarnide
fl “m‘3le
x“ «m
383 L 2-(sec-butylarnino) 322.3 D
L L .1 ((1R,3R,4R)hydroxy
1;; g
‘1: methylcyclohexylamino)-
‘ ML
U :L pyrimidine-S-carboxamide
384 4-((S) 334.2
ropylpropylamino)
S)hydr0xycyclohexylamino
)pyrimidine-5 -
carboxamide
385 4-((R) 334.2
cyclopropylpropylamino)
((1r,4R)—4-hydroxycyclohexylamino
)pyrimidine-5 -
carboxamide
386 4-(tert-butylamino)((1R,3R)- 322.2
3-hydroxycycloheptylamino
)pyrimidine-5 -
carboxamide
387 4-(tert-butylamino)((1S,3S)- 322.2
3 -hydroxycyc10hepty1arnino)—
pyrimidine-S-carboxamide
ATI—25 14175V1
Cmpd. Structure NAME MH+ Act.
A- Level
_:¢,_.m\ 4-(tert-butylarnino)((1 S,3R)- 322.2 D
I'VE? 3-hydr0xycycloheptylarnino)-
m: Rafi-wk };j__ pyrimidine-S-carboxamide
“if":
389 4-(tert-butylarnino)(4- 308.2 D
methyltetrahydro-2H-pyran
ylarnino)pyrirnidine-5 -
carboxamide
390 2-((1r,4r)—4- 336.2
hydroxycyclohexylamino)—4-(2-
methylpentan
ylarnino)pyrirnidine-5 -
carboxamide
391 ,4r)—4- 364.3
ethoxycyclohexylarnino)(2-
pentan
ylarnino)pyrirnidine-5 -
carboxamide
392 2-((1r,4r)—4- 350.2
methoxycyclohexylamino)
(2-rnethylpentan
ylarnino)pyrirnidine-5 -
carboxamide
393 " 2-((1r,4r)—4- 332.3
‘ hydroxycyclohexylamino)—4-(3-
methylbicyclofl . 1 . 1]pentan
ylarnino)pyrirnidine
amide
ATI—25 14175V1
Cmpd. Structure NAME MH+ Act.
A- Level
394 i 2-((R) 334.4 D
“we“ a.\ “:
L J cyclopropylethylamino)
:5 N L: ((1R,3R,4R)hydroxy
I! j methylcyclohexylamino)-
U My pyrimidine-S-carboxamide
395 2-((S) 334.2 D
cyclopropylethylamino)-4_
(( 1 Ra3R,4R)-3 -hydr0xy—4_
cyclohexylamino)-
pyrimidine-S-carboxamide
396 4-((1R,3R,4R)hydroxy 346.3
methylcyclohexylamino)(3 -
methylbicyclo [1 . 1 . 1]pentan
ylarnino)pyrirnidine-5 -
carboxamide
397 2-(2-cyclopr0pylpr0pan 348.3
ylarnino)((1R,3R,4R)
hydroxyrnethylcyclohexy1—
amino)pyrimidine-5 -
carboxamide
398 2-(sec-butylarnino)-4 _ 322.3
(( 1 Ra3R,4R)-3 xy—4_
methylcyclohexylamino)-
pyrimidine-S-carboxamide
399 4-(tert-butylarnino)(4- 320.2
ybicyclo [2.2. 1]heptan
ylarnino)pyrirnidine-5 -
carboxamide
ATI—25 14175V1
Cmpd. Structure NAME MH+ Act.
A- Level
400 Hg.‘
V. {3a 2-((1r,4r)—4- 360.2 D
cyclopropoxycyclohexylarnino)
( 1 -rnethy1cyclobutylarnino)-
pyrimidine-S-carboxamide
401 2-((1r,4r)—4- 348.2 D
ethoxycyclohexylamino)(1 -
cyclobutylamino)-
dine-S-carboxamide
402 2-((1r,4r)—4- 334.2
methoxycyclohexylamino)
(1 -rnethylcyclobuty1arnino)-
pyrimidine-S-carboxamide
403 (S)(1- 306.2
methylcyclobutylamino)
(tetrahydro-2H-pyran-3 -
ylarnino)pyrirnidine-5 -
carboxamide
2-((1R,3 S)-3 - 320.2
hydroxycyc10hexy1arnino)—4-(1 -
methylcyclobutylamino)-
pyrimidine-S-carboxamide
405 (S)(bicyc10[1.1.1]pentan 304.2
ylarnino)(tetrahydro-2H-
pyranylarnin0)pyrirnidine-5 -
carboxamide
ATI—25 14175V1
Cmpd. Structure NAME MH+ Act.
A- Level
406 4-(bicyc10[1.1.1]pentan 3182 D
o)((1R,3 S)—3-
hydroxycyclohexylamino)-
‘2‘ pyrimidinecarb0xarnide
”:3“?
407 4-(bicyc10[1.1.1]pentan 3042 D
ylarnino)(tetrahydro-2H-
pyrany1arnino)pyrirnidine-5 -
carboxamide
408 (R)(1- 346.2
cyclopropylethylamino)(4-
hydroxybicyc10[2.2.2]0ctan
ylarnino)pyrirnidine-5 -
carboxamide
4-((R) 402.2
cyclopropylethylamino)
((1r,4R)—4-(2,2,2-trifluoroethoxy
)cyclohexylamino)-
pyrimidine-S-carboxamide
410 2-((1r,4R) 360.2
cyclopropoxycyclohexylarnino)
((R)-1 -cyclopr0pylethyl-
amino)pyrimidine-5 -
carboxamide
411 348.2
ropylethylamino)
((1r,4R)—4-eth0xycyclohexy1—
amino)pyrimidine
carboxamide
ATI—25 14175V1
Cmpd. Structure NAME MH+ Act.
A- Level
412 xx. «1 2-(4- 346.2 D
m«EXT ybicyclo [2.2 .2]octan
<> ”reg”! ylarnino)—4-(1 -methylcyclo-
M“‘Vh”ux§: butylamino)pyrimidine
carboxarnide
fo‘ in...
413 H.» *- 3:9 4-(1 -rnethy1cyclobuty1arnino)- 306.2 D
N 3.3; le 2-(tetrahydr0-2H-pyran
<> 1L : w‘ ylarnino)pyrirnidine-5 -
mm m“ carboxarnide
L .1
414 2-((1r,4r) 375.2
(dimethylcarbarnoyl)cyclohexyl
amino)—4-(1 -rnethy1cyclobuty1-
amino)pyrimidine-5 -
carboxamide
415 4-(1 y1cyclobuty1arnino)- 402.2
,4r)(2,2,2-triflu0roethoxy
)cyclohexylamino)-
pyrimidine-S-carboxamide
416 2-((1r,4r)—4- 370.2
(difluorornethoxy)cyclohexyla
mino)(1 -rnethy1cyclobuty1-
amino)pyrimidine-5 -
carboxamide
417 4-(bicyc10[1.1.1]pentan 344.2
ylamino)(4-hydroxybicyclo
[2.2.2]octan
ylarnino)pyrirnidine-5 -
carboxamide
ATI—25 14175V1
Cmpd. Structure NAME MH+ Act.
A- Level
418 4-(bicyclo[1.1.1]pentan 373.3 D
ylamino)((1r,4r)
hylcarbarnoyl)cyclohexyl
amino)pyrimidine-5 -
carboxamide
419 4-(bicyc10[1.1.1]pentan 400.2 D
ylarnino)((1r,4r)(2,2,2-
trifluoroethoxy)cyclohexylamino
)pyrimidine-5 -
carboxamide
420 4-(bicyc10[1.1.1]pentan 368.2
ylamino)((1r,4r)
(difluorornethoxy)cyclohexylamino
)pyrimidine-5 -
carboxamide
421 4—<<R> 334.2
cyclopropylethylamino)
((1r,4R)—4-meth0xycyclohexylamino
)pyrimidine-5 -
carboxamide
422 4-((R) 306.2
cyclopropylethylamino)((S)-
tetrahydro-2H-pyran-3 -
ylarnino)pyrirnidine-5 -
amide
423 4—<<R> 320.2
ropylethylamino)
(( 1 R, 3 S)—3 -hydr0xycyclohexylamino
)pyrimidine
carboxamide
—294—
ATI—25 14175V1
Cmpd. Structure NAME MH+ Act.
A- Level
424 w... Nc. (R)(1- 306.2 D
3:3. I .«1 cyclopropylethylamino)
lmya hydro-ZH-pyran
m A.
E .a x. ylarnino)pyrirnidine
1 r‘1
: carboxarmde-
425 4-((R) 375.2 D
—%\.~5 .3; cyclopropylethylamino)
((1r,4R)—4-
L.l~é (dimethylcarbarnoyl)cyclohexyl
“ amino)pyrimidine
carboxamide
426 m .5: 4-((R) 370.2 D
3“»me_ cYclopr0py1€thylamin0)'2'
((1r,4R)—4-(diflu0r0rnethoxy)-
21L” cyclohexylamino)pyrimidine
carboxarnide
427 2-(bicyclo[1.1.1]pentan 346.3 C
ylarnino)(3-hydr0xy_4,4_
y1cyclohexylarnino)-
pyrimidine-S-carboxamide
428 "’7, ‘ 2-(cyclobutylamino)(3- 334.2 D
hydroxy-4,4-
dimethy1cyclohexylarnino)-
pyrimidine-S-carboxamide
ATI—25 14175V1
Cmpd. Structure NAME MH+ Act.
A' Level
429 fix an 2-(cyclobutylamino)(3- 334.2 D
L J 33:} hydroxy-4,4-
H1 ,s-‘k >34 dimethy1cyclohexylarnino)-
M x“ fl pyrimidine-S-carboxamide
430 4-(3-hydroxy-4,4- 334.2 D
dimethylcyclohexylamino)
(1 -rnethylcyc10propy1arnino)-
pyrimidine-S-carboxamide
431 :4. - is-_ . 4-(3 -hydr0xy-4,4- 334.2
dimethylcyclohexylamino)
(1 -rnethylcyc10propy1arnino)-
pyrimidine-S-carboxamide
432 2-(bicyclo[1.1.1]pentan 3463
{ “
ylarnino)(3-hydr0xy-4,4-
y1cyclohexylarnino)-
pyrimidine-S-carboxamide
433 4-(cyclobuty1arnino) 306.2
(( 1 R, 3 S)-3 -
ycyclohexylamino)-
pyrimidine-S-carboxamide
434 -‘ I” 4-(cyclobutylamino)((1r,4r)- 346.2
N '
cyclopropoxycyclohexylarnino)
pyrimidine-S-carboxamide
ATI—25 14175V1
Cmpd. Structure NAME MH+ Act.
A- Level
435 Why? 4-(cyclobutylarnino) 292.2 D
PM}JEWL (tetrahydro-2H-pyran
LJ “[4]“ ylarnino)pyrirnidine
”Ex fem carboxarnide
L ~.
436 “-‘k V lobutylamino)((1r,4r)- 3562 D
4-(difluor0rnethoxy)—
cyclohexylamino)pyrirnidine-5 -
carboxamide
437 4-(cyclobutylamino)((1r,4r)- 361.2
4-(dirnethylcarbamoyl)-
cyclohexylamino)pyrirnidine-5 -
carboxamide
438 4-((1R,3 S) 306.2
hydroxycyc10hexy1arnino)—2-(1 -
methylcyclopropylarnino)-
pyrimidine-S-carboxamide
439 2-(Cyclopentylarnino)-4_ 320.2
(( 1R3 S)'3 'hydTOXYCYCIOhexyI-
amino)pyrirnidine_5 _
carboxamide
2-((1r,4r)—4- 386 D
ycyclohexylamino)—4-(3-
(trifluorornethyl)bicyclo[1 .1 . 1]-
pentanylamino)pyrimidine-
-carboxarnide
ATI—25 14175V1
Cmpd. Structure NAME MH+ Act.
A- Level
441 4-((1R,3R,4R)hydroxy 400
methylcyclohexylamino)(3 -
(trifluorornethyl)bicyclo[1 .1 . 1]-
pentanylamino)pyrimidine-
-carboxarnide
442 2-((1r,4r)—4- 372.3
cyclopropoxycyclohexylarnino)
-4 _(3 _
methylbicyclo [1 . 1 . 1]pentan
ylarnino)pyrirnidine-5 -
carboxamide
443 ; 2-((1r,4r)—4- 360.3
cyc10hexy1arnino)(3 -
methylbicyclo [1 . 1 . 1]pentan
ylarnino)pyrirnidine-5 -
carboxamide
444 Hm 2-(3 ,3 - 356.1
difluorocyclobutylarnino)
((1R,3R,4R)hydr0xy
methylcyclohexylamino)-
pyrimidine-S-carboxamide
445 yclopr0pylpr0pan 346.3
o)(4-
hydroxybicyclo [2.2. 1]heptan
ylarnino)pyrirnidine-5 -
carboxamide
ATI—ZS 14175V1
Cmpd. Structure NAME MH+ Act.
A- Level
446 gum 2—(4— 346.3 D
:“: hydroxybicyclo [2.2. 1 ]heptan
ylarnino)(1 -
a :‘mmk LE:
133;th “ methylcyclopentylarnino)-
fix“ pyrimidine-S-carboxamide
447 4-(cyclobuty1arnino)-2—(4- 318.2 D
hydroxybicyclo [2.2. 1]heptan
ylarnino)pyrirnidine-5 -
carboxamide
448 (cyclobutylamino) 292.1
(tetrahydro-2H-pyran-3 -
ylarnino)pyrirnidine-5 -
carboxamide
lobutylamino)—2-(4_ 306.2
methyltetrahydro-2H-pyran_4_
ylarnino)pyrirnidine-5 -
carboxamide
450 (R)(1 - 332.2
cyclopropylethylamino)(4-
hydroxybicyclo [2.2. 1]heptan
ylarnino)pyrirnidine-5 -
carboxamide
451 2-(4- 332.2
hydroxybicyclo [2.2. 1]heptan
no)—4-(1-rnethylcyclobutylamino
)pyrimidine
carboxamide
ATI—25 14175V1
Cmpd. Structure NAME MH+ Act.
A- Level
452 2—(4- 334.2 D
hydroxybicyclo [2.2. 1]heptan
ylamino)(tertpentylamino
)pyrimidine
carboxamide
MNL 4-(bicyclo[1.1.1]pentan-2— 318.1 D
$.ngTIE ylamino)-2—(( 1r,4r)
AM 9Ti“ hydroxycyclohexylamino)-
»~"\ pyrimidine-S-carboxamide
454 .. 4-(1-ethylcyclopentylamin0)-2' 362-2
. ((1r,4r)—4-methoxycyclohexy1-
amino)pyrimidine-5 -
carboxamide
455 a. 4-(1 -ethylcyc10penty1arnino)-2— 348 .2
((1r,4r)hydr0xycyclohexy1—
pyrimidine-5 -
carboxamide
456 ‘ 4-(2-cyclopropy1propan 334_2
ylamino)-2—((IS,3S)
hydroxycyclohexylamino)-
pyrimidine-S-carboxamide
457 -‘
. 4-(2-cyclopr0pylpr0pan 334.2
- ylamino)-2—((IS,3R)
ycyclohexylamino)-
pyrimidine-S-carboxamide
ATI—25 14175V1
W0 45569
Cmpd. Structure NAME MH+ Act.
A- Level
458 (1:39.- yclo[1.1.1]pentan 330 D
sfi> ylamino)((1r,4r)
,5 ”a.“ hydroxybicyclo [2.2. 1]heptan
11“? w ylarnino)pyrirnidine
51-13;, P {A 1‘1
carboxamide
459 A“ ‘34 2-((R) 348.3 D
l j i“; cyclobutylethylamino)
: . '1 M
.4 L ((1R,3R,4R)hydroxy
\Tr 1:? methylcyclohexylamino)-
”Wink? xx? pyrimidine-S-carboxamide
2-((S)— 1 -cyc10butylethy1arnino)- 348.3
4-((1R,3R,4R)hydroxy
methylcyclohexylamino)-
pyrimidine-S-carboxamide
461 2-((R)-3,3-dimethylbutan 350.2
ylarnino)((1R,3R,4R)
hydroxy
methylcyclohexylamino)pyrimi
dine-S-carboxarnide
462 4-(bicyclo[2.1.1]hexan 360.2
ylamino)((1r,4r)
ethoxycyclohexylarnino)pyrirni
dine-S-carboxarnide
463 ,4r)cyclopropoxy- 388.2
cyclohexylamino)(1-
ethylcyclopentylarnino)-
pyrimidine-S-carboxamide
ATI—25 14175V1
Cmpd. Structure NAME MH+ Act.
A- Level
464 2-((1r,4r)ethoxy- 376.2 D
L H “fir;
K:"jgl‘“““~t] exylamino)(1 -
3“"?' i’ N “15.:
“j” yclopentylarmno)-.
3 3 [xx]:
pyrimidine-S-carboxamide
\x‘i‘wfl
465 “NT” 4-(2-cyclopr0pylpr0pan 334.2 D
RWY“?! ylamino)((1R,3R)
N "’3’” hydroxycyclohexylarnino)pyrirn
idine-S-carboxarnide
4-(2-cyclopr0pylpropan 334.2
ylamino)((1R,3 S)—3 -
hydroxycyclohexylamino)-
pyrimidine-S-carboxamide
467 4-(2-cyclopr0pylpr0pan 320.2
ylarnino)(tetrahydro-2H-
pyrany1arnino)pyrirnidine-5 -
carboxamide
468 (S)(2-cyclopr0py1propan 320.2
ylarnino)(tetrahydro-2H-
pyranylarnin0)pyrirnidine-5 -
carboxamide
—3,3-dirnethy1butan 350.3
ylarnino)((1R,3R,4R)
hydroxy
methylcyclohexylamino)-
pyrimidine-S-carboxamide
ATI—25 14175V1
Cmpd. Structure NAME MH+ Act.
A- Level
470 1 ,3R,4R)hydroxy 336.2 D
I“ ] methylcyc10hexy1arnino)
\Rm" a... ff a“
m r L ((R)—3-rnethylbutan
VT} i1: ylarnino)pyrirnidine-5 -
K v?! m":
carboxamide
471 «L‘- 4-((1R,3R,4R)hydr0xy 336.3 D
[ :1 cyc10hexy1arnino)
_, . ]
”fix-l ((S)rnethy1butan—2-
l ylarnino)pyrirnidine-5 -
. ‘ ‘1
carboxamide
472 2-(cyclopropylrnethylarnino) 320.1
((1R,3R,4R)hydr0xy
methylcyclohexylamino)-
pyrimidine-S-carboxamide
473 2-((1r,4r)—4- 348.3
methoxycyclohexylamino)
(1 -methylcyclopentylarnino)-
pyrimidine-S-carboxamide
474 2'(‘DKCYC10101V0p)ylamino)-4— 346.2
(( 1 Ra3R,4R)-3 -hydr0xy—4_
methylcyclohexylamino)-
pyrimidine-S-carboxamide
475 4-((1R,3R,4R)hydroxy 348.2
methylcyclohexylamino)(1 -
methylcyclopentylarnino)-
pyrimidine-S-carboxamide
ATI—25 14175V1
Cmpd. ure NAME MH+ Act.
A- Level
476 “a“
1 #1 4-(bicyclo[1.1.1]pentan 346.2 D
gmtl ylarnino)((1r,4r)
N T“
ethoxycyclohexylamino)-
Lil” pyrimidine-S-carboxamide
477 :n 4-(bicyclo[2.1.1]hexan 332.2 D
o)((1r,4r)_4_
hydroxycyclohexylamino)-
pyrimidine-S-carboxamide
478 ‘r"- 2-((1r,4r) 390.2
‘ " ethoxycyclohexylarnino)(1-
ethylcyclohexylarnino)-
pyrimidine-S-carboxamide
479 4-(2-cyclopropylpropan 360.2
, 4 __L
ylamino)(4-hydroxybicyclo
[2.2.2]octan
no)pyrirnidine
carboxamide
480 4-(2-cyclopr0pylpr0pan 389_2
,= .,
ylamino)((1r,4r)
(dimethylcarbarnoyl)cyclohexyl
amino)pyrimidine-5 -
carboxamide
481 i: - -6 4-(2-cyclopr0pylpr0pan 384.2
e" '
‘ ylamino)((1r,4r)
(difluorornethoxy)cyclohexyla
mino)pyrirnidine-5 -
carboxamide
—304_
ATI—25 14175V1
Cmpd. Structure NAME MH+ Act.
A- Level
482 H: R Tb 4-(2-cyclopr0pylpr0pan 416.2 D
*fiwfi ylamino)((1r,4r)(2,2,2-
:3; a.“ trifluoroethoxy)cyclohexy1arnin
LVMLCE o)pyrirnidinecarb0xarnide
23?:
483 374.2 D
\ FT“ 2-((1r,4r)cyclopr0poxy-
3 3T3 ”11“‘3é‘“‘~'].
exylamino)(2-
:33 ropylpropan
I L. 1‘
ylarnino)pyrirnidine
i: carboxamide
484 4-(bicyclo[1.1.1]pentan 318.1
ylarnino)((1S,3 S)
hydroxycyclohexylamino)-
pyrimidine-S-carboxamide
485 4-(bicyclo[1.1.1]pentan 318.2
ylamino)((1R,3R)
hydroxycyclohexylamino)-
pyrimidine-S-carboxamide
486 4-(bicyclo[1.1.1]pentan 358.2
o)((1r,4r)
cyclopropoxycyclohexylarnino)
pyrimidine-S-carboxamide
487 4-(bicyclo[2.1.1]hexan 372.2
ylamino)((1r,4r)_4_
cyclopropoxycyclohexylarnino)
pyrimidine-S-carboxamide
ATI—25 14175V1
Cmpd. Structure NAME MH+ Act.
A- Level
488 J 2-((1r,4r)—4- 362.3 D
ethoxycyclohexylamino)(1 -
methylcyclopentylamino)-
dine-S-carboxamide
489 f 2-(3-tert- 388.4 D
. butylbicyclo [1 . 1 . 1]pentan
ylarnino)((1R,3R,4R)
hydroxyrnethylcyclohexy1—
: pyrimidine
carboxamide
490 it? 2-(4-hydr0xy- 344 D
fi?§«:§ bicyclo [2 .2. 1]heptan
$2“ «3;; ylamino)—4-(3-rnethy1—
sifikk‘éwa bic clo[1.1.1] entan-l-
N; y p
SEN“: ylarnino)pyrirnidine
carboxamide
491 2-(tert-butylarnino) 322.3 D
(2+:
f T .. ((1R,3S,4S)hydroxy
:J ‘Itf
methylcyclohexylamino)-
dine-S-carboxamide
H z I if1 KW
492 jg; 2-((1r,4R) 404.2 D
cyclopropoxycyclohexylarnino)
((1R,3R,4R)hydr0xy
methylcyclohexylamino)-
pyrimidine-S-carboxamide
ATI—25 14175V1
Cmpd. Structure NAME MH+ Act.
A- Level
493 I“ 4-(3 -tert- 374.4 D
butylbicyclo[1 . 1 .1]pentan
ylamino)((1r,4r)
hydroxycyclohexylamino)-
pyrimidinecarb0xarnide
494 2-(ethy1amino)—4-((1R,3R,4R)- 294 D
3-hydr0xy
methylcyclohexylamino)-
pyrimidine-S-carboxamide
495 4-((1R,3 S)-3 - 308.2
hydroxycyclohexylarnino)
(isobutylarnino)pyrimidine-5 -
carboxamide
2-(sec-buty1arnino)((1R,3S)- 308.2
3 -hydroxycyc10hexy1arnino)—
pyrimidine-S-carboxamide
497 2-(sec-buty1arnino)((1R,3S)- 308.2
3 xycyc10hexy1arnino)—
pyrimidine-S-carboxamide
498 4-((1R,3 S)-3 - 322.2
hydroxycyclohexylarnino)
(pentany1arnin0)pyrirnidine-
oxarnide
ATI—25 14175V1
Table2
Structure nd Name
Level
2-(4-ethoxyphenylarnino) 376.2
((1 S ,2S)—2-
hydroxycyclopentylamino)-
pyrimidine-S-carboxamide
4-(quin01inylamino) 365.2
(tetrahydro-ZH-pyran
ylarnino)pyrirnidine-5 -
arnide
4-(1H-indaz01ylamino)
(tetrahydro-ZH-pyran
ylarnino)pyrirnidine-5 -
carboxarnide
2-((1r,4r)—4-
hydroxycyclohexylamino)
(phenylarnino)pyrimidine-5 -
carboxarnide
2-((1r,4r)—4-
(methylsulfonamido)cyclohexyla
mino)—4-
(phenylarnino)pyrimidine
carboxarnide
ATI—ZS 14175V1
Cmpd Structure Compound Name MH+ Act.
B- Level
6 2-((1r,4r)—4-
acetamidocyclohexylamino)
(phenylarnino)pyrimidine
arnide
7 2-((1r,4r)—4-
aminocyclohexylarnino)
(phenylarnino)pyrimidine-5 -
carboxarnide
8 f" 2-((1r,4r)—4-
(methylcarbarnoyl)cyclohexy1arn
ino)
(phenylarnino)pyrimidine
carboxarnide
9 - .sé.
’ nylarnino)(piperidin
ylarnino)pyrirnidine
carboxarnide
"1. -
-. 2-(1-acety1piperidinylarnino)-
4-(phenylarnino)pyrirnidine
carboxarnide
a 4-(phenylarnino)—2-(tetrahydro-
2H-pyrany1arnino)pyrirnidine-
-carboxarnide
ATI—ZS 14175V1
2012/034349
Cmpd Structure Compound Name MH+ Act.
B- iLevel
12 s; ., 2-(tert-butylarnino)
(phenylarnino)pyrimidine
carboxarnide
13 2-(4-
(diethylamino)phenylamino)
(phenylarnino)pyrimidine
carboxarnide
. 4-(phenylarnino)(5,6,7,8-
' tetrahydronaphthalen
ylarnino)pyrirnidine-5 -
carboxarnide
2-(2-methoxyphenylarnino)
(phenylarnino)pyrimidine
carboxarnide
16 2—(6-methoxypyridin
ylarnino)
(phenylarnino)pyrimidine
arnide
17 2-(3,4-dimethoxyphenylamino)-
4-(phenylamino)pyrimidine-5 -
carboxarnide
ATI—ZS 14175V1
WO 45569
Cmpd Structure Compound Name MH+ Act.
B- Level
18 2-(4-rnethoxy
methylphenylamino)
(phenylarnino)pyrimidine-5 -
arnide
19 4-(phenylarnino)-2—(3 ,4,5-
trimethoxyphenylarnino)pyrimid
ine-S-carboxarnide
2-(2,4-dimethoxyphenylamino)-
4-(phenylarnino)pyrirnidine
carboxarnide
21 '
‘ 1
_:, ”5"“ 2-(4-rnethylpyrirnidin
ylarnino)—4-
(phenylarnino)pyrimidine-5 -
carboxarnide
22 2-(2-phen0xyphenylamino)
(phenylarnino)pyrimidine
carboxarnide
23 2-(3,5-dimethoxyphenylarnino)-
4-(phenylarnino)pyrirnidine
carboxarnide
ATI—25 14175V1
Cmpd Structure Compound Name MH+ Act.
24 x
._ if“. I 2-(3-fluorophenylarnino)
' (phenylarnino)pyrimidine
carboxarnide
.A 1
_ 2-(3-methoxypheny1arnino)
(phenylarnino)pyrimidine-5 -
carboxarnide
26 “"
‘ 2-(3-ethoxyphenylarnino)
" (phenylarnino)pyrimidine
carboxarnide
27 2-(3-fluor0
‘ :
methoxyphenylamino)
(phenylarnino)pyrimidine-5 -
carboxarnide
28 1
,J - - 4-(pheny1arnino)—2-(rntolylamino
)pyrirnidine
arnide
29 , 1“: 2-(4-methoxybiphenyl
no)
(phenylarnino)pyrimidine
carboxarnide
ATI—25 14175V1
Cmpd Structure nd Name MH+ Act.
B- Level
~ =
,4 _ 4-(phenylamino)(0-
i E
‘ tolylamino)pyrirnidine
carboxarnide
31 2-(2,3-dihydro-lH-inden-l-
ylarnino)
(phenylarnino)pyrimidine-5 -
arnide
32 V 2-(5-acetamidO
> " methoxyphenylamino)
(phenylarnino)pyrimidine-5 -
carboxarnide
33 .. 2-(5-rnethy1—1H-pyraz01—3-
g ' ylarnino)
(phenylarnino)pyrimidine
carboxarnide
34 2-(5-rnethoxy
a «t h
methylphenylamino)
(phenylarnino)pyrimidine
carboxarnide
2-(cyclopropylmethylamino)
(phenylarnino)pyrimidine
carboxarnide
ATI—ZS 14175V1
WO 45569
Cmpd Structure Compound Name MH+ Act.
B- Level
36 1. 2-(cyclopr0py1arnino)
‘ ' (phenylarnino)pyrimidine
carboxarnide
37 =fi-:‘= 2-(4-carbamoylpiperidiny1)
' (phenylarnino)pyrimidine
carboxarnide
38 2-(4-methoxyphenethylarnino)-
4-(phenylamino)pyrimidine-5 -
carboxarnide
39 2-(3-fluor0benzylarnino)—4-
(phenylarnino)pyrimidine
carboxarnide
g 2-(4-morpholinopheny1amino)-
4-(phenylarnino)pyrirnidine
arnide
41 ' 2-(2-acetamidoethylamino)—4-
(phenylarnino)pyrimidine
carboxarnide
—314—
ATI—ZS 14175V1
Cmpd Structure Compound Name MH+ Act.
42 ‘33“ >5 4-(phenylarnino)(2-(thi0phen-
2-y1)ethy1arnino)pyrirnidine
carboxarnide
43 a -dimethoxybenzylamino)-
" " '"
nylarnino)pyrirnidine
carboxarnide
44 ,
, 2-(cyc10pentylamino)—4-
(phenylarnino)pyrimidine
carboxarnide
45 -
i; .. 2-(cyclohexylamino)
‘ ‘ (phenylarnino)pyrimidine
carboxarnide
46 V": 2-(SeC-butylarnino)
' (phenylarnino)pyrimidine
carboxarnide
47 a
‘ 2-(4-rnethylcyclohexylamino)
(phenylarnino)pyrimidine
carboxarnide
ATI—ZS 14175V1
Cmpd Structure Compound Name MH+ Act.
48 ethyl 4-(5 -carbarn0y1—4-
lamino)pyrimidin
ylamino)piperidine
carboxylate
49 I
-‘ 2-(cyclohexylmethylarnino)
(phenylarnino)pyrimidine
carboxarnide
50 2-(1 -benzy1piperidin
no)
(phenylarnino)pyrimidine
carboxarnide
51 4-(phenylarnino)(pyridin
' ylmethylamino)pyrirnidine
carboxarnide
52 F
i ' ‘ 7“ 2-(3,5-difluorobenzy1amino)—4-
“ (phenylarnino)pyrimidine
carboxarnide
53 4-(phenylamino)(1-
' “'17.
phenylethylamino)pyrimidine
carboxarnide
ATI—ZS 14175V1
2012/034349
Cmpd Structure Compound Name MH+ Act.
B- Level
54 v
3‘ 2—(2-ethoxybenzylamino)
(phenylarnino)pyrimidine
carboxarnide
55 2-(2,3-dirneth0xybenzy1arnino)-
4-(phenylarnino)pyrirnidine
carboxarnide
56 9"“; 4-(phenylamino)(1-
' _»_~_--
phenylpropylamino)pyrimidine-
-carboxarnide
57 2-(2,4-diflu0r0benzylarnino)—4-
(phenylarnino)pyrimidine
carboxarnide
58 .- 2-((2,2-dirnethy1—1,3 -di0x01an
"" y1)rnethylarnino)
(phenylarnino)pyrimidine-5 -
carboxarnide
59 ethylbutylamino)—4-
(phenylarnino)pyrimidine
carboxarnide
ATI—ZS 14175V1
WO 45569
Cmpd Structure Compound Name MH+ Act.
60 2-(2-rnethoxybenzylamino)
" (phenylarnino)pyrimidine-5_
carboxarnide
h 2-(2-
(dimethylamino)ethy1arnino)
(phenylarnino)pyrimidine
carboxarnide
62 ' 1-rnethy1pyrrolidin
' " yl)ethylarnino)
(phenylarnino)pyrimidine-5 -
carboxarnide
63 :j 4-(pheny1arnino)(2-(pyridin-
2-y1)ethy1arnino)pyrirnidine
carboxarnide
64 a- 4-(phenylarnino)_2_
((tetrahydrofuran—zyl
)rnethy1amin0)pyrimidine
carboxarnide
65 ' 2-(furany1rnethylarnino)
(phenylarnino)pyrimidine
carboxarnide
ATI—ZS 14175V1
Cmpd Structure nd Name MH+ Act.
66 a 2-(3,4-
dimethoxyphenethylamino)
(phenylarnino)pyrimidine-5 -
carboxarnide
67 f 2-(4-fluor0benzylarnino)—4-
(phenylarnino)pyrimidine
carboxarnide
68 "
f 4-(phenylarnino)
(propylamino)pyrirnidine
carboxarnide
69 2-(2-methoxyethylarnino)
(phenylarnino)pyrimidine
carboxarnide
70 F 2-(3,4-diflu0r0benzylarnino)—4-
(phenylarnino)pyrimidine
carboxarnide
71 nethylarnino)
(phenylarnino)pyrimidine
carboxarnide
ATI—ZS 14175V1
2012/034349
Cmpd Structure Compound Name MH+ Act.
B- Level
72 :j 4-(phenylamino)(2-
‘ phenylpropylamino)pyrimidine-
oxarnide
73 2-(benzylarnino)
:1: (phenylarnino)pyrimidine
carboxarnide
74 i"? 4-((1R,3S)
hydroxycyclohexylamino)
((R)-1,2,3,4-
tetrahydronaphthalen
ylarnino)pyrirnidine-5 -
carboxarnide
75 4-((1R,3S)—3-
hydroxycyclohexylamino)
((S)-1,2,3,4-
tetrahydronaphthalen
ylarnino)pyrirnidine-5 -
carboxarnide
76 4-((1R,3S)—3-
hydroxycyclohexylamino)
((R)—5 ,6 ,7 , 8-tetrahydr0quinolin-
6-ylamino)pyrirnidine-5 -
carboxarnide
ATI—ZS 14175V1
Cmpd Structure Compound Name MH+ Act.
77 4-((1R,3S)—3-
ycyclohexylamino)
((S)-5 ,6 ,7 , 8 -tetrahydr0quinolin-
6-ylamino)pyrirnidine-5 -
carboxarnide
V: -chrornany1amino)
((1 R,3 S)-3 -
hydroxycyclohexylarnino)pyrirni
dine-S-carboxarnide
5_ 2-((R)-chr0rnanylamino)
‘ " ((1R,3S)
hydroxycyclohexylarnino)pyrirni
dine-S-carboxarnide
80 (S)(isopropy1amino)
(5,6,7,8-tetrahydroquinolin
ylarnino)pyrirnidine-5 -
carboxarnide
81 (R)(isopropylarnino)
(5,6,7,8-tetrahydroquinolin
ylarnino)pyrirnidine-5 -
carboxarnide
82 (S)(isopr0pylarnino)
(1 ,2,3 ,4-tetrahydr0naphthalen
ylarnino)pyrirnidine-5 -
carboxarnide
ATI—ZS 14175V1
2012/034349
Cmpd Structure Compound Name MH+ Act.
B- Level
83 (R)(isopropylarnino)
(1 ,2,3 ,4-tetrahydr0naphthalen
ylarnino)pyrirnidine
carboxarnide
N 4-((1R,3S)—3-
hydroxycyclohexylamino)
((R)-1,2,3,4-
tetrahydronaphthalen-Z-
ylarnino)pyrirnidine
carboxarnide
_: 4-((1R,3S)—3-
I 8
hydroxycyclohexylamino)
((S)-1,2,3,4-
tetrahydronaphthalen-Z-
ylarnino)pyrirnidine-5 -
arnide
86 j : 2-(cyclohexylamino)
(phenylarnino)pyrimidine-5 -
carbonitrile
87 4-((1R,3S)—3-
hydroxycyclohexylamino)
((S)-5 ,6 ,7 , 8 -tetrahydr0quinolin-
7-ylamino)pyrirnidine-5 -
carboxarnide
ATI—ZS 14175V1
2012/034349
Cmpd Structure Compound Name MH+ Act.
B- Level
88 ,3S)—3-
hydroxycyclohexylamino)
((R)—5 ,6 ,7 , 8-tetrahydr0quinolin-
7-ylamino)pyrirnidine-5 -
carboxarnide
89 2-((R)(4-
. .
. ‘
‘ :3.
fluoropheny1)ethylarnino)
((1 R,3 S)-3 -
hydroxycyclohexylarnino)pyrirni
dine-S-carboxarnide
90 —1-(4-
_ ' .
. 3‘
fluoropheny1)ethylarnino)
((1R,3S)
hydroxycyclohexylarnino)pyrirni
dine-S-carboxarnide
91 (S)(isopr0pylarnino)
(5,6,7,8-tetrahydroisoquinolin
ylarnino)pyrirnidine-5 -
carboxarnide
92 (R)(isopropylarnino)
(5,6,7,8-tetrahydroisoquinolin
ylarnino)pyrirnidine-5 -
carboxarnide
93 4-((1R,3R,4R)hydroxy
methylcyclohexylarnino)((S)-
,6,7,8-tetrahydroquinolin
ylarnino)pyrirnidine-5 -
carboxarnide
ATI—ZS 14175V1
Cmpd Structure Compound Name MH+ Act.
B- Level
94 4-((1R,3R,4R)hydroxy
methylcyclohexylamino)((R)-
,6,7,8-tetrahydroquinolin
ylarnino)pyrirnidine-5 -
carboxarnide
95 . 4-((1R,3S)—3-
”h g“ hydroxycyclohexylamino)
,6,7,8-
tetrahydroisoquinolin
ylarnino)pyrirnidine
carboxarnide
‘ 4-((1R,3S)—3-
' V ' '
hydroxycyclohexylamino)
((R)-5,6,7,8-
tetrahydroisoquinolin
ylarnino)pyrirnidine-5 -
carboxarnide
97 4-((1R,3S)—3-
hydroxycycloheptylarnino)
((S)-5 ,6 ,7 , 8 -tetrahydr0quinolin-
6-ylamino)pyrirnidine-5 -
carboxarnide
98 4-((1R,3S)—3-
hydroxycycloheptylarnino)
((R)—5 ,6 ,7 , ahydr0quinolin-
ino)pyrirnidine-5 -
carboxarnide
—324—
ATI—ZS 14175V1
Cmpd. Structure Compound Name MH+ Act.
Level
lohexy1arnino)((1r,4r)- 344.2
\x La, “z” 4-ethoxycyclohexyl-
LMLg -"L"\‘n K“: amino)pyrirnidine-5 -carb0nitrile
Claims (65)
1. A compound of formula (I): and ceutically acceptable salts, tautomers, isomers, enantiomers, and isotopologues f, wherein: R1 is substituted or unsubstituted C1-8 alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted non-aromatic heterocyclyl, substituted or unsubstituted alkylcycloalkyl, or substituted or unsubstituted alkylheterocyclyl, provided that R1 is not 1-aminocyclohexyl; R2 is substituted or unsubstituted C1-8 alkyl, substituted or unsubstituted saturated cycloalkyl, substituted or unsubstituted alkylcycloalkyl, or substituted or unsubstituted non-aromatic heterocyclyl; provided the compound is not minoethylamino)(methylamino)pyrimidinecarboxamide, 2-(2-aminopropylamino)(cyclohexylamino)pyrimidinecarboxamide, 2-(2-aminooxoethylamino)(cyclohexylamino)pyrimidinecarboxamide, 2-(2-aminoethylamino)(cyclohexylamino)pyrimidinecarboxamide, (S)(2-aminopropylamino)(cyclobutylamino)pyrimidinecarboxamide, (R)(1-aminomethyloxobutanylamino)(cyclobutylamino)pyrimidine carboxamide, lopentylamino)(methylamino)pyrimidinecarboxamide, or 2-(1-acetylpiperidinylamino)(cyclopropylamino)pyrimidinecarboxamide, wherein when a C1-8 alky group is substituted, the C1-8 alkyl group is tuted with halogen, alkyl, hydroxyl, alkoxy, alkoxyalkyl, amino, alkylamino, carboxy, nitro, cyano, thiol, thioether, imine, imide, amidine, guanidine, enamine, aminocarbonyl, acylamino, phosphonato, phosphine, thiocarbonyl, sulfonyl, sulfone, sulfonamide, ketone, aldehyde, ester, urea, urethane, oxime, hydroxyl amine, amine, aralkoxyamine, N-oxide, hydrazine, hydrazide, hydrazone, azide, isocyanate, ocyanate, e, thiocyanate, , or O(alkyl)aminocarbonyl; wherein when a group, other than a C1-8 alkyl group, is substituted, the group is substituted with halogen, alkyl, hydroxyl, alkoxy, alkoxyalkyl, amino, alkylamino, carboxy, nitro, cyano, thiol, her, imine, imide, amidine, guanidine, enamine, aminocarbonyl, acylamino, phosphonato, phosphine, thiocarbonyl, sulfonyl, sulfone, sulfonamide, ketone, de, ester, urea, urethane, oxime, hydroxyl amine, alkoxyamine, aralkoxyamine, N-oxide, hydrazine, hydrazide, hydrazone, azide, isocyanate, isothiocyanate, cyanate, thiocyanate, oxo, B(OH)2, O(alkyl)aminocarbonyl, cycloalkyl, or a heterocyclyl.
2. The nd of claim 1, wherein R1 is a branched C1-8 alkyl.
3. The nd of claim 2, wherein R1 is isopropyl, sec-butyl, isobutyl, tert-butyl, 2,3-dimethylbutyl, isopentyl, 2-methylpentyl, neopentyl, tert-pentyl, or 3-methylpentyl.
4. The compound of claim 1, wherein R1 is a substituted or tituted cycloalkyl, wherein when the cycloalkyl is substituted, the cycloalkyl is substituted with halogen, alkyl, hydroxyl, alkoxy, alkoxyalkyl, amino, alkylamino, carboxy, nitro, cyano, thiol, thioether, imine, imide, amidine, guanidine, enamine, aminocarbonyl, acylamino, phosphonato, phosphine, thiocarbonyl, sulfonyl, sulfone, sulfonamide, ketone, aldehyde, ester, urea, urethane, oxime, yl amine, alkoxyamine, aralkoxyamine, N-oxide, hydrazine, hydrazide, hydrazone, azide, isocyanate, isothiocyanate, cyanate, thiocyanate, oxo, B(OH)2, O(alkyl)aminocarbonyl, lkyl, or a heterocyclyl.
5. The compound of claim 4, wherein the cycloalkyl is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, o[1.1.1]pentyl, bicyclo[2.2.1]heptyl, or bicyclo[2.2.2]octyl.
6. The compound of claim 4, wherein the cycloalkyl is substituted with one or more halogen, -CF3, -(C1-4 , -(C1-6 cycloalkyl), -NR2, -(C0-3 alkyl)OR, -(C0-3 alkyl)OR”, -NRC(O)R’, -C(O)R’, -C(O)NR2, -C(O)OR’, or -NRS(O)2R’, n each R is independently H, or C1-4 alkyl, wherein the alkyl is optionally fluorinated, each R’ is independently C1-4 alkyl, wherein the alkyl is optionally fluorinated, and each R” is independently a C1-6 cycloalkyl, n the C1-6 cycloalkyl is optionally nated.
7. The compound of claim 4, wherein the cycloalkyl is substituted with one or more methyl, ethyl, t-butyl, cyclopropyl, -CF3, -F, -OH, -OCH3, -OCHF2, -OCF3, - OCH2CH3, -OCH2CH2F, F3, -O(cyclopropyl), -CH2OH, -CH2OCH3, -C(CH3)2OH, -NH2, -NH(CH3), -NHC(O)CH3, -C(O)NHCH3, -C(O)N(CH3)2, or -NHSO2CH3.
8. The compound of claim 1, wherein R1 is a substituted or unsubstituted nonaromatic heterocyclyl, wherein when the heterocyclyl is substituted, the heterocyclyl is substituted with halogen, alkyl, hydroxyl, alkoxy, alkoxyalkyl, amino, mino, carboxy, nitro, cyano, thiol, thioether, imine, imide, amidine, guanidine, e, aminocarbonyl, acylamino, phosphonato, phosphine, thiocarbonyl, sulfonyl, e, sulfonamide, ketone, aldehyde, ester, urea, urethane, oxime, hydroxyl amine, alkoxyamine, aralkoxyamine, e, hydrazine, hydrazide, hydrazone, azide, isocyanate, isothiocyanate, cyanate, thiocyanate, oxo, B(OH)2, O(alkyl)aminocarbonyl, cycloalkyl, or a heterocyclyl.
9. The compound of claim 8, wherein the heterocyclyl is oxetanyl, pyrrolidinyl, tetrahydropyranyl, 1,4-dioxaspiro[4.5]decanyl, or piperidyl.
10. The compound of claim 9, n the piperidyl is substituted with -C(O)R’, or -C(O)OR’, wherein R’ is C1-4 alkyl, wherein the alkyl is optionally fluorinated.
11. The compound of claim 1, wherein R1 is a substituted or unsubstituted alkylcycloalkyl, wherein when the alkylcycloalkyl is substituted, the ycloalkyl is substituted with halogen, alkyl, hydroxyl, alkoxy, alkoxyalkyl, amino, alkylamino, carboxy, nitro, cyano, thiol, thioether, imine, imide, amidine, guanidine, enamine, aminocarbonyl, ino, phosphonato, phosphine, thiocarbonyl, sulfonyl, sulfone, amide, ketone, aldehyde, ester, urea, urethane, oxime, hydroxyl amine, alkoxyamine, aralkoxyamine, N-oxide, hydrazine, hydrazide, hydrazone, azide, isocyanate, isothiocyanate, cyanate, thiocyanate, oxo, B(OH)2, O(alkyl)aminocarbonyl, cycloalkyl, or a heterocyclyl.
12. The compound of claim 11, wherein R1 is (C1-3 alkyl)cyclopropyl, (C1-3 alkyl)cyclobutyl, (C1-3 alkyl)cyclopentyl, or (C1-3 alkyl)cyclohexyl.
13. The nd of claim 11, wherein R1 is –(CH2)cyclopropyl, -CH(CH3)cyclopropyl, -CH(CH3)cyclobutyl,–CH(CH3)cyclohexyl, or -C(CH3)2cyclopropyl.
14. The compound of claim 1, wherein R1 is a substituted or unsubstituted alkylheterocyclyl, wherein when the alkylheterocyclyl is substituted, the eterocyclyl is substituted with halogen, alkyl, hydroxyl, alkoxy, alkoxyalkyl, amino, alkylamino, carboxy, nitro, cyano, thiol, thioether, imine, imide, amidine, guanidine, enamine, aminocarbonyl, acylamino, phosphonato, phosphine, rbonyl, sulfonyl, sulfone, sulfonamide, ketone, aldehyde, ester, urea, urethane, oxime, hydroxyl amine, alkoxyamine, aralkoxyamine, N-oxide, hydrazine, hydrazide, hydrazone, azide, isocyanate, isothiocyanate, cyanate, thiocyanate, oxo, B(OH)2, O(alkyl)aminocarbonyl, cycloalkyl, or a heterocyclyl.
15. The compound of claim 14, wherein R1 is -(C1-4 tetrahydrofuranyl, -(C1-4 alkyl)dioxolanyl, (C1-4 alkyl)furanyl, (C1-3 thiophenyl, or -(C1-3 alkyl)pyridyl.
16. The compound of claim 1, wherein R2 is a tuted or unsubstituted C1-8 alkyl, wherein when the C1-8 alky group, excluding cycloalkyl, heteroaryl and aryl groups, is tuted, the C1-8 alkyl group is substituted with halogen, alkyl, hydroxyl, alkoxy, alkoxyalkyl, amino, alkylamino, carboxy, nitro, cyano, thiol, thioether, imine, imide, amidine, guanidine, enamine, aminocarbonyl, acylamino, phosphonato, phosphine, thiocarbonyl, sulfonyl, sulfone, sulfonamide, ketone, aldehyde, ester, urea, urethane, oxime, hydroxyl amine, alkoxyamine, aralkoxyamine, N-oxide, hydrazine, hydrazide, hydrazone, azide, isocyanate, isothiocyanate, cyanate, thiocyanate, B(OH)2, or O(alkyl)aminocarbonyl.
17. The compound of claim 16, wherein R2 is methyl, ethyl, n-propyl, isopropyl, n-butyl, tyl, isobutyl, tert-butyl, 3-methylbutyl, 2,3-dimethylbutyl, 3,3-dimethylbutyl, 2,3,3-trimethylbutyl, tert-pentyl, isopentyl, 3-pentyl, 3-methylpentyl, 2-methylpentyl, or 2,4-dimethylpentyl.
18. The compound of claim 16, wherein R2 is substituted with one or more -(C1-4 alkyl), -(C0-3 alkyl)OR, -C(O)NR2 or -NRCOR’, wherein each R is independently H, or C1-4 alkyl, wherein the alkyl is optionally nated, and each R’ is independently C1-4 alkyl, wherein the alkyl is optionally fluorinated.
19. The compound of claim 16, wherein R2 is substituted with one or more -OH, -OCH3, or -CH3.
20. The compound of claim 1, wherein R2 is a substituted or unsubstituted cycloalkyl, wherein when the cycloalkyl is substituted, the cycloalkyl is substituted with halogen, alkyl, hydroxyl, alkoxy, alkoxyalkyl, amino, alkylamino, y, nitro, cyano, thiol, thioether, imine, imide, amidine, ine, enamine, aminocarbonyl, acylamino, onato, phosphine, thiocarbonyl, yl, sulfone, sulfonamide, ketone, aldehyde, ester, urea, urethane, oxime, hydroxyl amine, alkoxyamine, aralkoxyamine, N-oxide, hydrazine, hydrazide, one, azide, isocyanate, isothiocyanate, cyanate, anate, oxo, B(OH)2, O(alkyl)aminocarbonyl, cycloalkyl, or a heterocyclyl.
21. The compound of claim 20, wherein R2 is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, bicyclo[1.1.1]pentyl, o[2.1.1]hexyl, or bicyclo[2.2.1]heptyl.
22. The compound of claim 20, wherein R2 is substituted with one or more -CF3, -(C1-4 alkyl), -(C1-6 cycloalkyl)-(C0-3 alkyl)OR, -(C0-3 alkyl)C(O)NR2, -NR2, or -NRCOR’, n each R is independently H, or C1-4 alkyl, wherein the alkyl is optionally fluorinated, each R’ is independently C1-4 alkyl, wherein the alkyl is optionally fluorinated, and wherein the cycloalkyl is optionally fluorinated.
23. The compound of claim 20, wherein R2 is substituted with one or more methyl, ethyl, isopropyl, -cyclopropyl, -CF3, -CH2OH, -OH, -OCH3, -OCH2CH3, -C(O)NH2, -NHC(O)CH3, or -NHC(O)CH2CH3.
24. The compound of claim 1, n R2 is a substituted or unsubstituted ycloalkyl, wherein when the alkylcycloalkyl is substituted, the alkylcycloalkyl is substituted with halogen, alkyl, hydroxyl, alkoxy, alkoxyalkyl, amino, alkylamino, carboxy, nitro, cyano, thiol, thioether, imine, imide, amidine, guanidine, enamine, aminocarbonyl, acylamino, phosphonato, phosphine, thiocarbonyl, sulfonyl, sulfone, sulfonamide, ketone, aldehyde, ester, urea, ne, oxime, hydroxyl amine, alkoxyamine, aralkoxyamine, N-oxide, ine, hydrazide, hydrazone, azide, isocyanate, isothiocyanate, cyanate, thiocyanate, oxo, B(OH)2, O(alkyl)aminocarbonyl, lkyl, or a heterocyclyl.
25. The compound of claim 24, wherein R2 is a tuted or unsubstituted (C1-3 alkyl)cyclopropyl, (C1-3 cyclobutyl, (C1-3 alkyl)cyclopentyl, or (C1-3 alkyl)cyclohexyl, wherein when the R2 is substituted, the R2 is substituted with halogen, alkyl, hydroxyl, alkoxy, alkyl, amino, alkylamino, carboxy, nitro, cyano, thiol, thioether, imine, imide, amidine, guanidine, e, aminocarbonyl, acylamino, onato, phosphine, thiocarbonyl, sulfonyl, sulfone, sulfonamide, ketone, aldehyde, ester, urea, urethane, oxime, hydroxyl amine, alkoxyamine, aralkoxyamine, N-oxide, ine, hydrazide, hydrazone, azide, isocyanate, isothiocyanate, cyanate, thiocyanate, oxo, B(OH)2, O(alkyl)aminocarbonyl, cycloalkyl, or a heterocyclyl.
26. The compound of claim 24, wherein R2 is -(CH2)cyclopropyl, -(CH2)cyclobutyl, -CH(CH3)cyclopropyl, -CH(CH3)cyclobutyl, -CH(CH2CH3)cyclopropyl, -C(CH3)2cyclopropyl, or -CH2CH2cyclobutyl.
27. The compound of claim 1, wherein R2 is a substituted or unsubstituted non-aromatic heterocyclyl, wherein when the heterocyclyl is substituted, the heterocyclyl is substituted with halogen, alkyl, yl, alkoxy, alkoxyalkyl, amino, alkylamino, carboxy, nitro, cyano, thiol, thioether, imine, imide, amidine, guanidine, enamine, aminocarbonyl, ino, phosphonato, phosphine, rbonyl, sulfonyl, sulfone, sulfonamide, ketone, aldehyde, ester, urea, urethane, oxime, hydroxyl amine, alkoxyamine, aralkoxyamine, N-oxide, hydrazine, hydrazide, hydrazone, azide, isocyanate, isothiocyanate, cyanate, anate, oxo, B(OH)2, O(alkyl)aminocarbonyl, lkyl, or a heterocyclyl.
28. The compound of claim 27, wherein R2 is oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, piperidyl, piperidinonyl or oxaspiro[4.5]decanyl.
29. The compound of claim 27, wherein R2 is tuted with one or more -(C1-4 alkyl), -(C0-3 alkyl)OR, or -C(O)R’, wherein each R is independently H, or C1-4 alkyl, wherein the alkyl is optionally fluorinated, and each R’ is independently C1-4 alkyl, wherein the alkyl is optionally fluorinated.
30. The compound of claim 20, wherein R1 is a cycloalkyl, optionally substituted with one or more halogen, -CF3, -(C1-4 alkyl), -NR2, -(C0-3 alkyl)OR, -(C0-3 OR”, -NRC(O)R’, -C(O)R’, -C(O)NR2, -C(O)OR’, or -NRS(O)2R’, wherein each R is independently H, or C1-4 alkyl, wherein the alkyl is optionally fluorinated, each R’ is independently C1-4 alkyl, wherein the alkyl is optionally fluorinated, and each R” is independently a C1-6 cycloalkyl, wherein the cycloalkyl is optionally fluorinated.
31. The nd of claim 1, wherein the compound at a concentration of 10 μM ts JNK1 by at least about 50%.
32. The compound of claim 1, wherein the compound is selected from or a pharmaceutically able salt, tautomer, stereoisomer, or enantiomer thereof.
33. A compound selected from or a ceutically able salt, tautomer, isomer, or enantiomer thereof.
34. A compound of formula (IB): (IB) and pharmaceutically acceptable salts, tautomers, stereoisomers, enantiomers, and isotopologues thereof, wherein: R3 is substituted or unsubstituted C1-8 alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted non-aromatic heterocyclyl, substituted or unsubstituted alkylcycloalkyl, or substituted or unsubstituted alkyl-(non-aromatic heterocyclyl); R4 is substituted or unsubstituted C1-8 alkyl, substituted or unsubstituted cycloalkyl, or substituted or unsubstituted non-aromatic cyclyl; provided the compound is not 4-(isopentylamino)(3-(2-methylpiperidinyl)propylamino)pyrimidinecarbonitrile; (2S,2'S)-dimethyl 2,2'-(5-cyanopyrimidine-2,4-diyl)bis(azanediyl)bis(4- methylpentanoate); (2S,2'S)-diethyl 2,2'-(5-cyanopyrimidine-2,4-diyl)bis(azanediyl)bis(3-methylbutanoate); 4-(cycloheptylamino)(3-(2-methylpiperidinyl)propylamino)pyrimidine carbonitrile; 4-(4-methylcyclohexylamino)(3-(2-methylpiperidinyl)propylamino)pyrimidine carbonitrile; or 2-(3-(diethylamino)propylamino)(4-methylcyclohexylamino)pyrimidinecarbonitrile, wherein when a C1-8 alky group is substituted, the C1-8 alkyl group is substituted with halogen, alkyl, hydroxyl, alkoxy, alkoxyalkyl, amino, alkylamino, y, nitro, cyano, thiol, thioether, imine, imide, amidine, guanidine, enamine, aminocarbonyl, acylamino, phosphonato, phosphine, rbonyl, sulfonyl, e, sulfonamide, ketone, aldehyde, ester, urea, ne, oxime, hydroxyl amine, alkoxyamine, aralkoxyamine, N-oxide, hydrazine, hydrazide, hydrazone, azide, isocyanate, ocyanate, e, thiocyanate, B(OH)2, or O(alkyl)aminocarbonyl; wherein when a group, other than a C1-8 alky group, is substituted, the group is substituted with halogen, alkyl, hydroxyl, alkoxy, alkoxyalkyl, amino, alkylamino, carboxy, nitro, cyano, thiol, thioether, imine, imide, amidine, guanidine, enamine, aminocarbonyl, acylamino, phosphonato, phosphine, thiocarbonyl, sulfonyl, e, sulfonamide, ketone, aldehyde, ester, urea, urethane, oxime, hydroxyl amine, alkoxyamine, xyamine, N-oxide, hydrazine, hydrazide, hydrazone, azide, isocyanate, isothiocyanate, cyanate, thiocyanate, oxo, B(OH)2, O(alkyl)aminocarbonyl, cycloalkyl, or a cyclyl.
35. The compound of claim 34, wherein R3 is a branched C1-8 alkyl.
36. The compound of claim 35, wherein R3 is isopropyl, sec-butyl, isobutyl, tert-butyl, 2,3-dimethylbutyl, isopentyl, 2-methylpentyl, neopentyl, tert-pentyl, or 3-methylpentyl.
37. The compound of claim 34, wherein R3 is a substituted or unsubstituted cycloalkyl, wherein when the cycloalkyl is substituted, the lkyl is substituted with halogen, alkyl, hydroxyl, alkoxy, alkoxyalkyl, amino, alkylamino, carboxy, nitro, cyano, thiol, thioether, imine, imide, amidine, guanidine, enamine, aminocarbonyl, acylamino, phosphonato, phosphine, thiocarbonyl, sulfonyl, sulfone, sulfonamide, ketone, aldehyde, ester, urea, urethane, oxime, hydroxyl amine, alkoxyamine, aralkoxyamine, N-oxide, hydrazine, hydrazide, hydrazone, azide, isocyanate, isothiocyanate, cyanate, thiocyanate, oxo, B(OH)2, O(alkyl)aminocarbonyl, cycloalkyl, or a heterocyclyl.
38. The compound of claim 37, wherein the cycloalkyl is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, bicyclo[1.1.1]pentyl, bicyclo[2.2.1]heptyl, or bicyclo[2.2.2]octyl.
39. The compound of claim 37, wherein the cycloalkyl is substituted with one or more halogen, -CF3, -(C1-4 alkyl), -(C1-6 cycloalkyl), -NR2, -(C0-3 alkyl)OR, -(C0-3 alkyl)OR”, -NRC(O)R’, -C(O)R’, -(C0-3 C(O)NR2, -C(O)OR’, or -NRS(O)2R’, n each R is independently H, or C1-4 alkyl, n the alkyl is optionally fluorinated, and each R’ is independently C1-4 alkyl, wherein the alkyl is optionally fluorinated, and each R” is independently a C1-6 cycloalkyl, wherein the cycloalkyl is optionally fluorinated.
40. The compound of claim 37, wherein the lkyl is substituted with one or more methyl, ethyl, t-butyl, ropyl, -CF3, -F, -OH, -OCH3, -OCHF2, -OCF3, -OCH2CH3, -OCH2CH2F, -OCH2CF3, -O(cyclopropyl), -CH2OH, -CH2OCH3, )2OH, -NH2, -NH(CH3), -NHC(O)CH3, )2C(O)N(CH3)2, -C(O)NHCH3, -C(O)N(CH3)2, or -NHSO2CH3.
41. The compound of claim 34, wherein R3 is a substituted or unsubstituted non-aromatic heterocyclyl, wherein when the heterocyclyl is substituted, the heterocyclyl is tuted with n, alkyl, hydroxyl, alkoxy, alkyl, amino, mino, carboxy, nitro, cyano, thiol, thioether, imine, imide, amidine, guanidine, enamine, aminocarbonyl, acylamino, phosphonato, phosphine, thiocarbonyl, sulfonyl, sulfone, amide, ketone, aldehyde, ester, urea, ne, oxime, hydroxyl amine, alkoxyamine, aralkoxyamine, N-oxide, hydrazine, hydrazide, hydrazone, azide, isocyanate, isothiocyanate, e, thiocyanate, oxo, B(OH)2, O(alkyl)aminocarbonyl, cycloalkyl, or a heterocyclyl.
42. The compound of claim 41, wherein the cyclyl is oxetanyl, tetrahydrofuranyl, ydropyranyl, piperidyl, piperidinonyl or 1,4-dioxaspiro[4.5]decanyl.
43. The compound of claim 34, wherein R4 is a substituted or unsubstituted C1-8 alkyl, wherein when the C1-8 alky group, excluding cycloalkyl, heteroaryl and aryl groups, is substituted, the C1-8 alkyl group is substituted with halogen, alkyl, hydroxyl, alkoxy, alkoxyalkyl, amino, alkylamino, carboxy, nitro, cyano, thiol, her, imine, imide, amidine, guanidine, enamine, aminocarbonyl, acylamino, phosphonato, phosphine, thiocarbonyl, sulfonyl, e, sulfonamide, ketone, aldehyde, ester, urea, urethane, oxime, hydroxyl amine, amine, aralkoxyamine, N-oxide, hydrazine, hydrazide, hydrazone, azide, nate, isothiocyanate, cyanate, thiocyanate, B(OH)2, or O(alkyl)aminocarbonyl.
44. The compound of claim 43, wherein R4 is methyl, ethyl, yl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, 3-methylbutyl, 2,3-dimethylbutyl, 3,3-dimethylbutyl, 2,3,3-trimethylbutyl, tert-pentyl, isopentyl, 3-pentyl, 3-methylpentyl, 2-methylpentyl, or 2,4-dimethylpentyl.
45. The compound of claim 34, wherein R4 is a substituted or unsubstituted lkyl, wherein when the cycloalkyl is substituted, the cycloalkyl is substituted with halogen, alkyl, hydroxyl, alkoxy, alkoxyalkyl, amino, alkylamino, carboxy, nitro, cyano, thiol, thioether, imine, imide, amidine, ine, e, aminocarbonyl, acylamino, phosphonato, phosphine, thiocarbonyl, sulfonyl, sulfone, sulfonamide, ketone, aldehyde, ester, urea, urethane, oxime, hydroxyl amine, alkoxyamine, aralkoxyamine, N-oxide, hydrazine, hydrazide, hydrazone, azide, isocyanate, isothiocyanate, cyanate, thiocyanate, oxo, B(OH)2, O(alkyl)aminocarbonyl, cycloalkyl, or a heterocyclyl.
46. The compound of claim 45, wherein R4 is cyclopropyl, utyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, bicyclo[1.1.1]pentyl, bicyclo[2.1.1]hexyl, or bicyclo[2.2.1]heptyl.
47. The compound of claim 45, wherein R4 is substituted with one or more halogen, -CF3, -(C1-4 alkyl), -(C1-6 cycloalkyl), -(C0-3 alkyl)OR, -(C0-3 alkyl)C(O)NR2, -NR2, or -NRCOR’, wherein each R is independently H, or C1-4 alkyl, wherein the alkyl is optionally fluorinated, each R’ is independently C1-4 alkyl, wherein the alkyl is optionally fluorinated, and wherein the cycloalkyl is optionally fluorinated.
48. The compound of claim 45, wherein R4 is tuted with one or more methyl, ethyl, isopropyl, -cyclopropyl, -CF3, -CH2OH, -OH, -OCH3, -OCH2CH3, -C(O)NH2, -NHC(O)CH3, or -NHC(O)CH2CH3.
49. The compound of claim 34, wherein R4 is a substituted or unsubstituted non-aromatic heterocyclyl, wherein when the cyclyl is substituted, the heterocyclyl is substituted with halogen, alkyl, hydroxyl, alkoxy, alkoxyalkyl, amino, alkylamino, carboxy, nitro, cyano, thiol, thioether, imine, imide, amidine, guanidine, enamine, aminocarbonyl, acylamino, onato, phosphine, rbonyl, yl, sulfone, sulfonamide, ketone, aldehyde, ester, urea, urethane, oxime, hydroxyl amine, alkoxyamine, xyamine, N-oxide, hydrazine, hydrazide, hydrazone, azide, isocyanate, isothiocyanate, e, thiocyanate, oxo, B(OH)2, O(alkyl)aminocarbonyl, cycloalkyl, or a heterocyclyl.
50. The compound of claim 49, wherein R4 is oxetanyl, tetrahydrofuranyl, ydropyranyl, piperidyl, piperidinonyl or 1,4-dioxaspiro[4.5]decanyl.
51. The compound of claim 45, wherein R3 is a cycloalkyl, optionally substituted with one or more halogen, -CF3, -(C1-4 alkyl), -NR2, -(C0-3 alkyl)OR, -(C0-3 alkyl)OR”, )R’, ’, -C(O)NR2, -C(O)OR’, or -NRS(O)2R’, wherein each R is independently H, or C1-4 alkyl, wherein the alkyl is optionally fluorinated, each R’ is independently C1-4 alkyl, wherein the alkyl is optionally fluorinated, and each R” is independently a C1-6 cycloalkyl, wherein the lkyl is optionally fluorinated.
52. The compound of claim 34, wherein the compound at a concentration of 10 μM inhibits JNK1 by at least about 50%.
53. The compound of claim 34, wherein the compound is selected from or a pharmaceutically acceptable salt, tautomer, stereoisomer, or enantiomer thereof.
54. A pharmaceutical composition comprising an ive amount of a compound of claim 1, 32, 33, 34, or 53, or a pharmaceutically acceptable salt, tautomer, isotopologue, or stereoisomer thereof, and a pharmaceutically acceptable carrier, excipient or vehicle.
55. An in vitro method of inhibiting a JNK1 or JNK2 kinase in a cell expressing said JNK1 or JNK2 kinase, comprising contacting said cell with an effective amount of a compound of claim 1, 32, 33, 34, or 53, or a pharmaceutically acceptable salt, tautomer, isotopologue, or stereoisomer thereof.
56. The use of a compound of any one of claims 1 to 53, in the manufacture of a medicament for inhibiting a JNK1 or JNK2 .
57. The use of a compound of any one of claims 1 to 53 in the manufacture of a medicament for the ent of a liver ic disorder, or diabetes or metabolic syndrome leading to a liver fibrotic disorder.
58. The use of claim 57, wherein the liver fibrotic disorder is non-alcoholic steatohepatitis, steatosis, cirrhosis, primary sclerosing gitis, primary biliary cirrhosis, tis, hepatocellular oma, or liver fibrosis coincident with chronic or repeated alcohol ingestion, with infection, with liver transplant, or with drug induced liver injury.
59. The use of claim 57, wherein the liver fibrotic disorder is non-alcoholic steatohepatitis, steatosis, hepatitis, or cirrhosis.
60. A compound according to claim 1, ntially as herein described or exemplified.
61. A compound according to claim 34, substantially as herein described or ified.
62. A pharmaceutical composition according to claim 54, substantially as herein described or exemplified.
63. A method according to claim 55, substantially as herein described or exemplified.
64. A use according to claim 56, substantially as herein bed or exemplified.
65. A use according to claim 57, substantially as herein described or exemplified.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161478076P | 2011-04-22 | 2011-04-22 | |
US61/478,076 | 2011-04-22 | ||
US201161555339P | 2011-11-03 | 2011-11-03 | |
US61/555,339 | 2011-11-03 | ||
PCT/US2012/034349 WO2012145569A1 (en) | 2011-04-22 | 2012-04-20 | Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ614776A NZ614776A (en) | 2015-06-26 |
NZ614776B2 true NZ614776B2 (en) | 2015-09-29 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11325890B2 (en) | Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith | |
AU2015201030B2 (en) | Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith | |
AU2016244228B2 (en) | Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith | |
NZ614776B2 (en) | Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith |